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ABSTRACT
Rheumatoid arthritis (RA) is a severely debilitating disease that affects 1% o f  the 
Western population. In addition to suffering pain and deform ation o f joints, patients are 
also at a higher risk o f  developing cardiovascular co-m orbidities and experience a lower 
life expectancy as a result, Evidence for a link between RA and cardiovascular disease 
(CVD) is overwhelm ing and the large RA -associated inflammatory burden is thought to 
be responsible for the developm ent o f  such distal pathologies; inflam m atory m ediators 
characteristic o f  RA cause injury to the endothelium  ultim ately resulting in endothelial 
dysfunction, a precursor to CVD. Therefore the main aim o f this thesis w as to 
characterise the vascular phenotype o f  a murine model o f  RA. Secondary aims w ere to 
relate changes in vascular function to the extent o f  experim ental arthritis and to explore 
causative m echanism s therein.
The well described collagen-induced murine (m CIA) model o f  human RA was used in 
all experim ents. Subsequently paw and aortic tissue and blood were collected from both 
arthritic and non-im m unised aged-m atched controls. The severity o f  arthritis was 
confirm ed by clinical arthritic scoring and histological assessm ent o f  the paws. Isom etric 
tension studies were used to investigate vascular function in the isolated tissues in the 
absence and presence o f various pharm acological inhibitors, the latter depending on the 
particular system under investigation. Lastly a role for matrix m etalloproteinase-9 
(M M P-9) was investigated. To this end levels were quantified in paw and aortic 
hom ogenates and plasm a by ELISA, and cellular sources o f  this gelatinase explored 
using im m unohistochem istry.
Aortae taken from arthritic animals displayed increasing contractile dysfunction 
(evidenced by a reduced capability to constrict to specific m ediators K+ and the agonist 
5-hydroxytryptam inc com pared to normal control vessels) with increasing severity o f  
experimental arthritis. Interestingly, and in contrast to many studies in the literature, 
endothelial function appeared unchanged throughout disease. Subsequent investigations
ruled out a role for increased production o f  nitric oxide and prostacyclin in this 
pathology. Conversely aortic (and also paw and plasm a) levels o f  MMP-9 were shown 
to associate with increasing contractile dysfunction and indeed that contractile function 
was com prom ised following exposure o f  control aortic tissues to exogenous MMP-9. A 
role for neutrophils and m acrophages in M M P-9 production and arthritis progression 
was confirm ed by their concom itant presence in paws.
These findings suggest that systemic and vascular wall levels o f MMP-9, related to 
inflammation at the jo in t site, may play a prom inent role in the development o f vascular 
dysfunction in this experim ental model. As such this thesis goes someway to elucidating 
the potential m echanism s o f  vascular dysfunction in RA. Importantly identification o f  
the earliest changes in vascular function following the initial onset o f RA, and the 
pathological m echanism s therein, may result in a re-evaluation o f current treatments or 
indeed the developm ent o f new therapies.
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CHAPTER 1
INTRODUCTION  
1.1. Rheumatoid Arthritis
RA is a multi factorial systemic disease characterised by chronic inflammation, prim arily 
o f the small synovial joints in the hands and feet. It is an autoimmune disease in which 
cells o f  the normally protective immune system propagate an aggressive attack on host 
antigens resulting in pain and disability for the sufferer. The exact trigger for this change 
in immunity is unknown (Goronzy and W eyand 2005).
Processes underlying the disease include hyperplasia o f the synovial membrane and 
infiltration o f  inflam m atory cells resulting in structural damage to bone, cartilage and 
ligaments within the jo in t (Cho, Cho et al. 2007). Patients experience tenderness, 
stiffness, jo in t swelling and fatigue (M akelainen, Vehviiainen-Julkunen et al. 2008) and 
a subsequent poorer quality o f  life. Progression o f  the disease from a self-lim iting phase 
to a chronic progressive stage can result in extra-articular manifestations with which 
comes an increased m ortality rate and lower life expectancy (M yllykangas-Luosujarvi, 
Aho et al. 1995; Kaplan 2006; Cho, Cho et al. 2007; Turesson, Jacobsson et al. 2008). It 
is now widely acknow ledged throughout the literature that patients with RA are at risk 
o f developing cardiovascular complications. Indeed approxim ately half the deaths 
observed in RA patients can be attributed to cardiovascular disease (Goodson 2002).
1.1.1. Epidemiology and Aetiology of Rheumatoid Arthritis
The disease affects approxim ately 0.5 - 1% o f  the population (Gabriel 2001); wom en 
account for two thirds o f  this num ber with typical age o f  onset between forty and sixty. 
While the aetiology o f  RA is unknown, a com bination o f environmental and genetic 
factors including smoking, viral infections, mechanical stress and specific hum an
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leukocyte antigen (HLA) alleles have been associated with its development (Silm an and 
Pearson 2002). However, no strong evidence exists for any hypothesis.
1.2. Pathogenesis of Rheumatoid Arthritis
Numerous cellular mechanism s and signalling pathways drive the inflam m atory 
processes leading to jo in t destruction in RA. Cells from both the innate and adaptive 
immune system are involved, the innate system being the primary producer o f cytokines, 
chemokines and matrix metalloproteinases (M M Ps), all o f which propagate the 
destructive process. To understand the pathogenesis o f RA it is important to first 
understand the normal environm ent o f  a jo int, and how this subsequently changes with 
disease.
1.2.1. The Normal Joint
The synovial join ts are com posed o f  two opposing bone surfaces covered in cartilage 
providing a smooth low friction exterior, responsible for weight-bearing and shock 
absorption. The articular faces o f the bone are surrounded by a capsule filled with 
synovial fluid, giving jo in t lubrication and a medium for the passage o f  nutrients and 
other m olecules between this fluid and the surrounding tissue (Knedla, Neumann et al. 
2007; O tero and Goldring 2007). The synovial m em brane lines this fluid filled capsule 
covering the jo in t cavity from bone to bone. This membrane is composed o f  synovial 
fibroblasts (SFs) and m acrophages which secrete a rich combination o f  products 
essential for maintenance o f  the join t including cytokines and proteases such as M M Ps 
(Knedla, Neum ann et al. 2007) (see figure I .la ) . The latter are secreted in balance w ith 
endogenous inhibitors, a factor that is o f  crucial importance in preserving hom eostasis o f  
the joint. For an overview o f  the cells and their function in a normal jo in t see table 1.1.
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Figure 1.1. Ovcniew of a Normal and a Rheumatoid Joint. A) The healthy joint. The thin synovial 
membrane consisting of synovial fibroblasts lines the joint capsule and contains the synovial fluid 
encapsulated between the articular ends o f the two bones. The fluid is acellular and there are no 
infiltrating cells in the joint. B) In the rheumatoid joint, the synovial membrane becomes hyperplastic, and 
inflammatory cells invade the membrane and surrounding area. Inflammatory cells such as neutrophils 
migrate into the joint space. Taken from Strand (2007)
Cell Type Function in the Normal Joint
Synodal Fibroblasts Maintain membrane
Osteoclasts/Osteoblasts Maintain bone synthesis/degradation
Chondrocytes Maintain cartilage
Innate Immune Cells
Protect joint from infection
Maintain membrane
Table 1.1. Cell Function in a Normal Joint. The predominant cell types and their roles within the 
healthy synovial joint.
SFs have general “house keeping” roles in ensuring the synovial fluid is kept at a 
constant volume and clear of debris, and as such maintain capsule integrity. The
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secretion o f  hyaluronic acid, lubricin and other glycoproteins also ensures that fluid 
viscosity and function arc sustained, protecting the jo in t from excessive pressure and 
general w ear and tear (M or, Abramson et al. 2005).
In the cartilage, chondrocytes sustain the balance o f  collagen and proteoglycan, the chief 
protein com ponents o f  cartilage. They obtain their nutrients by diffusion from the 
articular cartilage surface or the subchondral bone allowing continued synthesis and 
degradation o f  the glycosam inoglycan com ponents o f aggrecan and other cartilage 
matrix constituents. Under normal conditions the chondrocytes have low cell turn over 
and proliferation is limited. No other cell types from bone or joint space enter the 
cartilage in the healthy jo in t (Otero and Goldring 2007).
In the bone, osteoclasts and osteoblasts are responsible for bone resorption and bone 
synthesis respectively. In a highly regulated fashion, they control the volume o f bone 
tissue and ensure it is being constantly renewed (Fujisaki, Tanabe et al. 2007). 
Osteoblasts secrete bone extracellular matrix (ECM ) proteins which become mineralized 
to form functional bone. In contrast, osteoclasts remove bone by attaching themselves to 
the periosteum , the bone membrane, and sealing it o ff from the extracellular 
environment. Proteolytic enzymes are pumped into the sealed-off area degrading the 
membrane o f  the bone, following which acid is secreted by the osteoclast into the bone 
causing degradation. This process leaves pits and leads to an overall weakening o f  the 
bone surface (Horowitz, Xi et al. 2001). Importantly in a normal join t these two 
processes are carefully balanced.
Cells o f  the innate immune system are also resident within the normal synovial joint. 
M acrophages cover the synovial lining and mast cells are found near the capsule, their 
primary role being to protect the accllular synovial fluid from invading cells and 
pathogens (Eklund 2007). In health, these cells play a small role in preventing infection. 
However in RA they become destructive, with significant detrimental consequences for 
the joint.
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1.2.2. The Arthritic Joint
In the arthritic jo in t an orchestrated catalogue o f events occur, with each subset o f chain 
reactions playing a role in the process as a whole. The multi factorial nature o f the 
disease implicates many cells and effector molecules in the progressive damage to the 
joints. The specific trigger for RA is as yet unknown and investigations to elucidate this 
are ongoing.
Initially dendritic cells (DCs) play an important role in both the innate and adaptive 
immune responses in RA as well as providing an ongoing immune stimulus throughout 
the duration o f  disease. In the presence o f  inflam m atory stimuli they mature and adapt 
their gene expression to favour an antigen-presenting function. As such they are able to 
present arthritogenic molecules to the invading T-cells via the major histocompatibility 
complex (M HC) 11 (Gorm an and Cope 2008; Lebre and Tak 2009). This stimulates 
invading T-cclls resulting in adaptive immunity (Lebre and Tak 2008), and attraction o f 
both helper and cytotoxic T-cells to the site o f  inflammation (Miossec 2008). 
Additionally DCs are also capable o f secreting mediators which attract mononuclear 
cells, leading to broad expression o f chemokines and upregulation o f adhesion 
molecules further exacerbating the inflammatory response.
The T-cells stim ulated by the antigen-presenting cell (APC) nature o f  the DCs can elicit 
subsequent activation o f  B-cells resulting in antibody producing plasma cells (Lebre and 
Tak 2009). Furthermore, T-cells can also differentiate into T h l7  cells producing large 
volumes o f  the deleterious interleukin (IL) -  17 (IL-17) inducing inflammation in the 
cells o f the synovium  (M iossec 2008). O ther cytokines such as IL -1 and tumour necrosis 
factor-a (T N F-a) cause damage to the jo in t and also result in further attraction o f T- and 
B-cells (M iossec 2008) to the inflammatory site. In summary initiation o f the adaptive 
immune response as a result o f  DC and T-cell interactions and influences result in a 
chronic inflam m atory environment.
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In conjunction with this immune reaction, changes within the cells o f  the jo in t begin to 
occur. The rather quiescent normal phenotype is pushed via the actions o f  other cells and 
cytokines towards a highly inflam m atory destructive state. SFs becom e highly 
proliferative, stimulated by growth factors which further propagate cell m ultiplication by 
the production o f  mitosis factors, behaving in a “positive feedback” fashion. These cells 
also experience a decreased apoptosis and senescence rate. As a result the thickness o f 
the synovial mem brane can increase from a single cell layer o f  SFs, to a depth o f  more 
than 15 cells (see figure 1.1b). The thickening o f  the membrane so close to the articular 
surface o f  the bone forms the pannus, a sheet o f  granulated inflammatory tissue which 
drives into the extra-cellular matrix o f  the cartilage and subchondral bone, resulting in 
destruction o f  both (Abelcs and Pillinger 2006; O tero and Goldring 2007). M acrophages 
are also present here, helping to form the destructive face o f  the pannus.
Throughout the onset and progression o f  disease there is a large influx o f  macrophages 
into the joint. Indeed the num ber o f  m acrophages in the tissue correlates directly with 
disease severity (Kim, Kim et al. 2005) implying that they play an important role in 
inflammatory damage. M acrophages migrate into the jo in t as a result o f  inflam m atory 
cytokines, for exam ple II-1 and TN Fa, and chem okines stimulate their m ovem ent 
(Drexler, Kong et al. 2008). Additionally, these inflammatory m ediators initiate 
neovascularisation within the joint, resulting in an increased blood flow to the site o f 
inflammation. This allows continued infiltration o f  blood-borne cells (Knedla, Neum ann 
et al. 2007), and helps to sustain the prolonged initiation o f  inflam m ation and 
subsequent dam age to the join t (Tak and Bresnihan 2000; Mor, Abramson et al. 2005). 
The effect o f  inflammation on macrophages and SFs causes additional production o f 
inflammatory factors such as II-ip , TN F-a, transform ing growth factor-p (TGFP), 
inducible nitric oxide synthase (iNOS), prostaglandin E2 (PGE2) and a range o f 
chemoattractants (M or, Abramson et al. 2005) (see table 1.2).
2 0
Cell Type Inflammatory Mediators Produced
Chondrocytes MMPs, cathepsin, RANKL
Synovial Fibroblasts
Interleukins: IL-10, -4, -6, -8, -10, -12, -13, -17, -18, -21, 
TNF-a, TGFp, iNOS, PGE2 and a range of 
chemoattractants
Macrophages Inflammatory cytokines, chemokines and MMPs alter activation, induced by IL-1 and TNFa/RANKL
Neutrophils
RANKL, inflammatory cytokines, C-reactive protein, NO
and MMPs.
Mast Cells
Eicosanoids, cytokines, histamine and the proteolytic 
enzymes chymase and tryptase
Table 1.2. Cells and their Contribution to Inflammation in RA.
On the articular end o f  the bone there is a loss o f  proteoglycan from the cartilage 
attributed to this infiltrating inflammatory milieu and a subsequent change in 
expression/activation o f  matrix degrading enzym es like the M M Ps in the synovial fluid. 
The function o f  chondrocytes in the cartilage is also altered after activation by 
inflammatory cytokines such as TN Fa, IL -1 p and IL -17 and leads to the further 
production o f  MMPs, cathepsin, and aggrecan-degrading enzymes, all o f  which 
contribute to collagen degradation (Otero and G oldnng 2007; van den Berg, van Lent et 
al. 2007). At this stage the jo in t is a site o f  increased tissue catabolism and suppressed 
repair.
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Also during this inflammation, neutrophils infiltrate into the join t and contribute to 
inflammation by producing receptor activator for nuclear factor k B Ligand (RA N K L), a 
member o f  the TNF superfamily. This ligand is also produced by SFs, m acrophages and 
chondrocytes (Haynes 2007) and is a key molecule involved in influencing osteoclast 
differentiation; expression o f  the ligand stimulates further production o f  RANKL, and 
pushes the function o f osteoclasts towards degradation (Drexler, Kong et al. 2008).
The mast cells that reside in the synovium o f  a normal join t are also activated during 
arthritis leading to dcgranulation and release o f  eicosanoids, cytokines, histam ine and 
the proteolytic enzymes chymase and tryptase. The latter two can directly degrade the 
matrix resulting in cartilage and bone destruction (Kobayashi and Okunishi 2002; 
Eklund 2007). Mast cells are activated by interaction with key com ponents o f  the 
complement system. They initiate and perpetuate the inflam m atory reaction prom oting 
tissue destruction and can recruit and stimulate other cell types. Moreover, these cells 
also stimulate angiogcncsis (Eklund 2007) resulting in increased blood flow and further 
infiltration o f  plasma cells exacerbating the prolonged inflammatory attack in the joint.
The com bination o f  all the above factors contributes to the aggressive and destructive 
nature o f  the disease. In addition to the physical disability and pain experienced, RA 
patients also face a poorer quality o f  life, and decreased life expectancy due to the 
systemic effects o f  RA. The severe inflammation characteristic o f  RA can exert 
damaging effects elsewhere in the body.
13. Rheumatoid Arthritis; a Systemic Disease
RA is a systemic disease and consequently, in addition to polyarthritis, other organs and 
tissues can be affected by the inflammatory overload in the circulation resulting in the 
development o f  extra-articular diseases (Kaplan 2006). These are described in detail 
throughout the literature although some difficulty lies in distinguishing between side- 
effects that arc a com plication o f RA and those that manifest as a direct result o f  the
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disease process (Y oung and Koduri 2007). For exam ple, skin thinning is a direct result 
o f the inflammatory burden, while an observed general malaise could be a result o f  the 
inactivity imposed on the patients due to pain upon movement. As such the latter is a 
consequence o f  being afflicted with RA, but not a direct disease response. Therefore, for 
the purpose o f  this thesis all complications and manifestations have been grouped 
together. Importantly, these extra-articular manifestations are associated w ith a 
shortening in the life expectancy o f the RA sufferer. It has now been established that co- 
morbid diseases play a large role in determ ining the health o f RA patients w ith respect 
to both disability, disease severity and mortality (M ikuls 2003).
CoapMcatious of Rhearaatoid Arthritis
Skin Thinning 
In feet bn
Systemic Vasculitis 
Rheumatoid Nodules 
Lung Disease/In feet bn  
Renal Amy b b o s  is 
Anaemia 
Cataract 
Osteoporosis 
Psoriasis
Myocardial Infarctbn 
Congestive Heart Failure 
Stroke
Peril ipheral Vascular Diseases
Leukaemia
Skin Cancer
Table IJ . Extra-Articular Features of RA.
Many RA-associated co-m orbidities have been identified, o f  which, a significant 
proportion are related to CVD. Such diseases are now recognised as being m ajor 
contributors to the increased mortality rate am ong this patient cohort (Voskuyl 2006; 
Turesson, Jacobsson et al. 2008) and are responsible for one-third to one-half o f  all RA- 
related deaths (Reilly, Cosh et al. 1990). Cardiovascular events on average occur a 
decade earlier in RA patients than in the general population in the absence o f  traditional 
cardiovascular risk factors (Goodson 2002; Mikuls 2003; Kaplan 2006; Turesson and 
Matteson 2007). Indeed it is now commonly perceived that RA alone is an independent
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risk factor for the developm ent o f CVD events (M ontecucco and Mach 2009). Such 
manifestations include pericarditis, myocarditis, cardiac amyloidosis, coronary 
vasculitis, arrhythmia, valve diseases, congestive heart failure (Voskuyl 2006) and 
coronary calcification (Chung, Oeser et al. 2005). Suggested explanations for the CVD- 
related morbidity and mortality include:
•  Secondary effects o f physical inactivity due to the sedentary lifestyle led by 
RA patients,
•  Drugs used in the management o f  disease (Turesson and Matteson 2007),
•  The direct impact o f  the systemic inflam m atory load (Sattar and M clnnes
2005).
These are discussed below, however it is the general consensus amongst the literature 
that (1) and (2), cannot explain the stark increase in risk without the presence o f (3).
1 J .l. Physical Inactivity
In the general population, lack o f  exercise has a m ajor impact on the likely development 
o f CVD, and an increase in physical activity has been shown to improve the mortality 
rate for patients with CVD in the W estern W orld (Gielen, Sandri et al. 2009). M oreover 
there is significant evidence that in “at risk” populations, exercise benefits the patient by 
reducing cholesterol, dyslipidaemia, hypertension (M etsios, Stavropoulos-Kalinoglou et 
al. 2008), and possibly reducing inflammation (Kasapis and Thompson 2005). It is 
logical therefore that the immobility that RA can impose on the affected individuals 
leads to a greater risk o f  developing CVD. However, given the multifactorial nature o f  
both RA and CVD it would be far too simplistic to suggest that lack o f exercise/mobility 
alone could account for the reduced life expectancy.
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13 .2. Drugs Used in Management of RA
1 J.2.1. Current Therapies for RA
The current therapies used to treat RA can be divided into three broad spectrum groups; 
non-steroidal anti-inflam m atory drugs (NSAIDS), disease modifying anti-rheum atic 
drugs (DM ARDS) and biological therapies. W hile these drugs variously m anage pain 
and/or inflammation, some have unwanted side-effects that arc detrimental to organs and 
tissues, including the vasculature (see table 1.4).
DRUG MECHANISM OF ACTION EXAMPLE SIDE EFFECTS
NSAIDS
Broad inhibition of COX 
isoferms preventing synthesis 
of eicosanoids Results in pom 
relief and is antMndammatory
Paracetamol, ibuproien. 
(fdofenac Gastric bleeding and ulceration
COXIBS
Specttc inhibition of COX-2 
preventing synthesis of COX-2 
product Analgesic and anb- 
mlammatory
Celecoxib. rofecoxib
Can have canfovascular side affects due 
to increased amounts of thromboxane, 
and decreased amounts of prostacyclin 
leads to a prothrombobc environment
OMARDS
Moctfy diseasa progression by 
suppressing dmeaea activity 
and reducing joint damage Is 
anb-proMerabve and an 
imrmmoeuppreesant
Methotrexate
Can increase homocysteine levels in the 
serum and cause subsequent vessel 
damage.
■OLOGICAL
THERAPIES
Work by inhibiting various 
cytokine pathways
HHximab, etanercept.
adaNmumab (anb-TNF), 
anakinra (antML-1), rituximab 
(anb-B-ceN)
Infection, irritation at injection site, 
cancer, immune diseases. May promote 
atherogenesisand has been shovm to 
exacerbate existing CVD-related 
problems.
Table 1.4. Therapies Used for Treatment of RA. Summary of the Drugs used in the treatment of RA, 
their mechanism of action and possible side-effects.
13 2 .2. NSAIDS
NSAIDS act by inhibiting cyclooxygenase (COX) enzymes, the key enzym es 
responsible for the formation o f  eicosanoids from arachidonic acid. The eicosanoids 
produced encompass a sub-class called prostanoids, several o f which play im portant 
roles in the vasculature (see table 1.5).
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Prostanoid Function
Prostaglandin E2 Vasodilator
Prostacyclin Vasodilator
Thromboxane A2 Prothrombotic,
Vasoconstrictor
Table 1.5. Important Prostanoids in the Vasculature.
The eicosanoids produced by COX are potent m ediators o f  inflammation and produce 
oedema, pain and vasodilation. Blocking production o f  these PGs is associated with 
analgesia and a reduction in inflammation (Green 2001), hence their w idespread use in 
RA treatment. There arc two isoforms o f  COX; the constitutively expressed COX-1 
found in most tissues including vascular endothelium , stomach mucosa and kidneys 
(Mitchell and W arner 1999), and the inducible COX-2 induced in inflam m atory cells 
after stimulation by inflammatory cytokines (Grosser, Fries et al. 2006; G luszko and 
Bielinska 2009) and is largely responsible for inflammation and hyperalgesia (M am ett 
and Kalgutkar 1999).
The prostanoids produced by COX-1 play a role in gastric protection [50] and therefore 
broad spectrum inhibition has detrimental effects on gastric function. Due to this, COX- 
2 specific inhibitors (COXIBs) were produced which had a positive effect, halving the 
incidence o f  gastric side effects (Capone, Tacconelli et al. 2003). However these drugs 
are not without problems and have now been linked to an increased risk o f  
cardiovascular events (M oodley 2008), probably due to the developm ent o f  an 
imbalance between throm boxane and prostacyclin production. G iven that these 
prostanoids have pharm acologically opposing actions, thromboxane being a potent 
platelet aggregator and vasoconstrictor, and prostacyclin being an inhibitor o f  platelet 
aggregation and a potent vasodilator, COXIBS decrease the release o f prostacyclin and 
can therefore result in a disruption between pro- and anti-thrombotic prostanoids 
favouring a pro-throm botic environment. This promotes thrombosis and subsequent
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CVD events (M ikuls 2003). In addition any underlying vascular problems could be 
exacerbated by the use o f  these drugs.
1 3 .2 3 . DM ARDS
DMARDs act to modify the progression o f  RA by suppressing disease activity and 
reducing joint damage. O f this group the most popular and commonly used agent is 
methotrexate (M TX). This drug acts in an anti-proliferative and immunosuppressive 
manner, decreasing cell proliferation and increasing cell apoptosis, cytokine production, 
bone formation and adhesion molecule expression (W essels, Huizinga et al. 2008; Braun 
and Rau 2009).
With respect to cardiovascular-related problems, DM ARDs can have protective effects. 
It has been observed that use o f  these drugs has a positive effect on the lipid profile o f 
RA patients. Norm ally in early RA disease a higher low density lipoprotein (LDL) to 
high density lipoprotein (HDL) ratio manifests, predisposing patients to a risk for 
atherosclerosis. In a study where general DM ARDs were used, often in combination 
therapy (with other drugs such as corticosteroids), this ratio can be lowered, reducing the 
CVD risk (Park, Choi et al. 2002). Epidemiological studies have also indicated that 
MTX can provide a substantial survival benefit for the patients, largely by lowering 
cardiovascular m ortality (Choi, Heman et al. 2002). A review o f the literature reaffirms 
this (Salliot and van der Heijde 2009).
Contrastingly however, MTX has been associated with an increase in cardiovascular risk 
due to its use being associated with an increase in serum levels o f  homocysteine. 
Elevated plasm a hom ocysteine is related to CVD and is a recognised risk factor for 
thrombosis (Desouza, Keebler et al. 2002; Lonn, Y usuf et al. 2006), and so could 
possibly exacerbate existing problems or cause further damage in the vasculature. The 
deleterious m echanism o f  action o f  hom ocysteine is still a controversial topic o f 
research. However a significant role in endothelial damage via oxidative stress and the
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subsequent promotion o f atherosclerosis is the most widely accepted (W elch and 
Loscalzo 1998).
13.2.4. Biological Therapies
Biological therapies have been developed and are a direct result o f the clearer 
understanding behind disease mechanism. They encompass a wide range o f drugs which 
act by inhibiting specific cytokines/inflam m atory cells within the inflammatory 
pathways (sec table 1.6).
Drug Action
leflunomide Inhibits Pyrimidine Synthesis
Etanercept Binds TNF-a and TNF-0
Adalimumab Human anti-TNF-a antibody
Infliximab Chimeric anti-TNF-a antibody
Anakinra lnterteukin-1 receptor antagonist.
Table 1.6. Biological Therapies in RA.
A popular drug used within this cohort is the anti TN F-a therapy; examples o f this are 
etanercept, inflixim ab and adalimumab which all interact with TN Fa signalling.
With respect to anti-TN Fa therapy safety, initial reports were positive and encouraging. 
The post-m arketing data on the drug reassured its safety, reporting that after five years 
o f clinical use there was generally excellent tolerance (Day 2002). However wider use o f  
these various biological therapies has lead to the discovery o f  a broad spectrum o f side 
effects including infections, cancer, immune diseases, malignant disease, injection site 
irritation and heart failure (Olsen and Stein 2004). Additionally there has since been 
negative data reporting that TN F-a antagonists could exacerbate existing cardiovascular
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problems (Kwon, Cote et al. 2003). W ith regard to RA, recent evidence supports that 
such anti-TNFa therapy does not completely suppress inflammation and can indeed 
promote atherogcnesis (Cuchacovich and Espinoza 2009).
Use o f these therapies can increase the risk for developing or exacerbating existing 
cardiovascular problems. However the inflammatory burden on these patients is huge 
and is the main cause for the developm ent o f  dysfunction/CVD-related problem s. The 
interactions between the traditional and disease-related risk factors with respect to CVD 
development are complex and therefore any therapy administered should take into 
consideration the risks and benefits to the patient (Hall and Dalbeth 2005).
1JJ. Inflammatory Load
Much attention has been paid to the chronic inflammation experienced in RA and the 
subsequent systemic damage this wages on the rest o f the body. Importantly, 
considerable evidence also exists to support the role o f  inflammation in the pathogenesis 
o f atherosclerosis and CVD in general.
It is widely suggested within the literature that atherosclerosis and CVD are both true 
inflammatory disorders with the latter sharing a common pathology with synovitis and 
pannus formation (M ikuls 2003). This has progressed into the hypothesis that 
inflammatory mediators characteristic o f  RA become systemic and in doing so exert 
their effects at extra-articular regions within the rheumatoid patient (K aplan 2006). This 
is shown not only in cardiovascular-related problems but also through a higher incidence 
of lung problems, the developm ent o f  Reynauds phenomenon and pleuritis, all prim e 
examples o f  systemic extra-articular problems (Y oung and Koduri 2007).
Although several factors contribute to the high risk o f  CVD, systemic inflam m ation is 
the most influential. The sequence o f  events that lead to inflam m ation in RA is 
mimicked by events that occur in the vasculature. However to appreciate the dam age
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this could exert on the vessel it is first important to understand the structure and function 
of the healthy vasculature.
1.4. Vascular Function
1.4.1. Normal Structure and Function of the Arteries
Blood is ejected from the left ventricle o f  the heart into the aorta thus supplying organs 
and tissues o f  the body with oxygen and essential nutrients. Due to the regular pum ping 
of the heart the arteries must be able to withstand high pressures, and as such have thick 
muscular walls rich in elastin and collagen, im portant for maintaining both vascular 
compliance and the elasticity o f the vessel (Rang H P 2003) (see figure 1.2).
1.4.1.1. The Tunica Intima
The tunica intima, the innermost layer o f  the artery, is comprised o f  a single layer o f  
endothelial cells supported by an underlying internal elastic lamina. The endothelial 
cells form an interface between the circulating blood and the cells o f the vasculature 
through which nutrients can pass. Changes in local stimuli (eg an increase in pressure 
resulting in shear stress, or a change in humoral substances) affect endothelial cells, and 
in response these cells are able to alter their structure by secreting potent vasodilators or 
constrictors in order to maintain vascular tone (Bell, Johns et al. 1998). The endothelium  
is also important in vessel relaxation and protection as these cells are the prim ary 
producers o f  the potent vaso-dilator and -protector, nitric oxide (NO) (Forstermann and 
Munzel 2006). The endothelium is attached to a connective tissue bed containing 
basement membrane and ECM molecules. The supporting internal elastic lamina 
consists o f  a band o f  elastic tissue separating the intima from the tunica media (Ratcliffe 
2000).
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Figure 1.2. Simplified Structure of an Artery.
1.4.1.2. The Tunica Media
The tunica media consists o f a dense population o f  vascular smooth muscle cells 
(VSMCs) arranged concentrically with additional bands o f  elastin fibers between the 
layers. These cells contain the contractile filaments myosin and actin which allow the 
cells to constrict providing vessel resistance. Constriction occurs following a change in 
intracellular calcium (Ca2 ) levels and subsequent downstream phosphorylation cascades 
(sec below) (Hirano 2007).
1.4.1.3. The Adventitia
The external clastic lamina separates the media from the adventitia; an area rich in 
collagenous ECM molecules which also contains fibroblasts, blood vessels and nerves. 
The combination o f  the layers add rigidity to the vessel and provides elasticity, tensile 
stiffness and the ability to withstand compression (Ratcliffe 2000).
1.4.2. V asc u la r  S m ooth  M uscle C o n str ic tio n
VSMC constriction is mediated via an initial increase in intracellular Ca2 levels (see 
figure 1.3). The initial stimulus for this rise is the binding o f  a specific agonist (such as
noradrenaline, adrenaline, endothelin-1, serotonin, angiotensin II, phenylephrine etc.) to 
its G-protein coupled receptor (GPCR). Subsequently, phospholipase C (PLC), an 
enzyme specific for the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2), is 
activated resulting in cleavage o f PIP2 and the production o f the secondary messengers 
inositol phosphate (IP3) and diacylglycerol (DAG). IP3 migrates to the sarcoplasmic 
reticulum (SR) and binds to specific 1P3 receptors thus releasing intracellular Ca2* from 
the SR into the cytoplasm  (Somlyo and Somlyo 1994; W ebb 2003; Dale M. M 2004).
■) t 2+ 2+
The increase in cytoplasm ic Ca‘ triggers the formation o f the Ca -calmodulin (Ca 
/CaM) com plex, capable o f activating myosin light chain (M LC) kinase (MLCK) which 
subsequently phosphorylates MLC. This activates myosin ATPase and results in cross- 
bridge cycling and contraction. The termination o f  the signal reduces the intracellular 
Ca2* and thus decreases the activity o f MLCK. Subsequently MLC is dephosphorylated 
by MLC phosphatase (M LCP) and relaxation ensues (Hirano 2007).
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Figure 1.3. Regulation of SMC' C onstriction Agonists interact with their specific GPC R to promote 
contraction. Subsequent to this binding, intracellular levels of PLC arc increased promoting formation of 
IP3 and DAG. IP3 then binds to surface receptors on the SR and triggers the release of Ca2* from 
intracellular stores. This promotes formation of the Ca2*/C'aM complex which activates MLC kinase 
causing phosphorylation of MLC. Additionally the rise in intracellular calcium and the binding of agonists 
to their specific receptor can result in the conversion of GDP bound RhoA to GTP bound RhoA. This 
activates Rho kinase which phosphorylates MLCP rendering it inactive and unable to dephosphorylate 
MLC. maintaining contraction. Protein kinase G (PKG) antagonises the effect of Rho kinase resulting in 
active MLCP. which subsequently dephosphorylates MLC and the cell relaxes.
Once phosphorylated MLC has an increased sensitivity to intracellular Ca2+. This is due 
to a change in the Ca27tcnsion relationship and allows for a high level o f constriction to 
be maintained with less C a’2 present (high levels o f Ca*2 are toxic to the cell). The exact 
mechanism behind this is not fully elucidated but is thought to be regulated by the level 
of MLC phosphory lation (Hirano 2007). MLCP can only dephosphorylate MLC when 
accompanied by correct sub-units, one o f  which is the regulatory sub-unit, MYPT1. 
MYPT1 allows the correct configuration o f  the enzyme, increasing its specificity for 
MLC and can inhibit these interactions by becoming phosphory lated which prevents the 
necessary contact between MLCP and MLC (Hirano 2007). This is another way in 
which contraction is regulated within the VSMC.
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The RhoA Rho kinase pathway is the most extensively studied with regard to MLCP 
inhibition. GPCR stimulation leads to activation o f  Rho guanine exchange factors 
(GEFs) which result in the change o f the inactive GDP (guanosine diphosphate) bound 
Rho A to the active RhoA-GTP (guanosine triphosphate). This is able to then bind and 
activate Rho kinase, which phosphorylates M YPTl inhibiting MLCP activity (Sakurada, 
Takuwa et al. 2003; Hirano 2007; Wang, Zheng et al. 2009) (see figures 1.3, 1.4) and 
causing increased calcium sensitivity o f the contractile filaments (Gao, Portugal et al. 
2007). This pathway has been shown to be sensitive to intracellular Ca*2 levels with 
removal o f Ca ‘ decreasing the amount o f GTP bound RhoA, although the exact 
mechanism behind this is not known (Sakurada, Takuwa et al. 2003). This means that 
under slightly increased levels o f  intracellular Ca*2 (which occur after VSMC 
stimulation) contraction can be sustained.
CONTRACTION RELAXATION
MLCMLC
MLCP
MYPT
Rho KinaseRhoA-GTP
MLCP
MYPT
Figure 1.4. Regulation of MLC Phosphorylation Rho kinase phosphorylates the regulatory MYPT sub­
unit of MLCP rendering it unable to dephosphorylate MLC. This sustains contraction.
34
1.4.2.1. VSIMC depolarisation
Additionally there are two different membrane channels which can affect intracellular 
Ca 2 concentrations; the voltage-gated calcium channels or receptor-operated calcium 
channels. The form er are opened when the cell membrane becomes depolarised, for 
instance following exposure to a high potassium concentration, allowing the influx o f 
extracellular C a’: into the cell resulting in constriction (Rang H.P 2003; Catterall, Perez- 
Reyes et al. 2005). Similarly receptor-activated Ca*2 channels are opened following 
agonist stim ulation with the same end result.
1.4.2.2. Endothelin
Constriction can also occur via the action o f  endothelin (ET), o f which there are three 
isoforms, ET-1, ET-2 and ET-3. ET-1 is expressed constitutively in endothelial cells and 
plays a role in vascular homeostasis (Pollock, Keith et al. 1995). ET1 binds to ETA and 
ETB receptors on VSM Cs to exert vasoconstriction and ETB receptors on endothelial 
cells to produce NO and subsequent vasodilation. (Dashwood and Tsui 2002). in the 
vascular system ET-1 behaves as a potent vasoconstrictor and can also produce other 
vasoactive m olecules such as prostcyclin (PGI2) and NO which may regulate its actions 
via their opposing vasodilatory function (Dashwood and Tsui 2002).
1.42J. Angiotensin II
Angiotensin 11 (Ang II), produced as part o f  the angiotensin-renin system, plays a 
significant role in vascular homeostasis and is a m ajor target for blood pressure lowering 
drugs. It is formed following a series o f  proteolytic cleavages o f angiotensinogen to 
angiotensin I (A ng I) by renin, and subsequent cleavage o f Ang I to Ang II by 
angiotensin converting enzym e (ACE), the latter being found on endothelial cells. Ang 
II exerts its effects when it binds to its specific GPCR (de Gasparo, Catt et al. 2000) and 
stimulates activation o f  the PLC and IP3 pathway raising intracellular Ca+2 levels and 
eventually resulting in activation o f MLCK and subsequent contraction. Its
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physiological role is to maintain vascular hom eostasis via vasoconstriction-induced 
blood pressure control, and control o f intracellular Ca*2 levels (de Gasparo, Catt et al. 
2000; Do, Kim et al. 2009).
1.43. Endothelium-Dependent Relaxation
In normal conditions the endothelium behaves in a protective m anner and exerts anti­
thrombotic, anti-inflam m atory and anti-atherosclerotic effects (Ignarro and Napoli 2004) 
through fibrinolytic and anti-platelet mechanisms. This is achieved via release o f the 
vasoprotectivc m olecules PGI: and NO, the latter being able to regulate leukocyte 
adhesion, cytokine expression, VSMC proliferation/m igration and platelet aggregation 
(Hetzcl, Ballctshofer et al. 2005). Healthy endothelial cells undergo continual repair in 
response to mechanical and chemical injuries, crucial for homeostasis (Lerman and 
Zeiher 2005) and help in preventing the developm ent o f  thrombosis (Kirkpatrick, 
W agner e ta l. 1997)
1.43.1. Nitric Oxide
In 1980 Furchgott and Zawadzki made the observation that vessel relaxation via 
acetylcholine (ACh) was dependent on the presence o f intact functional endothelial 
cells. This was discovered by assessing vascular responses to ACh in isolated rabbit 
thoracic aorta. This work indicated that the action o f ACh on muscarinic receptors 
stimulated the release o f a vasodilator substance, then named endothelial-derived 
relaxing factor (EDRF) (Furchgott and Zawadzki 1980). Following many observations 
that EDRF shared several similarities to NO in terms o f  its mechanism o f action, in 1987 
the identity o f  EDRF as NO was confirmed (for a more detailed review o f  the decade o f  
discoveries surrounding NO see (Stuart-Sm ith 2002).
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1.4J.2. Nitric Oxide Production
NO is produced via the action o f  nitric oxide synthase (NOS). There are three isoforms 
of NOS; the two constitutively expressed isoforms, neuronal NOS (nNOS) and 
endothelial NOS (eNOS) and the endotoxin- and cytokine-inducible NOS (iNOS) 
(O'Shaughnessy, Vctsika et al. 2006).
1.433. Structure of NOS
NOS is a hom odim er and utilises both reductase and oxidase properties within different 
structural domains. The C-term inus is the reductase domain and contains the binding 
sites for the co-factors flavin mononucleotide (FM N) flavin adenine dinucleotide (FAD) 
and nicotinamide adenine dinucleotidc phosphate (NADPH). This is linked to the N- 
terminal oxygenase o f  the other monom er, which carries a prosthetic heme group and 
binds 5,6,7,8-tetrahydrobiopterin (BH4) and L-arginine (Forstermann and Munzel 2006; 
Xia, Misra et al. 2009). There is also a C a27CaM  binding site in NOS; binding o f  
Ca2*/CaM to this site initiates electron transfer which ultimately produces NO (W elland, 
Gamaud et al. 2008; Xia, Misra et al. 2009).
1.43.4. Electron Transfer and Production of NO
Electrons are transferred from the reductase dom ain bound NADPH via a mobile FMN 
group, which serves as a one electron donor, to the oxygenase haem group (W elland, 
Gamaud et al. 2008). W hen the electrons reach the haem group they activate and reduce 
oxygen (O 2). This process must occur twice to produce NO. Dimerisation o f  the enzyme 
is essential for the flavin to haem transport as electron transfer occurs from the reductase 
domain o f  one m onom er to the oxygenase dom ain o f  the other (Siddhanta, Presta et al. 
1998) (see figure 1.5)
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REDUCTASE OXIDASE Arginine + O
FMNNADPH Citruline + NO
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Figure 1.5. Structure of NOS. Electrons are shuttled from the reductase terminus of one NOS monomer, 
to the oxidase component of the adjoining monomer via FMN. The electron, upon reaching the haem 
group (Fe) reduces and activates the ()2 molecule producing NO.
1.4.3.5. NO-M ediated Vasorelaxation
An essential initiating step in the production o f  NO is Ca27CaM  complex formation in 
the endothelial cells. This can be induced in response to an agonist binding to a GPCR 
on the cell membrane (for example ACh to muscarinic receptors), or more likely in the 
intact blood vessel in-situ in response to increased shear stress. Binding o f this complex 
to eNOS activates the enzyme thus catalysing the formation o f  NO from L-arginine and 
molecular oxygen (Sullivan and Pollock 2006). This highly lipophilic and reactive 
molecule rapidly diffuses across the plasma membrane and extracellular space from the 
endothelial cells to the VSMCs. Once in the VSMC, NO activates the heme-containing 
target enzyme soluble guanylate cyclase (sGC) resulting in the conversion o f guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) (Bohme, G raf et al. 
1978) and a subsequent increase in the cellular levels o f  this secondary messenger. 
cGMP then activates cGM P-dependent PKG which phosphorylates downstream targets 
(see below) that regulate intracellular levels o f  Ca‘ (Birschmann and Walter 2004). The 
overall result is a reduction in the Ca‘ concentration resulting in smooth muscle 
relaxation (see figure 1.6).
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PKG can phosphoryate MYPT1 at sites adjacent to the phosphoylation site o f Rho 
kinase, exerting opposing actions to Rho kinase and activating the catalytic action of 
MLCP (Lincoln, Dey et al. 2001; Gao, Portugal et al. 2007). This activates MLCP 
resulting in dcpohsphorylation o f MLC and subsequent relaxation. Additionally PKG 
has also been implicated in RhoA-depcndent Ca2+ sensitisation, phosphorylating RhoA 
via cGMP, inhibiting it’s contact with Rho kinase and thus contributing to NO-mediated 
vasodilation (Sauzeau, Le Jeune et al. 20(H)).
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Figure 1.6. Mechanism of SMC Relaxation. Shear stress stimulates a release in calcium from the SR 
promoting formation of the Ca2’/CaM complex. This activates eNOS resulting in production of NO. NO 
diffuses to the VSMC and activates sGC resulting in production o f cGMP and initiating a downstream 
cascade of events, culminating in a decrease in Ca‘* availability and subsequent vessel relaxation.
39
1.4J.6. Prostacyclin (PG I2)
PGI2 is from the family o f  eicoasnoids, and is itse lf a prostaglandin. It is synthesised 
alongside other prostanoids by the conversion o f  arachidonic acid by cyclooxygenase 
(COX) in both the endothelium and VSM Cs but largely by the former. It is a potent 
vasodilator and an inhibitor o f platelet aggregation (Vane and Botting 1995). It induces 
vasodilation via activation o f  adenylate cyclase-coupled GPCR on VSMC and elevation 
of cAMP levels (Vanhoutte 1998). Subsequent activation o f  cAMP-dependent protein 
kinase (protein kinase A, PKA), leads to removal o f  calcium from the cytoplasm and 
thus promotes relaxation.
Both the endothelium  and VSMC work in conjunction to ensure vascular integrity and 
importantly to protect the blood vessels from everyday insults. However in a highly 
inflammatory environm ent, as observed systemically in RA, this protective function can 
become com prom ised and lead to vascular damage. It is such alterations in normal 
vascular function that arc thought to be involved in the genesis and progression o f  CVD 
in RA patients.
1.5. From Rheumatoid Arthritis to Cardiovascular Disease
1.5.1. Similarities between RA and CVD
As mentioned previously cardiovascular-related problem s are a huge burden for patients 
suffering from RA (Turesson, Jacobsson et al. 2008), to the extent that RA is now 
recognised as an independent risk factor for CVD (DeM aria 2002).
There is a large body o f  evidence in the literature supporting a role for inflammation in 
the developm ent o f  CVD in RA. That striking sim ilarities exist between both diseases 
reinforce this hypothesis. For instance the mechanism o f  damage in the synovium is 
paralleled by that which occurs in vascular disease (Pasceri and Yeh 1999; Flammer,
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Sudano et al. 2008). M oreover, the cascade o f  events that lead to atherosclerosis 
resembles stages that also occur in the rheumatoid jo int; T-cell and mast cell activation, 
an increased production o f inflammatory cytokines, and increased expression o f  
leukocyte adhesion m olecules are observed in both cases (Libby 2008) (see table 1.7).
Atherosclerosis Rheumatoid
Arthritis
Macrophage Activation t t
TNF-a t t
MMP Expression t t
IL-6 t t
Mast Cell Activation t t
T-Cell Activation t t
B-Cell Activation t t
Adhesion Molecule Expression t t
Neoangiogenesis t t
Table 1.7. (Jpregulated Processes Shared by RA and CVD.
In both RA and CVD, the secretion o f  proinflam m atory cytokines is increased and the 
subsequent effect o f  this is o f  utmost importance in disease progression. Elevated levels 
are deleterious in the joint, and similar dam aging metabolic effects are exerted in the 
vasculature and can promote atherogenesis (Sattar, M cCarey et al. 2003). 
Atherosclerosis develops into a chronic, systemic and diffuse disease w hich focuses at 
distant and multiple sites in various vascular beds. The mechanism behind the varying 
distribution o f  disease is unknown, but the seem ingly sporadically affected regions have 
led to the hypothesis that the interactions between the vascular wall and circulation are 
the primary cause o f  the damage (Lerman and Zeiher 2005). IL-1, IL-6 and TN F-a are 
notably high in plasma during RA disease and are therefore in prime position to alter the
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function o f distant tissues, the vascular wall being an exam ple o f  this (Sattar, McCarey 
etal. 2003).
Figure 1.7 sum m arises the role o f inflammation in the developm ent o f early vascular 
disease in RA. Elevated levels o f inflammatory cytokines characteristic o f RA could 
elicit vascular changes (Libby 2008), resulting in endothelial dysfunction, now proposed 
to be an early event in the atherogenic process and a novel predictor o f CVD (Sattar and 
Mclnnes 2005).
Endothelial
Dysfunction
R heum atoid
Arthiritis
Cardiovascular
D ise a se
Increased inflammatory cytokines in 
the circulation
Increased inflammatory 
cytokines in the synovium  
(11-1, IL-6, TNF-a)
Endothelial cell dam age  
D ecreased NO production 
Increased superoxide production 
Smooth m uscle proliferation
Flgare 1.7. Hypothesised Progression from RA to CVD.
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1.5.2. Endothelial Dysfunction
Following inappropriate endothelial cell activation (in response to various pathological 
insults) endothelial cell dysfunction ensues. Increased exposure to inflammatory 
cytokines is a prim e example o f  such an insult that induces characteristic changes in 
endothelial function including loss o f vascular integrity, increased expression o f 
leukocyte adhesion molecules such as VCAM and ICAM, phenotypic switch from 
protective to prothrombotic, increased production o f cytokines and subsequent 
upregulation o f  HLA genes and MHC m olecules (Bijl 2003)
Normally endothelial cells do not bind leukocytes, a process inhibited by NO (Hetzel, 
Balletshofer et al. 2005). However in inflammatory situations such as in RA, the 
presence o f  IL-1 and TN Fa can induce production o f  MHC m olecules which are able to 
activate neutrophils and subsequently induce endothelial cell injury (Bratt and Palmblad 
1997). These early changes to the environm ent surrounding the endothelium  cause 
phenotypic changes, including the production o f leukocyte adhesion m olecules and 
chemokines which attract m ononuclear cells to the vessel wall. The adhesion molecules 
facilitate the binding o f  monocytes to the endothelium  which results in the w idening o f  
intracellular spaces between the endothelial cells. This induces increased endothelial 
permeability allowing the movement o f  leukocytes from the lumen into the sub- 
endothelial space and arterial intima. Such cell m igration provides the stim ulus for the 
initiation and progression o f  inflammation within the arterial wall itse lf (Libby 2008). 
The now injured endothelium  also has increased susceptibility to other insults resulting 
in an exaggerated response to the classical risk factors (Bacon, Stevens et al. 2002) such 
as smoking. Once monocytes have migrated into the intima, they differentiate into 
macrophages where they encounter modified lipids. These modified lipids are a result o f 
oxidation o f HDL and LDL by ROS in the blood and can be engulfed by m acrophages 
forming “foam cells” . This represents the initial stage in the production o f  a fatty streak 
(Carter 2005), a significant precursor to chronic disease. With respect to RA the key step
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in this sequence o f  events is the initial insult followed by endothelial activation and 
dysfunction.
A significant consequence o f endothelial cell activation and dysfunction is impaired 
endothelium-dependent relaxation. This is a key issue in the advancem ent o f  disease, 
and while largely due to a decrease in the bioavailability o f endothelium -derived NO 
(Kawashima and Yokoyama 2004; Hetzel, Balletshofer et al. 2005), decreased synthesis 
of prostacyclin (Simionescu 2007) has also been reported. G iven that a large body o f 
literature suggests that CVD in RA patients may be associated w ith endothelial 
dysfunction, the m echanism (s) underlying that underlie this process w arrant further 
investigation.
l i J .  Endothelial Nitric Oxide Synthase Dysfunction
While the development o f  endothelial dysfunction is norm ally associated with a 
reduction in bioavailablc NO (K awashim a and Yokoyama 2004; Hetzel, Balletshofer et 
al. 2005), the latter may have various origins, for instance a decrease in 
expression/activation o f  eNOS. Indeed this has been dem onstrated in a pig model o f 
physical endothelial injury by denudation (Lee, Tse et al. 2007) where significantly 
lower concentrations o f eNOS were evident in subsequently isolated and cultured 
regenerated endothelial cells com pared to native cells, and therefore less bioavailable 
NO.
Studies have also dem onstrated that a decrease in functional eNOS is associated w ith the 
production o f  superoxide (*02-) (Rabelink and Luscher 2006), a significant contributor 
to the pathogenesis o f endothelial dysfunction. Under norm al conditions eNOS 
catalyses the formation o f  NO and L-arginine (see section 1.4.3), how ever due to the 
high redox potential o f  the enzym e it has the ability to produce #0 2 - and due to the 
electron transfer across the eNOS dimer is normally tightly controlled (Forsterm ann
2006). If the movement o f  electrons to L-arginine and m olecular O 2 becomes
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dysregulated, for instance in the absence o f  BH4 or other co-factors (see figure 1.8) 
(Gross and Levi 1992; Forstermann and Munzel 2006; R abelink and Luscher 2006) 
electrical “uncoupling" o f eNOS can lead to the production o f  dam aging *02- anions 
instead o f NO, thus promoting oxidative stress. Importantly, uncoupled eNOS has been 
identified as a risk factor for athrerosclerosis (Rabelink and Luscher 2006) as it is 
observed as a result o f  smoking, high blood pressure and other traditional risk factors 
(Forstermann and Munzel 2006).
The result o f  this uncoupling is an overall decreased production/bioavailibility o f NO 
and subsequent removal o f vascular protection. M oreover, *02- reacts very rapidly with 
any residual (or perhaps iNOS-dcrived) NO producing peroxynitrite (ONOO). This 
molecule is extrem ely harmful to the cells o f  the vasculature (Forsterm ann and Munzel 
2006; Sullivan and Pollock 2006) causing oxidative dam age to proteins, lipids and DNA 
(Beckman 1996) and exacerbating endothelial dysfunction. Interestingly, recent studies 
indicate that peroxynitrite may also have a deleterious effect on prostacyclin synthase 
(Zou and Ullrich 1996) thus also removing the protective benefits o f  this molecule.
Other reactive oxygen species which are not so rapidly broken down are products o f 
•O2- metabolism such as hydrogen peroxide and hypochlorous acid, both possessing 
oxidizing capabilties and therefore contributing further to oxidative stress in the vascular 
tissue (Munzel, Daiber et al. 2005). M oreover it has been suggested that once vessels are 
subjected to oxidative stress, the dysfunctional eNOS becom es further upregulated 
(Hink, Li et al. 2001). This therefore contributes to added dam age and dysregulation, 
exacerbating the proinflam m atory environm ent o f  the tissue, rem oving the protective 
molecules and increasing endothelial/vascular dysfunction.
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Figure 1.8. eNOS I ncoupling eNOS uncoupling due to unavailability o f the essential cofactors results in 
production of supcroxide and a decrease in the natural protective mechanisms o f the endothelial cells.
Hypotheses surrounding the development o f CVD in RA centre largely on endothelial 
dysfunction, and in particular the uncoupling o f eNOS and as such, experimental 
evidence exists in support o f this (Haruna, Morita et al. 2006). This is thought to arise 
following insult to the endothelium by inflammatory cytokines characteristic o f  RA. 
However problems that arise within the vasculature are norm ally m ultifactorial and 
other underlying changes to the structure and function o f  cells w ithin the vessel wall can 
occur after an initial damaging insult. This could result in other changes that are 
deleterious to function.
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1.5.4. Changes to Smooth Muscle Cell Function
I.5.4.I. Phenotypic Switching
Many vascular diseases are characterised by intimal hyperplasia; the proliferation of 
SMCs within the intimal layer o f the arteries and an additional increase in the volume o f 
extracellular matrix proteins within the vessel wall (Newby and Zaltsman 2000). Under 
normal conditions the VSM Cs exhibit a quiescent contractile phenotype with a low level 
of proliferation, serv ing to maintain vascular tone by playing a role in contraction and 
expressing contractile proteins (Owens 1995) (see figure 1.9). It is thought that 
inhibitory actions derived from ccll-matrix interactions between basement membrane 
components, cell surface intcgrins and soluble m ediators maintain the quiescent state 
(Thyberg, Blomgrcn et al. 1997).
In response to injury VSM Cs rapidly increase their rate o f proliferation and migration 
(from the media to the intima) and additionally start to play a critical role in vessel 
repair. This is similar to the phenotype expressed during development and is regarded as 
a “synthetic phenotype” (Owens, Kumar et al. 2004). The result o f this phenotypic 
switching is to produce a thickening o f  the arterial wall, thus eventually narrowing the 
vessel lumen (see figure 1.9). It is important to note that there are many varying 
phenotypes, other than those mentioned above, which can be seen throughout cell 
maturation as well as disease progression. For exam ple during development there will be 
differential expression o f various proteins over time to achieve the fully functioning 
adult cell. However the two definitions described help to establish the alteration o f 
VSMC from the normal function with respect to vascular changes without confusing 
other intermediate phenotypes the cells may exhibit at various times. The change in this 
vascular phenotype is important in the developm ent and progression o f  many diseases 
including hypertension and atherosclerosis. Additionally it has been observed that in 
patients with RA intimal-mcdia thickening is comm onplace and correlates directly with
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disease severity and moreover often is a predictor for the development o f atherosclerotic 
plaques (for a recent review see (Tanasescu, Jurcut et al. 2009)).
Elastin
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Vascular Smooth 
Muscle Cells
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Endothelial Cells
Lumen
Intima
Media
Intima
Media
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Oxidised Lipids 
0  IL-1.TNFa.M M Ps
Figure 1.9. Change* to the Vasculature and Intimal Thickening. A. Normal structure of the vessel 
showing the intima and media. B. Inflammation in the vessel. Inflammatory mediators such as IL-1, TNFa 
and MMPs are present in the layers of the vessel. VSMCs, endothelial cells, and foam cells (FCs) are 
activated promoting proliferation and migration of VSMCs. These move from the media into the intima.
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Phenotypic switching is a complex process, and is regulated by a variety o f factors 
present in the circulation such as cytokines, chem okines, inflammatory mediators, lipids 
and reactive oxygen species (ROS) (Owens, Kumar et al. 2004). Physical factors such as 
mechanical stretch, a result o f  the high pulsatile force o f  the blood that the vessel is 
exposed to (Shyu 2009), can also induce changes within the VSMC that affect cell 
alignment, cell differentiation, migration and vascular remodelling. VSMC phenotype is 
also regulated by cell-cell and cell-matrix contacts. It must be noted that intimal 
thickening is a multifactorial process with migration o f other cell types to the vessel wall 
(Bayes-Genis, Campbell et al. 2002).
Chronic inflammation can play a role in this process by disrupting normal vessel 
function. Leukocytes secrete inflammatory m ediators causing damage and influencing 
cells elsewhere to further produce cytokines and chemokines. These can assist in cell 
activation and proliferation and as such, the actions o f  leukocytes are widespread 
(Singer, Salinthone et al. 2004).
The cytokines produced by inflam m atory cells can have additional detrimental effects 
on vessel function; TN Fa and IL-1 can both prom ote smooth muscle proliferation and 
ECM remodelling (W ills, Thom pson et al. 1996), confirmed through extensive 
experimental investigations. M oreover with regard to the progression o f vessel damage, 
these cytokines can stimulate adherence o f  LDL to the endothelium and VSMCs (Ross 
1999) propagating further harm. With respect to VSM C proliferation, Rectenwald et al 
(2000) conducted a series o f experim ents investigating neo-intimal hyperplasia 
following vessel injury. Here it was observed that mice lacking functional TNFa, and in 
a separate experiment, mice lacking the IL-1 receptor, both failed to produce intimal 
thickening as observed in their control counterparts (Rectenwald, M oldawer et al. 2000), 
indicating a key role for these cytokines in the progression o f this anomalie. 
Furthermore, other animal studies have confirmed the positive role cytokines can play in 
the development o f  vessel disease, observing that in an IL-1 knockout mouse model, 
atherosclerosis progression is notably reduced (Hoge and Amar 2006). Moreover, the
49
inflammatory effects o f  these cytokines are not limited to inducing changes to VSM Cs 
only. For example IL-1 also acts as a growth factor for fibroblasts and lym phocytes, and 
can activate T- and B- cells (Libby, W arner et al. 1988) which can all exert a dam aging 
effect in the vessel wall.
Another contributor to damage is the production o f »02- by inflam m ation-activated 
monocytes (Peri, Chiaffarino et al. 1990). This not only causes endothelial dysfunction 
(see 1.5.3) but can also contribute to damage to the VSM Cs alongside that caused by 
inflammatory cytokines and growth and chemotactic factors also produced by these cells 
under inflammation (Assoian, Flcurdelys et al. 1987).
In addition to inflammation there are also extracellular structural changes in the vessel 
wall which can affect VSMC function and proliferation. These are novel pathw ays and 
are not entirely characterised, but have the potential to lead to exciting new 
developments in this field.
An example o f  this is the cadherin family o f  proteins which form extracellu lar cell-cell 
contacts. This is discussed in more detail in subsequent chapters. B riefly, when these 
contacts become com prom ised it is thought to have an effect on dow nstream  signalling 
cascades which can result in changed protein expression. Experim ental work has shown 
that a change in the structure, or cleavage o f  the extracellular com ponent o f  these 
molecules can result in VSMC proliferation. In one case a reduction in the am ount o f  N- 
cadherin on the VSMC membrane was observed following stim ulation o f  cultured 
VSMCs with platelet derived growth factor (PDGF), a change which was attributed to 
the proteolytic activity o f  M MP and resulted in disruption o f  cell-cell contacts. These 
observations occurred during VSMC proliferation highlighting a role for M M Ps in this 
change (Uglow, Slater et al. 2003).
The MMP family o f proteins is a group o f  enzymes involved in extracellu lar m atrix 
remodelling and is thought to be heavily involved in structural dam age to the vessel wall
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(Raffetto and Khalil 2008). Specific M MPs have been shown to p lay  an im portant role 
incadherin signalling as well as partaking in extracellular rem odelling (Uglow, S later et 
a l 2003). It is known that throughout the inflammation in RA there is an increase in the 
expression o f MMPs both locally in the synovial fluid, and also in the serum o f  these 
patients (Tchetvcrikov, Ronday et al. 2004). Hypothetically this increase could have a 
detrimental effect on the vasculature causing cadhcrin shedding or other dam aging 
changes, and could possibly stimulate the proliferation o f V SM Cs and prom ote 
subsequent intimal hyperplasia.
1.6. Matrix M etalloproteinases
An important group o f  cn /ym cs that would seem to be com m on denom inators in the 
pathogenesis o f RA and cardiovascular-related diseases are the M MPs. These are a 
family o f  proteolytic enzym es capable o f  degrading and rem odelling the ECM  and 
connective tissue proteins (Raffetto and Khalil 2008). They are essential in biological 
processes such as embryonic developm ent, morphogenesis, reproduction, tissue 
resorption and remodelling, but also play an im portant role in pathologies such as 
inflammation, CVD, arthritis and cancer (Ram, Sherer et al. 2006). W hile M M Ps are 
mainly found in the extracellular milieu, it has been reported that some are found 
intracellularly (Ganea, Trifan et al. 2007).
While the many MMPs have a variety o f  expression patterns and functions, they are 
classified into subgroups according to their substrates, for exam ple gelatinases, 
stromelysins, and collagenascs (Chow, Cena et al. 2007) (see table 1.8.). M M Ps are 
zinc-dependent endopcptidases and are all synthesised in the latent form o f  the 
molecule, as a pro-M M P or zymogen. They require activation by proteolytic rem oval o f  
a pro-peptide domain before becoming fully functional (Tallant, M arrero et al. 2009). 
This is achieved by removal o f the pro-domain which inteferes w ith the catalytic zinc to 
maintain dormancy (Chow, Cena et al. 2007) -  removal o f  this dom ain exposes the
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catalytic site. This “Cysteine Switch” is a common feature o f all the MMPs (Van Wart 
and Birkedal-Hansen 1990) and is crucial for MMP regulation.
MMP Expression or Function Substrates
Collage naaes
Coiagenase-l/MMP-1 Development, tissue repair, malignant 
tumours
Col LII. II. VII, VII. X aggrecan
Colagenase-2/MMP-8 Leukocytes cartilage Col I. II. HI aggrecan
Colagenase-3/MMP-13 Bone development invasive tumours Col I. H. HI. IV. IX X *V  gelatin, 
fibronectin. lammin. aggrecan
Gelatinases
Gelatmase A/MMP-2 Degradation of basement menbrane and 
of fibnllar coilagens alter intial cleavage 
by collagenases Invasion of malignant 
tumours
Col I. IV. V. VH. X gelatin. Ibronectin.
Geiatinase B. MMP-9 Col IV. V, VH. )Q. W , XVII. gelatin, 
elastin. fibrillin
Matnlysns
Matnlysirvt'MMP-7 Constitutively expressed m ductal 
epithelial cells of exoenne glands
Col IV. elastin fibronectin. lamimn. 
ntdogen. tenascm. osteonectin
Matnlysirv2MMP-26 Uterus, placenta reproductive 
processes
Col IV, gelatin, fibronectin. fibnn. 
fibnnogen. type I gelatin
Stromelysins
Stromelysirv1/MMP-3
Keratinocytes and fbrobfasts
Col IV. V. VH, IX X HV fibronectin. 
elastin gelatin, lammin. aggrecan
Stromefysm-2/MMP-10
Col IV. V. IX X »V fibronectin. elastin. 
gelatin, lamimn. aggrecan
Table 1.8. K.iamplcs of MMP Sub-groups Tabic showing examples of some of the MMP sub-groups, 
their substrates and functions.
1.6.1. G elatinases
Of the many MMPs described above, the gelatinases MMP-2 and MMP-9, (gelatinase-A 
and gelatinase-B respectively) are o f particular importance in disease pathology. These 
enzymes differ in their expression; MMP-2 is expressed constitutively in many cells 
(Salo. Lyons et al. 1991) whereas MMP-9 is induced in inflammatory conditions in 
certain cells (Chakraborti, Mandal et al. 2003), and as such this molecule plays 
important roles in the pathology o f inflammatory disease. As the name would suggest, 
their main substrate is gelatin (a denatured collagen) though a wide range of substrates 
has now been reported (see table. 1.9).
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Substrates for MMP-9
Gelatin 
Elastin 
Fibronectin 
Proteoglycan core protein 
Myelin 
Collagen Type 17 
Collagen Type 11 
Collagen Type 10 
Collagen Type 7 
Collagen Type 5 
Collagen Type 4
Table 1.9. Substrates for \1MP-9.
MMP-9 has several regions within it which allow for correct enzymatic function. The N- 
tenninal signal peptide dom ain directs the pro-M M P to the endoplasmic reticulum 
(Ram, Sherer et al. 2006) in order for it to follow the normal secretory pathw ay 
(Moscana A 2003) before rem oval o f the pro-peptide domain and emzym e activation. 
Other sub-units within the molecule confer specificity for the substrate(s), allow 
cleavage by inhibitors o f  the m olecule, and provide structural support for the enzym e 
(see figure 1.10) (Ram, Sherer et al. 2006).
It is crucial that M M P function is tightly controlled to avoid excess catabolism  o f  the 
ECM and as such, there are several ways in this is achieved; the enzym es can be 
degraded and cleared to remove enzymatic function, or it can be com partm entalised for 
later secretion when appropriate. The cysteine switch, common to all M M Ps is an 
important mechanism for regulation and enzymes which can are able to activate M M Ps 
wil be under further regulation. M oreover transcription o f these proteins can altered to 
increase and decrease gene expression (Chakraborti, Mandal et al. 2003). W ith respect to 
MMP-9, the enzyme is under strict control at gene transcription, synthesis, secretion, 
activation inhibition and glycosylation (Ram, Sherer et al. 2006).
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Catalytic Domain
Contains the catalytic machinery - the zinc 
binefng site, a calcium ion and a 
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Flgare 1.10. Structure of MMP-9. Schematic of the structure of MMP-9 and the function o f the 
individual sub-units.
The gelatinases are under varying levels o f  transcriptional control due to the contrasting 
constitutive and inducible nature o f  the enzymes. MMP-2 is expressed widely in almost 
all cells and is affected minim ally by growth factors and cytokines (Salo, Lyons et al. 
1991), whereas conversely M MP-9 is induced in certain cells under the influence o f  IL- 
ip, TNF-a, PDGF, endothelial growth factor (EGF) (Chakraborti, Mandal et al. 2003), 
and TGF-p (Salo, Lyons et al. 1991). Interestingly growth factors and cytokine have 
been reported to have a synergistic effect on M MP expression emphasising the varying 
control this enzym e is under (Fabunmi, Baker et al. 1996; Bond, Fabunmi et al. 1998). 
Contrastingly neutrophils, which produce M M P-9 during their development, store the 
protein and thus when activated release it via de-granulation (Ram, Sherer et al. 2006). 
These m echanism s allow for varying control and secretion throughout inflammation.
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Gelatinase activity can also be regulated via secretion and activation; M M P-9 like other 
MMPs is secreted as an inactive zymogen, and must be activated by  rem oval o f  a p ro ­
peptide domain. This enables conformational changes resulting in the zinc ion being 
accessed by a hydrolytic w ater molecule and thus activation o f the enzym e can occur. 
Several different protcascs are able to activate MMP-9, for exam ple strom elysin and 
MMP-2. Additionally chem ical mediators and extreme environm ents can also activate 
MMP-9, such as ROS, low pH and changes in temperature (Visse and Nagase 2003). 
Interestingly leukocytes are able to activate M M P-9 via chemical m ediators; neutrophils 
produce hypochloric acid which can activate pro-M M P-9 (Ram, Sherer et al. 2006).
In addition to activation, M M P activity can be hindered by the presence o f  tissue 
inhibitors o f MMPs (TIM PS) (Ganca, Trifan et al. 2007) o f  which there are four (TIM P- 
1, -2, -3 and -4) (Brew, Dinakarpandian et al. 2000). These are secreted alongside 
variable amounts o f MMPs (Van den Steen, Dubois et al. 2002; Ram , Sherer et al. 2006) 
and can inhibit at a 1:1 ratio. The overall structure o f the TIM P m olecule behaves like a 
wedge and is able to fit into the active site o f  the MMP just as the substrate  would. M ost 
TIMPs can inhibit the m ajority o f  M MPs with a few exceptions (V isse and Nagase 
2003). Active M MP-9 is inhibited by both TIMP-1 and TIMP-2 (G ruber, Sorbi et al. 
19%). Naturally occurring antagonists o f  M MPs also exist, such as a2 m acroglobulin 
and plasminogen activator inhibitor (PAI), but the M M P-inactivating ability o f  these is 
limited (Rannou, Francois et al. 2006).
Following translation M M P-9 is regulated in three ways via glycosylation, dim erisation 
and degranulation (see section 1.7.1.2). Primarily M M P-9 is heavily glycosylated w ith 
three possible sites for N-linked glycans assisting with m aintaining the stability o f  the 
protease. Secondly, due to free cysteine residues the enzym e is able to form covalently 
bonded dimers and complexes, used to control activation o f  the enzym e (Van den Steen, 
Dubois et al. 2002; Ram, Sherer et al. 2006). The method o f  granulation prevents release 
of MMP-9 until the cell that stores the MMP-9 itself is activated.
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Id normal tissues, M M P-9 and the TIMPs are in a balance vital for m aintaining 
homeostasis. W hen this balance tips the effect can become deleterious and dam aging to 
cells and tissues. It is important to note that not all M MPs are deleterious in disease, in 
fact in certain circum stances they can be beneficial.
IJLL MMP-9 in RA
There are many studies relating MMP-9 and RA in both humans and animal models o f  
disease. It is widely accepted that this enzyme is upregulated in the jo in ts and is a 
primary cause o f  destruction to cartilage (Yoshihara, N akam ura et al. 2000). M oreover, 
an imbalance between M MP-9 and TIM P has been observed with a decrease in the 
amount o f  TIM P being secreted by the synovial cells o f  RA patients (Jackson, Arkell et 
al. 1998) exacerbating the effect o f MMP-9. This, accompanied with the excess 
activation o f  other degrading enzymes, swiftly contributes to the chain o f  events 
associated with cartilage destruction (Ram, Sherer et al. 2006). Indeed a study 
performed by Itoh et al using a mouse model o f arthritis emphasises the impact M MP-9 
has on the jo ints and dem onstrates that elevated M M P-9 plays a pivotal role in damage 
showing that while arthritis still develops in the absence o f  this enzyme, it takes on a 
significantly m ilder form (Itoh, M atsuda et al. 2002).
In RA MMP-9 is produced by inflammatory cells and inflammatory mediators. Primary 
cellular sources o f  the enzyme are macrophages, osteoclasts, synovial fibroblasts and 
neutrophils, while cytokines such as IL l-0 , TN F-a and interferon-y (IFNy) can promote 
MMP-9 activation and secretion (Van den Steen, Dubois et al. 2002; Tchetverikov, 
Ronday et al. 2004; Chia, Chen et al. 2008; Garvin, Nilsson et al. 2008). A role for 
MMP-9 in RA is supported by the observation o f  a ten fold increase in circulatory 
MMP-9 in patients with RA compared to healthy control patients (Chang, Lin et al. 
2008).
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1.63. MMP-9 and Vascular Disease
MMPs have also been implicated in vascular disease as defects in the synthesis and 
breakdown o f  the ECM are seen as key processes in the development and stability o f 
atherosclerotic plaques (Rodriguez, Orbe et al. 2007). ECM remodelling is maintained 
via a careful balance o f proteases and their inhibitors and disruption can result in 
damage and athcrothrom bosis as shown in figure 1.11 (Rodriguez, Orbe et al. 2007). As 
in RA they are secreted as propeptides and need activation before they are enzymatically 
functional.
Collagen Fibres
Pro-MMP---------------
Thrombin
Plasm in 
Cytokines
Cell Migration/Proliferation Plaque Rupture Neovascularisation
Thrombosis
Figure I.II. Maintenance and Breakdown of the ECM.
MMPs and in particular the gelatinases have been associated with destructive roles 
within the vasculature. Primarily, with regard to plaque formation, they have been seen 
to be essential for the formation o f new blood vessels, contributing to neovascularisation 
of the plaque (M oreno, Purushothaman et al. 2004). As such there is substantial 
evidence in the literature supporting the role that MMPs play in the formation, 
progression and subsequent de-stabilising o f  the atherosclerotic plaque. In addition to
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MMPs there are a plethora o f other proteases which may play a detrimental role at the 
vessel wall however M M Ps will form the main focus o f  this thesis.
MMP-9 has also been associated with other destructive roles resulting in com prom ised 
vessel function. In an animal model o f Kawasaki disease, a disease characterised by 
vasculitis or inflammation o f  middle sized arteries, it was observed that such arterial 
inflammation was associated with MMP-9 upregulation, resulting in breakdown o f  
elastin and subsequent aortic aneurysm (AA) formation (Lau, Duong et al. 2008). 
Although AA is associated with autoimmune diseases, there is no evidence in the 
literature that it is a co-m orbidity o f RA. Despite this, the active role that MMPs play in 
vessel diseases such as AA and atherosclerosis makes investigating the behaviour o f  this 
enzyme o f  high importance. Further supporting this is the observation that MMP-9 has 
been im plicated in the progression o f AA in other diseases. For instance in a m ouse 
model o f  M arfan syndrome, a connective tissue disorder within which thoracic AA is a 
life threatening complication, weakening o f the aortic wall is associated with a loss o f  
vascular compliance. The degeneration o f elastic fiber integrity observed in this m odel 
has been associated with an increased presence o f gelatinases (Chung, Au Yeung et al.
2007) implying they could be responsible for this degeneration. Since elastic fibers 
within the vessel wall are responsible for elasticity, fragmentation o f this structure by 
both M MP-9 and -2 is associated with a deterioration in compliancy and this has been 
proven by appropriate experimental work (Chung, Au Yeung et al. 2007). Importantly it 
has also been observed that MMP-9 and -2 inhibition by doxycyclin (a MMP inhibitor) 
prevents A A in the mouse model o f  this syndrome (Chung, Yang et al. 2008) supplying 
further support for the role o f  MMPs in this process. Additionally, in a knock-out m ouse 
model, M M P-9 gene deletion reduces the formation o f  AA also highlighting the role the 
enzyme plays in this mechanism (Ikonomidis, Barbour et al. 2005). All o f these results 
provide evidence for the deleterious nature o f  M M P-9 in the vessel wall.
Furthermore there have been suggestions that M M P-9 could play a role in the 
modulation o f  aortic contraction. Chew et al 2004 hypothesised as a result o f their work
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in AA, that MMP-9 is upregulated and results in subsequent aortic dilation by inhibiting 
Ca2* mobilisation and influx (Chew, Conte et al. 2004). The decrease in intracellular 
Ca2~ as a result o f this would prevent formation o f the Ca2+/CaM complex and 
subsequent MLCK activation and SMC contraction. This was shown after incubating rat 
tissue in the presence o f  MMP-9 and M MP-2 which prevented vessels reaching and 
m aintaining their maximal constriction. Additionally, alongside this, MMP-9 appeared 
to have an inhibitory effect on KC1 induced constrictions. In this work, the elastin 
structure w as maintained (Chew, Conte et al. 2004), indicating that MMP-9 did not 
damage the ECM in the manner seen in the AA models. An interesting study by Raffetto 
et al 2007 concluded that MMP-2 could potentiate vascular hyperpolarisation in veins 
resulting in vascular relaxation. This is achieved via the Bka Ca2+ channel and 
subsequent blocking o f  the channel halted the MMP-2 effect, suggesting that MMP-2 
may activate the potassium (K ) channels causing lack o f Ca2> influx and thus relaxation 
(Raffetto, Ross et al. 2007).
The evidence above supports various theories for the role that MMP-9 could play in 
vascular damage and the loss of function that ensues. Due to the highly inflammatory 
nature o f  RA it is possible that this could be happening as a direct result o f an increase in 
circulating MMPs and subsequent damage to the vasculature, however more reaserch 
must be done in the RA context to elucidate mechanisms behind this.
In sum m ary, RA is a multifactorial systemic disease, a result o f which is a damaging 
inflam m atory environment within the circulation with detrimental effects upon the rest 
o f  the body. This systemic inflammatory burden results in cardiovascular-related disease 
and a subsequent lower quality o f  life with shortened life expectancy. Little is known 
regarding the pathology behind this and in order to increase our knowledge, significant 
research is underway to determine the mechanisms and key factors involved. To 
facilitate such activity, animal models are widely utilised as valid tools in determining 
underlying mechanisms in such pathologies.
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1.7. Models o f  Rheumatoid Arthritis
There are several models o f  inflammatory arthritis all designed to further the 
understanding o f  disease pathology, some o f  which are discussed in more detail later on 
in this thesis. Defining the molecular and pathological events that lead to the severe 
inflammatory arthritis seen in RA patients is essential and could lead to new approaches 
for controlling the disease.
Despite the fact that none o f  the models are a perfect replica o f the human disease there 
are compelling reasons for the use o f  such representations in the laboratory. C onditions 
surrounding the disease can be tightly controlled allowing for direct com parison o f  
results. Secondly it can be induced with ease, with a high rate o f  incidence perm itting 
straightforward tissue sampling, and thus relatively simple characterisation o f  tissue, 
cellular and molecular mechanisms. Pharmacologically-speaking therapies can be 
administered in tightly regulated doses and blood/tissue responses can be easily 
quantified.
In human RA external factors and person to person variability play a huge role in the 
development and progression o f the disease, and as such, the disease can m anifests itse lf 
in patients in very different ways. This can prove difficult with respect to treating each 
individual, and cause variations in observations made between patients. Therefore w ith 
regard to disease discovery, the simplicity o f  these models is a great benefit for the 
researcher. O f particular interest to this thesis is the murine collagen-induced arthritis 
(mCIA) model, which involves development o f  an inflammatory arthritis in m ice post­
inoculation with type II collagen (CII) in complete Freunds adjuvant.
1.7.1. Murine Collagen-Induced Arthritis
In 1977 Trentham  et al reported in the rat that following immunization w ith CII, an 
erosive polyarthritis, mediated by an autoimmune response to the rat jo in t CII, 
subsequently developed (Trentham, Townes et al. 1977). This procedure has since been
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replicated in the mouse (Courtenay, Dallman et al. 1980; Bruhl, Cihak et al. 2009; 
Hartog, Hulsman et al. 2009; Lindblad, Mydel et al. 2009; Palframan, Airey et al. 2009; 
Svelander, Erlandsson-Harris et al. 2009). The significance o f  this model is the 
production o f  auto-antibodies to CII. The latter forms a major component o f  the jo in t 
cartilage and indeed is expressed exclusively in the joints (Cho, Cho et al. 2007). D uring 
disease CII becomes a significant focus for aggressive inflammation. Im portantly 
antibodies to CII have been found in RA patients in the early stage o f  the disease 
indicating that CII could play an important role in initiating the human condition (Cho, 
Cho et al. 2007).
From a pathological point o f  view this mCIA model and human RA are very sim ilar. 
Histologically, they both involve synovitis and pannus formation, the latter progressing 
to cartilage dam age and bone erosion. Susceptibility o f  animals to induction o f  this 
disease is dictated by expression o f specific MHC class II molecules (W ooley, Luthra et 
al. 1981). This has parallels with the human condition as it is well established that 
inherited susceptibility to RA is associated with the genes encoding the hum an M HC 
class II m olecules (HLA-DR4 and HLA-DR1 alleles) (Todd, Acha-Orbea et al. 1988)
1.7.2. Animal susceptibility to CIA
As susceptibility is conferred by the expression o f  MHC genes, mCIA is a largely T- 
cell-dependent disease (Staines and W ooley 1994). The MHC molecules are highly 
polymorphic integral membrane proteins which serve the following functions. Firstly 
they act as ‘s e lf  structures so the antigen-specific T-cells can recognise them , and 
secondly can behave as receptors which bind antigens and present them to T-cells in 
order to provoke an immune response (Luross and W illiams 2001).
Extensive variation exists within the MHC subgroups o f  molecules; the class II 
chromosomal region encompasses nearly 1,000,000 base pairs, and includes at least 14 
different genes (in humans). During splicing these genes can be differently assorted to
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produce a highly variable set o f  proteins which are expressed on the cell surface 
(Grcgersen, Silver et al. 1987). It has been observed that animals possessing the M HC II 
I-A isotype and within this the allele I-Aq, are susceptible to mCIA (Myers, Rosloniec et 
al. 1997; Luross and W illiams 2001). This is analogous to the situation in human RA, in 
which expression o f  particular subtypes o f  the DR4 and DR1 alleles are strongly 
associated with susceptibility to the disease (W illiams, Inglis et al. 2005). Subsequently 
the DBA/1 strain o f  mice is com m only used for the induction o f  arthritis as they posses 
this allelic variation, and therefore have a heightened susceptibility for positive 
induction o f  the disease.
In mCIA it is proposed that APCs capable o f  presenting the CII antigen complexed w ith  
the I-Aq MHC variant on the T-cell surface can prom ote initiation o f arthritis. T his 
results in production o f  T-cells that are specific for CII (Luross and W illiams 2001). In 
mice, if  this allelic variation is present, a strong T- and B-cell response will occur due to 
this antigen presenting complex following immunisation with heterologous (chick) C II. 
Specificity o f  the allele was described by W ooley et al in 1980 who found that despite 
the ability o f  several murine strains to mount a large anti-CII immune response after 
inoculation, only the animals with the I-Aq allele present developed arthritis (W ooley, 
Luthra et al. 1981). Similarly another variant, the I-Ar allele confers susceptibility to 
porcine or bovine collagen-induced arthritis in mice. The severity o f  arthritis has been 
observed to be dependent on the collagen source. Immunisation with heterologous 
collagen seems to elicit a more aggressive arthritis compared to an autologous collagen 
injection (Holmdahl, Karlsson et al. 1989).
1.73. Pathogenesis of CIA
mCIA is induced after the administration o f two identical inoculations, consisting o f  an 
emulsion o f  complete Freund’s adjuvant and chick CII, administered three weeks apart. 
It has been noted that during the period between inoculations, an increase in levels o f  IL- 
6 and TNFa occur and after the second immunisation, concentrations o f  these and
62
additionally IL -ip  are higher in the joint (M arinova-M utafchieva, W illiams et al. 1997). 
This again represents a similarity to the human condition where increased plasma levels 
oflL-1 (Shore, Jaglal et al. 1986), and TN F-a are observed and have been associated 
with joint damage (van den Berg 2001).
In the mCIA model, immediately after the second immunisation, DCs begin to present 
CD, increase MHC II expression and thus induce T-cells to activate B-cells in a highly 
specific immune attack against the CII component (Cho, Cho et al. 2007). At the sam e 
time, DCs also start to express higher levels o f  chem okines and cytokines. At this initial 
phase in the disease, and prior to clinical signs o f  arthritis, MHC II-expressing cells 
(DCs and T-helper cells) arc found to accumulate in the synovial membrane. In parallel 
with, and as a direct result o f  this cell accumulation, neutrophils and macrophages also 
begin to invade the joint (Luross and W illiams 2001) secreting proteolytic enzymes and 
cytokines as they do so.
The anti-CII antibodies produced in this environment by the DCs and T-helper cells, are 
of the IgG2 subset, a family o f  IgG molecules involved in induction o f the complement 
system (Cho, Cho et al. 2007). The activation o f  the complement system results in the 
production o f  chemokines and infiltration o f  inflammatory cells helping to supplem ent 
the initial stages o f  the inflammatory attack. This process has similarities to human 
disease as com plem ent activation occurs as described in section 1.2.2. The 
autoandbodies produced in this response work in a sim ilar way to natural antibodies 
normally produced against invading antigens. Antibodies specific for the self-CU initiate 
a specific attack against the CII residing in the cartilage (Flem ing and Tsokos 2006).
The infiltrating macrophages and proliferating SFs that invade the joint, begin to attack 
the cartilage and bone, as in human disease, producing the eroding pannus. Other cells 
which reside here, for example the DCs and granulocytes also produce destructive 
factors (Luross and W illiams 2001) contributing further to cartilage and bone 
destruction (sec figure 1.12).
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Development of anti-CII immunity 
APCs present CII to T-cells
^  Chemokine and cytokine
production by DCs
Anti CII antibodies bind collagen 
1 
Complement Activation
I Chemokine production
Chemotaxis for Neutrophils and Macrophages 
Panmis Formation Increased secretion of chemotaxic material and pro inflammatory cytokines 
MMPs cathepsin elastase
Synovial Fibroblast Activation 
ECM/bartilage Degradation Increased inflammatory cytokine production
Hyperplasia of SFs and macrophages. 
Increased osteoclastogenesis
I
Bone/Cartilage and 
Joint Destruction
Ffgare 1.12. Pathogenesis of mCIA.
Once disease is initiated, each event in the inflammation pathway assists in maintaining 
and furthering the aggressive immune response. The downstream cascade o f  events is 
aggressive and fast acting with every step favouring tissue damage and destruction. In 
short, mCIA is a self-perpetuating disease driven by tissue damage and cellular changes.
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1.7.4. Relevance of the mCIA Model
The mCIA model is a highly relevant model o f  RA due largely to the similarities in the 
histopathology o f both diseases shown by pannus developm ent, a large inflammatory 
cell infiltration, jo in t dam age, synovitis, neovascularization and bone erosion 
(Holmdahl, Karlsson et al. 1989; Quinones, Estrada et al. 2005) and both have 
genetically restricted susceptibility as mentioned in section 1.7.2. They are both immune 
diseases with production o f  antibodies to CII, the importance o f  this in mCIA is shown 
by induction o f  inflam m atory arthritis in naive animals after transfer o f CII 
autoantibodies from an arthritic animal (Staines and W ooley 1994). There are also 
similarities in factors that affect the disease, for example it has been noted that RA and 
mCIA are sim ilarly influenced by female sex horm ones and pregnancy (Waites and 
Whyte 1987; Holmdahl, Karlsson et al. 1989).
The mCLA model provides a valuable research tool due to its “controllability”, and most 
important in validating its use as an experimental model is the emergence o f therapeutic 
strategies for the m anagem ent o f  RA patients as a direct result o f the use o f mCIA.
Although knowledge has been gained with regard to underlying pathologies o f RA, 
more is still to be done in order to appreciate it as a systemic disease. It is increasingly 
recognised that RA patients have other underlying health problems, particularly those o f 
a cardiovascular nature. M oreover it is becoming clear that this could be due to the 
burden o f  inflammation their body must withstand.
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1.8. Hypothesis
In this thesis the following hypothesis will be investigated:
Due to the highly inflammatory nature o f  RA and similarities o f this exhibited in the 
murine model o f  RA vascular dysfunction will ensue following the clinical onset o f 
arthritis. This will be characterised by a decrease in bioavailable NO both in the vessel 
and circulation. Serum levels o f inflammatory mediators will be increased and thus 
contribute to the detrimental effect on the vasculature. Endothelial dysfunction will be 
observed in isolated blood vessels.
1.9. Aims
Assess endothelial dependent relaxation in aortic tissue from experimentally arthritic 
and normal mice.
Measure vessel levels o f  eNOS and iNOS in vessels from experimentally arthritic 
animals.
Assess plasma levels o f  NO, T N F a, IL-6, and 1L-1 (3 levels in these vessels.
Compare O 2- and ONOO in normal and arthritic vessels as a marker o f oxidative stress.
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CHAPTER 2
EXPERIMENTAL MATERIALS AND GENERAL METHODS
2.1 Mice
All work with animals was performed in accordance with the United Kingdom A nim als 
(Scientific Procedures) Act 1986 and under the authority o f  Home Office Personal 
(30/7627) and Project (30/2361) Licences. The technique used to create the anim al 
model o f arthritis is an adapted vesion o f  the method developed by Trentham et al 
(Trentham, Townes et al. 1977). Throughout the work pertaining to arthritis assessm ent, 
DBA/1 animals were used due to their heightened susceptibility for mCIA as a result o f  
their genetic make-up (as discussed in section 1.7.2).
Male DBA/1 mice aged 6-8 weeks were purchased from Harlan Sprague Dawley Inc. 
and housed in conventional cages. All mice had ad libitum access to normal chow and 
water and were given a settling in period o f  one week before being used for 
experimentation. Mice were subjected to a continual light.dark cycle o f  12:12 hours, 
between the hours o f  8am to 8pm. The temperature range in the animal house was 
maintained between 19 - 23’C, and humidity at 55±10%. At appropriate time points (see 
below for more detail), mice were euthanised under Schedule 1 o f  the United Kingdom 
Animals (Scientific Procedures) Act 1986 by inhalation o f  carbon dioxide (CO 2). Each 
mouse was placed in a cham ber and exposed to a rapidly rising concentration o f  CO 2 at a 
flow rate o f 3 1/min until no vital signs o f life were observed.
2.2 Induction o f Murine Collagen Induced Arthritis
Following the settling in period (see section 2.1), mice were anaesthetised with 
isofluorane (5 1/min) and oxygen (41/min) and immunised (see below) with type II chick
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sternal collagen (C-9301, Sigma Aldrich) and complete Freunds adjuvant (CFA). This 
adjuvant was used to assist with initiating the immune reaction in the presence o f chick 
Cll. C FA  was prepared by grinding lOOmg M ycobacterium tuberculosis (dried weight) 
(H37 RA, DIFCO) into 20ml o f  incomplete Freunds adjuvant (F-5506, Sigma Aldrich) 
using a mortar and pestle. The chick CII (5mg) was dissolved overnight at 4°C in 2.5ml 
o f 0.02%  (v/v) acetic acid (A /0400/PB17, Fisher Chemicals) and then added to an equal 
amount o f  CFA. This mixture was emulsified by passing through a 19 gauge needle ~20 
times before injection.
On day  0 mice received lOOpl o f the CII/CFA emulsion in two 50|il injections 
intraderm ally (ID) via a 27 gauge needle after anaesthesia. Each injection was given at a 
separate site on the right lateral side at the base o f  the tail. M ice were returned to their 
cages to recover, and were subsequently checked several times a week to ensure the 
injection site was not ulcerated and that their general health was satisfactory. Between 
days 0  and 21 the behaviour o f the immunised mice was as observed prior to the first 
CII/CFA injection. On rare occasions animals did develop arthritis before day 21, this 
arthritis was very mild and animals were given the second CII/CFA injection (in line 
with o u r established protocol (Nowell, W illiams et al. 2009) .On day 20 the chick CII 
was dissolved in 0.02%  (v/v) acetic acid, and on day 21 was m ade into an emulsion with 
an equal volume o f  CFA as before. Animals were anaesthetised and ID injections 
adm inistered to two separate sites at the right lateral side near the base o f the tail. After 
day 21, arthritis progressively developed and to minimise suffering, all mice were given 
free access to the opiate-derived painkiller buprenorphine (tem gesic) (Schering-Plough) 
via drinking water at a concentration o f 0.4mg/l. This was the favoured pain killer as 
anti-inflam m atory analgesics would hinder the progression o f  disease.
The onset o f  arthritis usually occurred from day 21 onwards. Throughout disease mice 
were regularly anaesthetised with isofluorane (as above, for restraint) and the severity o f 
the arthritis measured by assigning a score to each o f  their paws and measuring paw
6 8
swelling. This was achieved by measuring the hind paw diameter using a micrometer 
(Kroeplin 0-100mm), and also by observing the physical appearance o f the paws (see 
figure 2.1). The scoring criteria arc outlined below. Animals were also weighed over the 
experimental timecourse. If the weight o f any one animal dropped by >20% (compared 
with weight prior to arthritis development) on two consecutive days the animal was 
humanely removed from the experiment (less than 1% occurrence). To prevent 
malnutrition, food pellets were made more accessible for the animals by placement in 
the bottom o f the cage.
Paw Score Description
0 Normal
1 Mild/moderate erythema (redness) and swelling
2 Severe erythema and swelling affecting entire paw joint
3 Up to three joints affected by arthritis
4 Greater than three paws affected by arthritis
5 Deformed paw or joint with ankylosis (stiffness)
Figure 2.1. Hind Paws from mCIA Mice. Picture showing successful induction of arthritis in the hind 
paws. A. Paw scoring 0. This paw is normal with no signs of redness and the digits are thin. B Paw 
scoring 2. This paw is showing more inflammation with redness and swelling of the ankle joint and paw. 
C Paw scoring 2-3. The ankle joint is inflamed, as well as the two digits on the left (compared to the index 
digit). D. Paw scoring 4. The entire paw, ankle and all digits are inflamed and swollen.
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The sum o f  the scores for the four paws in each mouse gave an indication o f disease 
severity. M ice were euthanised at time points defined by mild, moderate and severe 
arthritis according to the criteria below:
Combined Paw Score Severity
o • MOd
6-10 Moderate
1 1 - 1 4 + Severe
Any animal with a paw score o f 5 in any one paw, or a combined clinical score o f 14 or 
more, was humanely removed from the experiment.
2 3  Collection of Experimental Samples
23.1 Plasma
At appropriate time points mice were euthanised as described above (section 2.1). 
Blood (approxim ately 0.2 -  1ml) was then collected as soon as practical via cardiac 
puncture using a 19 gauge needle and transferred to EDTA-coated vacutainers (EDTA 
Coated Vacutainers, BD) on ice, or on occasion blood was collected using a heparin 
(10,000units/10ml, Leo Laboratories Ltd)-coated syringe and put on ice in an 1.5 ml 
Eppendorf tube. Subsequently all blood samples were transferred to 1.5ml Eppendorf 
tubes and centrifuged for 20 minutes at 14,000rpm (16464g) at 4°C. The resulting 
plasma supernatant samples were stored separately at -80°C until required for analysis.
23.2 Tissue
(i) Aortae
Following euthanasia and blood collection the chest cavity and abdomen were quickly 
opened using small scissors, and 200pl heparin injected into the left ventricle o f the 
heart. The lungs, diaphragm, intestine, stomach and liver were removed for ease o f
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dissection. The exposed aorta was then vented ju st above the renal arteries and the left 
ventricle perfused slowly w ith -  lm l o f gassed (95%  oxygen/5% carbon dioxide) Krebs 
buffer (see appendix) to rem ove blood from the vessel. Subsequently the thoracic aorta 
was carefully excised from the chest cavity using curved scissors and placed in fresh 
Krebs buffer. Loose fat and connective tissue were then removed from the outside o f the 
vessel which was then either;
a) cut into rings for m yography (see 2.4)
b) embedded in OCT for histology (see 2.5.2i)
c) homogenised in RIPA buffer for protein analysis (see 2.5.1 i)
d) snap frozen in liquid nitrogen (N2) and stored at -80°C for further use.
(ii) Paw s
Following euthanasia paws were collected from mice. Forepaws were removed just 
above the “wrist jo in t” , quickly snap frozen in liquid N 2 and stored at -80°C for further 
use. Hind paws were rem oved near the base o f the tibia and fibula, ju st before they meet 
the ankle. Hind paws were scored along the base o f  the paw with a scalpel blade, before 
being immersed com pletely in Neutral Buffered Solution Formalin (NBSF) (H T501128, 
Sigma Aldrich), to ensure the solution could penetrate the joint..
2.4 Studies o f Aortic Function Using the Danish Multi-Myograph
This method represents a m odification o f  the one used by Cai et al (Cai, Khoo et al. 
2005) and based on a technique originally developed by Mulvaney and Halpem 
(Halpem, M ulvany et al. 1978).
At appropriate times points mice w ere euthanised as described in section 2.1, and blood 
and the aorta were removed as in sections 2.3.1 and 2.3.2i. After removal the vessel was 
cut in to rings o f 2mm length (each individual aorta producing 4-5 rings) under a X20
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microscope using a scalpel blade and a ruler for scale. These were mounted in separate 
baths o f the M ulvany myograph (M ulti-wire M yograph System 610M Danish Myo- 
Technology, with one or two four-bath m yographs being used to study tissues from one 
or two animals respectively on any given day). Individual rings were bathed in 5ml 
Krebs buffer at all times and the temperature was maintained at 37°C, regulated by the 
steel block upon which the bath is placed. Baths were continually gassed with 95% 
oxygen/5% carbon dioxide. Once mounted, each ring was held between two prongs, one 
connected to a micrometer to allow manual increase o f  tension, the other connected to a 
force transducer to allow measurement o f  ring tension. The myograph output was 
connected to a PC and recorded and analysed using M yodaq and Myodata (Aarhaus, 
Denmark) software respectively. The data was also displayed on the myograph LED for 
each ring tension.
After m ounting the rings were subjected to an equilibration period o f 20 minutes 
following which any tension on the rings and gas were removed and the myograph was 
zeroed. A baseline tension o f  5mN (or 15mN in prelim inary experiments, see below) 
was then established manually via the m icrom eter over a gradual period o f  30 or 10 
minutes respectively, increasing the tension at a rate o f  0.5mN/min. A rest period o f  20 
minutes then followed during which the tension was manually adjusted in order for it to 
maintain the desired baseline. The tissues were then exposed for five minutes to 6x10' 
2M K* in Krebs to condition the vessels to contraction. Peak tension was noted at 5 
minutes, following which vessels were washed 8  times with Krebs and left to rest for 20 
minutes to re-equilibrate. If the baseline resting tension had decreased during this time 
(and at any other time in the experiment after washing) it was manually re-constricted to 
5mN. After the equilibration period tissues were incubated for five minutes with the 
appropriate constricting agent (lO ^M ) followed by 5 minutes with the appropriate
relaxing agent ( lO^M). Following washing 8  times with Krebs solution a further resting
•2period o f  20 minutes was allowed. To ensure accuracy a stock solution o f 10 M was
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made up o f  the agonists was and then diluted accordingly to achieve the desired final 
concentration in the bath.
Unless stated otherwise constriction responses were measured using the agonist 5 - 
hydroxytryptamine (5HT). To test tissue viability vessels were initially constricted to 
their maximum by adding increasing concentrations o f 5HT (10'9M tolO '5M) in half-log 
increments (see below). Following the plateau with the highest concentration o f 5HT, a 
single bolus concentration o f lO^M ACh was added to ensure normal endothelial 
function (by relaxation o f  the vessel via endothelium-derived NO generation). If any 
ring failed to relax they were subsequently excluded from further experimentation. 
Vessels were then washed 8  times in Krebs and left to re-equilibrate for 20 minutes.
Starting Agonist 
Concentration (M)
Volume added to 
the Bath ( pi)
Final Concentration 
in Bath (M)
10"6 5 10‘9
10-6 10 3 e l0 ‘9
10-5 3.5 I0 '8
10'5 10 3 e l0 ‘8
u r4 3.5 10*7
10”4 10 3 e l0 '7
10° 3.5 lO’6
10‘3 10 SelO"6
10'2 3.5 10'5
Subsequently vessels were reconstricted to 70-80% o f  the maximum established 
previously using increasing concentrations o f  5HT as before. 70-80% was normally 
achieved at a concentration o f either 10’7M or 3 e l0 ’?M. After plateau at 70-80% vessels 
were subjected to a concentration response to ACh (10'9M to l0 '5M in half log
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increments) (see below), each step following the previous only after the vessel was at a 
steady tension.
Starting Agonist 
Concentration (M)
Volume added to 
the Bath ( pi)
Final Concentration 
in Bath (M)
10"6 5 10'9
10-6 10 3 e l0 ’9
10'5 3.5 10‘8
i<r5 10 3 e l0 '8
kt4 3.5 10'7
10-4 10 3 e l0 ’7
ACh
Concentration
Volume added to 
the Bath (pi)
Final Concentration 
in Bath (M)
10"6 5 10’9
10"6 10 3 e l0 ’9
10*5 3.5 10‘8
10'5 10 3 e l0 '8
10"4 3.5 10'7
10"4 10 3 e l0 ‘7
10'3 3.5 lO'6
10'3 10 3el0"6
10‘2 3.5 10‘5
Results were noted for each ring at the plateau o f  the response. Relaxation responses to 
Ach were then expressed as a percentage o f the 5HT-induced tone. Where appropriate 
data was averaged for each animal/condition and counted as one n-value. Values for 
animal/condition were combined and expressed as mean ± SEM.
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2.5 Sample Preparation
2.5.1 Homogenising
(i) Aortae
Aorta were homogenised in lOOpl RIP A buffer (see appendix) using a lOOpl close- 
fitting glass rod (attached to a drill (Black and Decker)) and homogenisation tube 
(Jencons). The frozen aorta was placed in ice cold R1PA buffer in the tube and 
homogenised for six 10 second bursts. The aorta was left on ice during the
homogenising, essential for avoiding the build up o f  excess heat which could potentially
damage the sample. The homogenate was removed from the tube using a glass pipette 
and transferred to a 1.5ml Eppendorf tube before spinning in a centrifuge for 30 m inutes 
at 14000rpm (16464g) at 4°C. The supernatant was removed and frozen at -80°C for 
further use.
(ii) Paws
Paws were homogenised as the aortae but using 500pl R1PA buffer and a 1ml close- 
fitting glass rod and homogenisation tube (Jencons). The homogenate was centrifuged 
and the supernatant stored as described in 2.5. l(i).
2.5.2 Histology
(i) Aortae
Rings o f  2m m  were cut from the excised aorta (described previously 2.3.2i) and placed 
in OCT (LA M B/O CT Embedding Medium, Thermoshandon) on a metal chuck pre­
cooled in liquid N 2 . The aorta was held in the desired orientation using forceps while 
OCT was placed on and around the vessel segment and allowed to partially freeze in 
order to hold the aorta in place. Once the position o f the aorta was secured it was 
immersed in O CT and the whole block was frozen in liquid N2 . Subsequently sections 
of 7pm w ere cut on a cryostat and mounted onto Colourfrost Plus glass slides (9991001,
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Thermoshandon) to ensure maximum adherence to the glass slide. These w ere then 
stored at -80°C ready for staining.
(II) Paws
Hind paw joints were removed from DBA/1 arthritic animals post euthanasia and 
immersed in NBSF for a week as previously described (2.3.2ii). It is necessary to 
decalcify the joints after fixing so that they can be cut, and this was achieved by soaking 
the paws in a decal solution consisting o f 10% (v/v) formic acid (BDH), and 5% (v/v) 
formaldehyde (F I635 Sigma Aldrich) in distilled water. The solution was made up fresh 
and changed twice-weekly until paws were decalcified. The latter was confirm ed using 
an ammonium oxalate assay adapted from (Gamble 2008) capable o f  detecting levels o f 
calcium in the supernatant o f  the paw-bathing solution. Am m onium  oxalate was 
prepared by dissolving ammonium oxalate in water over heat until it failed to dissolve 
and a precipitate formed. Following this an excess was added to ensure high saturation. 
Briefly to assess calcium in the joint, 2ml o f supernatant was neutralised to pH7 using 
hydrochloric acid HCI, and mixed with concentrated ammonium oxalate in a universal 
container. The presence o f  calcium was indicated by the formation o f  a white precipitate 
(calcium hydroxide). W hen a precipitate no longer formed, the jo in ts were deem ed free 
o f calcium and samples were ready for further processing. This norm ally occurred after 
approximately three weeks in the decal solution.
Subsequently jo ints were dehydrated using a Thermoshandon Tissue Processing Path 
Centre machine. The paws were immersed and agitated in increasing concentrations o f 
ethanol; 70% (v/v) for 30 minutes, 90% (v/v) for 90 minutes, 100% ethanol for one hour 
(repeated three times) and then in xylene for three incubations each lasting an hour 
Finally join ts were immersed in four changes o f  wax, following which they were 
removed an set in paraffin wax using the Thermoshandon Histocentre. Once set in wax 
joint sections o f  7pm were cut on a microtome and mounted on Colourfrost Plus glass 
slides before storing at room temperature until ready for staining.
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2.6 Histology
2.6.1 Haematoxylin and Eosin Staining
This method was used in order to assess the histological changes to the paws, and to 
confirm successful induction o f  mCLA. Haematoxylin and eosin (H & E) staining was 
used as the haematoxylin stains nuclei purple and eosin stains the cytoplasm and fibrous 
tissue pink. This provides the contrast necessary for evaluation o f  changes in cellu lar 
content o f  the joints.
Paws were removed and treated as mentioned in Section 2.5.2ii. After sectioning the 
slides were deparaffiniscd by immersing in three changes o f xylene (3 x 5  mins) and 
then in descending concentrations o f  ethanol (100%, 100%, 90% and 70% all v/v) for 
three minutes each. Slides were then hydrated in running tap water for 5 minutes, rinsed 
in distilled water and stained in haematoxylin (351946T, Jencons) for 90 seconds. Slides 
were washed in tap water for a further 5 minutes and immersed in Scotts tap w ater (S- 
5134, Sigma Aldrich) for 30 seconds to enhance the blue stain o f  the haem atoxylin. A 5 
minute wash in tap water and rinse in distilled water followed this to remove any excess 
Scotts tap water. Slides were then stained with eosin (352065W , Jencons) for 90 seconds 
and washed in tap water for 5 minutes once more before dehydrating in 5 minute washes 
in ascending concentrations o f ethanol (70%, 90%, 100%, 100% all v/v) and then in 3 
changes o f  xylene for 5 minutes each. Slides were mounted with DePex and kept at 60° 
overnight in order for them to set.
Figure 2.2 shows an example section o f  a normal paw and an arthritic paw outlining the 
areas o f  inflammation. For more detail on the scoring are and criteria see section 4.4.2.
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Figure 2.2. H and E Stained Joints. A. Normal Ankle Joint. 1. The synovial membrane, 2. The 
surrounding connective tissue, 3. The joint space, 4. The layer of cartilage covering the articular end of the 
bone. B. Severely arthritic ankle joint. 1. The inflamed synovial membrane, 2. Inflammatory cells in 
connective tissue 3. Exudate that has infiltrated the joint space. 4. Inflammatory cells invade the bone (at 
X4 magnification).
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2.6.2 Safranin O and Fast Green Staining.
This method was used to highlight the areas o f  cartilage depletion within the joint. 
Safranin O binds to the cartilage (Rosenberg 1971) leaving a red band. As such when it 
is degraded there is a “bleaching” effect on the colour allowing the amount o f depletion 
to be measured compared to the original depth o f staining (see 4.4.2.2 for more detail). 
Fast green is the counter stain and stains the rest o f  the cells. Figure 2.3 shows a normal 
joint stained with Safranin O and Fast Green.
The slides were deparaffinised, hydrated and stained with haematoxylin as previously 
described (section 2.6.1). Sections were then washed and immersed in Scotts tap water 
before washing for 5 minutes in running tap water and staining in Fast Green (F-7252, 
Sigma Aldrich) for 5 minutes. After this, slides were immersed in 1% (v/v) acetic acid 
for 10 seconds and stained with Safranin O (S-2255, Sigma Aldrich) for a further 5 
minutes. The Safranin O was washed o ff with two distilled water rinses and then 
immersed in 100% ethanol before dehydrating to xylene as described in 2.6.1. Slides 
were mounted using DePex and left over night at 60°C.
To measure cartilage depletion the overall depth o f  cartilage and the amount stained a 
“bleached” red was measured (see figure 2.4). These measurements were taken at five 
random points along the concave articular edge o f  the tibia using the inbuilt graticule in 
the microscope. The results were expressed as average original depth o f cartilage along 
the bone edge ± SEM.
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Figure 2.3. Normal llind Paw Joint Stained with Safranin () and Fast Green. The Saf O shows the 
cartilage as a bright red band on the articular surfaces of the joint, (at X4 magnification).
Figure 2.4. Safranin O and Fast Green Staining in Normal and mCIA Joints. A. Shows deep red 
staining of Safranin O in the cartilage of the tibia in a normal healthy joint. The white line indicates the 
depth of cartilage (xlO magnification). B. As A, at x20 magnification. C. Safranin O staining in a severely 
arthritic joint. The two lines indicate the original depth of cartilage, and the depth of depletion due to 
arthritis (at xlO magnification). D shows an example of this at a higher magnification (x20 magnification).
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2.7 Protein Detection
2.7.1 Bradford Protein Assay
This method is a modified version o f one developed by Bradford et al (Bradford 1976). 
This protein assay was performed using the Coomassie Plus (Bradford) protein assay kit 
(Thermoscientific). Two columns o f Bovine Serum Albumin (BSA) (supplied) standards 
were set up with concentration limits o f lOpg/ml to 0.3125pg/ml in a 96 well flat- 
bottomed plate. Standards and samples were diluted in 0 .0 1M phosphate buffered saline 
(PBS) in a 1 in 100 dilution (total volume 200pl) in the top row o f wells. All samples 
including the standard were run in duplicate. Standards and samples were diluted 1 in 2 
by adding lOOpI o f protein dilution to the next well with lOOpl PBS and mixing. This 
dilution was repeated 5 times down the plate with the last row o f wells containing PBS 
only, thus behaving as a blank. lOOpl o f  Coomassie Blue reagent was added to each well 
and allowed to react for 1 0  minutes before absorbance was measured using a 
spectrophotom eter at a wave length o f  595nm. A standard curve was plotted from the 
BSA results and the concentration o f  protein in the sample calculated from this.
2.7.2 ELISA
Paw specimens, serum and aortae were removed and treated as previously described in 
2.3.
For all kits, experiments were carried out according to m anufacturer’s guidelines. 
Briefly all reagents were made as instructed and samples were thawed and diluted as 
appropriate. Plates came pre-coated with the prim ary antibody. 50pl o f assay diluent 
and a further 50pl o f  standard, control or sample were added to each well. The plate was 
tapped to ensure thorough mixing before incubating for 2  hours at room temperature.
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After this incubation period each well was aspirated and washed 3 times using the wash 
buffer provided. Excess liquid was removed from the wells by inverting and blotting 
against paper towels. lOOpl o f the mouse conjugate specific for the protein o f interest 
was then added to the wells and left for 2  hours at room temperature before washing as 
before. The substrate solution was then added and the plate incubated in the dark at 
room temperature for 30 minutes. The stop solution was then added at a volume o f 
lOOpl and the plate was gently agitated to ensure full mixing. The optical density was 
measured at 450nm. A standard curve was plotted, and protein concentrations were 
calculated from this.
2.8 Statistical Analysis
The statistical analysis used to interpret data sets is discussed in more detail in each 
chapter. Briefly, in the case where two conditions are to be compared, the student’s t-test 
was used to determine if the averages were significantly different. In the case o f three or 
more data cohorts, a one-way ANOVA followed by Newman-Keuls was utilised.
It is important to note that in some experimental work, due to time constraints a small n- 
value was attained. Under these circumstances the experiments may not be sufficiently 
powered to adequately represent the sample mean, or to detect an actual difference 
between sample groups. In these cases more work is needed to determine this; the data 
was included in this thesis as a discussion point.
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CHAPTER 3
OPTIMISING VASCULAR RESPONSES IN 8 -  10 WEEK OLD
MALE DBA/1 MICE
3.1 Introduction
In order to measure functional changes to the vasculature in the mCIA model it was 
necessary to ensure that a reproducible “norm al” model was established in DBA/1 mice 
for appropriate comparison. To do this, it was essential to perfect the technique o f  
dissecting, cleaning and mounting the vessel on the myograph. Therefore in initial 
experiments vessels from C57BLV6 animals (surplus to requirement from other studies) 
were assessed. This was in-keeping with the principles o f the “three R ’s” (reduction, re­
use and refinement) as outlined in the Home Office Personal Licence guidelines, and 
had the additional benefit o f  being more financially viable. Once reproducible results 
had been attained with the C57BIV6 tissues, the technique would be repeated in the 
DBA/1 mice, and further optimised if necessary.
At the time o f  starting this work no measurements o f  isolated vascular function in the 
DBA/1 species, or in the mCLA model, were evident in the published scientific 
literature. W hile many such studies had been performed in other species and strains, 
varying responses were observed between them. Therefore it was deemed vital to 
optimise responses in DBA/1 animals in case they differed from the norm. At this point 
it was also decided that only male mice would be used for this study (for reasons 
outlined below).
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3.1.1 Sex Differences
With respect to vessel function, differences have been observed between responses in 
tissue from male and female mice. In experiments conducted by Karanian et al (1996) 
male canine tissue appeared to be more reactive to constricting agents than that from  
female counterparts, resulting in a significantly larger constriction after exposure to the 
agonist (Karanian and Ramweil 1996). This was reiterated also in work done by 
Lamping et al (2001) who, whilst investigating serotonin-induced constrictions in m ale 
and female mice, saw a significantly larger response from the latter. Interestingly this 
was not echoed in the endothelium-dependent relaxations, with both sexes displaying 
similar responses (Lamping and Faraci 2001). This finding has been further supported in 
studies performed by Rubanyi et al (1997) who observed no difference in endothelial- 
mediated relaxation responses in aorta from both male and female mice (Rubanyi, Freay 
et al. 1997). Contrastingly however, studies by Fluang et al (1998) and Kauser et al 
(1994) both showed a larger production o f endothelium-derived NO in tissue from  
female compared to male mice. The resulting greater relaxation responses to ACh in the 
females was subsequently attributed to greater oestrogen production compared to m ales 
(Kauser and Rubanyi 1994; Huang, Sun et al. 1998). Interestingly oestrogen is now 
largely recognised as a protective molecule in the vasculature, exerting beneficial effects 
on endothelial cells by increasing their production o f  both NO and PGL (M iller and 
Duckies 2008). For a review on the vascular actions o f oestrogens see M iller and 
Duckies 2008. Furthermore, the finding that pre-menopausal women have a low er 
incidence o f  CVD compared with age-matched male counterparts and postm enopausal 
women also supports the role for oestrogen as a protective molecule, as the difference in 
incidence is attributed to the changes in the levels o f this hormone between the three 
cohorts (Villar, Hobbs et al. 2008). See the introduction o f Villar, Hobbs et al 2008 for 
further information regarding this.
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Sex differences have also been observed in the successful induction o f experim ental 
arthritis. For instance male mice are more susceptible than female mice to mCLA, the 
increased oestrogens o f the females seemingly preventing/suppressing the disease 
(Holmdahl, Jansson et al. 1986), why this is the reverse to the situation in human disease 
is unknown and thus open to speculation. In order to control for such variation it was 
decided that male mice would be used throughout this thesis.
In addition to differences observed between sexes, inter-species variation is also 
common and can affect expected outcomes with respect to experimental work. A 
relevant example o f this is the elevated level o f  acetylcholinesterase observed in the 
DBA mouse strain versus C57BL/6 mice (discussed in section 3.1.2).
3.1.2 Acetylcholinesterase
Acetylcholinesterase (AChE) cleaves the neurotransmitter ACh, commonly found at 
synapse junctions, to produce choline and acetic acid (Rao, Swamy et al. 1991; 
Sussman, Harel et al. 1991). With regard to vascular biology ACh is commonly used to 
elicit endothelium-dependent relaxation in isolated blood vessels (see sections 1.4.3 and 
2.4). It has been reported that levels o f  AChE can vary between species o f  mice, and in 
particular higher levels have been noted in DBA/1 animals compared to C57BL/6 mice 
(Schwab, Bruckner et al. 1990). Due to the lack o f  information in the literature regarding 
AChE levels in isolated tissues, it was unclear whether this enzyme could interfere with 
vessel relaxation during an ACh concentration response experiment. If the enzym e was 
upregulated in the vessels it could cleave ACh prior to it inducing vasorelaxation, and as 
such, falsely suggest endothelial dysfunction. In order to overcome this problem, w hilst 
assessing the initial vessel function, carbachol (CC) was also used as a comparator. This 
is a drug that binds and activates muscarinic receptors in the same manner as ACh, but is 
resistant to degradation by AChE (Foster 1986; Streichert and Sargent 1992).
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3.13 Common Vasoactive Agents
Vasoconstrictors commonly used in m yography are the alpha adrenoceptor agonists 
phenylepherine (PE) and noradrenaline (NA), with ACh being a common vasodilator 
Along with serotonin (5-HT) these agents (see table 3.1.) were chosen to initially 
characterise responses in isolated vascular tissue from DBA/1 mice before deciding on 
appropriate agonists for subsequent studies. All vasoconstrictors in this table function by 
interacting with specific receptors on the VSMC triggering a downstream signalling 
cascade resulting in increased intercellular Ca2+ levels and subsequent vasoconstriction 
(see 1.4.2). The relaxing agents behave by increasing the formation o f the Ca2+/CaM  
levels resulting in stimulation o f  eNOS and thus production o f  the vasodilator NO (see 
1.4.3).
AGONIST RECEPTOR MODE OF ACTION
EXPECTED
RESULT
Phenylepherine
Alpha-adreno receptor 
at on SMCs
PLC, IP3, DAG a s  
secondary m essengers Constriction
Noradrenaline
Adrenoreceptors Ch a 2 
on SMCs
PLC -  IP3, DAG a s  
secondary m essengers
Constriction
5-HT
5HT iB receptors on 
SMCs
Increases intracellular 
Ca2*
Constriction
Acetylcholine
M3 R eceptors on 
endothelial cells
Activates eNOS Relaxation
Carbachol
M3 R eceptors on 
endothelial cells
Activates eNOS Relaxation
Table 3.1. Agonists and Expected Responses in the Vasculature. Vasoactive agents to be tested in the 
DBA/1 mice, their mode of action and the expected result, m3 is the muscarinic 3 receptor.
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3.2 Aims
Optimise responses in C57BL/6 animals to ensure correct dissection/m yography 
technique and obtain reproducible constriction and relaxation responses.
Establish a suitable method with appropriate vasoactive agents to obtain reproducible 
“normal” vascular responses in 8-10 week old male DBA/1 mice.
33 Experimental Materials and Methods
33 .1 Mice
An in-house strain o f C57BL/6 male mice aged 10-12 weeks were used for prelim inary 
experimentation. DBA/1 male mice aged 8-10 weeks were used for subsequent 
determination o f “normal” vascular function. For detail see section 2.1.
33.2 Collection of experimental Tissue
Aortic tissue was collected from both strains o f animal as described in section 2.3.2i.
3 3 3  Studies of Aortic Function using the Multi Myograph.
Aortae from both C57BL/6 and DBA/1 mice were mounted on a myograph and 
responses to the vasoactive agents outlined in table 3.1 were measured as described in 
section 2.4. In order to assess duplicate responses with the same vessel, concentration 
responses were, on occasion, repeated. For duplicate responses, baths were washed out 8  
times with fresh Krebs buffer following a constriction/relaxation response, and the 
tissues left to rest for 2 0  minutes before repeating the appropriate response.
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33.2 Measurement of Constriction and Relaxation Function
333.1 Establishing Responses in C57BL/6 Mice
The vasoactive agents PE and ACh were used to measure preliminary constriction and 
relaxation responses respectively in tissues from male C57BL/6 mice. A baseline 
tension o f  15mN as outlined in (Cohen, W eisbrod et al. 1999; Horvath, Orsy et al. 2005) 
was set manually, in order to mimic the mean arterial pressure that would be found in 
vivo, and the protocol outlined in section 2.4 then followed.
33.2.2 Establishing Responses in DBA/1 Mice.
The vasoconstrictors PE, NA and 5HT were used on separate occasions to assess 
constriction responses in DBA/1 male mice. To determine the most efficient relaxing 
agent, relaxation responses to increasing concentrations o f  either ACh or CC were 
assessed in tissues pre-constricted with the appropriate agent to 70-80% o f  the previous 
maximum. Initial experiments were carried out using PE following the establishm ent o f 
a 15mN baseline tension set. However, it was immediately apparent that the vessel size 
in the DBA/1 strain was approximately 15% smaller (estimated) than the C57BL/6 
animals. Following an abnormal first response to PE (see section 3.4.2.1) and due to the 
smaller size o f  the DBA/1 mice/vessels compared to C57BL/6 animals, it was deem ed 
necessary to decrease the baseline tension. Following this, observational prelim inary 
experiments were carried out in these vessels investigating a range o f  length-tension 
relationships. There was no available information in the literature regarding this 
technique in DBA/1 animals and subsequently the results o f  experiments involving 
varying baseline tensions deduced that 5mN was an appropriate level o f  tension for this 
work. M ethods using a baseline tension o f 5mN have been previously docum ented in 
experimental work performed in mouse aortae (Judkins, Sobey et al. 2006; Zemse, 
Hilgers et al. 2007).
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3.4 Results
3.4.1 Responses in CS7/BL6 Mice
Concentration responses to PE and ACh were utilised to measure constriction and 
relaxation responses respectively in the aortae o f male C57BL/6 mice aged 10-12 weeks 
in order to obtain reproducible results. Vessels responded well, constricting to a 
maximum tension o f  ~20mN (~5mN developed tension) and relaxing to -90%  o f the 
previously induced maximum (see figure 3.1). These results were reproducible and as 
such the method was repeated in the DBA/1 strain.
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Figure 3.1. Vascular Responses in the Aorta of C57BL/6 Male Mice to PE and ACh. A. Maximum 
constriction response to the vasoconstrictor PE. B. Responses to the vasoconstrictor PE to 70-80% of 
maximum response. C. Response to vasodilator ACh following induced constriction of 70-80% of 
maximum (n=4).
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3.4.2 V ascu lar R esponses in DBA/1 Mice
3.4.2.1 Phenylepherine
Responses to PH were measured in the aortac o f  male DBA/1 mice aged 8-10 weeks. 
After the initial constriction tissues were washed x8 and left to rest. During this resting 
period vessels reconstricted to above the initial baseline tension. Vessels were washed 
again in an attempt to return the tension to baseline, however this could not be resumed 
(see figure 3.2).
Increasing concentrations of PE
z
E
14
WASH
WASHVASH
Figure 3.2. Vascular Responses in the Aorta of DBA/1 Male Mice to PF^ . PE was used to constrict the 
aorta at increasing half log increments using concentrations of 10-9M to 3el0-5M (arrow heads). After 
maximum constriction was reached, vessels were washed x8 to return to baseline (wash). Vessels did not 
return to baseline and re-constricted without presence of agonist after multiple washes.
3.4.2.2 Responses in DBA/1 mice to the V asoconstrictor NA.
Due to the abnormal response o f the DBA/1 vessels to PE, an alternative vasoconstrictor 
was assessed. In this instance responses were measured in the aortae o f male DBA/1 
mice aged 8-10 weeks to NA after a baseline tension of 5mN was manually set. The 
maximum constriction reached was not very large and to test the reproducibility o f these 
responses the 70-80% responses were repeated several times. The vessels appeared to
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become desensitized to the agonist, with each subsequent exposure resulting in a slightly 
smaller constriction (see figure 3 .3).
3.423  Responses in DBA/1 mice to the Vasoconstrictor 5HT.
Responses were measured in the aortae o f  male DBA/1 mice aged 8-10 weeks to the 
vasoconstrictor 5HT. Prior to the constrictions the baseline was manually set to 5mN. 
This agonist elicited a large contraction that was found to be reproducible after 
num erous exposures (see figure 3.4).
34X4 Relaxation responses in DBA/1 Mice.
Responses were measured in the aortae o f  male DBA/1 mice aged 8-10 weeks to the 
relaxing agents CC and ACh after pre-constriction to 70-80%  o f the maximum by 5HT. 
Relaxation responses to CC were significantly sm aller than those to ACh (p<0.05) and 
more variable (see figure 3.5).
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Figure 3.3. Vascular Responses in the Aorta of DBA/1 Male Mice to NA. A. The initial exposure to all 
concentrations of NA reaching their maximum constriction. B, C. Consecutive responses to NA to a 
concentration of 3el0-7M to reach -70-80% of the previous maximum. (n=5).
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Figure 3.4. Vascular Responses in the Aorta of DBA/1 Male Mice to 5HT. A, Exposure to 5HT 
showing the maximum constriction reached. B and C show repeat responses to a stepwise concentration 
response of 5HT reaching 70-80% of the maximum (n=5).
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Figure 3.5. Vascular Responses in the Aorta of DBA/1 Male Mice to ACh. Responses to (A) CC and
(B) ACh. Maximum relaxation values (Rmax) from each curve are significantly different as determined 
by students T-test (p<0.05, n=5).
3.43 Summary of Agonists.
Table 3.2 shows a summary o f  agonists tested and the responses achieved in the aorta 
from the DBA/1 animals.
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AGONIST RESULT IN DBA/1TBSUE
Phenylepherine
Vessels contracted however the effect o f the 
agonist could not be removed by washing and 
baseline tension could not be resumed.
Noradrenaline
Vessels contracted however repeat ej^osure 
caused desensitisation and contractions were 
quite small.
5-HT* Vessels contracted and with reproducible results.
Acetylcholine* Vessels relaxed
Caibachol Vessels relaxed
Table 3.2. Table of Agonists Tested and Observed Results. * Denotes the agonists chosen for further 
work.
3.5 Discussion
3.5.1 Vessel Constriction
Responses to PE/ACh in C57BL/6 anim als have been previously characterised and are 
well documented in the scientific literature. As such, results obtained from these 
experiments were to behave as a com parator for confirming correct technique. However 
when it came to reproducing the responses observed in the C57BL/6 mice in the DBA/1 
strain the results differed.
PE appeared to have a high affinity for the receptors on the smooth muscle o f  the
animals resisting removal by washing, for which there was no obvious explanation in the
literature. A “one o f f ’ prasozin experiment was carried out, whereby the alpha
adrenoreceptor blocker was added to the tissue (at lO^M) following PE-stim ulated
contraction. This effectively removed the effects o f  PE showing that binding was not
entirely irreversible but as a result o f this adverse response this agonist was deem ed
unsuitable for further work in the DBA/1 strain. Further investigations into the
mechanisms behind this are outside the scope o f  this project.
96
Similarly, NA was considered unsuitable due to the decreased sensitivity exhibited by 
the vessels following repeat exposure. The initial constrictions were not very high and 
the gradual diminishment o f them over time made the agonist an unfavourable one. The 
increased insensitivity could be to do with the receptor function, they could becom e 
dysfunctional after repeat exposure, or they could be internalised or degraded after 
stimulation. Interestingly with respect to this it has been observed that in the rat, 
following long term ( 6  days) in vivo infusion with NA, the receptor becom es 
desensitised exhibiting a decreased constriction (Seasholtz, Gurdal et al. 1997) how ever 
the instant effect o f NA has not been investigated. Similarly after exposure there could 
be an upregulation in proteases capable o f inhibiting NA function. Alternatively there 
could be fewer NA receptors found in the VSMCs than for example the 5HT receptors 
resulting in the smaller constriction exhibited here. However, as nothing is known about 
the distribution or expression o f these receptors in the vessels from the DBA/1 strain, 
these are hypothetical suggestions, and investigating this further is again outside the 
scope o f the project.
5HT produced non-variable large constrictions with each repeated concentration 
response and these were reproducible for at least four concurrent exposures. As a result 
of this, 5HT has been chosen as the appropriate agonist for measuring vascular function.
Three different responses were obtained with respect to each o f the vasoconstrictors
tested in these vessels, which could be in part due to the difference in their m ode o f
action. The three agonists investigated here all elicit VSMC constriction, but do so via
different receptors, and thus vary in their downstream signalling cascade (see figure
3.6). NA, a catecholamine, exerts effects via the a  and P adrenoceptor subtypes, either
activating PLC or inhibiting adenylate cyclase resulting in constriction (aj and a 2
subtypes respectively). PE is a selective di antagonist and thus constricts smooth m uscle
by means o f  the PLC pathway via the increase o f the intracellular secondary m essengers
IP3 and DAG. 5HT contrastingly interacts with 5HT2A receptors on the VSMCs, also
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stimulating constriction in this manner. These receptors in the VSMCs o f the DBA/1 
strain have not been characterised and as such, differential expression/distributions o f 
these may provide explanation for the difference in the observed responses. 
Alternatively the different downstream signalling initiated by NA could explain the 
difference in constriction observed between the small NA-induced constriction, and the 
significantly larger PE- and 5HT-induccd constrictions.
Adenylate
Cyclase
IP, + DAG
CONSTRICTION
Figure 3.6. Pathways Involved in VSMC Constriction. Diagram showing the different receptors and 
pathways via which 5HT, NA and PE exert VSMC constriction
3.5.2 Vessel R elaxation
Relaxation responses to both ACh and CC in the DBA/1 animals were smaller than 
those observed in the C57BL/6 animals. This may suggest that the reported (Schwab, 
Bruckner et al. 1990) higher activity o f AChE in the DBA/1 does have an effect on 
relaxation responses to these agents. However, the observation that ACh-induced
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stimulating constriction in this manner. These receptors in the VSMCs o f the DBA/1 
strain have not been characterised and as such, differential expression/distributions o f 
these may provide explanation for the difference in the observed responses. 
Alternatively the different downstream signalling initiated by NA could explain the 
difference in constriction observed between the small NA-induced constriction, and the 
significantly larger PE- and 5HT-induced constrictions.
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Figure 3.6. Pathways Involved in VSMC Constriction. Diagram showing the different receptors and 
pathways via which 5HT, NA and PH exert VSMC constriction
3.5.2 V essel R elaxation
Relaxation responses to both ACh and CC in the DBA/1 animals were smaller than 
those observed in the C57BL/6 animals. This may suggest that the reported (Schwab, 
Bmckner et al. 1990) higher activity o f AChE in the DBA/1 does have an effect on 
relaxation responses to these agents. However, the observation that ACh-induced
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responses were greater than those achieved by CC (an agent that is resistant to AChE- 
induced hydrolysis) would argue against such an action. Moreover, this difference in 
responses to ACh and CC is not a novel finding, having been previously noted in studies 
by Walch et al. This group reported that in human pulmonary vessels, CC was a less 
potent agonist for binding and activating muscarinic receptors than ACh (Walch, Taisne 
etal. 1997).
Muscarinic receptors are G-protein coupled receptors and 5 subtypes (M |- M5) exist, o f 
which three (M | -  M 3) are well characterised. Stimulation o f the receptors M |, M 3 and 
M5 activate the IP3 pathway; M 2 and M4 activate inhibition o f AC and a subsequent 
reduction in intracellular Ca2+. The role o f  the M 3 receptor, to which ACh and CC bind 
in the vasculature is excitatory however on the endothelial cells the end result is 
production o f  NO and subsequent vasodilation (Dale M. M 2004). That a limited 
selectivity o f  CC for certain muscarinic receptor subtypes has been reported (Walch, 
Taisne et al. 1997), may provide explanation for the varying responses elicited to ACh 
and CC in DBA/1 animals. However as the expression and distribution of the M 3 
receptor has not been characterised in this strain there is no certainty for this 
explanation, and as such, is merely speculative.
It is possible therefore that the distribution o f  these receptors and their susceptibility to 
activation by these agents is different in DBA/1 mice compared to others. However, 
given the working hypothesis o f this thesis and the fact that ACh elicited substantial and 
reproducible relaxation responses rendered further intricate pharmacological dissection 
of this issue a fool’s errand. As such, ACh was used in all future experiments to assess 
endothelial function.
There are some very obvious differences observed in these animals compared to well
documented results across the literature for the more commonly used C57BL/6 strain.
Unfortunately the complete vascular phenotype o f  the DBA/1 animals is not defined,
and to attempt to do so in order to validate and understand these results would be a
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lengthy and time consuming process. For the purposes o f this thesis and w ith in  this 
chapter the normal vessel function o f male DBA/1 animals has been elucidated and 
optimal agonists and conditions to asses this confirmed. The next question to address is 
whether successful induction o f mCIA in these animals leads to subsequent changes in 
vascular function. This will be assessed utilising the methodology determ ined in this 
chapter and using vessels taken from animals at various stages o f the disease.
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CHAPTER 4
VASCULAR AND HISTOLOGICAL CHARACTERISATION  
OF AN EXPERIMENTAL MODEL OF ARTHRITIS
4.1 Introduction
In Chapter One the large body o f  information regarding the role o f endothelial 
dysfunction in the progression o f  human RA was summarised, and the main m echanisms 
discussed. It is widely suggested that the inflammation characteristic o f RA, and once 
thought to simply affect the joints, becomes systemic and exerts damaging effects at the 
vessel wall. The consequence o f the systemic inflammatory insult to the endothelium  
during RA is the development o f endothelial dysfunction (see figure 1.7) (Sattar and 
Mclnnes 2005; Libby 2008). This evidence provides the reasoning behind the hypothesis 
that endothelial function will be compromised in the mCIA model.
4.1.1 Vascular Function in Experimental Arthritis
There is no documentation within the scientific literature outlining the effect o f  mCIA 
on vascular function. However in an alternative model, the adjuvant-induced arthritis 
(AdA) model (Henderson B 1995), endothelial dysfunction has been investigated in 
some depth (see below). Similar to mCLA, AdA is a T cell-dependent disease that shares 
some features o f  human RA; swelling o f  the paws, cartilage degradation (although to a 
lesser degree than mCIA and human disease), loss o f  join t function and inflammatory 
cell infiltration in the joints (Hegen, Keith et al. 2008).
Using the rat AdA model, Can et al (2002) investigated the presence o f  endothelial 
dysfunction by examining endothelium-dependent and -independent relaxations in the 
isolated thoracic aorta. This study demonstrated that endothelium-dependent relaxation 
was diminished in arthritic animals, and that this impairment was inhibited by the
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antioxidant vitamin E, indicating a role for oxidative stress in the developm ent o f 
endothelial dysfunction in this model. Endothelium-independent relaxation rem ained 
unchanged (Can, Cinar et al. 2002) implying dysfunction at the endothelial but not 
vascular smooth muscle level. Further studies have observed endothelial dysfunction in 
this model to be associated with an increase in eNOS protein levels, ROS production 
and a decrease in levels o f  BH4 (the essential eNOS co-factor), again suggesting a role 
for oxidative stress (Haruna, Morita et al. 2006). That treatment with BH4 prevented the 
endothelial dysfunction, indicates that the latter could be the result o f  eNOS 
“uncoupling” in this model (Haruna, M orita et al. 2006) (see 1.5.3). Further support for 
a role for oxidative stress comes from observations o f increased serum peroxynitrite, 
iNOS, eNOS and NO metabolites accompanying diminished relaxation responses in this 
pathology (Nozaki, Goto et al. 2007). Interestingly administration o f  fluvastatin (a 
cholesterol-lowering statin with pleiotropic anti-inflammatory effects (Ray and Cannon 
2004)) in this model has positive effects on the vasculature, improving endothelium - 
dependent relaxation, increasing serum BH4 levels and decreasing levels o f  oxidative 
stress markers (Haruna, Morita et al. 2007). That no such studies have been reported in 
the mCIA model suggests that further research in this more accurate model regarding the 
systemic effects o f  RA, is warranted.
In human RA it has been suggested that the development o f an imbalance between ROS 
(normally produced as part o f  cell metabolism and protection) production and the 
antioxidant behaviour o f the cells contributes to vascular pathology. Indeed, low 
circulating levels o f  antioxidants have been implicated in the developm ent o f  RA in 
previously healthy patients (Filippin, Vercelino et al. 2008). Additionally there is 
evidence within the literature that oxidative stress plays a role in the developm ent o f 
CVD in RA. To this end inflammatory mediators produced at the synovial m em brane 
are postulated to become systemic and produce a ‘pro-atherogenic profile’ in the 
patients. Consequently an increase in oxidative stress, as demonstrated by a higher level 
of ROS and impaired anti-oxidant activity (Ku, Imboden et al. 2009), leads to dam age at 
the vessel wall. Importantly, whatever the mechanisms responsible for vascular
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dysfunction in RA, it would seem that this process is multifactorial and com plex. 
Indeed it is possible that the dysfunction may not only involve the endothelium  given 
that changes in vascular smooth muscle structure/function are implicated in other 
vascular pathologies such as hypertension, arterial stiffness, atherosclerosis and 
aneurysm formation to name but a few.
With regard to AdA, while an increase in vascular smooth muscle contractility has 
recently been reported (Nozaki, Goto et al. 2007), rather contrastingly a previous study 
observed no change in contractility in this model compared to control anim als (Fontaine, 
Herchuelz et al. 1984). That this information is conflicting and that no such studies in 
the mCIA model have been reported, again suggests that further research in this area is 
essential.
4.1.2 Histological Assessment of Arthritis.
As explained in Chapter One there are many changes occurring in the jo in t throughout 
the induction o f experimental arthritis starting with a rapid infiltration o f  inflam m atory 
cells in to the bone and culminating with cartilage and bone destruction. This also occurs 
in the human disease and can be seen through histological assessment.
To confirm successful induction o f mCIA, clinical assessment o f  experim ental arthritis 
is necessary. Paws should be scored routinely to determine the amount o f  swelling and 
redness (erythema) at any given time (see section 2.2 for examples o f the clinical signs 
o f experimental arthritis). Additionally histological assessment is necessary to assess the 
architectural changes to the joint; synovial inflammation, cartilage degeneration and 
erosion o f  bone are particularly useful measurements which are relevant to RA.
4.2 Aims
To induce mCIA in 8-10 week old male DBA/1 mice.
To determine the effect o f  mCIA on vascular function.
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43 Method
43.1 Mice
Male DBA/1 mice aged 8-10 weeks were purchased (Harlan Laboratories) and housed 
according to section 2.1.
43.2 Induction of mCIA
Experimental arthritis was induced in DBA/1 mice and subsequently assessed according 
to the clinical scoring criteria described in section 2.2.
4 3 3  Collection of Experimental Samples
At appropriate time points (see section 2.2) animals were euthanised as described in 
section 2.1. Subsequently the thoracic aortae and paws were harvested as described in 
sections 2.3.2i and 2.3.2ii respectively.
43.4 H & E Staining.
7pm Sections from a representative sample o f  paw joints were stained with H & E for 
assessment o f  inflammation according to the method and criteria described in section
2.6.1. Scores for each paw from either the mild, moderate or severe cohort are expressed 
as the mean ± SEM. The criteria outlined in table 4.1 are based on previous studies in 
our laboratory (Bull, W illiams et al. 2008). Synovial hyperplasia is assessed by the level 
of thickening at the synovial membrane. Normally one layer o f  cells thick, an increase in 
depth is observed as inflammation progresses. Infiltration is judged by the volume o f  
infiltrating inflammatory cells into the jo in t itself, and is measured in the extracellular 
space by the talus and tibia joint. This is scored on a scale o f 1-5 with increasing cell 
numbers/visible area o f  jo int with inflammatory cells present. Bone and cartilage 
erosion can be observed by the attachment o f  inflammatory cells to the surface o f  the 
bone, slight pitting o f the bone surface and subsequent apparent infiltration o f
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inflammatory cells into the bone. Finally cellular exudate is assessed by the presence o f  
inflammatory cells infiltrating the normally acellular joint space between articular ends 
of the talus and tibia cells in the synovial space. For familiarisation purposes, initial 
scoring was carried out by two people. Subsequently this process was perform ed by the 
author o f this thesis, though frequent checks were carried out by an experienced and 
independent observer to ensure consistent and impartial assessments were being made.
Scoring Criteria Description Score Scale
Synovial Hyperplasia
Thickening of the synovial 
membrane surrounding the 
synovial capsule
0 - 3
Infiltrate
The volume of infiltrating 
cells in the surrounding 
tissue
0 - 5
Cartilage Depletion and 
Bone Erosion
The amount of cartilage 
and bone eroded by the 
infiltrating celb
0 — 3
Exudate
The amount of celb 
infiltrating into the joint 
space
0 - 3
Table 4.1. Criteria for Scoring H & E Stained Paws.
43.5 Safranin O and Fast Green Staining
to order to assess pathological changes to the ankle joint, sections from the hind paws o f  
normal animals and those with experimental mCIA were stained with safranin O and 
fast green. Cartilage depletion was then assessed histologically as described in 2.6.2. 
Results are expressed as the mean distance (pm ) o f cartilage depleted ±  SEM.
43.6 Study of Isolated Vascular Function in the mCIA model
At appropriate time points aortae were removed from normal and arthritic m ice and 
prepared for myography as described in section 2.3.2i. Responses were m easured as 
described in section 2.4.
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43.6.1 Vasoconstriction
Tissues were initially depolarised by exposure to 6xlO ‘2M K+ for 5 minutes. Following 
washing and re-establishment o f baseline tension the agonist 5HT was used for 
assessment o f vasoconstriction as described in section 2.4.
43.6.2 Endothelium-Dependent Relaxation
Experiments to assess endothelium-dependent relaxation followed the protocol as 
described in section 2.4. Briefly, isolated vessels were first exposed to increasing 
concentrations o f 5HT (10'9M to 10‘5M) and a maximum constriction response obtained. 
Following washout they were re-constricted to 70-80% o f their previous maximum 
before being exposed to increasing concentrations o f  ACh (10‘9M to 10'5M) to assess 
endothelium-dependent relaxation. Following washing and appropriate reconstriction, 
endothelium-independent relaxation was assessed by exposing the tissues to increasing 
concentrations o f the NO donor sodium nitroprusside (SNP, 10*9M to 10'5M) (S0501, 
Sigma Aldrich).
43.7 Statistical Analysis
43.7.1 Histology
H & E stained sections o f  arthritic paws were scored and the results described as mean ± 
SEM for each criteria. To assess cartilage degradation the original depth and depth o f 
depletion were measured at five points on the end o f  the bone and expressed as 
percentage depleted mean ± SEM, and com pared using the one way analysis o f variance 
(ANOVA) and subsequent Student N ewm an-Keuls multiple range test.
43.7.2 Isometric Tension Recording
All data are expressed as mean ± SEM. Constriction responses to K+ and 5HT are 
expressed as developed tension in mN. Peak at 5 minute K -induced constrictions and 
Rmax (maximum response) and EC50 (concentration to produce 50% of maximum
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response) values for responses to 5HT are compared by one way ANOVA followed by 
Student Newman-Keuls multiple range test. Relaxation responses to either ACh or SNP 
are expressed as a percentage o f the appropriate 5HT-induced constriction. All 
concentration response data was first fitted to sigmoid curves using GraphPad Prism 
software and resulting EC50 and Rmax values then compared by ANOVA followed by 
Student Newman-Keuls multiple range test. Differences were considered significant 
where p<0.05.
4.4 Results
4.4.1 Arthritis Induction and Progression of the Disease
In all mice used in this thesis there was 100% incidence o f mCIA. To assess disease 
progression o f  mCIA, paws were measured/clinically scored with regard to the criteria 
outlined in section 2.2. Figure 4.1 illustrates the timeline o f  arthritis development, the 
animals having been banded in three distinct groups o f  mild, moderate and severe 
according to their total paw score as appropriate (see section 2.2). For normal animals 
there were no physical changes to their paws (data not shown). Mild arthritis was 
evident around days 24 -  28, moderate arthritis was reached around days 28 -  32, and 
severe arthritis at around day 29/30 -  35.
It is important to note that arthritis progressed differently in each animal, and as such 
there are limitations o f  the scoring criteria. The existence o f a “grey area” between the 
days o f  disease onset and a possible overlap between the severities is impossible to 
avoid. This can be seen in figure 4.1 A; a minority o f  animals reached “moderate” on 
days 34 and 35. Despite this, the utmost care was taken to be consistent in the approach 
to scoring and in doing so minimise such issues.
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Figure 4.1. Arthritic Progression in mCIA. A. Progression of arthritis in animals scoring an overall 
severity of mild (blue) (n=17), moderate (green) (n=19) and severe (red) (n=19) arthritis. B. The increase 
in paw diameter thickness as disease progresses from mild (n=17), to moderate (n=l9) and severe (n=24) 
arthritis. Mild n=, moderate n=, severe n= n > 17
4.4.2. H isto logical analysis
4.4.2.1 II & K Staining
Sections taken from the appropriately diseased paws were stained with H & E. 
Histological assessment o f each section was performed; four pathological features were 
scored namely: synovial hyperplasia, infiltration o f  inflammatory cells/fibroblasts into 
the joint, the level o f  exudate in the joint space and bone and cartilage degradation (see 
table 4.1).
Following H & E staining figure 4.2 outlines the areas o f inflammatory arthritis within
the paw that are scored as described in table 4.1. The clinical progression o f arthritis
from normal to mild, moderate and severe was reflected in the histological changes
within the inflamed paw and the subsequent scores. A significant thickening o f the
synovial membrane in the joints o f animals was observed with increasing disease
severity (fig 4.2A). This progressive change was accompanied by a large influx o f
inflammatory cells (fig 4.2B), an increase in the level o f exudate evident in the joint
space (fig 4.2C), and extensive cartilage and bone damage (fig 4.2D). Unfortunately due
to poor resolution the exact cell type can not be determined by the photos. It was
presumed that these cells would be a mixture o f macrophages, neutrophils, T-cells and
fibroblasts. The scores and differences between severities are shown in figure 4.3.
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Figure 4.2. An Example of Severe Inflammation in the Joint. A, C, E and G. Ankle joint from an 
animal with severe inflammatory arthritis (Original magnification x4). B. Arrow indicates inflamed 
synovium (arrow) (at X10 magnification). D Circle defines an area within the joint affected by a large 
influx of inflammatory cells in to the synovium (magnification xlO). F. Arrows show bone and cartilage 
damage inflammatory cells are visualised invading the bone (at XlO magnification). H. Black arrow 
signifies presence of joint exudate, nuclei of inflammatory cells stained purple (magnification x20).
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Figure 4 3 . Analysis of H & E Staining in Paws from mC’IA Animals. A. Graph showing the changes 
in synovial hyperplasia in differently affected paws, mild n=18, moderate n=23, severe n=16. B. Graph 
showing the changes in infiltrating cells in arthritic paws, mild n=15, moderate n=23, severe n=17. C. 
Results from paws scored for the level of exudate in the joint space, mild n=18, moderate n=23, severe 
n=15, and D. Results for paws scored for the degradation of cartilage and bone, mild n=18, moderate 
n=23, severe n=15. *p<0.05, **p<0.01, ***p<0.001 (according to one-way ANOVA followed by 
Newman-Keuls test for significance).
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4412 Safranin O and Fast Green Staining
Proteolytic degradation o f  articular cartilage and bone is a characteristic feature o f RA. 
Cartilage destruction attributed mainly to serine proteinases and matrix 
metalloproteinases produced by SFs, macrophages and chondrocytes (Ronday, van der 
Laanetal. 2001).
Molecules o f safranin O are small enough to penetrate the matrix o f the cartilage 
following which they bind to the glycosam inoglycan side-chains o f the cartilage in a 1:1 
ratio (Kiviranta, Jurvelin et al. 1985) producing a deep red staining (see figure 4.4). 
Enzymatic digestion o f the cartilage disrupts the binding o f the dye producing a 
bleaching effect on the colour intensity. As the original band o f cartilage is still visible 
in the section, the amount o f cartilage that has been depleted can be measured (see figure
4.5)
Sections from paws with clinical signs o f  arthritis were stained with safranin O and fast 
green to assess the level o f  dam age in the cartilage surrounding the bones. 
Measurements o f  the original depth o f  cartilage and the depth o f the lighter staining 
areas were taken at 5 points along the band o f  cartilage on the end o f  the tibia (see figure
4.5). The depleted volume was expressed as a percentage o f  the original total. As the 
clinical score progressed, the percentage o f  cartilage depleted increased. Bones from 
normal paws showed no cartilage degradation (see figure 4.6)
111
Figure 4.4. Normal Hind Paw Joint Stained with Safranin O and Fast Green. The Safranin O stains 
the cartilage and thereby a bright red band is visible on the articular surfaces of the bones (at X4 
magnification).
Figure 4.5. .Safranin () and Fast Green Staining in Normal and mCIA Joints. A. Shows deep red 
staining of Safranin O in the cartilage of the tibia in a normal healthy joint. The white line indicates the 
depth of cartilage (x20 magnification). B. As A, at x40 magnification. C. Safranin O staining in a severely 
arthritic joint. The two lines indicate the original depth of cartilage, and the depth of depletion to arthritis 
(at x20 magnification). D. An example of the bleaching effect at a higher magnification (x40 
magnification).
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Severity C artilage Depth (pm ± s.e.m ) C artilage Depletion (pm ±& e.m )
Normal 3.80 ±0.59 0
Mild 3 98 ±0.23 0.45 ± 0.22
Moderate 3.78 ±0.81 0.69 ±0.21
Severe 3 .30 ±0.70 2.87 ± 0.41
Figure 4.6. Cartilage Depletion in mCIA. A. The increase in cartilage depletion (expressed as 
percentage depletion -  calculated from data in table B) with the progression of arthritis. The paws from 
normal animals showed no degradation and thus there is no bar. *** indicates p<0.001 compared to mild 
and moderate according to one-way ANOVA analysis and Newman-Keuls post test for significance. B. 
Raw data for cartilage depletion in pm, mild n=8, moderate n=9, severe n=6.
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4.4.3. V ascular Function in the mCIA model.
4.4.3.1 Constriction Responses
Vascular function was assessed in the aortae of mCIA animals at appropriate time points 
after disease induction. These were compared to responses of vessels from normal 
animals that were sacrificed as age matched controls. Firstly responses were measured by 
depolarisation of the VSMCs by the addition o f 6xlO‘2M K + in Krebs buffer in order to 
condition the tissue. Vessels were allowed to constrict for 5 minutes at which point the 
maximum constriction reached was recorded. These constrictions showed that tissues 
from animals with experimental mCIA failed to reach the same constriction as those from 
normal (see figure 4.7).
* * *
* * * * * *
Normal
i------------------I T
Mild Moderate Severe
Figure 4.7. Developed Tension Following K+-induced Depolarisation in Normal and mCIA Animals.
Vessels were depolarised using 6xlO-2M K+ and the maximum constriction reached after 5 minutes was 
recorded, normal n=8, mild n=7, moderate n=6, severe n=7, ***p<0.001 compared to normal.
After depolarisation tissues were washed and allowed to equilibrate following which 
responses to 5HT were assessed. Similar responses to those observed for depolarisation 
with K + were observed; as arthritis progressed from mild to moderate and severe, the
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ability o f the vessels to constrict in response to 5HT was significantly reduced (see figure 
4.8). All data sets for Rmax and EC50 values were compared to each other. Rmax values 
for responses from severe and moderate tissue were found to be significantly lower 
(p<0.001) than responses from both normal and mild tissue. Rmax values for mild tissue 
responses were also significantly higher (p<0.05) compared to those from normal tissue. 
EC50 values for diseased tissue were all significantly higher than EC50 values for normal 
tissue (p<0.001) however no statistical difference existed between disease cohorts.
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Figure 4.8. V ascular Responses in the mCIA Model. Graph showing concentration response curves to 
5HT in vessels from normal (n=5) animals compared to vessels from A, mild (n=7), B, moderate (n=6) and 
C, severe (n=5) animals. *** p<0.001 compared to normal * p<0.05 compared to normal.
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Rmax Values (mN) Level of Significance 
Compared to Normal
Normal 6.22 ±0.14
Mild 5.47 ± 0.28 *
Moderate 3.96 ±0.11 ***
Severe 3.75 ±0.16 ***
EC50 Values (M) Level of Significance Compared to Normal
Normal 5.46 x 10-8
Mild 9.69 x 10-* ***
Moderate 1.05 x 10'7 M H t
Severe 8.81 x 10-* 1rtrk
Table 4.2. Rmax and EC50 values for Vascular Constriction in the mCIA Model. Rmax values shown 
as developed tension in mN, and EC50 in concentration (M). *p<0.05, ***p<0.001 (compared by one-way 
ANOVA followed by Newman-Keuls statistical analysis.
4A3.2 Relaxation Responses
Relaxation responses were originally measured using the method outlined in section 2.4 
(all tissues were re-constricted to 70-80% o f their maximum response to 5HT before 
exposure to ACh). Vessels from all animals relaxed fully, and no significant difference 
between groups were observed (see figure 4.9). Rmax and EC50 values are compared in 
table 4.3.
However, since the extent to which tissues are constricted can have a significant effect on 
their subsequent ability to relax (more constriction/less relaxation and vice versa), these 
experiments were repeated using a new protocol. To this end tissues from mild, moderate 
and severe animals were again constricted to 70-80% o f their appropriate maximum 
response to 5HT. Importantly normal tissues were constricted to corresponding levels by 
altering the concentration o f 5HT applied (for concentrations used see table 4.4). 
Concentration responses to ACh were then earned out as above. As shown in figure 
4.10, this set o f experiments confirmed that there was no apparent difference in relaxation 
responses between tissues from normal, mild, moderate and severe animals. For Rmax 
and EC50 values see table 4.5
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Figure 4.9. Initial Relaxation Responses to ACh in the mCIA Model. Vessels were constricted to 70- 
80% of their previously induced maximum before relaxing using the agent ACh. A. responses from normal 
(n=6) and mild (n=5) tissues, B. Responses from normal and moderate (n=5) tissues, C responses from 
normal and severe (n=5) tissues.
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Rmax Values (%)
Normal 73.37 ± 5.09
Mild 76.78 ± 3.37
Moderate 83.82 ±12.52
Severe 83.42 ± 6.51
EC50 Values (M)
Normal 3.44 x 10*
Mild 3.86 x 10*
Moderate 2.31 x 10-8
Severe 4.94 x 10*8
Table 4J. Rmax and EC50 Values for the Initial Relaxation Responses. Values shown as developed 
tension for the Rmax values (%) and the EC50 values in concentration
Developed constriction attained 
at 70>80% of maximum 
(approximate) (mN)
Concentration range needed 
to reach this (M)
Concentration range needed 
to reach this in normal tissue
(M)
MHd 5.5 3x10'7 10'7 - 3x10*7
Modarate 4 3x10*7 -10* 10"7 - 3x10'7
Severe 3.5 3x10‘7 -10* 10*7
Table 4.4. Concentrations of 5HT used to Obtain Similar Constrictions. The concentrations 
(approximate) listed were used to elicit the same level of constriction in vessels from normal animals as 
mCIA animals. Vessel relaxation responses were then measured from the same level of tension.
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Figure 4.10. Relaxation Responses in the Aortae from the mCIA model. Vessels from normal animals 
were constricted to the same level of tension as vessels from mCIA animals in order to directly compare 
vessel relaxation. Responses from tissue taken from normal (n=6) animals compared to tissue taken from A 
mild (n=5). B moderate (n=5) and C severely (n=5) affected animals.
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Rmax Values (%)
Normal 65.00 ±1.54
Mild 66.08 ±4.14
Normal 61.65 ±1.33
Moderate 80.26 ± 8.55
Normal 68.71 ±2.14
Severe 68.16 ±3.20
EC50 Values (M)
Normal 3.24 x 10-*
Mild 5.30 x 10-*
Normal 2.54 x 10-*
Moderate 2.72 x 10-“
Normal 1.25 x 10-*
Severe 1.29 x 10-*
Table 4.5. Rmax and EC50 Values for Relaxation Data. Rmax values are expressed as maximum 
percentage relaxed (%), and EC50 values as the concentration (M) needed to obtain 50% of the relaxation 
observed.
To ensure that the relaxation capability o f the VSMCs was not compromised in anyway 
responses to the NO-donor SNP were also measured. There were no apparent differences 
between these responses in any group o f animal (see figure 4.11) with regard to EC50 
values and Rmax values (see table 4.6).
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Figure 4.11. Relaxation Responses to SNP. A Relaxation responses to SNP from normal (n=3)and mild 
(n=5) vessels. B. Responses from normal and moderate (n=4) vessels, and C. From normal and severe 
(n=3) vessels.
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Rmax Values (%)
Normal 100.10 ±2.01
Mild 94.67 ± 3.66
Moderate 98.10 ±2.90
Severe 97.89 ± 2.48
EC50 Values (M)
Normal 1.36 x 10*®
Mild 3.08 x 10-®
Moderate 2.29 x 10-®
Severe 1.23 x 10*®
Table 4.6. Rmax and EC50 values for Relaxation Responses to SNP. Rmax values are expressed as the 
naximum relaxation (%) and EC50 values as concentration (M).
4.5 Discussion
45.1. Successful Induction of mCIA
The successful induction o f mCIA in DBA/1 mice was apparent by the level o f paw 
swelling shown clinically and the extent o f inflammatory cell influx and changes to 
cartilage and bone shown histologically. In all cases the progression in the clinical signs 
of arthritis were accompanied by sequential histological changes within the paw. These 
were shown by higher levels o f inflammatory cells invading the joints and the joint space, 
synovial thickening within the joint and by the increased levels o f cartilage and bone 
degradation. The latter was further confirmed using safranin O and fast green staining to 
assess in detail the progressive level o f cartilage erosion.
The scoring criteria for this model attempts to distinguish between mild, moderate and 
severe arthritis and was established in order to effectively evaluate the 
relationship/timeline between the possible development o f vascular dysfunction and the 
progression o f experimental arthritis. While every effort was taken to adopt a consistent 
and unifying approach to the clinical assessment criteria, uncontrollable biological factors 
on occasion made this difficult. Since each mouse affected with mCIA has a unique 
timescale for the progression o f disease, individual animals sometimes could reach mild, 
moderate or severe disease at different time points, post-second injection. The majority 
of animals reached the appropriate disease stage as outlined in section 4.4.1, however this 
was not always the case. For example arthritis in one animal may take 5 days to present 
itself, following which it progresses to severe in 3 days. Alternatively a mouse could 
show slight swelling on day 23 and from this point progress slowly to moderate arthritis 
at day 26, and reach severe at day 32. Every effort was therefore taken to group animals 
of similar disease aetiology when investigating the mild, moderate and severe categories. 
The “tight” nature o f the data described above would suggest that any possible problems 
due to such idiosyncratic variations have been minimised.
4.5.2. Changes to the Vasculature as a Result of mCIA
From these experiments it was observed that as the number o f joints affected increased 
and clinical symptoms o f arthritis deteriorated, the ability o f the isolated aortic rings to 
constrict to either K* or 5HT became significantly reduced. Interestingly, this was not 
accompanied by a reduction in the ability o f the vessel to relax to ACh.
452.1  Vessel Constriction in the mCIA Model
The initial observation made with regard to vessel function in aortae from the mCLA 
animal was the change in the ability o f the vessel to constrict following K+-induced 
depolarisation, implying a change in the contractile ability o f the VSMCs. This change 
was further confirmed by the responses to 5HT, with maximal constrictions in vessels 
from mCLA animals failing to reach those o f their normal counterparts. Such responses 
for all diseased groups were significantly lower than the constrictions attained in normal 
tissues with regard to Rmax. The maximum contractile ability o f the vessels from 
arthritic animals deteriorated with disease severity; aortae taken from mild animals had a
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small decrease in the maximum constriction reached, moderate and severe vessels were 
further inhibited in this ability. In addition to the change in Rmax values, EC50 values 
were also significantly reduced in responses from diseased tissues compared to normal, 
implying that there may be a decrease in sensitivity to 5HT in these diseased vessels. This 
could be due to differential expression o f receptors with progression o f disease, or 
compromised interactions between agonist and receptor. Additional experiments could be 
performed to determine the levels o f the receptor present (perhaps by western blot), or an 
attempt could be made to visualise the effect o f binding on the cell (by calcium 
signalling) to determine the downstream effect o f the agonist on the VSMCs. However, 
given that contractile responses to both K* and 5HT are impaired would argue against a 
defect in receptor-medicated responses. Moreover such experiments would prove time- 
consuming and somewhat outside the scope o f this project. Instead focus will be placed 
on investigating the mechanistic changes that underlie the contractile dysfunction. While 
this will be addressed experimentally in later chapters o f this thesis, as a prelude it is 
appropriate to speculate as to their nature here.
Within the inflammatory setting a large number o f events are occurring resulting in 
upregulation o f a wide range o f cytokines, chemokines and inflammatory cells and 
mediators (Kaplan 2006) both in the joint and the vasculature. Once in the circulation, 
these individual factors may initiate a downstream cascade o f events resulting in damage 
to the cells therein. In order to prevent this damage occurring, the cells o f the vasculature 
may change their function in an attempt to self-protect, perhaps by increasing the 
production o f protective molecules such as NO and PGI2. These potent vasodilators are 
the products o f NOS or COX activity respectively and possible “inflammation-induced” 
upregulation o f these enzymes could lead to such an action. This in turn would serve to 
counteract the effects o f K+ and 5HT and dampen maximal constriction. The diminished 
constriction observed in the mCLA model could therefore be a result o f an increase in the 
production o f the vaso-protective and vasodilatory molecules. This may follow the 
pattern observed with constriction “dampening” increasing with arthritic severity and as 
such investigating production o f these vasodilators is o f utmost importance. This will be 
discussed below and investigated in the following chapters.
43.2.2 Changes in NO Levels
Upregulated levels o f eNOS at both the mRNA and protein level have been shown to be 
associated with endothelial dysfunction in a model o f diabetes mellitus (Hink, Li et al. 
2001). In this model eNOS became dysfunctional, however the timeline for this change 
was not discussed, allowing for speculation that initially functional eNOS may be 
upregulated before endothelial dysfunction occurs. If this occurred in mCIA model, such 
upregulation could be the cause o f an overproduction o f NO.
A further possibility is the upregulation o f iNOS and consequently uncontrolled 
overproduction o f NO. Indeed, in RA it is well documented that iNOS is upregulated and 
is a producer o f large amounts o f NO (Cuzzocrea 2006). This is perhaps unsurprising as 
iNOS is speculated to be induced following a surge in inflammatory mediators such as 
IL-ip and TNFa (Gibson, Constantin et al. 2005), cytokines which are upregulated in 
both human disease (Shore, Jaglal et al. 1986; van den Berg 2001) and mCIA (Marinova- 
Mutafchieva, Williams et al. 1997). Moreover, in an alternative, bacterial cell wall- 
induced model o f arthritis, increased production o f  inflammatory cytokines is associated 
with an upregulation o f iNOS gene expression and increased circulating NO levels 
(Wahl, McCartney-Francis et al. 2003). Such an increase in the present model would 
certainly contribute to decreased responsiveness/sensitivity to 5HT in isolated tissues.
4.5.23 Changes in PGI2 Levels
PGI2 is a potent vasodilator and inhibitor o f platelet aggregation and VSMC proliferation 
(Funk and FitzGerald 2007), and therefore plays an essential role in maintaining vessel 
tone. COX-2, a producer o f PGI2 is known to be upregulated under inflammatory 
conditions (Suleyman, Demircan et al. 2007) thus increasing circulating levels of this 
molecule in inflammatory systems. Additionally, an increase in the urinary metabolite o f 
this molecule has been detected in human RA (Hishinuma, Nakamura et al. 2001). As 
such it is possible that in the mCIA model there will be higher levels o f circulating PGI2 
indicating a role for this molecule in the development o f decreased responsiveness to 
5HT.
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Currently there is limited evidence surrounding these hypotheses in the vasculature o f the 
mCIA model and subsequent investigation will be provided in detail in the following 
chapter.
AS.2A Vessel Relaxation in the mCIA Model
Despite many reports in the literature o f endothelial dysfunction in RA-affected human 
(Sattar and Mclnnes 2005; Libby 2008) and animal models (Can, Cinar et al. 2002; 
Haruna, Morita et al. 2006; Haruna, Morita et al. 2007; Nozaki, Goto et al. 2007), it 
would appear that the model described in this thesis is not overtly characterised by this 
condition. Why this should be the case is open to speculation.
In line with current research publications, adult male DBA/1 mice were used for the 
studies (Inglis, Notley et al. 2007; Andreakos, Rauchhaus et al. 2009; Nowell, Williams 
et al. 2009) aged 8 10 weeks, an age at which they are considered adult. However, 
comparatively speaking, the age o f arthritis onset in these animals is much younger than 
observed in human RA; DBA/1 mice are "skeletally" adult, (at 8-10 weeks their skeletal 
development is complete, personal communication Dr AS Williams) and so the age o f 
onset would be proportional to a 16-18 year old human. Conversely the average age o f 
disease onset in humans is 40-50 years. While the mice may be deemed adult, they may 
still be "vascularly" immature. This leads to speculation as to whether the “young” mouse 
vessels are prone to the development o f endothelial dysfunction. It is well recognised that 
as vessels age they lose their natural resistance to ROS and other damaging agents 
(Csiszar, Labinskyy et al. 2007), and thus the relatively young age o f these animals could 
mean compensatory mechanisms in response to mCLA prevent endothelial dysfunction. 
For example, the generation o f anti-oxidant molecules such as superoxide dismutase, 
heme oxygenase, catalase, peroxidase/peroxiredoxin (Forstermann 2008) to name but a 
few are capable o f protecting against ROS and superoxide damage.
Natural resistance o f the vessel to these damaging species is diminished as the vessels 
age. Age-related vascular pathologies in humans have been attributed to an increase in 
ROS production, coupled with a decrease in natural resistance, an occurrence which 
becomes more frequent with age (Csiszar, Labinskyy et al. 2007). Indeed the longevity o f 
a species is associated with the ability o f the vessel to prevent damage by these reactive
species (Labinskyy, Mukhopadhyay et al. 2009). As such, due to the relatively short 
lifespan o f the DBA/1 species (C57BL/6 in comparison live on average to 22 months 
(Storer 1966)) it may be speculated that the protective changes are perhaps unlikely to be 
occurring and in fact, these vessels may be more prone to oxidative damage. Nonetheless, 
endothelial dysfunction remains absent in this model.
An additional argument opposing this “age theory” is that endothelial dysfunction has 
been reported in children who present risk factors such as diabetes mellitus, or have high 
circulating levels o f C-reactive protein (Urbina, Williams et al. 2009). Moreover, juvenile 
arthritis has been described to affect children under the age o f 16 (Hayward and Wallace 
2009), and be accompanied by vascular impairment; capillaries o f the microcirculation 
become widened and exhibit other structural abnormalities speculated to herald the onset 
of endothelial dysfunction (Gorska, Kowal-Bielecka et al. 2008).
An alternative theory is that endothelial dysfunction might be present in the mCLA model, 
but the means by which it was assessed may not be appropriate/sensitive enough. For 
instance in rabbit aortic segments incubated with oxidised-low density lipoprotein (ox- 
LDL), varying relaxation responses were observed depending on the vasodilator used 
(Bocker, Miller et al. 2001). In this study relaxation responses to thrombin were 
impaired while those to ADP unaffected. In the present studies ACh was used and 
elicited responses comparable to those o f “normal” animals, indicating no change in 
endothelial function. ACh is an M3 muscarinic receptor agonist and the “agent of 
choice” in in vitro experiments investigating endothelial function. While further studies 
with other endothelium-dependent vasodilators were a possibility, it was deemed of 
higher importance to assess the possible mechanical changes occurring to the VSMCs 
and to investigate changes in endogenous vasodilator production.
These results do not entirely discount the presence o f endothelial dysfunction in the 
mCLA model. Since disease progression is only permitted over a short time course there 
may not be enough time for this condition to become overt. Indeed other changes that 
could be less noticeable in the patients with human disease may develop first in the 
animal model. However it does not appear that the changes relating to endothelial 
dysfunction outlined in the hypothesis are occurring in this model in our hands.
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As a result o f this experimental work it is obvious that the original proposed hypothesis 
for the endothelial dysfunction that would present in a model o f mCLA can be discounted. 
However this work has deduced that there is a problem with the contractile function of 
the vessel and as such, the aim is to elucidate the mechanism(s) responsible for such 
changes. In order to do this, the theory that constriction is muted due to an over 
production o f vasodilatory compounds will be investigated.
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CHAPTER 5
VASCULAR DYSFUNCTION IN MCIA: A ROLE FOR NO AND
COX?
5.1 Introduction
In Chapter Four no discemable endothelial dysfunction was observed in the mCLA 
model. Furthermore, the ability o f the VSMC to relax to exogenous NO (in the form of 
SNP) was not compromised. It was observed that vessels from diseased animals 
constricted in response to agonist stimulation; this vascular response decreased with 
increasing arthritis severity. Although defects in the contractile apparatus may be present 
in the VSMCs, given the ability o f NO and PGI2 to dampen vessel contraction it is 
important to first assess any possible role these vasodilators may play in the development 
o f this dysfunction.
5.1.1 U p re g u la tio n  o f  N O S Iso fo rm s
Information regarding the activity and expression o f NOS isoforms in this model remains 
unclear. Although it has been suggested that upregulation may occur (see Chapter Four) 
this is merely speculation. Aberrant NOS isoform activity could potentially affect basal 
tone; excess production o f NO may result in a continual partially dilated vessel and the 
possibility o f low blood pressure. Alternatively, the change in vessel function observed 
could be due to the loss o f compliance leading to vessels becoming stiffer and unable to 
constrict. In this scenario, hypertension could ensue (Zieman, Melenovsky et al. 2005; 
Tsioufis, Dimitriadis et al. 2007). Indeed the observation that vessel stiffening occurs in 
hypertensive patients, and that such hypertension is not an uncommon pathology 
observed in patients suffering from RA (for a recent review see (Panoulas, Metsios et al. 
2008)) gives fuel to this theory. Interestingly, levels o f both iNOS and eNOS are 
upregulated in spontaneously hypertensive rats (Vaziri, Ni et al. 1998) emphasising the 
need to investigate the roles o f these enzymes in this model.
If eNOS levels/activity remain stable and functional, the proposed change in NO 
bioavailability may be due to altered iNOS activity, which perhaps would not be an
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▼unexpected occurrence in this inflammatory disease. Indeed in human RA an increased 
level of endogenous NO due to upregulation o f iNOS, reflected as an increase in serum 
NO metabolites, has been described (Yki-Jarvinen, Bergholm et al. 2003). Moreover, in- 
vitro observations show an increase in iNOS mRNA levels in cultured human VSMCs 
following stimulation with inflammatory cytokines IL-1 and TNF-a (MacNaul and 
Hutchinson 1993), both o f which are characteristic o f mCIA and human RA. Additional 
factors may also play a role in this “NO hypothesis” . For instance, vascular endothelial 
growth factor (VEGF), a pro-angiogenic cytokine, is upregulated in the paws o f mCLA 
animals (Choi, Kirn et al. 2009) and plays an important role in the initial stages of arthritis 
(Lu, Kasama et al. 2000). It has been observed that during angiogenesis VEGF can 
induce expression o f both eNOS and iNOS resulting in an increased production of NO 
(Kroll and Waltenberger 1998). Contrastingly a decrease in endothelial cell eNOS 
mRNA and protein levels following stimulation with TNFa has been observed (Jantzen, 
Konemann et al. 2007) perhaps questioning a role for eNOS in the vascular pathology 
observed in this thesis.
Due to the multi factorial nature o f the disease model a myriad o f events are occurring 
throughout disease progression. Taken together the above observations certainly suggest 
that a role for increased NO production in the mCIA model merits greater scrutiny.
5.1.2 M a rk e rs  o f  N O S A ctiv ity
A common method o f assessing in-vivo eNOS activity is by determining plasma 
concentrations o f the more stable oxidative products o f NO metabolism, namely nitrite 
(NO2 ) and nitrate (NO3 ), subsequently described widely as total NO (NOx). This 
measurement is based on the fact that eNOS-derived NO rapidly reacts with both oxy- 
and deoxy-haemaglobin (deoxy-Hb) to produce N0 3 ‘ and iron-nitrosylhaemoglobin 
respectively (Liu, Miller et al. 1998). Alternatively NO that fails to react with Hb is 
oxidized to N 0 2 in the plasma (Shiva, Wang et al. 2006) and can be further converted to 
NO3' (Kelm, Schafer et al. 1997). Moreover, NO when inhaled or added to the blood, is 
also rapidly converted to these NO-metabolites (Lauer, Preik et al. 2001). Importantly 
circulating NOx levels in eNOS -/- animals are reduced by half compared to normal
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A
counterparts (Godecke, Decking et al. 1998) confirming the usefulness o f this parameter 
in assessing in vivo eNOS activity.
There are several things to consider when measuring NOx since the rate of NO 
metabolism is highly dependent on its location, concentration and indeed the 
concentration o f other bioreactors in the immediate environment. For example 
juxtaposition with cellular membranes, differences in p 0 2, the presence o f ROS, changes 
in pH and the concentration o f transition metals all have various positive and negative 
influences on NO bioavailability (for review see (Kelm, Schafer et al. 1997). Moreover, 
additional quantification difficulties may arise due to the abundant nature of N 0 2' in the 
laboratory. Extra precautions are therefore required to limit contaminating N 0 2‘ in blood 
collection tubes and avoid overestimation o f NOx levels (Dejam, Hunter et al. 2005). 
Importantly, the above parameters should not overtly affect measurements taken in the 
present study since they should have equal influence on both control and diseased 
animals. Indeed changes in NOx should appropriately reflect disease activity and the role 
of NO therein.
5.13  U p re g u la tio n  o f  C O X  p ro d u c ts
COX products such as prostanoids play important roles in vascular homeostasis and both 
COX-1 and -2 may potentially mediate changes to vessel function under the 
inflammatory conditions imposed by the mCLA model. For instance, COX-1 is 
upregulated in human umbilical vein endothelial cells (HUVECs) following exposure to 
VEGF (Bryant, Appleton et al. 1998). Interestingly concomitant NOS isoform 
upregulation was absent in this study, possibly reflecting differential regulation o f vein 
and arterial enzymes. However, upregulation o f COX-1 in endothelial or smooth muscle 
cells in the mCLA model could lead to a significant increase in the production o f PGI2, 
the vasodilatory properties o f which could mediate the observed dampening of 
contraction.
The more likely mediator in the disruption o f normal vessel function in RA is inducible 
COX-2, widely demonstrated to be upregulated in inflamed tissues (Suleyman, Demircan 
et al. 2007) and the primary producer o f PGI2 (for review see (Funk and FitzGerald 
2007). That a four-fold increase in the urinary metabolite o f PGI2 has been described in
human RA (Hishinuma, Nakamura et al. 2001) indicates a possible role for PGI2 
regulation in this inflammatory disease. Further investigations in the present model are 
therefore warranted.
5.1.4 In h ib itio n  o f  N O S a n d  C O X
5.1.4.1 Nc -N itro-L-A rginine M ethyl E ster (LNAM E) and 1400W
Inhibition o f NOS activity was assessed using the L-arginine analogue N°-nitro-L- 
arginine methyl ester (L-NAME), and N-(3-(Aminomethyl)benzyl)acetamidine (1400W). 
L-NAME is a widely used non-specific competitive NOS inhibitor while 1400W is the 
most selective inhibitor of iNOS known to date (Garvey, Oplinger et al. 1997). Indeed 
1400W is 5000- and 200-fold more potent against purified human iNOS than eNOS and 
nNOS respectively (Garvey, Oplinger et al. 1997). By conducting separate experiments 
with these agents the relative roles o f eNOS and iNOS in the contractile dysfunction 
observed in the mCIA model was investigated.
5.1.4.2 Indom ethacin
Indomethacin is a non-steroidal anti-inflammatory (NSAID) drug administered for pain 
relief in conditions such as RA (Hart and Boardman 1963), and widely used as a 
pharmacological tool in investigations o f vascular-derived COX products. By insertion 
of a methyl group into the active site o f COX (Prusakiewicz, Felts et al. 2004) 
indomethacin acts as an inhibitor (Ersoy, Orhan et al. 2008). Its use will initially provide 
general information with regard to the role o f COX-derived products in the contractile 
dysfunction observed in the mCLA model. More specific experiments may follow as 
appropriate.
5.2 Aims
To assess the role o f NOS in vessel dysfunction in the mCIA model utilising broad 
spectrum and specific NOS inhibitors.
Determine plasma levels o f NO metabolites to assess NO bioavailability in the mCIA 
model
133
To assess the role o f COX in vessel dysfunction in the mCIA model utilising a broad 
spectrum COX inhibitor.
5.3 Method
53.1 Induction of mCIA
mCIA was induced in male DBA/1 mice as described in section 2.2.
53.2 The role of NOS
53.2.1 Analysing the EfTect of the non-specific NOS inhib itor L-NAME
At appropriate time points mCIA and control animals were euthanised and blood (see 
below) and aortae removed. The latter was then prepared for myography as detailed in 
section 2.3.1 and 2.3.2ii. To assess the general role o f NOS isoforms in the aortic 
responses a non-specific inhibitor was used initially. To this end constriction responses 
were measured as outlined in section 2.4 but with the addition o f an incubation period 
with L-NAME (N5751, Sigma Aldrich). Following the constriction response to K+ 
vessels were incubated with L-NAME (3x1 O^M, a concentration widely used in the 
literature to completely inhibit NO production) for 30 minutes before responses to bolus 
additions o f 5HT and ACh were assessed as before (section 2.4), though this time to 
ensure inhibition o f endothelium-dependent relaxation. Following washing L-NAME 
was re-added to the bath and incubated for a further 30 minutes. Concentration responses 
to 5HT were then assessed as before (section 2.4).
53.2.2 Analysing the EfTect of the iNOS Inh ib ito r 1400W
Experiments as 5.3.2.1 above were repeated with 1400W (10'5M, W4262, Sigma Aldrich) 
(Alvarez, Briones et al. 2008) in place o f L-NAME. Following incubation with 1400W 
for 30 minutes vessels were subjected to bolus responses to 5HT and ACh as described in 
section 2.4. Importantly, endothelium-dependent relaxation to this bolus addition o f ACh 
(10'6M) was not affected by this agent (see results section 5.4.2). Constriction responses 
to 5HT were then assessed as before (section 2.4).
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Endothelium-dependent relaxation was also measured in these experiments as outlined in 
section 2.4 and 4.3.6.2. Briefly, following the maximum constriction response, vessels 
were washed, 1400W re-added and the tissues left to re-equilibrate before being re- 
constricted to 70-80% o f their previous maximum and subsequently exposed to 
increasing concentrations o f ACh (10'9M to 10*5M).
5J.2.3 NO M etabolites in the Blood
The Sievers® 280i NO Analyzer (NOA, Analytix UK) is a highly sensitive system with 
detection limits of less than 1 picomole (MacArthur, Shiva et al. 2007). The principle of 
using chemiluminescence to detect NOx is based on the reaction between NO and ozone 
(O3), which produces NO2 in an excited state (NO2*, see equation below). When the 
excited electron returns to its ground state it emits a photon (hv) that is detectable and 
amplified by a photomultiplying tube in order to generate an electrical signal.
NO + 0 3 —► N 0 2* + 0 2 
N 0 2* -+  N 0 2 + hv
The NOA is attached directly to the glassware (the reaction chamber) and generates the 
O3 for reacting with NO. The glassware contains a redox-active chemical solution which 
reduces the NOx to NO (MacArthur, Shiva et al. 2007). Samples are injected into this 
chemical solution in the reaction chamber where NO metabolites are reduced to NO and 
subsequently forced by the flow o f oxygen-free nitrogen into the NOA for detection.
At appropriate time points, serum was prepared from blood samples collected at the time 
of aortic tissue harvesting as described in section 2.3. Concentrations o f NO metabolites 
were subsequently measured using ozone-based chemiluminescesce (Rogers, Khalatbari 
et al. 2005). Briefly, 5ml o f tri-iodide reagent (70ml glacial acetic acid, 650mg iodine 
(I2), 20ml HPLC grade water, lg  potassium iodide (KJ)) was added to the reaction 
chamber with 20pl o f anti-foam (A5633, Sigma Aldrich) (to prevent foaming o f the 
serum), before heating to 50°C on a thermostatically-controlled hot plate (see figure 5.1). 
Oxygen-free nitrogen gas was bubbled through the reaction chamber to force the NO 
towards the NOA. On route the NO passes by a sodium hydroxide (NaOH) (1M) 
chemical trap necessary for removal o f oxygen-nitrogen compounds (eg N2O3) as well as 
preventing damage to the NOA from acid vapour (due to the acidic nature o f the tri­
iodide). Sodium nitrite standards for the calibration curve were made up in increasing 
concentrations from 62.5nM to lOOOnM and HPLC water was used as a control. lOOpl
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standards were injected into the reaction chamber and the peak electrical signal was 
recorded using the data collection package “Liquid” (part o f the NOAnalysis software 
suite). Serum samples were thawed in a 37°C water bath for one minute before injection. 
All standards and samples were repeated three times and measurements then averaged.
For signal analysis purposes the signal to noise ratio (and accuracy of area under curve 
(AUC) analysis) was improved by exporting the Liquid file to the data analysis and 
graphing software Origin 8.1 (Originlab*) and the "peak analysis" feature was utilised. 
Adjacent signal averaging was used to smooth the peak and determine manually the start 
and end point o f each peak. The AUC for each sample was measured and averaged and 
sample values for each group combined. This analysis results in improved repeatability 
of measurement.
NOA
ln«rt Carrier 
G as (Nj)
1M NaOH 
Trap Signal (mV)
Rubber Septum Injection Port 
Gas Outlet
Water Jacket
Gas Outlet
Thermostatically Controlled Hot Plate
Figure 5.1. Apparatus for Nitric Oxide Analysis. The sample is injected into the injection port, NO- 
related species are reduced/converted to NO and carried with the oxygen-free nitrogen through the 
chemical trap to the NOA, where the electrical signal is created. Reproduced with kind permission from Dr 
Andrew Pinder (Pinder, Rogers et al. 2009).
5.3.3 The role of COX
5.3.3.1 Analysing the Effect of the non-specific COX Inh ib ito r Indom cthacin
To assess the general role o f COX isoforms in the aortic responses, a non-specific
inhibitor was used. Experiments as 5.3.2.1 above were repeated with indomethacin (10
<M, 57413 Sigma Aldrich,) (Quinn, O'Brien et al. 2003) in place of L-NAME.
136
Jndomethacin was initially dissolved in ethanol and then diluted in Krebs buffer ensuring 
the final ethanol concentration at the tissue was no higher than 0 .0 1 % (v/v) (a 
concentration widely known to have no effect on vascular tone, personal communication 
Dr D Lang). Importantly, endothelium-dependent relaxation to a bolus addition of ACh 
(10"*M) following constriction with 5HT (10*6M) was not affected by this agent (see 
results section 5.4.5). Concentration responses to 5HT and ACh respectively were then 
performed as described above (see 5.3.2.2).
53.4 S ta tis tica l A nalysis
All data are expressed as mean ± SEM. 5HT-induced increases in tension are expressed 
as developed tension in mN. Relaxation responses are expressed as a percentage o f the 
immediately previous, agonist-induced maximum constriction. Isometric tension data 
were first fitted to sigmoid concentration curves using GraphPad Prism software and 
EC50 (concentration to produce 50% o f maximum response) and maximum 
constriction/relaxation (Rmax) values analysed by one-way ANOVA followed by 
Student Newman-Keuls multiple range test. Rmax values were plotted on a bar graph to 
compare values. For direct comparison o f EC50 values the negative log of the mean 
value and the standard error o f this mean was taken and plotted in a bar graph.
Data from NO analysis were expressed as average levels o f NOx in the serum, mean ± 
SEM. Results were analysed by one-way ANOVA followed by Student Newman-Keuls 
multiple range test. For all data sets, differences were considered significant where 
p<0.05.
5.4 Results
5.4.1 Vessel Constriction in the Presence of L-NAME
Preliminary experiments showed that the presence o f L-NAME had no significant effect 
ou the constriction responses to 5HT in normal tissues (see figure 5.2). Importantly the 
tissues failed to relax in response to ACh confirming complete eNOS inhibition (an 
example o f this is shown in the trace in figure 5.3). Vessels from experimentally arthritic 
animals exhibited the same impairment in 5HT-induced tension as observed in Chapter
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Four. In the presence o f L-NAME, while Rmax values for tissues from all three disease 
cohorts were marginally greater than those in the absence o f the eNOS inhibitor, these 
responses were still significantly lower than those observed in normals (see figure 5.4). 
No differences in EC50 values between any groups were observed (see table 5.1 for 
graphs and values).
1 2 -i
10-
■ Normal 
a Normal + LNAME
-10 9 -8 -7 -6 5 -4
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Figure 5.2. Responses from Normal Tissue in the Absence and Presence of L-NAME. No significant 
difference between responses (n=4).
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Figure 5.3. Representative Trace Showing Constriction and Relaxation Responses to Bolus 
Concentrations of 5HT and ACh (both 10'6\1) in Normal Tissues in the Presence of L-NAME. 
Arrows show the point at which agonists were added.
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Figure 5.4. Craphs Showing Contractile Responses in Y;essels from Normal and mCIA Animals in 
the Absence and Presence of L-NAME. A. Responses from normal (n=5) and mild (n=6) tissue, the latter 
in the absence and presence of L-NAME (n=6). B. The same responses in tissue from moderately (n=4) 
diseased animals with LNAME (n=4). C Responses in vessels from severe (n=5) animals and with LNAME 
(n=6). *p<0.05, **p<0.01 and ***p<0.001 for Rmax compared to normal analysed by one-way ANOVA 
followed by Newman-Keuls test.
139
Rmax Values (mN) Level of Significance 
Compared to Normal
Normal 10.80 ± 0.25 -
Mild 7.82 ± 0.92 *
Mild and LNAME 8.86 ±0.36 *
Normal 10.80 ± 0.25 -
Moderate 7.44 ±0.46 ***
Moderate and 
LNAME 7.67 ±0.22
***
Normal 10.80 ±0.25 -
Severe 7.44 ±0.30 ***
Severe and LNAME 8.34 ±0.28 ***
EC50 Values (M) Level of Significance Compared to Normal
Normal 4.08 x 10-®
Mild 7.04 x 10
Mild and LNAME 4.55 x 1C8
Normal 4.06 x 10-®
Moderate 7.60 x 10 ^
Moderate and 
LNAME 4.56 x 10*
Normal 4.08 x 10*
Severe 7.79 x 10-8
Severe and LNAME 6.45 x 10* -
Table 5.1. Rmax and EC50 Values for Constrictions in the Absence and Presence o f L-NAME. Raw
data for responses shown in figure 5.5. *p < 0 .05 , ** *p < 0 .0 0 1  compared to normal.
5.4.2 Vessel Constriction in the Presence of 1400YV
Preliminary experiments showed that 1400W had a minor, but not significant effect on 
5HT-induced constriction responses in tissues from normal animals (see figure 5.5). 
Additionally the iNOS inhibitor had no effect on normal vessel relaxation indicating the 
preservation of fully functional eNOS (see figure 5.6). Vessels from experimentally 
arthritic animals exhibited the same impairment in 5HT-induced tension as observed in 
Chapter Four. Incubation o f tissue from diseased animals with 1400W appeared to 
further dampen (significantly so in moderate (p<0.01) and severe (p<0.05) tissues) the 
maximum 5HT-induccd tension (Rmax). Importantly all Rmax values for constriction 
responses in vessels from diseased animals (in the absence or presence o f 1400W) were 
significantly (p<0.05) lower than those observed in normals (see figure 5.7). There was 
no significant statistical difference between the EC50 values for any groups (see table
Figure 5.5. Constriction Responses in the Absence and Presence of 1400W in Normal Tissue.
Constriction responses from normal tissue to 5HT in the presence and absence of 1400W (n=4).
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Figure 5.6. Representative Trace Showing Vessel Constriction and Relaxation in response to Bolus 
Concentrations of 5IIT and ACh (both lO^M) in Normal Tissues in the Presence of 1400W. Arrows 
show the points at which the agonists were added.
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Figure 5.7. Graphs Showing Constriction Responses in Tissue from Normal and mCIA Animals in 
the Absence and Presence of 1400VV. A. Constriction responses to 5HT from normal (n=5) and mild 
(n=4) tissue, the latter in the presence of 1400W. B. The same responses from moderate (n=3) tissue. C 
Responses from severe (n-3) tissues *p<0.05, **p<0.0l and ***p<0.00l for Rmax compared to normal 
analysed by one-way ANOVA followed by Newman-Keuls test. Bar indicates there is a significant 
difference between the two groups.
Normal
Mild
Mild + 1400W
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Rmax Values (mN) Level of Significance 
Compared to Normal
Normal 7.85 ±0  21 -
Mild 6 34 ±0  68 *
Mild and 1400W 5.00 ± 0.60 **
Normal 7 85 ±0.21 -
Moderate 4 99 ±0  29 ***
Moderate and 
1400W 3 .74 ±0  .15 compared to normal/moderate
Normal 7 85 ±0  21 -
Severe 4 83 ±0  30 mm
Severe and 14O0W 4 0 8 ± 0  11 compared to 
normal/moderate
EC50 Values (M) Level of Significance 
Compared to Normal
Normal 7 10 x 10-* -
Mild 7.90 x 10-® -
Mild and 1400W 7 64 x 10-* -
Normal 7.10 x 10-® -
Moderate 9.32 x 10-® -
Moderate and 
140GW 8.71 x 10-" -
Normal 7.10 x 10-" -
Severe 7 83 x 10-® -
Severe and 1400W 8.68 x 10-® -
Table 5.2. Rmax and EC50 Values for Constrictions in the Absence and Presence of 1400W. Raw  data
fbrrcsponses shown in figure 5.9. *p < 0 .05 , ** *p < 0 .0 0 1  compared to normal unless indicated otherwise.
S A 3  Vessel Relaxation in the Presence of 1400W
Relaxation responses were measured in vessels from normal and mCIA animals 
Mowing 5HT-induced constriction to 70-80% o f maximum in order to compare 
maximum relaxation responses in the presence o f 1400W. The responses observed 
confirm that this agent had no effect on the eNOS-mediated relaxation responses to ACh. 
Incubation o f tissue from mild and severely diseased animals with 1400W had no effect 
on relaxation responses. However in tissues from moderately affected animals, relaxation 
responses were significantly (p<0.01) greater in the presence o f 1400W (see figure 5.8). 
EC50 values were not different between any groups (see table 5.3)
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Figure 5.8. Graphs Showing Relaxation Responses in Tissue from Normal and mCIA Animals in the 
Absence and Presence of 1400W. A. Relaxation responses to ACh from normal (n=5) and mild (n=4) 
tissue, the latter in the presence of 1400W. B. The same responses from moderate (n=3) tissue. C 
Responses from severe (n=) tissues **p<0.0l for Rmax compared to normal, analysed by one-way 
ANOVA followed by Newman-Keuls test. .
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Rmax Values (%) Level of Significance
Normal 67.93 ±1.67 m
Mild 62.78 ± 3.92 -
Mild and 1400W 68.11 ±5.86 -
Normal 67.93 ±1.67 m
Moderate 67.52 ± 3.63 -
Moderate and 
1400W 86.55 ± 5.29
** Compared to 
Normal/Moderate
Normal 67.93 ±1.67 -
Severe 68.60 ±3.10 -
Severe and 1400W 71.62 ±2.23 ■i
EC50 Values (M) Level of Significance Compared to Normal
Normal 3.44 x 10 m
Mild 5.97 x 10-® m
Mild and 1400W 9.15 x 10"® m
Normal 3.44 x 1C8 m
Moderate 3.67 x 10 ■i
Moderate and 
1400W 4.13 x 10-8 ■i
Normal 3.44 x 10-® m
Severe 3.46 x 10 ^ m
Severe and 1400W 3.76 x 10 ■* m
Table 5.3. Rmax and E C 5 0  Values for Relaxations in the Absence and Presence of 1400W . Raw  data
for responses shown in figure 511.  **p<0 .01  compared to normal unless otherwise stated.
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5.4.4 Analysis of Serum  NO M etabolites Using O zone-Based 
Chem ilum inescence
Serum was prepared as appropriate from normal and mCIA animals. NO metabolites 
were analysed using ozone-based chemiluminescence. No differences between groups 
were observed (see figure 5.9).
2.0-i
N orm al M ild  M odera te  S evere
Figure 5.9. Serum  NO C oncentrations. NO metabolites were measured in the serum o f normal 
(n~7) and mild (n=9), moderate (n=4) and severely (n=4) arthritic animals and expressed as 
serum NO* (pM ).
5.4.5 Vessel C onstric tion  in the Presence of Indom ethacin
Preliminary experiments showed that the presence o f indomethacin had no significant 
effect on the constriction responses to 5HT in normal tissues (see figure 5.0), or the 
endothelium-dependent relaxation response to ACh (see figure 5.11). Incubation o f tissue 
from diseased animals with indomethacin had no significant effects on their ability to 
constrict in response to 5HT (see figure 5.12). Rmax values were significantly (p<0.01) 
lower in vessels from mild, moderate and severely diseased animals compared to normal 
in both the absence and presence o f indomethacin. There was no difference between 
EC50 values for these constrictions (see table 5.4).
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Figure 5.10. Constriction Responses in Normal Tissue in the Presence of Indomethacin. Constriction 
responses from normal tissue to 5HT in the presence and absence of indomethacin, n=3.
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Figure 5.11. Representative Trace Showing Vessel Constriction and Relaxation in Normal Tissues in 
Response to Bolus Concentrations of 5HT and ACh (both 10^M) in the presence of Indomethacin.
Arrows show the point at which agonists were added.
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Figure 5.12. Graphs Showing Constriction Responses in Tissue from Normal and mCIA Animals in 
the Absence and Presence of Indomethacin. A. Constriction responses to 5HT from normal (n=3) and 
mild (n=3) tissue, the latter in the presence of indomethacin. B. The same responses from moderate (n=4) 
tissue. C Responses from severe (n=4) tissues **p<0.01, ***p<0.001 for Rmax compared to normal 
analysed by one-way ANOVA followed by Newman-Keuls test.
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Rmax Values (mN) Level of Significance Compared to Normal
Normal 7.77 ±0.32 -
Mild 5.11 ±0.26 **
Mild and 
Indomethacin 5.72 ±0.26
M
Normal 7.77 ± 0.32 -
Moderate 3.27 ±0.34 k k k
Moderate and 
Indomethacin 2.85 ±0.18
k k k
Normal 7.77 ± 0.32 -
Severe 4.28 ± 0.25 k k
Severe and 
Indomethacin 4.17 ±0.33
k k
EC50 Values (M) Level of Significance Compared to Normal
Normal 6.34 x 10"* -
Mild 9.39 x 10-* -
Mild and 
Indomethacin 1.06 x 10'7 -
Normal 6.34 x 10-® -
Moderate 8.64 x 10-* -
Moderate and 
Indomethacin 8.16 x 10-* -
Normal 6.34 x 10-* -
Severe 1.40 x 10-* -
Severe and 
Indomethacin 1.39 x 10** -
Table S.4. Rmax and EC50 Values for Constrictions in the Absence and Presence of Indomethacin.
Raw data for responses shown in figure 5.16. **p<0.01 compared to normal. Bar indicates statistical 
difference between groups.
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5.4.6 Vessel Relaxation in the Presence of Indomethacin
Relaxation responses were measured in vessels from normal and mCIA animals 
following 5HT-induced constriction to 70-80% o f maximum in order to compare 
relaxation responses in the presence o f indomethacin. The responses in the presence o f 
indomethacin demonstrated this agent had the ability to increase the amount o f 
relaxation the vessel could achieve (see figure 5.13). Rmax relaxation values in tissues 
from mild, moderate and severe animals were significantly (p<0.05) lower in the 
presence o f indomethacin compared to normal and the disease counterparts (see table 
5.5). EC50 values showed no difference for either moderate or severe cohorts, however, 
mild relaxation in the presence o f indomethacin demonstrated a lower EC50 value 
compared to normal.
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Figure 5.13. (Graphs Showing Relaxation Responses in Tissue from Normal and mCIA Animals in 
the Absence and Presence of Indomethacin. A. Relaxation responses to ACh from normal (n=6) and 
mild (n=4) tissue, the latter in the presence of indomethacin *p<0.05 compared to normal and mild. B. 
The same responses from moderate (n=4) tissue *p<0.05 compared to moderate, **p<0.01 compared to 
normal. C Responses from severe (n=3) tissues *p<0.05 compared to normal determined by one-way 
ANOVA followed by Newman-Keuls test.
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Rmax Values (%) Level of Significance
Normal 71.47 ±2.07 -
Mild 71.62 ±2.40 -
Mild and 
Indomothacin 82.82 ±181
* Compared to 
Normal/Ml id
Normal 71.47 ±2.07 -
Moderate 75.02 ±4.33 -
Moderate and 
Indomethacin 86.48 ± 2.92
* [* * Compared to 
Moderate/Normal
Normal 71.47 ±2.07 -
Severe 80.96 ± 2  18 -
Severe and 
Indomethacin 86 96 ± 2.56 * Compared to Normal
EC50 Values (M) Level of Significance Compared to Normal
Normal 4.06 x 10-8 -
Mild 6.10 x 10-® -
MNd and 
Indomethacin 8.82 x 10-®
*
Normal 4.08 x 10-®
Moderate 6.70 x 10-®
Moderate and 
Indomethacin 6.68 x 10-®
Normal 4.06 x 10-®
Severe 5.01 x 10-®
Severe and 
Indomethacin 4.35 x 10-®
Table 5.5. Rmax and EC50 Values for Relaxations in the Absence and Presence of Indomethacin. 
Raw data for responses shown in figure 5.18. *p<0.05, **p<0.01.
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5.5 Discussion
5.5.1 The Role of NO in Impaired Constriction Responses in the mCIA 
Model
§.5.1.1 Inhibition of NOS Isoforms
Following the observation o f impaired agonist-induced constriction responses in tissue 
from the mCLA model (Chapter Four), it was considered that excess production o f NO 
may play a role in this dysfunction. To investigate this possibility 5FIT-induced 
constriction was assessed in the presence o f a broad spectrum NOS inhibitor, L-NAME. 
Preliminary experiments showed that L-NAME did not induce increased constriction 
responses in normal tissues but did completely inhibit the relaxation responses to ACh, 
the latter confirming total eNOS inhibition. Subsequent studies confirmed the 
observations o f Chapter Four in that vessels taken from diseased animals exhibited 
blunted constriction responses. Interestingly, incubation with L-NAME produced only 
minor non-significant improvements in constriction responses in these tissues. While 
the latter may indicate that basal NOS activity is increased in the disease state, overall 
these data would suggest that increased production o f NO is not involved in the impaired 
agonist-induced constriction responses in the mCLA model.
To eliminate a specific role for iNOS in the mCLA impaired constrictor responses, 
experiments in the presence o f 1400W were also carried out. Importantly this agent had 
no effect on relaxation responses to ACh and therefore had no discemable action on 
eNOS. With regard to constriction responses to 5HT in tissues from diseased animals, 
in the presence 1400W further significant (at least for moderate and severe tissues) 
impairment was observed. While the reason for this action is unknown, there is a 
possibility that 1400W could interfere with the receptor function/reactivity to 5HT 
preventing the agonist from exerting its full effect. However these receptors are not 
characterised in this strain nor is any such phenomenon reported in the literature making 
this pure speculation. Regardless o f the mechanism underlying this minor effect o f 
1400W in these experiments, these results imply that with respect to the mCLA model,
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an increased production o f NO via iNOS is not the cause o f the decreased constriction 
observed in the diseased tissue.
In the presence o f 1400W relaxation responses to ACh in normal, mild or severe tissues 
showed no change compared to their appropriate controls. However, in tissue from 
moderately arthritic animals the presence o f 1400W caused a significantly larger 
relaxation compared to untreated moderate tissues. Again while there is no specific 
explanation for this action, the reduced constriction achieved may result in the vessel 
being more susceptible to a higher relative relaxation following stimulation with ACh; 
the less tension a vessel constricts to, the less relaxation is needed for its return to 
baseline. However, that this observation was not reproduced in severe tissue, which 
exhibited similar constriction responses, would argue against this. A further possibility 
is that 1400W may act as a substrate for eNOS rather than inhibitor for iNOS thus 
providing greater vasodilatory potential, although considering the vast difference in the 
affinity o f iNOS over eNOS for 1400W (Garvey, Oplinger et al. 1997; Boer, Ulrich et 
al. 2000), makes this unlikely. Indeed pinpointing this mechanism is not the main thrust 
o f this thesis. Importantly, these data do not seem to support a role for NO in the 
dampened constriction responses in tissues from mCLA animals.
A confounding factor in the measurement o f NOx described above is the presence o f 
excess haemoglobin (Hb) in the serum due to red blood cell (RBC) lysis. Hb has a high 
affinity for NO and thus binds rapidly, an action that may hamper the required reduction 
in the reaction chamber (described above). NO metabolites, Hb-bound or otherwise, will 
eventually be reduced. The Hb contamination has the disadvantage o f producing a 
broader peak for analysis thereby reducing the sensitivity o f the assay giving a lower 
estimation o f NOx (Rogers, Khalatbari et al. 2005). Interestingly, patients with RA have 
been reported to present haemolysis as a result o f the disease (Maharaj 1986). Whether 
this occurs in the mCLA model has not been described.
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Following centrifugation o f blood samples, taken from mCIA and control mice by 
cardiac puncture, the resulting serum invariably displayed a certain level o f “pinkness” 
due to the presence o f Fib. It is most likely that this is derived from RBC lysis during 
sample collection/preparation rather than pathological haemolysis. Even with the 
greatest o f care, and the fact that the procedure was standardised and identical for each 
blood retrieval, this was virtually impossible to avoid in our hands. As such this could 
certainly contribute to subsequent complications upon NO analysis. However given that 
serum taken from normal animals was similarly contaminated with Hb does not explain 
why a difference was not observed between mCIA animals and controls in the present 
study. More likely it would seem to confirm the data presented here indicating that the 
reduction in contractile ability in the mCIA model is not attributable to increased NO 
levels.
5.5.2 The Role of PGI2 in Impaired Constriction Responses in the mCIA 
Model
5.5.2.1 Inhibition of COX Isoforms during Vascular Assessment
To eliminate a specific role for COX in the mCLA impaired constrictor responses 
experiments were carried out in the presence o f indomethacin. This agent did not affect 
constriction or relaxation responses to 5HT and ACh respectively, the latter indicating 
no obvious effect on eNOS function. In the presence o f indomethacin constriction 
responses in the mCLA model showed no change compared to their normal counterparts, 
suggesting increased production o f COX products, namely PGI2, are not responsible for 
the decrease in vessel contractility observed in Chapter Four.
In the presence o f  indomethacin relaxation responses from mCLA tissue exhibited a 
significantly lower maximum relaxation capability compared to untreated disease 
controls and normals. The possibility that indomethacin acts as a substrate for COX 
would explain this change however there is no evidence in the literature to support this. 
Indeed given the widespread use o f indomethacin, this seems an unlikely theory. More 
likely is that another COX product may be affecting vessel tone. Endothelial COX is
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responsible for the production o f arachidonic metabolites, one o f which is the 
vasoconstrictor thromboxane A l (TXAi) (Vanhoutte 2009). Removal o f basal levels o f 
TXA| by indomethacin may therefore increase the relaxing potential o f the tissues seen 
here. While this is an interesting theory, to further characterise these issues is outside 
the scope o f this thesis.
COX activity in experimental arthritis has however been investigated in some depth by 
other groups. In the collagen antibody-induced arthritis (CALA) model, the presence o f a 
PGI2 receptor (IP) antagonist resulted in a reduction in the severity o f arthritis developed 
in experimental arthritis (Pulichino, Rowland et al. 2006). Furthermore emphasising the 
importance o f PGI2 signalling is the development o f a milder form o f experimental 
arthritis in an IP knockout model o f experimental arthritis (Honda, Segi-Nishida et al. 
2006; Pulichino, Rowland et al. 2006). In this CAIA model increased synovial levels o f 
PGI2 were also reported throughout the development o f disease (Pulichino, Rowland et 
al. 2006) an observation that has also been reported systemically in RA patients 
(Hishinuma, Nakamura et al. 2001). Why elevations o f PGI2 have been reported by 
others yet COX inhibition does not reverse the vascular dysfunction demonstrated in the 
present model is intriguing and there are several reasons why this may be. For instance 
the concentration o f indomethacin used may not be sufficient for total inhibition o f 
COX-2. That indomethacin is a broad spectrum inhibitor, and moreover was used at a 
concentration reported to be efficient by many in the published literature, makes this 
seem unlikely. However, the possibility remains that COX activity may have been 
upregulated to such an extent that it could not be inhibited by the ex vivo exposure to 
indomethacin.
Given that PGI2 signalling in VSMC is mediated via plasma membrane IP receptors,
leading to activation o f AC, the production o f cAMP and vasorelaxation (Vanhoutte
1998), a further way to assess the role o f PGI2 in mCLA vessel dysfunction would have
been to measure the cAMP levels in the isolated vessels. If COX was extensively
upregulated as suggested above then tissues would be expected to contain high levels o f
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cAMP which could mediate the dampened contraction responses. Unfortunately time 
constraints and availability o f tissue did not allow for such experiments to take place. 
Obviously such measurements would have been useful, but given the observations that 
follow in subsequent chapters, their absence does not detract from the impact o f this 
thesis.
Another possibility is that any change in COX-1 and COX-2 activity (which may or may 
not have occurred in the present model) could impact on the sensitivity o f the vessels to 
5HT. This theory is based on the observation that induction o f inflammation is capable 
of upregulating COX-2 and subsequently impairs vessel reactivity to NA in internal 
mammary arteries (Foudi, Louedec et al. 2009). If  this were the case in mCLA vessels it 
may explain the change in reactivity throughout the progression in disease. Indeed it 
would imply that changes to the vessel wall were permanent since indomethacin failed 
to reverse the diminished constriction. W ithout direct measurements o f COX activity, 
which are notoriously difficult to make, this cannot be proven one way or the other and 
again remains a topic o f speculation.
Essentially, the ex-vivo experiments described above demonstrate that indomethacin has 
no significant effect on vessel function and suggests that PGI2 does not contribute 
directly to the observed impaired contractile responses. Indeed a multitude o f other 
factors may be responsible for these irreversible alterations to vessel function. Some of 
these will be investigated in subsequent chapters
5.53 Batch Variation
Experiments carried out in this chapter have unearthed discrepancies in vessel function 
between batches. Constriction in normal vessels in the presence and absence o f L- 
NAME saw an average Rmax for developed tension o f 10.8mN. This surpassed previous 
observations described in Chapter Four where average Rmax values were 6.22mN. This 
was echoed in the mCIA tissue in this batch; constrictions from all three cohorts were
notably higher in the latter experiments. In addition to this, the trend in vessel 
dysfunction throughout the progression o f mCIA in this chapter was not as observed in 
Chapter Four. As all batches and animals therein were subjected to the same housing 
environment and conditions surrounding mCLA induction, differences may be attributed 
to batch-dependent biological variation. One cause o f this could be the age at which the 
mice were used; animals were purchased at 6 - 8  weeks, those falling into the lower 
spectrum may have slightly different vessel function. However, as animals were not 
subjected to experimentation until they are deemed adult, at 8 - 1 0  weeks, this would be 
an unexpected occurrence. Alternatively these differences could be attributed to the 
“grey area” described between cohorts. Animals from one cohort may display less or 
more severe characteristics due to the individual progression o f arthritis. This would also 
provide explanation for the observation in the indomethacin condition, where vessels 
from moderate animals failed to reach the Rmax attained by severe vessels.
In addition to contractile difference, slight variances in normal vessel relaxation are 
shown. With respect to their batch-mates and the progression o f mCLA no significant 
difference was seen between relaxations and adequate endothelial function was 
presumed.
Despite the changes shown here, throughout the work in this thesis the overall pattern 
was similar within each batch o f animals. To avoid any discrepancies every effort was 
made to ensure that animals were used from their respective batch for each experimental 
condition.
5.5.4 Further Work
Eliminating the role o f NOS and COX activity in the pathology o f decreased vasculature 
function has led to the conclusion that the contractile mechanism o f the smooth muscle 
is compromised. As such, this investigation will now focus on changes in the 
inflammatory milieu which could present structural/mechanical changes in VSMCs in
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this model. At present no findings similar to these have been described in this model. 
However, in a mouse model o f M arfans’ syndrome a decreased contractile ability has 
been observed. Subsequently this has been attributed to an increase in MMP-9, with 
elastin fragmentation and loss o f compliance observed as a consequence (Chung, Au 
Yeung et al. 2007). Related to this is the widely documented occurrence o f high blood 
pressure in human RA (Zieman, Melenovsky et al. 2005; Tsioufis, Dimitriadis et al. 
2007; Panoulas, Metsios et al. 2008), and that arterial stiffening is also an acknowledged 
pathology in this disease(Bazzichi, Ghiadoni et al. 2009). That these parameters have 
not until now been investigated in this model warrants further study.
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CHAPTER 6
VASCULAR DYSFUNCTION IN MCIA: A ROLE FOR MMP-9
6.1 Introduction
The data collected in Chapter Five indicates that the vascular 
mCIA animals cannot be directly attributed to changes in NOS 
more likely that structural/mechanical changes to the vascular 
dysfunction, though how this arises remains unclear.
An extensive literature search established that similar observations have been made in the 
vasculature of the mouse model o f Marfan syndrome (Chung, Au Yeung et al. 2007). The 
latter is a connective tissue disease in which thoracic aortic aneurysm (AA) is a life- 
threatening complication leading to aortic rupture, dissection and sudden death (El- 
Hamamsy and Yacoub 2009). In this model, receptor-mediated VSMC contraction and 
KMnduced depolarisation were markedly reduced compared to normal animals. 
Moreover, this dysfunction was associated with an increase in expression of the 
gelatinases MMP-2 and MMP-9 and elastin fragmentation (digestion of the elastic 
component o f the vessel wall) (Chung, Au Yeung et al. 2007). Importantly these MMPs 
play a significant role in the degradation o f elastin (Yasmin, McEniery et al. 2005), and 
in the Marfan model such an action appeared to contribute to the loss o f compliance in 
the vessel wall. It is important to note here that MMP-9 is not the only MMP with 
elastolytic capabilities, for example M M P-12 is also called metalloelastase. However the 
focus o f this thesis is to be largely on MMP-9 and as such this MMP is discussed in detail 
in this thesis.
Both the constitutive MMP-2, and the inducible MMP-9 have been associated with the 
development o f arterial stiffness and systolic hypertension (Yasmin, McEniery et al. 
2005; Flamant, Placier et al. 2007), pathologies which have been described extensively in 
human RA (Panoulas, Douglas et al. 2007; Bazzichi, Ghiadoni et al. 2009; Galarraga,
dysfunction present in 
or COX activity. It is 
wall contribute to this
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Khan et al. 2009). That increased levels of MMP-9 in particular have been observed in 
human RA, and moreover in experimental models o f the disease (Chia, Chen et al. 2008), 
demonstrates the need for more detailed investigations with regard to the role of MMP-9 
in vascular/blood pressure changes in the mCIA model.
6.1.1 MMP-9 in RA
MMP-9 is intrinsically involved in both disease progression and pathology in RA 
(described in more detail in section 1.6.2). Briefly, in human RA, an imbalance arises 
between the activity/levels o f MMP-9 and its endogenous inhibitor TIMP (Jackson, 
Arkell et al. 1998), and as such MMP-9 is regarded as a prime contributor to joint 
damage (Yoshihara, Nakamura et al. 2000). The importance o f this enzyme in RA is 
further highlighted by the observation that MMP-9 knock-out mice fail to develop 
antibody-induced experimental arthritis to the same degree as wild-types (Itoh, Matsuda 
et al. 2 0 0 2 ).
Primary cellular sources o f MMP-9 include macrophages, osteoclasts, SFs and 
neutrophils, with various cytokines such as ILl-p, TNF-a and IFNy promoting MMP-9 
activation and secretion (Van den Steen, Dubois et al. 2002; Tchetverikov, Ronday et al. 
2004; Chia, Chen et al. 2008; Garvin, Nilsson et al. 2008). Moreover, in a collagen type 
II-specific monoclonal antibody-induced arthritis model, limb joint MMP-9 levels are 
also increased in SFs, chondrocytes and monocytes (Chia, Chen et al. 2008). With regard 
to the present thesis, the question is whether an increase in MMP-9 associated with 
increasing arthritic severity is reflected in the vasculature and as such contributes to the 
observed vascular dysfunction.
6.1.2 Possible mediators of MMP-9 Upregulation
The extensive inflammatory pathways in the mCIA model (Marinova-Mutafchieva, 
Williams et al. 1997) imply that increased MMP-9 levels may be upregulated by a 
multitude o f mediators (Stolina, Bolon et al. 2008). O f these the cytokine IL-ip would 
seem to be o f particular relevance given that various studies have characterised a link
163
between M MP-9 and the activity of this cytokine. For instance following stimulation o f 
rat VSM Cs with IL-ip, an increase in the level o f MMP-9 mRNA was observed (Gurjar, 
DeLeon et al. 2001; Guijar, Deleon et al. 2001). Additionally stimulation of cultured 
myometrial smooth muscle cells with IL -lp also produced a similar dose-dependent 
increase in MMP-9 levels (Roh, Oh et al. 2000). As such these studies emphasise the 
positive effect IL -1 p has on MMP-9 production.
Importantly blood serum and joint tissue IL-1 p levels have been measured in the mCLA 
model (M D) thesis, Cardiff University, “STAT-1 and STAT-3 signalling in Collagen 
Induced Arthritis: Towards New Therapeutic Targets for Rheumatoid Arthritis” Dr Shaun 
Smale 2010). In both cases, while little change is observed following the initial 
immunisation, the gradual and significant rise from day 2 2  (see figure 6 .1  and 6 . 2  
respectively) follows the increase in disease severity described in the present thesis (see 
Chapter 4). As such the increase in IL -1 p shown here is associated with tissue damage, 
and given the studies described above, could well be involved in upregulating MMP-9 
production/activity. Whether changes in MMP-9 follow those o f IL-ip is unknown. 
Further investigations are therefore essential.
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Figure 6.1. Serum IL-ip Levels in the mCIA model. Reproduced from MD, Cardiff University, “STAT- 
1 and STAT-3 signalling in Collagen Induced Arthritis: Towards New Therapeutic Targets for Rheumatoid 
Arthritis” (2010) Dr Shaun Smale with kind permission.
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Figure 6.2. Paw Homogenate IL-10 Levels in the mCIA model. Reproduced from MD thesis, Cardiff 
University, “STAT-1 and STAT-3 signalling in Collagen Induced Arthritis: Towards New Therapeutic 
Targets for Rheumatoid Arthritis” (2010) Dr Shaun Smale with kind permission.
The working hypothesis o f this chapter is that MMP-9 will be upregulated in the aorta in 
conjunction with increasing arthritic score and therefore contribute to increasing vascular 
dysfunction.
6.2 Aims
To investigate any changes to blood pressure following mCIA induction (measurement o f 
this parameter in this model has not been reported previously).
To measure the levels o f MMP-9 in the paw, serum and aorta from naive animals and 
arthritic mice at varying stages o f disease severity
To examine the effect o f IL -lp on the contractility o f aortic samples taken from naive 
animals and whether this may also induce MMP-9 production.
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To investigate the effect o f exogenous MMP-9 on the contractility o f naive vessels.
To assess ex-vivo whether an MMP-9 inhibitor can reverse the vascular dysfunction 
observed in aortic tissues isolated from animals with mCIA.
To determine the site/where MMP-9 is localised within arthritic paws during mCIA.
6.3 Methods
6.3.1 Induction of mCIA
Animals were housed as described in section 2.1. Following a settling in period mCLA 
was induced in 6 - 8  week DBA/1 animals as described in section 2.2.
63.2 Blood Pressure Analysis by Photoplethysmography
Blood pressure analysis was carried out in a room preheated and maintained at 26-30°C 
and all readings were undertaken on a heated mat at 30°C to limit extraneous effects of 
temperature. Importantly at temperatures higher than 23°C blood flow to the caudal 
artery o f the tail is enhanced as part o f the mouse thermoregulation system, a process 
necessary for accurate blood pressure measurement (Krege, Hodgin et al. 1995). To 
achieve such measurements animals were restrained (for up to ten minutes) in a small 
mouse holder (Kent Scientific) enclosed in a dark tube to avoid over-saturation o f the 
light signal (see below) and to minimise stress for the animal. To further minimise stress 
effects animals were trained prior to the commencement o f this experimental procedure 
by subjecting them to daily ten minute periods in the restrainer whilst wearing the blood 
pressure measuring apparatus (see below) as previously suggested (Krege, Hodgin et al. 
1995). Importantly it was also essential that the animals remained very still to avoid 
movement interference.
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Systolic blood pressure was measured in the animals using a non-invasive Harvard 
Mouse Tail Photoplethysmography Pressure Monitor (Harvard apparatus USA). This 
apparatus utilises a tail cuff consisting of a plastic tube lined with a rubber bladder, 
placed at the base o f the tail to occlude blood flow (the O-cuff), and a non-invasive infra­
red light diode blood flow sensor placed distal to the occlusive cuff to monitor the pulse 
signal wave. The light source illuminates a small area o f the tail, and attempts to measure 
the pulse, recording it as the pulse signal wave. Initially both cuffs were slipped on to the 
tail ensuring that the infra-red light was positioned to cross the tail in the same orientation 
every time. The balloon within the O-cuff was then inflated to a given pressure (around 
200mm Hg) in order to halt blood flow. Following careful and slow cuff release the 
infra-red sensor detected the first appearance o f blood flow on its return to the tail vessel. 
At the point where the increase in pulse signal wave becomes linear (see figure 6.5) the 
pressure value o f the cuff is noted to represent the animal’s systolic blood pressure. 
Maximum cuff pressure (mm/Hg), cycling interval (min), and inflation-deflation rates 
(mmHg/sec) were kept constant by the Harvard Mouse Tail Photoplethysmography 
Pressure Monitor to which the cuffs were attached. The BP monitor was connected to a 
PC via a PowerLab bridge amplifier and the data visualised using Chart for Windows 
(AD Instruments, UK).
Repeat measurements (a minimum of 8  for each animal) were taken over a period o f ten 
minutes once the animal had settled calmly in the restraining cage. An average o f these 
measurements was then calculated for each animal.
As can be seen from the trace in figure 6.3, there are several points at which the pulse 
could be taken. To avoid introducing bias into these measurements, the criteria for the 
point at which the measurement would be taken was pre-agreed; previously published 
mouse blood pressure has been seen to be around 120mm/Hg (Krege, Hodgin et al. 1995; 
Tilley, Audoly et al. 1999). In preliminary measurements, the point at which the pulse 
signal wave became linear that was closest to these values was taken as the reading point 
and subsequently used for all future measurement. Following which all measurements 
were taken blindly and by two different assessors to minimise variability.
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Figure 6.3. Diagram Depicting the Trace from the Blood Pressure Sensor. The top graph represents 
the pulse signal wave, the bottom the change in pressure. As the air is released from the balloon the 
pressure on the vessel decreases and blood flow resumes in the vessel. The pressure is taken when the 
increase in the pulse signal wave becomes linear -  depicted here with the black line. From the graph below 
this the blood pressure can then be read. This trace shows the blood pressure as 119.41 mm/Hg.
Blood pressure readings were taken in naive animals before the induction of arthritis, 
following which measurements were taken from each o f the arthritic severity groups at 
appropriate time points.
6.3.3 Tissue and Serum  Collection
Serum was collected from animals post-euthanasia at appropriate time points as described 
in section 2.3.1. Tissue and paws were removed and treated as described in section 2.3.2i, 
and 2.3.2ii respectively.
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*3.4 Analysing Levels o f  M M P-9 in the m C IA  M odel by ELISA
Total MMP-9 levels in aortic and paw homogenates, and serum samples were detected by 
ELISA (Mouse Total MMP-9 Quantikine ELISA Kit R and D, MMPT90) as described in 
section 2.7.2. Following this the total protein levels were elucidated (see section 2.7) in 
Older to normalise the data. It is important to note here that measuring total MMP-9 
levels does not allow a determination o f the role active MMP-9 solely plays in the 
development o f vascular dysfunction.
* 3 3  M yography: Incubations w ith  IL -ip
DBA/1 mice aged 6-8 weeks were obtained from Harlan and housed as described in 
section 2.1. At appropriate time points mCLA and control animals were euthanised by 
inhalation o f CO2 and the aorta removed and prepared for myography as described in 
section 2.3.2i. Following excision and cleaning, aortic rings were incubated following a 
previously described protocol (Zemse, Hilgers et al. 2007). Briefly rings were placed in 
2ml of Dulbecco’s Modified Eagle Medium (DMEM) (IX), liquid (low glucose) (22320- 
022, GIBCO), supplemented with foetal calf serum (FCS) (10% v/v),
penicillin/streptomycin (lOOpg/ml) and 200 mM glutamine. To this IL-lp (401-ML/CF, 
R&D Systems) was added to a final concentration o f 70pg/ml (as observed previously in 
mCIA plasma, (University o f Wales School o f Medicine, Cardiff University) “STAT-1 
and STAT-3 signalling in Collagen Induced Arthritis: Towards New Therapeutic Targets 
for Rheumatoid Arthritis” Dr Shaun Smale) or 700pg/ml (see figure 6.3). Tissues were 
then incubated for twenty four hours (see Results) in a 37°C humidified CO2 buffered 5% 
incubator (Hera cell 150, Heraeus).
After twenty four hours aortic rings were removed and placed in the myograph bath with 
wanned (37°C) oxygenated Krebs solution before being mounted on wire prongs. 
Contractile function was measured by means o f responses to high K+ (60mM), increasing 
concentrations o f 5HT and relaxation responses were measured to increasing 
concentrations o f ACh following pre-constriction to 70-80% of the previously attained 
maximum (see section 2.4).
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In subsequent experiments 24 hour incubations with 700pg/ml IL-ip were repeated in the 
presence o f either L-NAME (3xlO’5M), 1400W (10‘5M), or indomethacin (10'6M) (all as 
used in Chapter 5). Contraction and relaxation responses were then measured as 
described above and in section 2.4.
6 J .6  In v es tig a tin g  th e  E ffect o f  I L - lp  on M M P -9  E xp ress io n  in  th e  A o rta
Whole vessels were removed from naive animals (section 2.3.2i) and incubated for 24 
hours with 700pg/ml o f IL-ip in supplemented DMEM as described in section 6.3.5. 
Following this vessels were removed and homogenised in lOOpl RIP A buffer as 
described in section 2.3.2i. Subsequently the protein concentration was established as 
described in section 2.7.1., and MMP-9 levels were detected in this sample by ELISA 
(see 2.7.2.).
6.3.7 M y o g rap h y : In cu b a tio n s  w ith  M M P -9 .
63.7.1 Preliminary Experiments: Vessel Exposure to MMP-9
63.7.1.1 The Effect of Active Human Recombinant MMP-9 on Pre-constricted 
Vessels.
In order to assess acute effects o f MMP-9 on normal vessels, tissues were removed from 
naive animals as described in 2.3.2i, before being mounted on a myograph and vessel 
function measured as described in section 2.4. Following this a bolus concentration o f 
5HT was added to the vessels and rings were allowed to constrict to -70-80%  of the 
observed previous maximum. At this point active human recombinant MMP-9 (75ng/ml) 
(PF024 Calbiochem) was added to two of the four rings to investigate a direct effect on 
vessel function. Responses were observed for approximately twenty minutes to 
investigate potential differences from the controls.
63.7.1.2 Acute Incubation with MMP-9.
In similar experiments tissues from naive animals were incubated for one or three hours 
in the absence o f presence o f MMP-9 (75ng/ml added directly to the Krebs in the organ
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baths) before contraction and relaxation responses were performed as described in section 
2.4.
6.3.7.2 Acute and Chronic Exposure of Naive Tissues To Normal and Pathological 
Levels of MMP-9 In Vitro.
Following measurement o f MMP-9 levels in plasma from both normal (control) and 
mCIA animals (as described above), “normal” and “severe” values were established 
(15ng/ml and 75ng/ml respectively, see results section 6.4.2. Subsequently vessels from 
naive animals were incubated in vitro with “normal” and “severe” concentrations o f 
MMP-9 to mimic the in vivo RA conditions. Specifically aortic segments were placed 
into the well o f a tissue culture plate containing 2ml o f culture media (see section 6.3.5 
for media constituents), in the absence or presence o f MMP-9 (15ng/ml or 75ng/ml). 
These were then incubated for either three (acute) or twenty four (chronic) hours in an 
incubator at 37 °C gassed with 5% CO2 in air before being mounted on the myograph and 
vascular function assessed using the previously described standard procedure (section
2.4).
6.3.73 Incubation with “Severe” Levels of MMP-9 in the presence of a MMP-9 
Inhibitor.
In further experiments twenty four hour incubations with MMP-9 (75ng/ml) (as in
6.3.7.4) were repeated in the absence or presence o f a MMP-9 inhibitor (10'7M) (444252, 
Calbiochem) a concentration able to inh ib it. Subsequently tissues were mounted on the 
myograph and vascular function assessed using the previously described standard 
procedure (section 2.4). It is important to note that at this concentration this inhibitor may 
also inhibit MMP-1 and M M P-13.
6.3.8 E x  vivo E ffect o f  M M P -9  In h ib itio n  on V a sc u la r  F u n c tio n  in  T issues 
fro m  M o d era te ly  D iseased  A rth r itic  A n im al.
Aortic tissues from moderately diseased mCIA animals were harvested as described 
above (section 6.3.3) and then incubated in media (described in 6.3.5.) in the absence and
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presence o f a MMP-9 inhibitor (10'7M) for twenty four hours. Subsequently tissues were 
mounted on the myograph and vascular function assessed using the previously described 
standard procedure (section 2.4).
6.3.9 L ocalisation and C ellular Sources o f M M P-9 in m CIA joints by 
I m m u nohistochem istry
6.3.9.1 Localisation
Immunohistochemistry (IHC) was utilised to detect total MMP-9 and macrophages and 
neutrophils in the arthritic joint. Paws were removed from appropriate mCIA animals 
(see section 2.3.2ii) and fixed, sectioned, de-paraffinised and hydrated as previously 
described (section 2.5.2ii and 2.6.1 respectively). Detection o f MMP-9 in the sections 
was achieved using the Vectastain ABC (goat) kit (PK-4005, Vector Laboratories). All 
incubations were carried out at room temperature. Following hydration, slides were 
immersed in tris-buffered saline (TBS) (0.02M Tris, 0.15M NaCl) for five minutes. 
Subsequently excess liquid was carefully removed while avoiding disturbance or drying 
and the sample then enclosed by a hydrophobic barrier drawn on the glass using a pap 
pen (22309, Ted Pella. Inc). The latter helped to minimise the volume of antibody used, 
and also to standardise the volume o f each incubation. Using a plastic Pasteur pipette 
sections were then covered with two drops o f hydrogen peroxide (0.03% v/v) (216763, 
Sigma Aldrich) and incubated at room temperature for thirty minutes in order to quench 
any hydrogen peroxidase activity. Next sections were immersed for five minutes in TBS 
before incubating with diluted normal serum (supplied in kit) for twenty minutes. Excess 
liquid was then blotted from the sample before incubation with the primary antibody; 
anti-MMP-9 (1/200) (sc-6841, Santa Cruz). This was left for thirty minutes before 
washing for five minutes in TBS and then applying the biotinylated secondary antibody 
(supplied in kit) for a further thirty minutes. Following this samples were incubated for 
five minutes with Vectastain ABC reagent (supplied in kit), washed in TBS and then 
incubated with two drops of the DAB substrate solution (SK-4100, Vector Laboratories) 
for five minutes. Slides were then immersed in tap water and counterstained with 
haematoxylin for ninety seconds, followed by a wash in tap water for five minutes, and a
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rinse in Scotts tap water (to enhance the blue o f the haematoxylin) for thirty seconds. 
After this slides were dehydrated by washing in ascending concentrations of alcohol 
(70%, 90%, 100% v/v x 3) for three minutes each and then immersing in three changes o f 
xylene for five minutes. Lastly slides were mounted with DePex/DPX and set by heating 
at 60°C overnight.
63.9 .2  Macrophages
Paws were removed from appropriate mCIA animals (see section 2.3.2ii) and fixed, 
sectioned, de-paraffinised and hydrated as previously described (section 2.5.2ii and 2.6.1 
respectively). Detection o f macrophages in the sections was achieved using the 
Vectastain ABC (rat) kit (PK-4004, Vector Laboratories). Subsequently slides were 
washed in TBS, sections circled with a pap pen and exposed to hydrogen peroxide and 
further TBS washing as above. They were then incubated with 2x (the block was 
increased by this value to prevent background staining) diluted normal (supplied in kit) 
serum for 20 minutes. Next excess liquid was blotted from the sample before being 
incubated with the primary antibody; rat anti-F4/80 (1/100) (a monoclonal antibody used 
widely as a marker for mouse macrophages) (GTX26640, AutogenBioclear). This was 
left on the sample for thirty minutes before washing for five minutes in TBS and then 
applying the biotinylated secondary antibody (supplied in kit) for a further thirty minutes. 
Samples were then incubated for five minutes with two drops o f the Vectastain ABC 
reagent (supplied), washed in TBS and then exposed to two drops o f the DAB substrate 
solution (SK-4100, Vector Laboratories) for five minutes. Slides were immersed in tap 
water and counterstained with haematoxylin before dehydration and mounting as 
mentioned in section 6.3.9.1.
6 3 .9 3  Neutrophils
Paws were removed from appropriate mCIA animals (see section 2.3.23ii) and fixed, 
sectioned, de-paraffinised and hydrated as previously described (section 2.5.2ii and 2.6.1 
respectively). Neutrophils were detected using the Vectastain ABC (rat) kit (PK-4004, 
Vector Laboratories). Subsequently slides were washed in TBS, sections circled with a 
pap pen and exposed to hydrogen peroxide and further TBS washing as above. Following 
incubation with diluted normal serum (supplied in kit) for 20 minutes, excess liquid was 
blotted from the sample before exposure to the primary antibody; anti-Ly-6G (1/100) (a
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mouse neutrophil marker) (551459, BD Pharmingen). This was left for thirty minutes 
before washing for five minutes in TBS and applying the biotinylated secondary antibody 
(supplied in kit) for a further thirty minutes. Samples were then incubated for five 
minutes with two drops o f the Vectastain ABC reagent (supplied in kit), washed in TBS 
and then exposed to two drops o f the DAB substrate solution (SK-4100, Vector 
Laboratories) for five minutes. Slides were immersed in tap water and counterstained 
with haematoxylin before dehydration and mounting as mentioned in section 6.3.9.1.
For all IHC positively stained cells were identifiable by their brown colour in contrast to 
the blue/purple o f the haematoxylin stained nuclei o f the negative cells. Sections were 
visualised using a microscope; staining was apparent from X4 magnification upwards.
63.9.4 Quantification of Immunohistological Staining of Joint Sections.
To quantify the percentage o f infiltrating cells sections were initially visually analysed to 
ascertain areas high in staining. Subsequently the stained area of interest was 
photographed at X20 or X40 magnification and five areas of 250pm2 identified within 
this field were quantified and averaged. Quantification involved calculating the area o f 
staining (object) according to the colour intensity o f the stain compared to the contrasting 
remainder o f the slide (area) and was expressed as % object/area. This criteria was 
manually set using Image-Pro Analyzer software and applied to all pictures taken from 
that batch to control for any inter-batch variation in staining intensity that might occur.
With all staining a negative control; rat or goat IgG (2026, 2028 respectively Santa Cruz) 
was run on a serial section o f the sample o f interest. Staining was deemed satisfactory if 
the cells o f interest were clearly shown by brown staining on the positive section and 
there was no false positive staining on the negative control.
6 3 .1 0  S ta tis tic a l A nalysis
Blood pressure data, expressed as mean ± SEM, was analysed by one-way ANOVA 
followed by Student Newman-Keuls multiple range test. Data from MMP-9 ELISAs were 
expressed as average levels o f total MMP-9 in either group for the paw homogenates,
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serum ± SEM and analysed by one-way ANOVA followed by Student Newman-Keuls 
multiple range test if  three or more groups required comparison. If only two groups were 
present for comparison the Student’s t-test was utilised.
5HT-induced increases in tension are expressed as developed tension in mN. Relaxation 
responses are expressed as percentage relaxation o f the previously induced maximum, 
following constriction to 70-80% o f  the maximum. Isometric tension data were first 
fitted to sigmoid concentration curves using GraphPad Prism software and EC50 
(concentration to produce 50% of maximum response) and maximum 
constriction/relaxation (Rmax) values obtained. If  three groups were present for analyses 
a one-way ANOVA followed by Student Newman-Keuls multiple range test was utilised. 
If only two groups were presented then data was analysed by the Students t-test.
For IHC results are expressed as mean ± SEM % object/area and analysed by one-way 
ANOVA followed by Student Newman-Keuls multiple range test. For all data sets, 
differences were considered significant where p<0.05.
6.4 R e s u lts
6.4.1 Blood Pressure
The tail-cuff systolic blood pressure measurements showed no apparent difference 
between any o f the groups (see figure 6.4). Average results ± SEM were as follows; 
normal 112.5 ± 4.38 mm/Hg, mild 115.8 ± 4.25 mm/Hg, moderate 105.9 ± 3.35 mm/Hg 
and severe 119.5 ± 3.79 mm/Hg.
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Figure 6.4. Blood Pressure Measurements. Systolic blood pressure readings from normal (n=7) (naive) 
animals and animals with mild (n=6), moderate (n=7) and severe (n=6) experimental arthritis.
6.4.2 M M P-9 Levels in N orm al and  m C IA  A nim als
Tissue samples o f aorta and paw, and blood serum was taken from DBA/1 normal 
animals, and those with mCLA at appropriate time points. Aorta and paw samples were 
homogenised and levels o f total MMP-9 were detected by ELISA. In paw and aortic 
homogenates, levels o f total MMP-9 were seen to increase following the onset of arthritis 
(see figure 6.5). In serum, levels o f MMP-9 in severe disease surpassed those seen in 
mild and moderate disease (see figure 6.5C). In the aortic samples absolute levels o f total 
MMP-9 were a lot lower than in the paws, however the pattern o f change was similar 
with elevated levels associated with increasing arthritis severity.
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Figure 6.5. MMP-9 Levels the mCIA Model. MMP-9 levels in A. Paw, B. Aorta and C. Serum samples. 
Paw Samples; normal (n=5), mild (n=6), moderate (n=12) and severe (n=6). Aortic Samples; normal 
(n=3), mild (n=6), moderate (n=3) and severe (n=5). Serum Samples normal (n=!0), mild (n=5), moderate 
(n 6) and severe (n=7). In all cases *p<0.05, **p<0.01 compared to Normal determined by one-way 
ANOVA followed by Newman-Keuls test.
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6.4.3 Incubations with IL-ip.
6.4.3.1 Incubations with IL -ip  (70pg/ml) for Twenty Four Hours.
Aortae from naive normal animals were incubated in the absence or presence of IL-ip 
(70pg/ml) for twenty four hours as described above. Initial responses to high K+ showed 
no difference in the maximum constriction between control and treated tissues (see figure 
6.6). However, following a step-wise concentration response to 5HT the Rmax values 
were slightly yet significantly lower for tissues incubated with IL-1 p. No differences 
between EC50 values were observed (see figure 6.7, and table 6.1). Following re- 
constriction to 70-80% of this maximum with 5HT (10‘6M), vessels were subjected to 
increasing concentrations o f ACh (see section 2.4). A significantly impaired Rmax to 
this agent was seen in IL-lp-treated tissues, whereas EC50 values remained unchanged 
(see figure 6.7, and table 6.1).
Control IL-1B
Figure 6.6. High K \ Graphs showing constriction responses following exposure to K+ (6xl0'2M) in the 
absence (Control) and presence of IL-ip (70pg/ml) for twenty four hours, n=6.
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Figure 6.7. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively in 
Control Tissue in the Absence and Presence of 70pg/ml IL-ip for Twenty Four flours. A. Constriction 
responses to 5HT in tissues from normal control animals treated in the absence and presence of IL-1P for 
twenty-four hours. B. Relaxation responses to ACh for the same tissue. Rmax *p<0.05 compared to 
normal, n=6.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Signifcance
Control 7.32 ± 0.32 -
♦ IL-ip 70pg/ml 24 hours 6.15 ±0.26 *
Relaxation Rmax (Mean ± 
SEM) (%) Level of Signiicance
Control 48.94 ± 4.92 -
♦ IL-1p 70pg/ml 24 hours 34.46 ±3.06 *
Constriction EC50 (M) Level of Signiicance
Control 6.28 x 10-® -
♦ L-1P 70pg/ml 24 houre 3.75 x 10*® -
Relaxation EC50 (M) Level of Signiicance
Control 1.70 x 10'7 -
+ L-1p 70pgfml 24 hours 2.54 x 10-7 -
T ile  6.1. Rmax and EC50 Values for Constriction and Relaxation Responses in Vessels Incubated 
to  Twenty Four Hours in the Absence and Presence of 70pg/ml IL-ip. Raw data for responses shown 
ii figure 6.8. *p<0.05 compared to normal.
1432  Incubations with IL-lp (700pg/m l) for Twenty Four Hours 
While serum levels o f IL -ip  in the mCIA model have been measured as 70pg/ml (MD 
Thesis, Cardiff University, “STAT-1 and STAT-3 signalling in Collagen Induced 
Arthritis: Towards New Therapeutic Targets for Rheumatoid Arthritis” Dr Shaun Smale 
2010) the extent o f  IL -ip  production at a cellular in the vessel wall is unknown. Given 
(hat such “local concentrations” could well be significantly higher than that seen in the 
•emm, in these experiments a higher (10 fold excess) concentration o f IL -ip (700pg/ml) 
was used to assess the potential effect on vessel function.
180
Kf responses were again largely unaffected by incubation with IL-lp (see figure 6.8), 
however marked differences were observed in the Rmax values for constriction responses 
to 5HT. Indeed vessels incubated with IL-1 p contracted to a significantly (p<0.001) 
lower level than control tissues (see figure 6.9). This was not echoed in the EC50 values 
for 5HT or the relaxation responses to ACh (see table 6.2).
Control IL-1B
Figure 6.8. High K+. Graphs showing constriction responses following exposure to K+ (6x10 2M) in the 
absence and presence of IL-1P (700pg/ml) for twenty four hours. n=6.
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Figure 6.9. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Twenty Four Hours in Control Tissue in the Absence and 
Presence of 700pg/ml IL-ip. A. Constriction responses to 5HT B. Relaxation responses to ACh in the 
same tissue. Rmax ***p<0.001 compared to control determined by one-way ANOVA followed by 
Newman-Keuls test, n=6.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Signiicance
Control 8.14 ±0.32 -
♦ IL-1p 700pg/ml 24 hours 6.21 ± 0.21 ikirk
Relaxation Rmax (Mean 1 
SEM) (%) Level of Signiicance
Control 44.1 ± 3.87 -
+ IL-ip 700pg/ml 24 hours 48.69 ±4.86 -
Constriction EC50 (M) Level of Signiicance
Control 8.39 x 10-® -
+ IL-1p 700pg/ml 24 hours 1.11 x 10-® -
Relaxation EC50 (M) Level of Signiicance
Control 1.94 x 10'7 -
+ IL-lp 700pg/ml 24 hours 2.24 x 10*7 -
Table 6.2. Rmax and EC50 Values for Constriction and Relaxation Responses in Vessels Incubated 
for Twenty Four Hours in the Presence and Absence of 700pg/ml IL-lp. Raw data for responses shown 
in figure 6.11. ***p<0.001 compared to control.
6.43.3 Incubations with IL-ip (700pg/ml) and L-NAME
It has been reported that IL -ip  can upregulate iNOS activity and therefore increase NO 
production (Dinarello 2002). To investigate whether such an effect is responsible for the 
dampened response to 5HT described above, the experiments in section 6.4.3.3 were 
repeated in the presence o f L-NAME (3x l0 ’5M). Subsequent constrictions to K (6x10
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*M were similar in control and treated tissues (see figure 6.10). In response to increasing 
concentrations of 5HT again no significant difference in either the Rmax or EC50 values 
were observed (see figure 6.11 and table 6.3). Therefore it would seem that NOS 
inhibition restored contractile function in IL-lp-treated tissues.
Control IL-1B + LNAME
Figure 6.10. High K+. Graphs showing constriction responses following exposure to K+ (6xlO'2M) in the 
absence and presence of IL-ip (700pg/ml) and LNAME (3xl0'sM) for twenty four hours. n=3
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Figure 6.11. Graph Showing Constriction Responses to 5HT Following an Incubation period of 
Twenty Four hours in Control Tissue in the Absence and Presence of 700pg/ml IL-ip and LNAME
(3xl05M).n=3.
Developed Tension Rmax 
(Mean ± SEM) (mN)
Control 6.01 ±0.18
+ IL-ip 700pg/ml 24 hours 6.30 ±0.14
Constriction EC50 (M)
Control 4.18 x 10*8
+ IL-ip 700pg/ml 24 hours 3.67 x 10-®
Table 6.3. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty Four 
Hours in the Presence and Absence of 700pg/ml IL-ip and LNAME (3xlO-5M). Raw data for 
responses shown in figure 6.11.
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6.4.3.4 Incubations with IL -ip  (700pg/ml) and 1400W
1400W was used to investigate the specific actions of iNOS. Vessels were incubated as 
previously for twenty four hours in the absence or presence of IL-ip (700pg/ml)/1400W 
(10 5M). Although responses to K" (6xlO'2M) were slightly higher in the presence of IL- 
ip/1400W, this difference failed to reach significance (see figure 6.12). Constriction and 
relaxation responses to 5HT and ACh respectively, measured as in section 6.4.3.4, shown 
no significant differences between treatment groups for either Rmax or EC50 values (see 
figure 6.13 and table 6.4).
Control IL-1B + 1400W
Figure 6.12. High K+. Graphs showing constriction responses following exposure to K+ (6xlO'2M) in the 
absence and presence of IL-ip (700pg/ml) and 1400W (10'5M) for twenty four hours. n=3 check control
responses.
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Figure 6.13. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Twenty Four Hours in Control Tissue in the Absence and
Presence of 700pg/ml IL-ip and 1400W (10-5M). A. Constriction responses to 5HT. B. Relaxation 
responses to ACh in the same tissue. n=3.
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Developed Tension Rmax 
(Mean ± SEM) (mN)
Control 5.42 ±0.13
+ IL-ip 700pg/ml 24 hours 6.79 ±0.53
Relaxation Rmax (Mean ± 
SEM) (%)
Control 41.00 ±6.12
+ IL-ip 700pg/ml 24 hours 32.68 ±9.06
Constriction EC50 (M)
Control 8.72 x 10-8
+ IL-ip 700pg/ml 24 hours 6.38 x 10*
Relaxation EC50 (M)
Control 1.67 x 10*7
+ IL-ip 700pg/ml 24 hours 1.23 x 10’7
Table 6.4. Rmax and ECSO Values for Constriction Responses in Vessels Incubated for Twenty Four 
Hours in the Presence and Absence of 700pg/ml IL-ip and 1400W (10-6M). Raw data for responses 
shown in figure 6.13.
6.4.3.5 Incubations with IL-ip (700pg/ml) and Indomethacin
To investigate whether the IL-lp-mediated decrease in constriction demonstrated above 
was attributable to COX upregulation, responses were assessed following incubation with 
indomethacin. Tissues were incubated as before for twenty four hours in the absence or 
presence o f IL-ip (700pg/ml)/indomethacin (lO^M). Constriction responses to K+ 
showed no difference between control and treated tissues (see figure 6.14). However, 
maximum constriction responses to 5HT were significantly (p<0.05) lower in IL- 
1 p/indomethacin-treated tissues compared to controls (see figure 6.15), though no change
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in EC50 values was observed (see table 6.5). No differences were observed for 
relaxations to ACh (see figures 6.15 and table 6.5).
Control IL-1B + Indo.
Figure 6.14. High K \ Graphs showing constriction responses following exposure to K+ (6xlO'2M) in the 
absence and presence of IL-1P (700pg/ml) and Indomethacin ( lC^M) for twenty four hours. n=3
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Figure 6.15. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Twenty Four Hours in Control Tissue in the Absence and 
Presence of 700pg/ml IL-ip and Indomethacin (10-6M). A. Constriction responses to 5HT B. 
Relaxation responses to ACh in the same tissue. *p<0.05 compared to normal determined by students t-test, 
n=4.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Signifcance
Control 8.55 ± 0.38 -
+ IL-ip 700pg/mi 24 hours 7.39 ± 0.22 *
Relaxation Rmax (Mean i  
SEM) (%) Level of Signifcance
Control 44.36 ±6.17 -
+ IL-1p 700pg/ml 24 hours 60.7 ±3.32 -
Constriction EC50 (M) Level of Signifcance
Control 6.61 x 10-8 -
+ IL-ip 700pg/ml 24 hours 8.90 x 10-® -
Relaxation EC50 (M) Level of Signifcance
Control 1.28 x 10'7 -
+ IL-1p 700pg/ml 24 hours 1.45 x 107 -
Table 6.5. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty Four 
Hours in the Presence and Absence of 700pg/ml IL-lp and Indomethacin. Raw data for responses 
shown in figure 6.20. *p<0.05 compared to control.
6.43.6 MMP-9 Levels Following Stimulation with IL-lp (700pg/ml).
Aortae isolated from naive animals were incubated as above in the absence and presence 
of IL-lp (700pg/ml) for twenty four hours before being homogenised and levels of 
MMP-9 therein assessed by ELISA (see figure 6.16.). No difference between control and 
treated tissues was observed; Control 27.92 ± 7.91 pg/mg protein, IL -ip incubation, 
33.57 ± 12.02 pg/mg protein.
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C o n tro l 7 0 0 p g /m l IL-1B
Figure 6.16. Levels of MMP-9 in Isolated Aortae from Control Animals Following Incubation with 
and without IL-ip (700pg/ml, twenty four hours). n=5 for both.
6.4.4 Incubations w ith M M P-9
6.4.4.1 The Acute Effect of M MP-9 on 5H T Pre-C onstricted Tissues
Following constriction of aortic rings from naive animals to 5HT (10‘6M) a bolus 
concentration o f MMP-9 (75ng/ml, a concentration observed in the circulation of 
severely arthritic mCIA animals, see section 6.4.2) was added and left to incubate for 20 
minutes. Subsequently no difference was observed between control and MMP-9-treated 
tissues, (see figure 6.17) both demonstrating the “drift” in tension towards baseline over 
time that is characteristic o f this tissue (unpublished observations). Importantly this 
demonstrates that MMP-9 (at least at 75ng/ml) does not induce an acute endothelium- 
dependent (or indeed otherwise) relaxation response.
192
12  -
10
Z
E
c0
1 
c  0)
20 Minutes
Control
Control
MMP-9 (75nq/ml) 
MMP-9 (75ng/ml)
Figure 6.17. V essel Responses to a Bolus A ddition of MMP-9. Following constriction to 5HT a bolus 
concentration of MMP-9 was added to the vessels (depicted by the line) and left for 20 minutes.
6.4.4.2 One H our Incubation with M M P-9 in the M yograph
Aortic rings from naive animals were incubated in the absence (control) or presence o f 
MMP-9 75ng/ml for one hour as described above (see section 6.3.7.2). Subsequently 
constriction responses to FC (6xlO '2M) were measured and although MMP-9-treated 
vessels constricted slightly less, the difference to control was not significant (see figure 
6.18). Furthermore constriction responses to 5HT were again no different (for either 
Rmax or EC50 values) (see figures 6.19 and table 6.7). Relaxation responses to ACh 
following re-constriction with 5HT to 70-80% o f the maximum were again unaffected by 
this acute exposure to MMP-9. Rmax and EC50 values are shown in table 6.6.
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Control MMP-9
Figure 6.18 Graphs Showing Constriction to K+ (6xlO'2M) Following One Hour Incubation in the 
Absence (Control) and Presence of MMP-9 (75ng/ml). n=3
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Figure 6.19. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following One Hour Incubation of Naive Tissue in the Absence (Control) and Presence of MMP-9 
(75ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the same tissue. n=4.
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Developed Tension Rmax 
(Mean ± SEM) (mN)
Control 10.00 ±0.26
1 hour 75ng/ml MMP-9 9.47 ± 0.30
Relaxation Rmax (Mean ± 
SEM) (%)
Control 73.14 ±9.24
1 hour 75ng/ml MMP-9 90.50 ± 19.43
Constriction EC50 (M)
Control 1.09 x 10-7
1 hour 75ng/ml MMP-9 1.07 x 107
Relaxation EC50 (M)
Control 5.38 x 10-8
1 hour 75ng/ml MMP-9 3.15 x 10’7
Table 6.6. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for One Hour in 
the Absence and Presence of MMP-9 (75ng/ml). Raw data for responses shown in figure 6.25.
6.4.4.3 Three Hour Incubation with MMP-9 in the Myograph
Experiments were repeated as 6.4.4.3 above but incubations were for three hours. 
Subsequent contraction responses to K+ were not different between control and MMP-9- 
incubated vessels (see figure 6.20). Maximum constriction responses to 5HT indicated 
that vessels incubated with MMP-9 failed to constrict to the level attained by control 
tissues (see figure 6.21), with a significantly (p<0.05) lower Rmax achieved. No 
difference was observed for EC50 values (see table 6.7). Relaxation responses to ACh 
showed no difference between treatment groups (see figure 6.21 and table 6.7).
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Figure 6.20. Graphs Showing Constriction to K* (6xlO'2M) Following Three hour Incubation in the 
Absence (Control) and Presence of MMP-9 (75ng/ml). n=4.
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Figure 6.21. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively, 
Following Incubation of Naive Tissue for Three hours in in the Absence (Control) and Presence of 
MMP-9 (75ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the same tissue. 
*p<0.05 compared to control determined by students t-test, n=4.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
Control 8.52 ± 0.32 -
3 hour 75ng/ml MMP-9 6.4010.63 *
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 83.01 ± 3.97 -
3 hour 75ng/ml MMP-9 89.17 ±3.53 -
Constriction EC50 (M) Level of Significance
Control 1.93 x 10‘7 -
3 hour 75ng/ml MMP-9 2.16 x 10'7 -
!
Relaxation EC50 (M) Level of Significance
Control 4.14 x 10-* -
3 hour 75ng/ml MMP-9 1.06 x 10‘7 -
Table 6.7. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Three Hours 
in the Presence and Absence (control) of 75ng/ml MMP-9 *p<0.05 compared to control..
6.4.4.4 T hree H our Incubation w ith M MP-9 in Tissue C ulture Medium.
Three hour incubations were repeated in the tissue culture media as a precursor to 
investigating long-term incubations, thus ensuring the media per se had no adverse effect 
on vessel function. Additional experiments were added to utilise the concentration of 
MMP-9 observed in naive animals (15ng/ml, see 6.4.2). Following this incubation rings 
were suspended in the myograph (as described 2.4) before responses to K+, 5HT and ACh 
were measured as before (see section 2.4). For experiments with MMP at 15ng/ml
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subsequent responses to K+ were not different between tissues (see figure 6.22). For 
maximum 5HT-induced constrictions Rmax values were significantly (p<0.05) lower for 
vessels incubated with MMP-9 (see figure 6.23). EC50 values for 5HT remain 
unchanged. Relaxations responses to ACh showed no difference following this 
incubation (see figures 6.23 and table 6.8).
6n
C o n tro l  M M P-9
Figure 6.22. Graphs Showing Constriction to K+ (6xlO-2M) Following Three Hour (TC) Incubation 
in the Absence (Control) and Presence of MMP-9 (15ng/ml). n=3
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Figure 6.23. Graphs showing Constriction and Relaxation Responses to 5I1T and ACh Respectively 
Follow ing an Incubation period of Three Hours (TC) in Control Tissue in the Absence and Presence 
of MMP-9 (15ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the same 
tissue. *p<0.05 compared to control determined by students t-test, n=3.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
Control 6.78 ± 0.26 -
3 hour 15ng/ml MMP-9 5.74 ± 0.25 *
| i
Relaxation Rmax (Mean 1 
SEM) (%) Level of Significance
Control 75.44 ±4.16 -
3 hour 15ng/ml MMP-9 77.47 ± 5.70 -
Constriction EC50 (M) Level of Significance
Control 1.31 x 10'7 -
3 hour 15ng/ml MMP-9 1.56 x 10'7 -
Relaxation EC50 (M) Level of Significance
Control 8.68 x 10-“ -
3 hour 15ng/ml MMP-9 9.38 x 10-* -
Table 6.8. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Three Hours 
(TC) in the Presence and Absence (Control) of MMP-9 (15ng/ml).
For three hour incubations with MMP-9 at 75ng/ml, subsequent constrictions to K+ 
showed no difference between control and treated tissues (see figure 6.24). Maximum 
constrictions to 5HT following exposure to MMP-9 were significantly (p<0.05) lower 
compared to control tissues (see figure 6.25), while EC50 values showed no change. 
There was no difference in relaxation responses to ACh (see figure 6.25 and table 6.9).
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Figure 6.24. Graphs Showing Constriction to K+ (6xlO'2M) Following Three Hour (TC) Incubation in 
the Absence (Control) and Presence of MMP-9 (75ng/ml). n=4.
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Figure 6.25. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Three hours (TC) in the Absence (Control) and Presence of MMP- 
9 (75ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the same tissue. *p<0.05 
compared to control determined by students t-test, n=4.
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Developed Tension Rmax 
(Mean i  SEM) (mN) Level of Significance
Control 9.12 ±0.32 -
3 hour 75ng/ml MMP-9 7.71 ± 0.28 *
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 65.44 ±4.89 -
3 hour 75ng/ml MMP-9 71.02 ±3.23 -
Constriction EC50 (M) Level of Significance
Control 1.48 x 10'7 -
3 hour 75ng/ml MMP-9 1.50 x 10'7 -
Relaxation EC50 (M) Level of Significance
Control 9.70 x 10*8 -
3 hour 75ng/ml MMP-9 8.80 x 10** -
Table 6.9. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Three Hours 
>(TC) In the Presence and Absence (Control) of MMP-9 (75ng/ml).
1644.5 Incubation with Normal and “Severe” Levels of MMP-9 in Tissue Culture 
Medium for Twenty Four Hours.
> Aortae were removed from naive animals and incubated in tissue culture media for 
twenty four hours in the absence or presence o f MMP-9 (15 or 75ng/ml). Vessel 
responses to K+, 5HT and ACh were then measured as described in section 2.4. 
'Constrictions to K+ showed no difference in vessels incubated with MMP-9 (15ng/ml) 
compared to controls (see figure 6.26). Maximum responses to 5HT again showed no
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statistical difference, however relaxation responses following exposure to MMP-9 failed 
to reach the same level as controls (see figure 6.27). For Rmax and EC50 values see 
table 6.10.
6*1
Control MMP-9
Figure 6.26. Graphs Showing Constriction to K+ (6xlO-2M) Following Twenty Four Hour (TC) 
Incubation in the Absence (Control) and Presence MMP-9 (15ng/ml). n=3
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Figure 6.27. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Twenty Four hours (TC) in Control Tissue in the Absence and
Presence of MMP-9 (15ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the 
same tissue. **p<0.0l compared to control determined by students t-test, n=3.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
Control 8.61 ± 0.60 -
24 hour 15ng/ml MMP-9 10.27 ±0.88 -
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 68.45 ± 2.05 -
24 hour 15ng/ml MMP-9 52.54 ± 2.07 * *
i
Constriction EC50 (M) Level of Significance
Control 1.70 x 10'7 -
24hour15ng/ml MMP-9 1.27 x 10‘7 -
;i
Relaxation EC50 (M) Level of Significance
Control 2.45 x 10'7 -
24 hour 15ng/ml MMP-9 2.42 x 10'7 -
TfcMe 6.10. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty 
Hours (TC) in the Presence and Absence (Control) of MMP-9 (15ng/ml).
triction responses to K+ showed no significant difference in tissues exposed to the 
er concentration o f MMP-9 (75ng/ml, see figure 6.28). However, responses (Rmax) 
■to 5HT in the same tissues were significantly (p<0.05) lower than controls (see figure 
56.29), with EC50 values presenting no change. Maximum relaxation responses to ACh 
were also significantly (p<0.05) different with those in MMP-9-treated tissues greater 
than controls. EC50 values again showed no difference (see table 6.11)
8c
Control MMP-9
Figure 6.28. Graphs Showing Constriction K+ (6xlO-2M) Following Twenty Four Hour Incubation in 
the Absence (Control) and Presence MMP-9 (75ng/ml). n 4.
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Figure 6.29. Graphs showing Constriction and Relaxation Responses to 5HT and ACh Respectively 
Following an Incubation period of Twenty Four hours (TC) in the Absence (Control) and Presence of 
MMP-9 (75ng/ml). A. Constriction responses to 5HT B. Relaxation responses to ACh in the same tissue. 
*p<0.05 compared to control determined by students t-test, n=4.
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Control
hour75ng/ml MMP-9
Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
13.63 ±0.86
9.45 ± 0.86
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 44.92 ± 2.60 -
Rhour75ng/ml MMP-9 66.15 ±5.18 *
K Constriction EC50 (M) Level of Significance
Control 8.99 x 10"® -
H hour 75ng/ml MMP-9 1.35 x 10‘7 -
Relaxation EC50 (M) Level of Significance
Control 1.84 x 10-7
24 hour 75ng/ml MMP-9 2.16 x 10*7
6.11. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty 
Haws (TC) in the Presence and Absence (Control) of MMP-9 (75ng/ml).
Incubation with “Severe” Levels o f MMP-9 in the presence of an MMP-9
t
experiments were carried out to determine the effect o f an MMP-9 inhibitor 
re vessels. A s such, tissues were incubated in the absence or presence o f the MMP- 
ibitor for tw enty four hours in tissue culture media as before. This exposure had no 
leant effect on  subsequent constriction responses to K+ (see figure 6.30) or 5HT or
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relaxation responses to ACh (figure 6.31). Rmax and EC50 values for this data are shown 
in table 6.12.
Control MMP-9 Inhibitor
Figure 6.30. Graphs Showing Constriction Responses to K+ (6 x 10-2M) Following an Incubation 
period of Twenty Four hours (TC) in the Absence (Control) and Presence of an MMP-9 Inhibitor. 
n=4.
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Figure 6.31. Graphs showing Constriction Responses to 5HT Following an Incubation period of 
Twenty Four hours (TC) in Control Tissue in the Absence and Presence of an MMP-9 Inhibitor. A.
Constriction responses to 5HT B. Relaxation responses to ACh in the same tissue, n=4.
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Developed Tension Rmax 
(Mean ± SEM) (mN)
Control 7.12 ±0.26
MMP-9 Inhibitor 7.51 ±0.15
Relaxation Rmax (Mean ± 
SEM) (%)
Control 58.89 ± 3.36
MMP-9 Inhibitor 56.74 ± 4.70
Constriction EC50 (M)
Control 9.52 x 10-®
MMP-9 Inhibitor 7.09 x 10-*
Relaxation EC50 (M)
Control 1.82 x 10'7
MMP-9 Inhibitor 1.47 x 10'7
6.12. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty 
Hoars (TC) in the Presence and Absence (Control) of an MMP-9 Inhibitor.
tly vessels from naive animals were incubated in the absence or presence of 
-9 (75ng/ml) for twenty four hours, with the MMP-9 inhibitor being added to some 
as appropriate. Constriction responses to K+ (6xlO'2M) were again largely 
by any o f the incubation conditions (see figure 6.32). Incubation with the 
-9 inhibitor reversed the dampening effect o f MMP-9 on maximum constriction 
to 5HT (figure 6.33). EC50 values and relaxation responses to ACh showed no 
e (see figure 6.33 and table 6.13)
2 1 4
Control MMP-9 MMP-9 + Inhibitor
Figure 6.32. Graphs Showing Constriction Following Twenty Four Hour (TC) Exposure to K+ (6x10' 
2VI) in the Absence (Control) and Presence of MMP-9 (75ng/ml), and MMP-9 and a MMP-9 
Inhibitor. n=4 for all.
215
co
c/>
co
I -
■Da>
CLo
a>
>a>
Q
16-. ■
14- ▲
12- ▼
10-
8-
6-
4-
2-
0-
-110
Control
24 hr MMP-9 & Inhibitor 
24 hr MMP-9
B
T -
-9
T “
-8
“T "
-7
T "
-6
Log [5HT] (M)
-5
-I
-4
co
<D
0£
100
Log [ACh] (M)
Figure 6.33. Graphs showing Vessel Responses with MMP-9 (75ng/nl) in the Presence and Absence 
(Control) of an MMP-9 Inhibitor. A. Constrictions responses. B. Relaxation responses. *p<0.05 
compared to normal determined by one-way ANOVA followed by Newman-Keuls test n=4.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
Control 11.42 ±0.79 -
24 hour 75ng/ml MMP-9 8.71 ± 0.56 *
24 hour 75ng/ml MMP-9 
AND MMP-9 Inhibitor 11.20 ±0.07 -
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 49.42 ± 2.60 -
24 hour 75ng/ml MMP-9 66.15 ±5.18 -
24 hour 75ng/ml MMP-9 
AND MMP-9 Inhibitor 60.69 ± 8.52 -
;
Constriction EC50 (M) Level of Significance
Control 1.07 x 10'7 -
24 hour 75ng/ml MMP-9 1.35 x 10'7 -
24 hour 75ng/ml MMP-9 
AND MMP-9 Inhibitor 1.35 x 10'7 -
Relaxation EC50 (M) Level of Significance
Control 1.84 x 10‘7 -
24 hour 75ng/ml MMP-9 2.16 x 10*7 -
24 hour 75ng/ml MMP-9 
AND MMP-9 Inhibitor 1.76 x 10'7 -
Table 6.13. Rmax and EC50 Values for Constriction Responses in Vessels Incubated for Twenty
Foar Hours (TC) in the Presence and Absence (Control) o f MMP-9 (75ng/ml) and MMP-9 with
MMP-9 Inhibitor.
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6.4.5 Ex-vivo Incubation  o f A ortae from  M oderate-scored mCIA with M MP-9 
Inhibitor
In these experiments tissue was removed from naive and moderate-scored mCIA animals 
as appropriate and incubated in TC media in the absence and presence of the MMP-9 
inhibitor for twenty four hours. Following this vessel responses to K+, 5HT and ACh 
were assessed as previously described above. The presence o f the MMP-9 inhibitor had 
no effect on K -induced contractions, “moderate” vessels still failing to reach the tension 
achieved by control tissue (see figure 6.34). Incubation with the inhibitor had a minor but 
not significant effect on the responses to 5HT in moderate tissue (see figure 6.35). EC50 
values were not different. Relaxation responses to ACh were similar in all tissues. This 
was shown statistically with no difference between Rmax and EC50 values (see table 
6.14).
5*1
Control Moderate Mod. + MMP-9 Inhib.
Figure 6.34. Graphs Showing Constriction Responses to K+ (6xlO-2M) Following Twenty Four Hour 
(TC) Incubation from Control and Moderate tissue, the latter in the Absence and Presence of an 
MMP-9 Inhibitor. **p<0.01 determined by one-way ANOVA followed by Newman-Keuls test, Control 
n=5, moderate n=8, moderate and MMP-9 inhibitor n=8.
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Figure 6.35. Graphs Showing Vessel Responses from Control and Moderate Tissue, the latter in the
Absence and Presence of a MMP-9 Inhibitor. A. Constrictions responses. B. Relaxation responses. 
Control n=5, moderate n=8, moderate and MMP-9 inhibitor n=8. *p<0.05, **p<0.01 compared to control.
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Developed Tension Rmax 
(Mean ± SEM) (mN) Level of Significance
Control 7.12 ±0.26 -
Moderate 5.26 ± 0.38 * * *
Moderate + MMP-9 
Inhibitor 5.86 ± 0.22
* *
Relaxation Rmax (Mean ± 
SEM) (%) Level of Significance
Control 55.43 ± 0.96 -
Moderate 63.11 ±4.23 -
Moderate + MMP-9 
Inhibitor 61.58 ±4.12 -
Constriction EC50 (M) Level of Significance
Control 9.52 x 10-® -
Moderate 9.43 x 10* -
Moderate + MMP-9 
Inhibitor 1.1 x 10-7 -
Relaxation EC50 (M) Level of Significance
Control 1.62 x 107 -
Moderate 1.64 x 10'7 -
Moderate + MMP-9 
Inhibitor 1.21 x 10’7 -
Table 6.14. Rmax and EC50 Values for Constriction Responses in Control and Moderate Vessels 
Incubated for Twenty Four Hours (TC), the Latter in the Presence and Absence of a MMP-9 
Inhibitor.
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6.4.6 Im m u n o h isto ch em istry : L ocalisa tion  a n d  C e llu la r  Sources o f M M P-9 in 
m C IA  jo in ts
6.4.6.1 Localisation of MMP-9 staining
Paws were removed as appropriate from naive animals (and represent normal anatomy) 
and those with mild, moderate and severe scores for mCIA. Sections of joints were 
stained for MMP-9 (total) to observe the change in expression of this enzyme with the 
progression of arthritis. To demonstrate antibody specificity a negative control was used; 
briefly a serial section from each sample measured was incubated with an isotype control 
immunoglobulin at the same concentration as the primary antibody in place of the 
primary antibody. Representative staining for MMP-9 is shown in figure 6.36. As 
indicated (figure 6.37) MMP-9 expression is present in the joint proximal to bone areas 
and in the cellular infiltrate. Residing in this infiltrate will be immune cells such as DCs, 
T-cells, B-cells, mast cells, neutrophils, monocytes macrophages and others, all of which 
contribute to inflammation and bone destruction (for an overview o f the inflammatory 
process in the rheumatoid joint see Chapter 1, section 1.2.2). Figure 6.38 shows an 
example of MMP-9 staining in a normal joint and joints taken from mCLA animals.
MMP-9 was observed and measured within the infiltrate in the joint space and levels of 
this enzyme were observed to increase with increasing arthritic severity. Results are 
shown for both these areas in figure 6.38. Statistical analyses showed no significant 
difference between the means for any groups although an obvious trend is observed.
2 2 1
Figure 6.36. Positive and Negative Staining for MMP-9. A. Shows negative staining following 
incubation with an IgG isotype control. B. Positive staining with the MMP-9 antibody.
Figure 6.37. Example of MMP-9 Staining. MMP-9 is indicated by the presence of brown around the 
purple nuclei shown here by black arrow heads. MMP-9 staining in the joint space in A. a normal joint, B. 
a mild joint, C. a moderate joint and D a severely arthritic joint (at X 40 magnification).
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Figure 6.38. Percentage of MMP-9 Staining in Normal and mCIA Joints. A. MMP-9 staining in the 
cellular infiltrate o f normal, mild, moderate and severe joints. For definition o f y-axis see section 6.3.9.4.
6.4.6.2 S taining for M acrophages in the mCIA Jo in t
In these experiments appropriate paw sections (as above) were stained for F4/80, the 
macrophage antigen. Antibody specificity was demonstrated by using a negative control; 
a serial section from each sample was incubated with an isotype control immunoglobulin. 
Representative staining for F4/80 is shown in figure 6.39. Macrophages were observed in 
the infiltrate (figure 6.40) and near the bone surfaces (figure 6.41) indicating a role for 
them in bone destruction. The numbers o f macrophages present also increased with 
arthritic severity (see figure 6.42). In serial sections, the production o f MMP-9 could be 
localised to macrophages (see figure 6.43). On occasion macrophages could be observed 
in the hyperplastic synovial membrane, an occurrence which was associated with MMP-9 
production (see figure 6.44). This was a rare occurrence and as such was not quantified.
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Figure 6.39 Negative and Positive Staining for F4/80 A. Negative staining following incubation with an 
IgG isotype control and B. Positive staining with the F4/80 antibody in a serial section shown in the 
infiltrate. C. Negative staining using an isotpye control and D. Positive staining using the F4/80 antibody in 
serial sections o f the talus and tibia.
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Figure 6.40. Macrophage Staining in Normal and mCIA Joints. Macrophages are indicated by the 
presence o f large brown blobs surrounding the purple nuclei shown here by black arrow heads. 
Macrophage staining in the joint space in A. a normal joint, B. a mild joint, C. a moderate joint and D a 
severely arthritic joint (at X40 magnification).
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Figure 6.41. Macrophage Staining in the Talus/Tibia Area. Macrophages are indicated by the presence 
of large brown blobs surrounding the purple nuclei shown here by black arrow heads. Macrophage staining 
at the talus tibia joint in A. a normal joint, B. a mild joint, C. a moderate joint and D a severely arthritic 
joint (at X 40 magnification).
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Figure 6.42. Macrophage Staining in the Arthritic Joints. A, Percentage of macrophages in the cellular 
infiltrate. B. Macrophages present in the talus/tibia joint. **p<0.01 compared to normal. For definition of 
y-axis see section 6.3.9.4
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Figure 6.43. Localisation of MMP-9 to Macrophages in the Joint. A. Positive staining for macrophages 
(black arrows) in the joint near the bone surface. B. A serial section of the same joint showing areas 
positive for MMP-9 staining (black arrows) near the bone in the joint (at X40 magnification).
BONE
Figure 6.44. Macrophage Staining in the Hyperplastic Synovial Membrane. Staining in the talus/tibia 
in an arthritic joint for A. macrophages and B. MMP-9, both indicated by black arrow heads (at X 40 
magnification).
6.4.6.3 Staining for Neutrophils in the mCIA Joint.
In these experiments appropriate paw sections (as above) were stained for the presence of 
Ly6G, a neutrophil marker. Again, in order too demonstrate antibody specificity a 
negative control was used at the same concentration as the primary antibody. 
Representative staining for Ly6G is shown in figure 6.45. On analysis neutrophils were 
found to be present in the cellular infiltrate and, contrasting to the location of MMP-9 and 
macrophages, the bone marrow shown by figures 6.46 and 6.47 respectively. The number 
o f neutrophils in the joint was seen to increase from normal to mild and continue 
throughout the progression o f arthritis (see figure 6.48). In serial sections the production
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o f MMP-9 appeared to be more closely associated with the presence o f macrophages than 
neutrophils (see figure 6.49).
Figure 6.45. Negative and Positive Staining for Ly6G. A. Negative staining following incubation with an 
IgG isotype control and B. Positive staining with the Ly6G antibody in a serial section shown in the 
infiltrate
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Figure 6.46. Neutrophil Staining in the Normal and mCIA Joints. Neutrophils are indicated by the 
presence o f large brown blobs surrounding the purple nuclei shown here by black arrow heads. Neutrophil 
staining in the joint space in A. a normal joint, B. a mild joint, C. a moderate joint and D a severely arthritic 
joint, (all at X40 magnification).
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Figure 6.47. Neutrophil Staining in the Bone Marrow. At X20 magnification.
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Figure 6.48 Neutrophil Staining in the Joints. A. Percentage of neutrophil staining in the joint infiltrate. 
B. Percentage of neutrophil staining in the bone marrow. **p<0.01, ***p<0.001 compared to normal. For 
definition of y-axis see section 6.3.9.4
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Figure 6.49. Localisation of MMP-9, Macrophage and Neutrophil Staining. Serial sections of a 
moderately arthritic joint staining for MMP-9 (top), macrophages (middle) and neutrophil (bottom) as 
indicated by arrowheads (at X40 magnification).
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6.5 Discussion
6.5.1 Overview
To investigate the effects o f mCLA on blood pressure, non-invasive tail-cuff 
photoplethysmography was utilised. Data collected over the time course of the 
experiment indicated that following the onset, and during the progression of mCIA there 
was no measurable change in blood pressure.
To assess the hypothesis that MMP-9 may be responsible for the observed reduction in 
vessel contractility aorta, paw and blood serum samples were taken from DBA/1 normal 
animals, and those with mCIA at appropriate time points. Following homogenisation of 
aortae and paws, levels o f total MMP-9 in both the resulting homogenate and blood 
serum were assessed. The data showed that levels o f MMP-9 increased over the course of 
mCLA in each case, although these changes did not necessarily reflect changes in vascular 
contractility. Importantly the pattern o f contractile dysfunction was more closely 
mirrored by aortic rather than serum MMP-9 changes, indicating perhaps that the 
detrimental effect was due to local as opposed to systemic MMP-9 production.
As IL -lp has been reported to have a positive effect on MMP-9 production (Roh, Oh et 
al. 2000; Guijar, DeLeon et al. 2001; Guijar, Deleon et al. 2001) (see section 6.1.2), the 
effect o f this cytokine on vascular function was investigated. In the presence of IL-lp (70 
or 700 pg/ml for twenty four hours) contractile responses to 5HT in tissues from naive 
animals were significantly depressed, thus resembling the responses observed in the 
mCIA model and indicating similarities between the effect of IL-ip and mCIA on vessel 
contractility. However, unlike the mCIA model, exposure to IL-ip also produced 
significant impairment o f endothelium-dependent relaxation. For further clarification of 
the mechanism(s) involved the above experiments were repeated as appropriate in the 
presence o f either an eNOS, iNOS or COX inhibitor. Following eNOS or iNOS 
inhibition contraction responses were normalised, indicating a possible role for 
eNOS/iNOS-derived NO in the initial IL-ip-mediated decrease in vessel constriction. On 
the other hand inhibition o f COX was without effect discounting a role for prostacyclin.
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T o  further investigate a possible role for MMP-9 in this IL-ip-induced dysfunction, 
vessels that had been incubated with IL-ip for twenty four hours were homogenised and 
M M P-9 levels measured by ELISA. Importantly no change in expression of MMP-9 was 
observed.
G iven  the changes in MMP-9 levels described above, subsequently the direct effect of 
M M P-9 on vessel responses was measured. As with IL-lp, vessels from naive control 
anim als were removed, incubated in the absence and presence of MMP-9 and vessel 
contractility measured. A concentration of MMP-9 seen in “severe” animals had a 
detrimental effect on vessel contractility as observed in the mCIA model. The use o f a 
M M P-9 inhibitor subsequently prevented the development o f this dysfunction indicating 
th e  potential for MMP-9 to compromise the integrity o f the vessel. Importantly, such 
incubations were largely without negative effect on endothelial function.
T he reversibility o f damage hypothesised to be caused by MMP-9 in the mCIA model 
w as assessed using a MMP-9 inhibitor and aortic tissue taken from moderately diseased 
mCLA animals. Inhibition of MMP-9 ex-vivo showed no change to impaired vessel 
function.
Staining for the presence o f MMP-9, macrophages and neutrophils in the joints indicated 
an upregulation of all three following the onset and duration of arthritis. MMP-9 and 
macrophages were located in similar areas indicating that macrophages could be the 
primary producers o f articular MMP-9 in mCIA. This association was seen near bone 
within the joint emphasising the role o f these cells and this protease in bone degradation.
The main findings o f this Chapter are discussed in more detail below.
6.5.2 Blood pressure
Although no such reports o f BP measurement in the mCIA model have been published 
previously, similar measurements have been carried out in an experimental rat AIA 
model. Indeed analogous observations were made, with AIA having no effect on BP over
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the time course of the experiment ((Sakuta, Morita et al.). Interestingly in this model it 
was observed that infusion of Angll (see Chapter 1, section 1.4.2.3 for description) over 
the disease period resulted in increased sensitivity for development o f hypertension. 
Moreover an increase in the expression of ATi, the angiotensin receptor was 
subsequently observed (Sakuta, Morita et al.). These findings may indicate that increased 
expression of this receptor in human RA may be a risk factor for the development of such 
RA-associated pathologies and could explain the increased incidence of hypertension in 
human disease. No such reports regarding this hypothesis exist in the literature, however 
an increased production o f angiotensin converting enzyme (ACE) has been reported in 
the synovial fluid from RA patients (Veale, Yanni et al. 1992). This enzyme is 
responsible for the conversion of inert Angl to the potent vasoconstrictor/growth 
promoter Angll. If this increase in ACE was associated with a similar increase in Angll, 
the rise in circulating levels could certainly contribute to the observed hypertension in 
human RA. Interestingly administration of ACE inhibitors to sufferers of RA improves 
endothelial function, and furthermore is hypothesised to potentially reduce the risk of 
cardiovascular events in these patients (Flammer, Sudano et al. 2008).
As discussed in the introduction to this Chapter (see section 6.1) arterial stiffness and 
increased systolic hypertension are pathologies which have been described extensively in 
human RA (Panoulas, Douglas et al. 2007; Bazzichi, Ghiadoni et al. 2009; Galarraga, 
Khan et al. 2009). As such the development o f hypertension in mCIA would not have 
been an unexpected observation. Reasons for the negative result here could be due simply 
to an absence o f this pathology in this model. Since this experimental arthritis only 
progresses for a period o f 2 to 14 days, it may be too short for measurable hypertension to 
develop. Alternatively, early adaptive compensatory mechanisms (for example increased 
antioxidant/anti-inflammatory defences) could initially mask the pathological changes 
and result in no “net change” in blood pressure. Such suggestions are merely speculative 
and investigations of such mechanisms were well outside the scope of the current thesis. 
Alternatively however, problems encountered during both experimental work and data 
collection highlighted that the tail-cuff photoplethysmography technique may not be 
completely reliable.
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One issue could arise from the fact that interpretation o f the data was largely subjective. 
As can be seen from figure 6.1, the exact point at which the pulse is detectable is not 
overtly clear from the graph, indeed there are several points at which this could be taken. 
To remove this variability, criteria regarding the time point at which the reading was 
taken was pre-decided, as described in the graph. Consequently readings taken by the 
blinded analysers were generally consistent and variation between blinded assessments 
was minimal. On reflection a way to avoid this variability would be to set criteria which 
automatically discarded anomalous data. For example excluding data which was greater 
than two standard deviations away from the mean (Feng, Deerhake et al. 2009). 
However, if the method produced consistent results this would be an unnecessary step 
and as such there should be no need for such intervention.
Criticisms of the method also stem from problems encountered when executing 
experimental work. Due to the small size of the DBA/1 mice used, animals fell into the 
lower weight threshold recommended for the restraining device (weight range was ~18- 
24g, the smallest cage obtainable was suitable for mice 20-40g). Consequently, animals 
were often too small for complete prevention o f movement, problematic for both 
obtaining and maintaining the signals. Additionally, the tail length of the mice was only 
just long enough to be accommodated in the smallest of occlusion and sensory cuffs, 
causing further difficulty when obtaining readings. An accumulation of these factors 
could result in inaccurate measurements, loss of signal and undue stress to the animals, 
further affecting precision.
Manufacturers Kent Scientific suggest that light-based blood pressure analysis is not the 
most accurate technique; the light signal can be over-saturated by external sources of 
light, pressure signals can vary in rodents with dark skin and the extreme motion 
sensitivity makes accurate readings difficult. Moreover, the occlusion cuff length is 
inversely associated with the accuracy o f the blood pressure; longer cuffs produce lower 
blood pressure readings, whilst shorter cuffs give higher pressure readings (Bunag 1973). 
In DBA/1 animals, naive or with mCIA, the average blood pressure ranged between 105 
and 120mm/Hg. Previous studies in other murine strains suggest an average blood 
pressure o f around 120mm/Hg, and this was shown to correlate with blood pressure
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measured intra-arterially (Krege, Hodgin et al. 1995; Tilley, Audoly et al. 1999). No such 
information exists in the literature for the DBA/1 strain.
To achieve accurate blood pressure measurements, various techniques could be utilised. 
For instance anaesthetising animals would eliminate variation caused by motion 
sensitivity, although such an action in itself could influence blood pressure. On the other 
hand further non-invasive methods exist with greater sensitivity than the tail-cuff 
photoplethysmography used here. For example a technique using piezoelectric ceramic 
crystals (piezoplethysmography), that works in a similar way to photoplethysmography, 
detects a change in pulse via a cuff and is able to detect at a higher sensitivity (Bunag 
1973) both systolic and diastolic pressures (Reddy, Taffet et al. 2003). Similarly volume 
pressure recording could also be used to measure the blood flow and volume in the tail, 
and since it is not disrupted by movement or pigmentation, has increased reliability 
(Bunag 1973) and has been proven to be an accurate method for this measurement (Feng, 
Whitesall et al. 2008). Invasive techniques, while more complex, would perhaps provide 
more reliable readings. Suitable examples are the use o f  an in-dwelling intra-arterial 
catheter to record changes via a pressure transducer (Hatton, Qi et al. 2000), highly 
sensitive but requires surgery or alternatively radiotelemetry, where a very small radio­
transmitter is implanted in the body of the mouse, a method that has been used and is 
widely regarded as highly sensitive (Feng, Whitesall et al. 2008) and is now the gold 
standard for measuring rodent blood pressure (Plehm, Barbosa et al. 2006). Unfortunately 
use of these techniques did not comply with the project licence and as such could not be 
executed during this work.
Despite the issues encountered with tail-cuff photoplethysmography in the DBA/1 strain, 
the technique has been used reliably and successfully by others in this institution 
(Anning, Coles et al. 2005; Coles, Lewis et al. 2007). However, in this work mice were a 
different strain (12/15-LOX knockout mice and C57/BL6), older and weighing on 
average 25-3Og, indicating that perhaps the size o f the animals was the limiting factor in 
obtaining reproducible results in the mCIA model.
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While the chosen method for blood pressure measurement presented an unsatisfactory 
degree of variability and difficulty , if  ‘real’ changes in blood pressure occurred with 
arthritis progression then our equipment would have been sufficiently sensitive to pick up 
these differences. Further detailed studies are obviously required.
6.5.3 MMP-9 Levels in the m CIA M odel.
Varying levels o f total (pro- and active) MMP-9 were detected in serum and aortic and 
paw homogenates. In normal animals there was a low level of total MMP-9 detected in 
all three samples tested. Following the onset of arthritis the levels were seen to increase 
with arthritis severity. In aortic, paw and serum samples the increase in levels of total 
MMP-9 was associated with arthritis progression. Interestingly levels of MMP-9 present 
in the serum failed to reach significance compared to normal levels at the same time point 
as vascular dysfunction was demonstrated in this model. This could signify that vascular 
dysfunction is not dependent on serum levels o f MMP-9 but instead on local production 
within the vessel wall.
Large differences were observed between the amount o f MMP-9 present in paw and 
aortic samples (200pg/mg protein compared to lOOng/mg protein respectively). At the 
paw damage is being driven by a wide range o f cells, cytokines and deleterious enzymes, 
with MMP-9 playing an important role in bone and cartilage destruction (Yoshihara, 
Nakamura et al. 2000). The observation o f MMP-9 in the vessel wall is a novel finding in 
this model and provides credence to the notion that impaired constriction may be a result 
of MMP-9 activity; however the pathway o f events leading to this upregulation remains 
unknown.
Inflammatory cytokines such as IL-lp and TNFa are known to be upregulated in 
inflammatory situations and have on occasion been linked with increased MMP-9 
production (see section 6.1.3). As such this pathway could potentially be involved in the 
observed increase in vascular MMP-9. That IL -ip  levels had been measured and 
characterised in the mCIA model (see section 6.1.3) lead to the investigation o f the role 
of this cytokine in the upregulation of MMP-9.
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6.5.4 IL-lp Incubations
While the effect of IL-1(3 on vessel function and the role MMP-9 plays in any subsequent 
changes has not been previously investigated in the DBA/1 animal, similar work on 
vessel tension studies has been performed in rats. Following constriction with PE, IL-ip- 
mediated relaxation was largely inhibited by the presence of the MMP inhibitor 
doxycyclin, indicating a role for MMPs in this process (Lalu, Cena et al. 2006). In 
addition to this there are several conflicting reports regarding the effects of IL-ip on 
vessel function. Firstly with respect to contractility, incubation with IL-ip has been 
observed to have a direct effect on VSMC function, enhancing contractile responses to 
PE in endothelium-denuded vessels from hypertensive rats (Dorrance 2007). On the other 
hand decreased vessel sensitivity to PE has also been reported, as demonstrated by 
reduced aortic constriction following incubation with IL-ip, and subsequently attributed 
to increased production o f both COX and NOS products (Soler, Camacho et al. 2003). In 
order to clarify the action of IL-ip on vessel function, and to relate this to MMP-9 
production, incubations of naive DBA/1 aortae with this cytokine were performed.
An initial IL-ip concentration of 70pg/ml was chosen as a representative level of IL-ip 
in mCLA (as measured on day 35 MD thesis, Cardiff University, “STAT-1 and STAT-3 
signalling in Collagen Induced Arthritis: Towards New Therapeutic Targets for 
Rheumatoid Arthritis” Dr Shaun Smale 2010). Subsequently, since local tissue levels of 
this cytokine are likely to be very much higher, experiments were repeated with a ten­
fold excess concentration (700pg/ml). In both cases no significant change was observed 
in the developed tension achieved after exposure to K+, which conflicts with other studies 
(Lalu, Cena et al. 2006), and indicates that IL-ip had no lasting effect on VSMC 
depolarisation/calcium influx into the cells. As already outlined above, in the same 
tissues 5HT-induced constrictions were impaired. Moreover similar results were 
observed for relaxation responses; following twenty four hour incubation the ability of 
the tissue to relax was significantly decreased compared to controls. This echoes the 
findings of Jiminez-Altayo et al (2006), who demonstrated impaired relaxation responses 
after a similar fourteen hour incubation (Jimenez-Altayo, Briones et al. 2006). That such 
an action was not seen following a shorter incubation period of thirty minutes 
(Wimalasundera, Fexby et al. 2003) indicates the need for a prolonged exposure, and the
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possibility o f differential regulation o f downstream effectors following stimulation with 
IL-ip. However despite the initial decrease in relaxation function, following a twenty 
four hour exposure to a higher concentration o f IL-ip, no change was observed in the 
relaxation response (Wimalasundera, Fexby et al. 2003). This could be indicative of the 
vessels switching to a protective state and masking the initially observed deleterious 
effect o f the IL-lp. Unfortunately these investigation were not continued and as such this 
aberrant result remains unexplained.
The initial observations o f the present studies that in the presence of IL-ip responses to 
5HT are compromised, yet responses to K+ in the same tissue are unchanged is somewhat 
surprising. However that the observed difference is related to the mechanism via which 
contraction is elicited is a possibility. For instance K+ induces contraction by 
depolarising the plasma membrane and activation of Ca2+ influx via voltage-gated 
calcium channels. The absence o f an effect o f IL -lp on these channels would explain its 
lack o f effect on K+-induced contraction. On the other hand 5HT-induced constriction is 
mediated via interactions with the agonist and the 5HT2A receptor on the plasma 
membrane. This triggers a downstream cascade o f events ultimately resulting in Ca 
release from the intracellular stores and subsequent constriction. Therefore the 
dampening effect o f IL -ip on 5HT-induced tone may be due to a detrimental effect on 
intracellular signalling rather than affecting extracellular Ca2+ influx or alternatively 
compromised receptor/agonist interactions. Interestingly, Soler et al (2003) showed 
decreased contractility following IL -ip challenge in rat aortae and increased K+ channel 
activation in the vessel wall. Subsequent blocking o f these K+ channels restored vessel 
contractility (Soler, Camacho et al. 2003) indicating their activation played a role in the 
decreased contractile function. Therefore it may be of interest to investigate changes Ca2+ 
signalling in these conditions to see whether a similar effect on ion channels could be 
occurring and as such contribute to the different responses observed between stimulations 
with K+ and 5HT.
As a result of data in the literature regarding increased the blood vessel expression of 
NOS and COX isoforms following IL-ip exposure (Soler, Camacho et al. 2003), the
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effect o f such experimental conditions was investigated in this thesis. This was achieved 
utilising the inhibitors of NOS, iNOS and COX; L-NAME, 1400W and indomethacin 
respectively. Responses to 5HT in IL-ip-incubated tissues in the presence of L-NAME or 
1400W were not statistically different from the control responses, thus indicating a role 
for increased NO bioavailability in the dampening effect of IL-ip on contraction. On the 
other hand in the presence of IL -lp and indomethacin 5HT-induced responses were still 
impaired suggesting that COX-derived products do not contribute directly to the observed 
decrease in vessel function. This agrees with the observations of Soler et al, (2003); in 
IL-lp-induced vessel dysfunction, the role o f NO plays a more prominent role in the 
development of dysfunction than COX-related products (Soler, Camacho et al. 2003).
In these three experimental conditions relaxations responses were unchanged compared 
to normal indicating that the addition o f IL -ip and 1400W or indomethacin did not affect 
endothelial function. An important observation from these prolonged incubation 
experiments is that relaxation responses in normal vessels following twenty four hour 
incubation in tissue culture conditions failed to reach that achieved in previous “freshly- 
isolated” normal tissue. Similar observations have been reported previously (Jimenez- 
Altayo, Briones et al. 2006), and suggests that overnight incubation can damage the 
endothelium per se, resulting in endothelial dysfunction (Manoury, Etheridge et al. 2009) 
and reduced relaxation. The cause o f this damage has been attributed to the possible 
hypoxic nature of the TC environment, and additionally raised secretion of endotheliniA 
(Manoury, Etheridge et al. 2009) which may result in a constant level of basal 
constriction preventing complete vessel relaxation. In this thesis the manual pre-setting of 
baseline tension negates the latter possibility since the minimum set baseline would be 
higher than the resting tension. Constrictions and relaxation responses varied in these 
experiments despite identical experimental conditions. The unfavourable conditions of 
the TC environment coupled with biological variation mean that these changes may 
manifest themselves in slightly altered responses between animals. Despite this, the 
trends observed here between experimental conditions still ultimately showed the same 
changes.
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The data above did not provide any explanation for the role of MMP-9 in IL-ip-mediated 
effects on vessel function, indeed a role for increased NOS activity was more likely. To 
confirm the former, tissue incubated with IL -ip was homogenised and levels of MMP-9 
assessed by ELISA. There was negligible change in MMP-9 levels between tissues 
indicating MMP-9 production is not induced via IL -ip in these experiments. Interestingly 
it has been observed in the literature that exogenous NO can inhibit the production o f 
MMP-9 from IL-ip stimulated VSMCs in isolated rat aorta (Guijar, DeLeon et al. 2001). 
Therefore if IL -ip stimulates NOS isoforms to produce excess NO, resulting in 
dampened contractile responses, it may also be inhibiting the production of MMP-9. 
However, this is not necessarily an accurate representation of the underlying pathway of 
events in mCIA; it must be taken into consideration that mCIA is a multifactorial disease 
and that many other inflammatory cytokines may be involved in the observed vessel 
dysfunction. That MMP-9 does not play a role in the effect o f IL-ip in normal control 
tissue does not necessarily mean that it is not involved in the mCIA model.
Alternative cytokines have been implicated in the production of MMP-9 in RA and these 
may also be involved in producing the changes in vessel function described above. For 
instance TNFa, a key inflammatory cytokine in the progression of disease is described 
not only in the pathogenesis o f inflammatory arthritis (Marinova-Mutafchieva, Williams 
et al. 1997) but furthermore, has been associated with the production o f MMP-9 from 
both human (Lee and Moon 2005) and rat (Lee, Kim et al. 2009) VSMCs experimentally. 
In hindsight, it may have been o f interest to measure TNFa in the mCIA model, however, 
that IL -lp levels were already characterised lead to the studies carried out here.
6.5.5 Incubations with MMP-9
Primary cellular sources o f MMP-9 in human RA are macrophages, osteoclasts, synovial 
fibroblasts and neutrophils (Van den Steen, Dubois et al. 2002; Tchetverikov, Ronday et 
al. 2004; Chia, Chen et al. 2008; Garvin, Nilsson et al. 2008). The hypothesis that MMP- 
9 may be causing detrimental effects on vessel function in the mCIA model is supported 
by the wealth of information in the literature surrounding its activity in inflammatory
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diseases. To elucidate this further, the direct effect of MMP-9 on vessel function was 
assessed by exposing tissues to concentrations of MMP-9 that were observed in the 
serum of the mCIA model for varying periods o f time before measuring constriction and 
relaxation responses to K+, 5HT and ACh respectively.
Bolus addition o f MMP-9 following peak 5HT-induced constriction saw no change in 
maintained constriction compared to normal, contradicting published observations in the 
rat (Chew, Conte et al. 2004; Raffetto, Qiao et al. 2008). This could be due to the 
difference in MMP-9 incubation periods; Chew, Conte et al (2004) incubating for one 
hour, Raffetto, Qiao et al (2008) for 30 minutes compared to the twenty minutes here. 
Alternatively the difference could be due to the agonist used to elicit the constriction, 
with both methods in the literature utilising PE. This would indicate interference between 
MMP-9 and the agonist/receptor occurring more readily in the case of PE, therefore 
dampening constriction. Alternatively, species variation between rat and mouse could 
account for this difference. As receptor/agonist function in DBA/1 mice has not been 
characterised this is merely speculation and thus it would be unreliable to draw 
conclusions from this.
Responses to K+ in the presence o f MMP-9 were not different compared to normal 
vessels, indicating the changes observed in these conditions are not identical to changes 
occurring in mCIA. Interestingly MMP-9 has previously been associated with reduced 
K+-induced contractile function and reduced Ca2+ influx into VSMCs (Chew, Conte et al. 
2004). Moreover Chew, Conte et al (2004) observed that incubation of rat aortae with 
MMP-9 resulted in the inability o f the vessel to attain maximal PE-induced constriction. 
Such differences to the data presented in this thesis could again be due to a disparity in 
the methodology; in the study o f Chew et al (2004), MMP-9 was present in the bath with 
the vessel throughout the constriction responses while in this thesis it was washed out 
prior to K+ or 5HT exposure. It is possible therefore that the presence of MMP-9 may be 
necessary for a change in K+-induced contractility to occur. These observations do not 
eliminate a role for MMP-9 in the development o f vascular dysfunction, in fact that a 
decrease in K+ constriction in the mCIA model is observed supports the theory that vessel
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Idysfunction may be associated with local rather that systemic levels of MMP-9, as 
hypothesised following elucidation of tissue MMP-9 levels.
No change in vessel constriction was observed following a one-hour incubation with a 
“severe” concentration o f MMP-9. However a three hour incubation had a detrimental 
effect on vessel contractility. It remains to be seen whether this three hour incubation 
would be o f sufficient duration to alter the ECM structure, or indeed mechanistically alter 
contractile mechanisms. Instead MMP-9 may be interacting directly with the 5HT 
receptors altering downstream signalling and decreasing the maximal constriction 
attainable. As no other studies have investigated the effects of MMP-9 on 5HT-induced 
constrictions this is merely speculation. Interestingly relaxation function in these studies 
showed no change compared to control vessels indicating no detrimental effect on 
endothelial function.
Exposure to low “normal” levels o f MMP-9 also resulted in contractile dysfunction 
following a three hour incubation. This was an unexpected result; basal levels of 
expression seen in-vivo in non-diseased control animals should not affect vessel integrity. 
However the ex-vivo conditions to which the vessel was subjected could well change the 
vessel sensitivity resulting in an aberrant response. Moreover incubation in culture 
medium could impose hypoxic conditions and may not be conducive to fully functioning 
vessels (Manoury, Etheridge et al. 2009). Reversal of hypoxia may be achieved by 
increasing the oxygenation state o f the chamber the tissue was maintained in (Manoury, 
Etheridge et al. 2009), however at the time o f experimentation this was not known. 
Alternatively the low levels o f MMP-9 in this condition may enhance local production of 
MMP-9 in-situ causing altered vessel contractility.
Interestingly in subsequent experiments vessels exposed to low “normal” MMP-9 for 
twenty four hours exhibited no change in contractile function compared to controls. The 
difference in these results could be due to one of several reasons. For instance the initial 
insult to the vessel wall by MMP-9 could be reversed after a longer incubation due to the 
increased expression o f protective factors, thus masking the initial damage. Alternatively 
the enhanced sensitivity proposed above may be a transient effect with vessels
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equilibrating in the new environment, becoming less sensitive following the initial first 
few hours. Lastly, the apparent dysfunction observed after three hours could be an 
experimental anomaly. Interestingly the vessels in these experiments displayed signs of 
endothelial dysfunction, failing to relax to the level achieved by the normal vessels 
indicating the incubation period has compromised endothelial function.
Incubation with a high “severe” level o f MMP-9 for twenty four hours had a detrimental 
effect on 5HT-induced vessel constriction akin to that observed in mCIA. However, a 
somewhat confusing observation o f these experiments is that relaxation responses were 
far greater in vessels incubated with MMP-9 contradicting that observed following 
incubation with a low concentration o f MMP-9 for the same duration (see figure 6.39 and 
6.42). Importantly a large level o f variability was demonstrated between normal 
responses in this group o f experiments, even though tissues were isolated from the same 
batch o f animals and measurements made under identical conditions. Whether the latter 
can be attributed to a direct effect o f the tissue culture environment on the endothelium is 
a matter for speculation. At the very least it emphasises that care must be taken when 
interpreting data collected under such conditions.
Incubating the vessel with MMP-9 in the presence of a MMP-9 inhibitor removed the 
detrimental effect on vessel constriction, proving the deleterious effect o f MMP-9. 
Overall the data presented here indicates that “severe” concentrations of MMP-9 result in 
diminished vessel contractile function in naive vessels following a twenty four hour 
incubation period. Although the changes demonstrated do not directly mimic those seen 
in the mCIA aorta, it does not discount MMP-9 in the development of this pathology. The 
detrimental effect o f MMP-9 on vessel function has been previously documented (Chew, 
Conte et al. 2004; Chung, Au Yeung et al. 2007), and has subsequently been attributed to 
fragmentation o f elastin and loss o f elastic integrity (Chung, Au Yeung et al. 2007). 
However, that K+ responses were not impaired following conditions imposed here 
indicate that perhaps the detrimental effect o f MMP-9 incubation is not due entirely to the 
development o f a faulty contractile mechanism. Indeed MMP-9 may interfere with 
receptor/agonist interactions or perhaps cause damage via another unexplored pathway.
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The observations described here do not eliminate a role for MMP-9 in the development of 
this pathology in mCIA and indeed it is likely that other inflammatory mediators play a 
role in this disease, although to date such underlying mechanisms remain unclear
6.5.6 In cu b a tio n  o f  m C IA  tissue  w ith  a  M M P -9  in h ib ito r.
Following the observation that impaired constriction due to MMP-9 activity is reversible 
(Chew, Conte et al. 2004) the effect o f a MMP-9 inhibitor on diseased tissue was 
investigated. Vessels from moderately diseased mCIA animals were incubated for twenty 
four hours in the presence and absence o f a MMP-9 inhibitor. Subsequent vessel 
responses to K+ and 5HT were measured and remained impaired as described previously 
in this thesis. It is likely therefore that damage inflicted to the vessels via the chronic 
inflammatory state posed by mCIA is irreversible and cannot be altered by ex vivo MMP- 
9 inhibition. Possible structural changes to the wall, for example the induction of calcium 
deposition following damage to elastin fragments (Basalyga, Simionescu et al. 2004), 
could contribute to a pathology that is resistant to subsequent interventions. As such this 
may indicate that the earliest possible treatment to prevent such vascular damage in 
human RA is essential. Once established it may only be possible to moderate the 
pathology. Therefore a full understanding of the changes in the vasculature in RA is 
paramount if  appropriate treatment regimes, and indeed new drug targets are to be 
established. An alternative approach to assess the impact o f MMP-9 on the development 
o f this pathology could be to administer the inhibitor systemically as a therapy, or 
alternatively attempt to develop mCIA in a MMP-9 null mouse. This would give an 
indication of how detrimental MMP-9 alone is at the vessel wall. Unfortunately due to 
time constraints, to undertake either o f these was not feasable.
6.5.7 L ocalisation  o f M M P -9  in  th e  jo in t.
To investigate production and localisation o f MMP-9 in the joints, paw sections from 
mCIA animals were stained for MMP-9 and the presence o f macrophages and neutrophils 
These cells were chosen with respect to MMP-9 production since both neutrophils (Van
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den Steen, Proost et al. 2002) and macrophages (Tetlow, Lees et al. 1993; Dreier, Grassel 
et al. 2004; Kim, Kim et al. 2005) are known producers of MMP-9 in the arthritic 
environment.. Subsequently all three antigens were upregulated following induction of 
arthritis, with levels continuing to rise with increasing severity. Further investigation saw 
that MMP-9 and macrophages were largely present in the infiltrating cell mass, with 
levels o f both prominent in areas adjacent to bone tissue. Contrastingly, neutrophils were 
observed to a lesser extent in the infiltration in the joint space, and more predominantly in 
the bone marrow. While MMP-9 production could be visually localised to macrophages 
in serial sections from the paws, the same could not be achieved for neutrophils 
indicating that macrophages may be the primary producers o f MMP-9 and together these 
could be major contributors to bone destruction. However, it is important to note that 
these are not the sole producers o f MMP-9, with synovial fibroblasts, and osteoclasts also 
observed to contribute throughout this pathology (Van den Steen, Dubois et al. 2002; 
Tchetverikov, Ronday et al. 2004; Chia, Chen et al. 2008).
It is unclear how the production o f MMP-9 in the joints, may translate to the vessels. The 
work in this chapter has lead to the hypothesis that local production of MMP-9 at the 
vessel site is likely to be the causative factor in the development of contractile 
dysfunction. It seems unlikely that vessel production is mediated by macrophages, as 
infiltration of these into the vessel wall is typical following physical injury to the vessel 
(Hanke, Hassenstein et al. 1994) or during the development o f atheroscleoritc lesions 
(Bui, Prempeh et al. 2009) neither o f which occur during mCIA. As mCIA progresses for 
a relatively short time span, it neither seems likely that the initial insult to the vessel wall 
will have developed enough to allow for macrophages to infiltrate. Alternatively the 
production of MMP-9 may be due to VSMCs following the cytokine activity at the vessel 
wall. Indeed VSMC production o f MMP-9 has been observed in different pathologies; in 
a mouse model of Kawasaki disease (vasculitis commonly leading to coronary artery 
aneurysm) following TNFa stimulation, addition of doxycyclin (a MMP-9 inhibitor) 
reduced VSMC production o f MMP-9 and inhibited MMP-9 activity (Lau, Duong et al. 
2009). As previously discussed both of these cytokines are upregulated in mCIA and thus 
could potentially play a pivotal role regarding MMP-9 production from VSMCs.
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To confirm this vessel segments could be stained for MMP-9 and an attempt at localising 
the production sites could be made. Furthermore elastin fragments could be stained for in 
die vessel wall. Both o f these were attempted in aortic segments however problems with 
tissue orientation and maintaining tissue integrity throughout cutting and staining was 
compromised, resulting in unreliable data. Time constraints on the project hindered the 
attempted staining in the vasculature and optimising such proved impossible.
Additionally the activity o f MMP-9 could be assessed in the vasculature. This would 
perhaps give an estimation o f potential damage that might be caused at the vessel site. A 
method considered for this was zymography, however there are limitations of this 
technique, and it was not clear whether bands would be detected for the picomolar 
concentrations present in the aortic samples. Additionally as mentioned previously an 
abundance of sample volume was not available and as such an attempt was made to 
investigate the mechanism underlying vascular dysfunction. Measuring the activity could 
have been achieved by pooling samples, however this did not seem an appropriate way to 
measure this and ultimately the lack o f tissue resulted in zymography not being 
completed.
6 .6  S co p e  fo r  F u r t h e r  W o r k
6.6 .1  A r te r ia l  S tif fe n in g , H y p e r te n s io n  a n d  V a s c u la r  C a lc if ic a tio n
There are a multitude o f factors which could affect vessel function throughout the 
progression o f mCIA. Arterial stiffness, hypertension and vascular calcification have all 
been associated with human RA (Panoulas, Douglas et al. 2007; Panoulas, Metsios et al. 
2008; Wang, Yiu et al. 2009), and moreover, MMP-9 has been implicated in the 
development o f all three pathologies.
Early onset vascular calcification has been reported in the aorta of RA-afflicted patients 
(Wang, Yiu et al. 2009). Interestingly, calcium deposition occurs proximal to elastin 
fragments in the vessel, and in a destructive feedback loop, secretion of elastin fragments 
following ECM remodelling can induce calcium deposition (Basalyga, Simionescu et al.
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2004). That MMP-9 has been implicated in elastin degradation (Chung, Au Yeung et al.
2007) indicates there may be a role for the gelatinases in calcification. This proposal has 
been substantiated by work investigating the systemic effects of chronic kidney disease 
(CKD), which manifest as degeneration of elastic fibres, arterial stiffening and 
calcification, the development o f which has been associated with gelatinase activity 
(Chung, Yang et al. 2009).
As discussed previously the activity of this gelatinase has also been described in the 
inhibition of PE-induced vascular constriction (Chew, Conte et al. 2004; Chung, Au 
Yeung et al. 2007; Raffetto, Ross et al. 2007). Reduced constriction has been 
demonstrated in patients with renal disease who also exhibit a decreased responsiveness 
to NA contributing to hypertension (Hand, Haynes et al. 1995). Relating to this is the 
observation that in the spontaneously hypertensive rat (SHR) model of hypertension, a 
specific role for MMP-9 activity has emerged; there is an increase in production and 
enzymatic activity of MMP-9 in cultured VSMCs obtained from the model following 
stimulation with TNFa, suggesting that MMP-9 could be involved in the vascular 
remodelling associated with hypertension (Lee, Kim et al. 2009). This data supports the 
theory that gelatinases are associated with diminished constriction and subsequent 
development o f hypertension, a pathology that although not measurable after the two 
week period o f disease development could present if  disease were allowed to progress.
The evidence presented here outlines the importance of gelatinases in the production of 
aortic stiffening and, following observations in the mCIA model, it may be speculated 
that calcification could ensue in this scenario. However it is not known how early this 
might present itself in the mCIA model. To investigate this further it may be of interest to 
perform histology using the von Kossa staining in the aorta for the deposition o f calcium. 
If the early stages of aortic calcification were observed it could be o f benefit to intervene 
therapeutically to prevent this progression. One way o f doing this would be to adopt the 
use o f MMP-9 inhibitors in vivo. Alternatively, novel therapies have emerged utilising 
hyaluronic acid (HA) oligomers and TGFp. These used in combination attenuate TNFa- 
induced VSMC matrix calcification and gelatinase activity, and enhance elastin and 
collagen production, elastin cross linking and promoted elastin fiber formation in smooth
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muscle cell culture (Kothapalli and Ramamurthi). If further investigations saw the 
development of aortic calcification, this novel therapy may be utilised in an attempt to 
prevent this.
Additional pathways which may cause the development of arterial calcification involve 
mediators o f inflammation specifically involved in dysregulation at the RA joint site. For 
example Osteopontin (OPN) is a glycoprotein secreted by activated immune cells (eg T- 
cells, macrophages) at inflammatory sites. It mediates interactions between bones and 
osteoclasts and has a dual role in cell signalling. Evidence exists for the involvement of 
OPN in RA progression following discovery of OPN in the synovial fluid, the pannus 
(Gravallese 2003), and plasma (Bazzichi, Ghiadoni et al. 2009). Furthermore OPN- 
deficient animals are protected from joint destruction post-development of experimental 
arthritis (Yumoto, Ishijima et al. 2002). In addition to a role in RA, OPN has been 
implicated in arterial stiffness, and it has been suggested that OPN could be the bridge 
between the crucial point o f contact in the vascular bed, and the vascular damage that 
subsequently develops there, resulting in CVD (Bazzichi, Ghiadoni et al. 2009). An 
association between OPN and vascular calcification has also been described (Uz, 
Kardesoglu et al. 2009), and is prevalent in calcified atherosclerotic plaques (Ohmori, 
Momiyama et al. 2003). The production o f OPN at these damage sites comes from the 
VSMCs, and larger volumes are synthesised by macrophages following infiltration o f the 
vessel wall (O'Brien, Garvin et al. 1994), a pathology that, although not present in mCIA, 
could well develop if the disease was allowed to progress. Additionally some studies 
have shown that OPN can have a positive effect on VSMC proliferation (Gadeau, 
Campan et al. 1993). That OPN has been implicated in the development o f vascular 
calcification, and is known to be a key molecule in RA progression, it may be speculated 
that higher systemic levels o f this protein could be a factor in the vascular damage 
developed in the mCIA. Investigating this in current model could again use the Von 
Kossa staining for calcification, or alternatively blood or vessel homogenates could be 
assessed for the production o f OPN via western blot or ELISA.
Another candidate that may play a part in vascular dysfunction is RANKL. There are 
three molecules that control osteoclast function and thus bone resorption; the receptor
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activator of NFkB (RANK), its ligand (RANKL) and the natural decoy receptor for 
RANKL, osteoprotegerin (OPG) (reviewed in (Leibbrandt and Penninger 2008)). 
RANKL, discussed in the Introduction to this thesis, is required for osteoclast 
development, as demsonstrated in RANK/RANKL knock out animals by the absence of 
fully differentiated osteoclasts (Dougall, Glaccum et al. 1999). RANKL is also 
responsible for bone destruction during the development of RA (Drexler, Kong et al.
2008) due to the production of bone-resorptive osteoclasts (Collin-Osdoby 2004), 
increased levels o f which are observed in mCIA (Juarranz, Abad et al. 2005). OPG, 
RANKL and RANK have been implicated in vascular calcification following the 
observation that this pathology is associated with osteoporosis (Collin-Osdoby 2004). 
Furthermore experimental evidence implicates a protective role for OPG in preventing 
the development of this pathology (reviewed in (Collin-Osdoby 2004). As such, 
dysregulation of these factors resulting in an imbalance could potentially be responsible 
for the development of vascular calcification in the mCIA model of RA.
The pathways and pathologies listed above are speculation as to how vascular 
dysfunction might arise in the mCIA model, and there are several other mechanisms via 
which this could occur. Discussed below is one of these pathways which was chosen to 
be investigated in more detail; phenotypic changes to the VSMCs.
6.6.2 V SM C  H y p erp la sia
Many vascular diseases are characterised by intimal hyperplasia occurring via 
cytoskeleton breakdown and reorganisation allowing for cell movement and proliferation. 
MMP-9 produced by the VSMCs (Cho and Reidy 2002) has been implicated in this 
process; an MMP-9 deficiency has been observed to reduce VSMC proliferation and 
migration (Galis, Johnson et al. 2002) as it is this enzyme which is able to disrupt the 
ECM via their basement-membrane and elastin degrading capabilities (Senior, Griffin et 
al. 1991). It has been suggested that MMP-9 activity is necessary for this VSMC 
migration following arterial injury (Cho and Reidy 2002) and notion that is substantiated 
by the observation that MMP inhibition prevents VSMC proliferation (Bendeck, Conte et
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al. 2002). As MMP-9 is reported to play such a prominent role in VSMC physiology and 
subsequent development of vascular disease it is of importance to investigate pathways 
via which this could occur in the mCIA model.
The mediators and pathologies discussed above are just a few of the mechanisms via 
which vessel function may be compromised in this model of mCIA. Investigating VSMC 
calcification in this model was not viable due to the earlier problems encountered whilst 
attempting to stain for both MMP-9 and elastin. As such investigations focussed on the 
contribution phenotypic changes to VSMCs may play in the development of vascular 
dysfunction, and the role for MMP-9 therein. Possible mechanisms and subsequent 
results are discussed in more detail in Chapter 7.
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CHAPTER 7
N-CADHERIN, B-CATENIN AND CD9 -POSSIBLE 
CONTRIBUTORS TO VASCULAR DYSREGULATION IN 
INFLAMMATORY ARTHRITIS
7.1 Introduction
Data in this thesis has shown that contraction of isolated aortic rings is compromised 
following the onset of experimentally-induced arthritis; a role for excess vasodilation in 
this pathology via NO/prostacyclin has subsequently been discounted. Interestingly a role 
for the gelatinase MMP-9 has been established with increases in this enzyme being 
associated with increasing arthritic severity. Importantly in complimentary experiments 
incubation of naive vessels with MMP-9 caused similar vascular dysfunction to that 
observed in the mCIA model. Upregulation o f MMP-9 directly by IL-ip was discounted. 
The role of IL -lp in modulating MMP-9 cannot be entirely discounted in RA; the 
multifactorial nature o f the disease and complex cytokine milieu within the joint results 
in a myriad of events which could elicit changes driven indirectly by IL-ip and/or other 
inflammatory mediators.
MMP-9 has been associated with vascular dysfunction in other animal models of disease 
and several underlying mechanisms have now been established (see Chapter 1, section 
1.6.3). Intercellular adhesion via N-cadherin and CD9 may be relevant to the 
dysregulation o f vascular smooth muscle contraction.
7.1.1 N -C ad h erin
Cadherins are calcium dependent cell-cell adhesion molecules, mediating homophillic 
extracellular interactions. As such, cells expressing certain cadherins aggregate according 
to cell type (George and Beeching 2006). The cadherin superfamily is divided into 
several smaller families, the classical and best characterised consists of E-cadherin, VE-
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cadherin and N -cadherin (Takeichi 1990). These cadherins are transmembrane 
glycoproteins with three distinct domains; an extracellular domain (mediates cell-cell 
contacts), a transm em brane dom ain, and a cytoplasmic domain (Wheelock and Johnson 
2003) (see figure 7.1 for structure). Extracellular cadherin domains interact in a zipper­
like fashion. The presence o f  calcium  confers rigidity to the structure, ensures correct 
folding (Koch, Bozic et al. 1999) and provides protection against proteolytic digestion 
(Hyafil, Babinet et al. 1981). In the cytoplasm , the intracellular domain is attached to 
cytoskeletal com ponents such as actin, via a protein called p-catenin (George and 
Dwivedi 2004), and this forms the cytoplasm ic cell-adhesion complex (CCC). p-catenin 
is also a plasm a-associated protein with a dual function; governing cell contact and 
additionally partaking in cellular signalling (George and Dwivedi 2004; Gosens, Meurs et 
al. 2008). The localisation o f  p-catenin is controlled by a cytoplasmic multi-protein 
complex consisting o f  adenom atosis polyposis coli (APC), glycogen synthase kinase-3p 
(GSK3P) and axin/conductin w hich controls cytoplasmic levels o f p-catenin. Attachment 
o f p-catenin to the CCC is critical for N -cadherin to function correctly as an extracellular 
adhesion molecule (George and Dwivedi 2004).
Extracellular Domain
Cytoplasm
Intracellular Domain
Cytoskeleton
Figure 7.1. S tructure of N-Cadherin. Calcium molecules help to stabilise the external domain. Calcium, 
and cadherin together with P-catenin form the CCC .
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The dual functionality o f P-catenin results in its localisation, either membrane-associated 
or in the cytoplasmic/nuclear pool (George and Dwivedi 2004), being tightly regulated. 
When P-catenin is membrane-associated any free p-catenin is phosphorylated by the 
APC/GSK3p/axin complex and directed for ubiquitination and subsequent degradation by 
the proteasome (see figure 7.2) (Behrens, Jerchow et al. 1998; Brantjes, Barker et al. 
2002; George and Dwivedi 2004). This action occurs when the cells are in their adherent 
state and in the absence o f Wnt signalling.
The Wnt family are secreted glycoproteins which have been grouped into the canonical 
and non-canonical Wnts. Canonical Wnts stabilise cytoplasmic P-catenin resulting in 
transcription o f TCF/LEF target genes (Kawano and Kypta 2003) The receptor which 
activates this pathway contains two components: a member o f the frizzled (Fz) family and 
either one o f two single-span transmembrane proteins, low-density-lipoprotein-receptor- 
related proteins (LRP-5 and LRP-6) (Pinson, Brennan et al. 2000; Tamai, Semenov et al. 
2000). When upregulated, Wnt binds to Fz/LRP and, via the protein dishevelled (Dsh), 
inhibits the GSK-3P component o f the CCC (Shin, Her et al. 2005). This prevents p- 
catenin phosphorylation and subsequent ubiquitination and degradation, resulting 
ultimately in a build up o f p-catenin in the cytoplasm. P-catenin is now able to translocate 
to the nucleus whereby it associates with members o f the T-cell enhancer factor/lymphoid 
enhancer factor (TCF/LEF) transcription factor family (see figure 7.3) (Brantjes, Barker 
et al. 2002; George and Dwivedi 2004; Shin, Her et al. 2005; Clevers 2006; George and 
Beeching 2006). This promotes expression o f a series of target genes involved in cell 
proliferation/regulation such as the mitotic factor Cyclin D l, protease expression, pro- 
inflammatory enzymes and growth factors (Brabletz, Jung et al. 1999; Gradl, Kuhl et al. 
1999; Howe, Subbaramaiah et al. 1999; Shtutman, Zhurinsky et al. 1999; Tetsu and 
McCormick 1999).
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Figure 7.2. Controlled Localisation of p-catenin. When P-catenin is membrane associated, any free P- 
catenin is directed for ubiquitination (green triangles) and subsequent degradation.
Altered gene expression induced by W nt signalling results in phenotypic changes to the 
VSMC. Cadherins have long been understood to play a role in the development o f cancer 
(Agrez 1996), but recent evidence suggests that (loss of) cadherin-mediated cell-cell 
adhesion may play a part in the developm ent o f vascular disease. N-cadherin is expressed 
primarily on VSMCs (M oiseeva 2001; Jones, Sabatini et al. 2002), mediating cell-cell 
contacts between these cells. Disruption o f this contact results in phenotypic changes 
such as switching to a proliferating state subsequently leading to intimal hyperplasia. It 
is not difficult to see how this could contribute to vascular contractile dysfunction
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Figure 7.3. Changes in Gene Expression Following Wnt Upregulation. Wnt binds to the Fz/LRP 
receptor activating Dsh, resulting in inhibition o f GSK3P; subsequently P-catenin accumulates in the 
cytoplasm. Free P-catenin translocates to the nucleus whereby it associates with TCF and promotes gene 
expression.
Uglow et al investigated the hypothesis that constraints on proliferation were reliant on 
cells and their extracellular matrices being intact (Uglow, Slater et al. 2003). Interestingly 
a decrease in N-cadherin was observed in cultured VSMCs following stimulation with 
platelet derived growth factor-BB (PDGF-BB). This increase was associated with a 
translocation o f  p-catenin to the nucleus and furthermore, was apparently inhibited by 
TIMP overexpression, indicating a role for MMPs in this pathology. Additionally 
expression o f a truncated form o f N-cadherin inhibited cell-cell contacts subsequently 
enhancing cell proliferation (Uglow, Slater et al. 2003). Further studies have 
demonstrated an upregulation o f  N-cadherin (Jones, Sabatini et al. 2002), p-catenin 
(Wang, Xiao et al. 2002) and cyclin d l (Slater, Koutsouki et al. 2004), a cell cycle 
regulator (Tetsu and McCormick 1999; Kim and Diehl 2009), following balloon injury to 
vessels. As such this indicates a role for N-cadherin in VSMC phenotypic changes.
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With regard to a MMP/N-cadherin connection, Dwivedi et al (2008) have demonstrated 
that MMP-9 and MMP-12 (the metalloelastase) have direct N-cadherin cleaving 
capabilities. Indeed higher levels o f N-cadherin were observed in both MMP-9 and -12 
knockout animals, accompanied by reduced P-catenin and cyclin D1 following PDGF-BB 
stimulation. This data therefore implicates M MP-9/-12 in the breakdown of VSMC 
extracellular contacts and subsequent phenotypic switching (Dwivedi, Slater et al. 2009).
That N-cadherin shedding has been linked to MMP-9 activity has lead to the hypothesis 
that in the mCIA model increased MMP-9 levels may cause this shedding, resulting in 
vascular dysfunction due to phenotypic switching from a contractile to a synthetic one. 
Levels o f the intracellular and extracellular component of N-cadherin will therefore be 
measured in the aorta o f mCIA animals to ascertain whether this is so.
7.1.2 The Tetraspanin CD9
Tetraspanins form a large family o f proteins collectively known as TM4SF, the primary 
role o f which is membrane organisation (Kotha, Zhang et al. 2009). These proteins have 
four conserved membrane-spanning hydrophobic regions and possess two extracellular 
loops (Scherberich, Moog et al. 1998; Hemler 2001), enabling interaction with other 
tetraspanins, integrins, Ig superfamilies, growth factors, glycoproteins and intracellular 
signalling molecules (Hemler 2001; Kotha, Zhang et al. 2009; Suzuki, Tachibana et al.
2009). O f primary relevance to this thesis is the interaction with integrins, receptors that 
mediate both cell-cell and cell-ECM protein attachment. Integrins and their ligands also 
play key roles in cell signalling, regulation o f the cell cycle and help to maintain cell 
homeostasis (Hynes 2002). In forming these multi-protein interactions, tetraspanins 
develop transmembrane networks regulating cell motility, aggregation, fusion and 
signalling (Hemler 2001). Recent studies have suggested that changes to these molecular 
complexes could participate in the pathway o f changes involved in VSMC proliferation 
(Scherberich, Moog et al. 1998) and therefore could perhaps play a role in the 
development o f vascular dysfunction observed in this model.
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Heparin binding epidermal-like growth factor (HB-EGF) is a potent mitogen for VSMCs 
and can be expressed in a membrane-anchored form (proHB-EGF) that acts via cell-cell 
contact in a juxtacrine manner (Nishida, Miyagawa et al. 2000). Moreover, it can also be 
cleaved to form a stable auto- and paracrine growth factor (Nishida, Miyagawa et al. 
2000). CD9, a 24 KDa member of the tetraspanin family has been shown to uniquely 
interact with proHB-EGF and has been described as an activity enhancer of HB-EGF. 
While CD9 alone fails to induce growth factor activity (Higashiyama, Iwamoto et al. 
1995), when co-expressed CD9 and HB-EGF markedly stimulate juxtacrine growth 
(Nishida, Miyagawa et al. 2000). Interestingly tetraspanins have been detected in 
atherosclerotic aorta, implicating CD9 in atherogenesis (Nishida, Miyagawa et al. 2000). 
Additionally SMCs expression of CD9 is increased 2 fold in cells of the synthetic 
phenotype compared to those in the contractile state (Scherberich, Moog et al. 1998) 
providing support for the role for CD9 in cell proliferation.
CD9 can also form associations with Pi integrins on VSMCs (Kotha, Zhang et al. 2009). 
An abundance of CD9 has been described in the endothelium and smooth muscle of the 
vessel wall and an association o f CD9 with the fibronectin integrin a5Pi has been 
demonstrated (Kotha, Zhang et al. 2009). This has subsequently been associated with the 
PI3/Akt pathway which in VSMCs, plays a critical role in proliferation; Akt activity is 
important in the downstream down-regulation of contractile proteins (Kaplan- 
Albuquerque, Garat et al. 2003). CD9 blockade showed inhibition of Akt 
phosphorylation, a product o f the Akt/PIP3 pathway, and a subsequent reduction in 
formation of neointima following injury (Kotha, Zhang et al. 2009). Significantly CD9 
KOs have a diminished injury response and decreased intima formation compared to then- 
wild type counterparts (Kotha, Zhang et al. 2009), further implicating a role for CD9 in 
vascular dysregulation and a proliferative phenotype.
As a consequence of the observations above CD9 levels will be assessed in the mCIA 
model with a view to investigating the hypothesis that CD9 contributes to the RA- 
associated vascular dysfunction.
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7.2 Aims
To determine levels o f N-cadherin, (3-catenin and CD9 in tissues from normal and 
arthritic animals.
To assess VSMC hyperplasia in aortic segments by histological staining.
7.3 Methods
7.3.1 Mice
DBA/1 male mice aged 8-10 weeks were purchased, housed and euthanised as 
appropriate according to section 2.1.
7.3.2 Induction of mCIA
Experimental arthritis was induced as described in section 2.2.
7.3.3 Collection of experimental Tissue
Following induction of mCIA, at appropriate time points, aortae were collected from 
normal and mCIA animals post-euthanasia as described in section 2.3.2i.
Brain tissue was also collected from normal DBA/1 animals for use as a positive control 
since N-cadherin is known to be expressed here (Hatta, Nose et al. 1988; Walsh, Barton 
et al. 1990). Similarly testes were removed from DBA/1 normal animals for use as a 
positive control since CD9 is essential for sperm and oocyte fusion during fertilisation 
and has been detected in both human (Nakamura, Handa et al. 2001) and mouse 
(Kanatsu-Shinohara, Toyokuni et al. 2004) tissues.
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7.3.4 Protein Homogenisation
Aortae were homogenised as described in section 2.5.li. Brain and testicle tissue were 
homogenised as aorta, using RIPA buffer and a glass homogeniser.
7.3.5 Protein Assay
All extracts were assayed for protein content using the Bradford protein assay as 
described in section 2.7.1.
73.6 Western Blot
This method is a modified version o f one developed by Renart et al (Renart, Reiser et al. 
1979). Western Blots were run using the Mini-protean 3 Cell (165-3301, 165-3302, Bio- 
Rad) kit. 0.75mm glass plates were cleaned with methanol, assembled with running 
apparatus according to the Bio-Rad Mini-PROTEAN 3 Cell Instruction Manual. A 7.5% 
or 10% (depending on protein o f interest, see tables 7.1 and 7.2) v/v acrylamide SDS 
polyacrylaminde gel was made, allowed to set, then a 5% (v/v acrylamide) (see table 7.1) 
stacking gel poured on top with lanes inserted. 15pg protein sample (appropriate volume 
determined by Bradford assay) was added to an equal volume of Laemmli sample buffer 
(S3401, Sigma Aldrich) in a 1.5ml Eppendorf tube and heated for 5 minutes at 95°C. 
Samples were spun at 16464g for 30 seconds at 4°C before being loaded on to the gel 
alongside precision plus protein dual colour molecular weight standards (161-0374, Bio- 
Rad).
The gel was run at 200V for 1 hour in running buffer (13mM tris, 0.1% SDS, 944 mM 
glycine) after which the gel was removed from the glass plates and laid flat on a 
nitrocellulose membrane (RPN303F, GE Healthcare), which was sandwiched between 
two filter papers, and then two fiber pads. This was then immersed in transfer buffer 
(25mM tris, 192mM glycine, 20% methanol) and transferred for 2 hours at 100V. To 
ensure correct transfer, equipment was assembled according to manufacturer’s 
guidelines. Membranes were removed and checked for viable transfer (indicated by 
transfer of colour from the gel to the membrane) and placed in a universal container.
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These were then blocked in milk protein (for concentration see table 8.1) to reduce non­
specific binding.
Post-blocking membranes were probed with the appropriate primary antibody at a 
suitable concentration (see table 7.2). Following this, membranes were washed in milk 
protein made in wash buffer (0.02M tris, 0.15M NaCl (pH7.5) 0.1% v/v tween) (for 
concentration see table 7.1) for 2x5 minutes and 3x15 minutes before probing with the 
appropriate secondary antibody again at a suitable concentration (see table 7.2). Washing 
occurred as before but with TBS wash buffer, before exposure to luminol reagent (sc- 
2048 Santa Cruz) for 1 minute and development on to Hyperbond film (28-9068-37 GE 
Healthcare) and an X-omatic developer.
Percentage
Constituents
Gel Percentage 7.5%Gel 10%Gel
dH20 47.75 40
30% Acrylamide (A3449 
Sigma Aldrich) 25.25 33
1.5MTris pH 8.8 25 25
10% SDS (L4390, Sgma 
Aldrich) 0.1 0.1
10% Ammonium RarsulMe 
(APS) (A3678, Sigma 
Aldrich)
0.1 0.1
Tetramethyieihyienedi amine 
(TEMED) (T9281, Sigma 
Adrich)
0.08 0.04
Percentage
Constituents
Stacking Gel 5%
dH20 68
30%
Acrylamide 17
1M Trie pH 
6.8 12.5
10% SDS 0.1
10% (APS) 0.1
TEMED 0.01
Table 7.1. SDS Gel Constituents.
Antibody Block Primary Wash Secondary
ExtraceHutar N-Cadherin 
(ab76011, Abeam) 5% MHk One Hour 1/200 Overnight 5% Milk
Goat Anti-Rabbit IgG (Santa 
Cruz sc-2004)
hntraceNular N-Cadherki 
(ab76057, Abeam) 5% MHk One Hour 1/500 Overnight 5% Milk
Goat Anti-Rabbit IgG (Santa 
Cruz sc-2004)
GAPDH (ab ab0485, Abeam) 5% MHk One Hour 1/2000Overnight 5% Milk
Goat Anti-Rabbit IgG (Santa 
Cruz sc-2004)
P-Catenin (ab3602, Abeam) 6% MHk Overnight 1/1000 One Hour 6% Milk
Goat Anti-Rabbit IgG (Santa 
Cruz sc-2004)
CDS (sc-0148, Santa Cruz) 6% MiBc One Hour 1/200 Overnight 10% Gel" 6% Milk
Goat Anti-Rabbit IgG (Santa 
Cruz sc-2004)
Table 7.2. Antibody Concentration and Incubation Times. All gels were made at 7.5% unless otherwise 
stated.
For all proteins results were normalised to GAPDH levels. Protein levels were 
subsequently expressed as a ratio o f the control sample; relative optical density units 
(relative ODu). Quantification was achieved using a GS700 densitometer (Biorad) using 
Quantity One software (Biorad).
7.3.7 H and E Staining for Assessment of VSMC Hyperplasia.
Aortae were removed from mCIA-diseased animals as described in section 2.3.2i before 
being embedded in OCT (see section 2.5.2i). Following this aortic sections were stained 
using H and E as described in section 2.6.1. As aortae were not embedded in paraffin the 
initial xylene incubations were excluded from the protocol and aortic sections were fixed 
by immersion in acetone, following which they were treated in increasing concentrations 
o f ethanol. From herein the protocol was followed as described in 2.6.1. Care was taken 
at all times to maintain the integrity o f the vessel wall.
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7.4 Results
7.4.1 Levels of N-cadherin
Levels o f N-cadherin were assessed by western blot probing for the appropriate extra- 
and intra-cellular components. These antibodies detect the whole o f the N-cadherin 
molecule, and the intracellular component only, respectively. This was a direct measure 
o f cadherin cleavage; if intracellular cadherin was present but extracellular levels could 
not be detected this would be indicative o f shedding o f the extracellular component. 
Extracellular N-cadherin could not be detected in any experimental sample, whilst the 
positive control did produce bands (see figure 7.4). Intracellular N-cadherin was not 
detectable in normal tissues. Brain samples produced bands, as did aortic samples from 
mCIA animals. The latter produced variable bands throughout the progression of arthritis 
(see figure 7.5). Results were quantified and expressed as relative optical density (ODu) 
(see figure 7.6).
A
B
Figure 7.4. Representative Western Blot for Detection of Extracellular N-Cadherin. A. Extracellular 
N-cadherin (Ab 76011) expression in aortic homogenates from naive (normal) and arthritic mice of varying 
severity (as labelled). Bands for N-cadherin were detectable at ~100kDa. Each severity refers to an 
individual animal. B. Housekeeping gene GAPDH expression in the same blot (~40kDa). +ve control refers 
to relevant expression in mouse brain homogenate.
264
Figure 7.5. Representative Western Blot for Detection of Intracellular N-Cadherin. A, C. Intracellular 
N-cadherin (ab 76057) expression in aortic homogenates from naive (Normal) and arthritic mice of varying 
severity (as labelled). Each severity refers to an individual animal. Bands for intracellular N-cadherin were 
detectable at ~100kDa B, D. Expression of the housekeeping gene GAPDH in the same blot (~40kDa). 
+ve control refers to relevant protein expression in mouse brain homogenate.
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Figure 7.6. Graph Showing Expression of Intracellular N-cadherin in mCIA Aortic Homogenates. A.
Relative optical density of N-cadherin from normal, mild, moderate and severe artic homogenates. Results 
were normalised to GAPDH. n>2. (No statistics were performed given the low “n” values for “mild”). B. 
Representative blot for N-cadherin and GAPDH bands are shown at ~100kDa, and ~40kDa respectively).
7.4.2 Levels of p-catenin
P-catenin levels proved very difficult to both measure and quantify. Blots obtained were 
messy and showed non-specific binding and were therefore unfit for quantification. 
Figure 7.7 shows an example o f some of the blots obtained for this antibody. Here blots 
were blocked overnight with 6% milk, and exposed for one second on the x-ray film, 
however background staining remained high. The large amount of staining here could be 
due to non-specific binding, or too large a quantity of protein may have been loaded onto 
the gel.
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Figure 7.7. Example of Western Blot for p-catenin. Blotting for P-Catenin following one second 
exposure on the X-ray film. Bands were visible at -94 kDa.
7.4.4 Levels of CD9
Since it was hypothesised that CD9 levels would increase with arthritic severity, and due 
to limited sample availability, CD9 was measured only in severe aorta and mouse testicle 
as a positive control. Levels were not detectable in this aorta (see figure 7.8)
Severe Aorta Mouse Testicle
Figure 7.8. Representative Western Blot for CD9. Western blot for CD9 in samples taken from a severe 
aorta and a mouse testicle as a positive control at ~24kDa. No band was visible for the severe aorta.
7.4.5 Assessing VSM C H yperplasia .
Examples of sections cut from aortic segments are shown below, both taken from normal 
animals. As shown here sections varied in depth, a trait which can not be attributed to 
disease severity. As the minority of sections cut resembled 7.8A and D achieving
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accurate measurement o f vessel wall depth was difficult for comparison to normal 
vessels.
100um
i  *  iN ^
^  ^
5 0  um
Figure 7.9. Examples of Aortic Sections. Sections cut from OCT-embedded aortic sections from normal 
control animals. A. An aortic section representing the smooth muscle of the aorta (X20). B. A section 
which has collapsed following the motion of the cryostat blade (X20). C. A at X40. D. B at X40.
7.5 D iscussion
7.5.1 N -cadherin /p-catenin
Levels of N-cadherin were assessed in normal and mCLA. aortae to investigate whether 
alterations to these and subsequent changes in phenotype may be a precursor to vessel
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dysfunction. Neither intracellular nor extracellular N-cadherin could be detected in 
normal aorta implying this protein is not present in this tissue. In mCIA aorta 
extracellular N-cadherin was not detected, however an increase was observed in levels of 
intracellular N-cadherin presenting evidence for increased expression of N-cadherin, with 
shedding o f the extracellular component present. Hovever, this increase was irregular 
throughout mCIA severity bands, showing no real association with the progression of 
arthritis, and that neither the intra- or extra- cellular components were detectable in 
normal aortae is confusing. In addition, the irregular levels found in this tissue indicate 
that this area requires further investigation. Previous studies have shown a decrease in N- 
cadherin following stimulation with growth factors (Uglow, Slater et al. 2003), a change 
that was later attributed to MMP activity (Dwivedi, Slater et al. 2009). It was on these 
observations that the hypothesis was based; a decrease in extracellular N-cadherin will be 
observed as a result o f MMP-9 upregulation during the progression of mCIA. The 
consequences o f the experimental data presented here imply that alternative processes 
may be occurring; but does not entirely rule out a role for N-cadherin shedding.
Experiments to measure levels o f P-catenin were inconclusive. Expression in the tissue 
was high; however quantification was impossible due to the large level of non specific 
binding. Due to time constraints antibody conditions were not optimized to produce 
viable results. Time permitting it would be o f interest to optimize conditions or find 
alternative antibodies in order to fully investigate levels of this protein in the mCIA 
model. Investigations localizing P-catenin to the membrane or nucleus may also provide 
important information regarding the activity o f this protein during the development of 
vascular dysfunction.
That extracellular N-cadherin could not be detected at all is somewhat confusing. In 
normal animals, where cadherin shedding should be absent, the presence of intracellular 
N-cadherin should be accompanied by the extracellular component. The faint band 
obtained for intracellular N-cadherin in mCIA implies this protein is not present in 
abundance although upregulation in mCIA is indicated. That the band was just detectable 
signifies a scarcity o f this protein, and as such, detection limits of the antibody may be to
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blame for the lack of bands for the extracellular component. However using a positive 
control should in theory eliminate this possibility.
While the present evidence may still indicate a role for the upregulation of N-cadherin in 
changes to vessel function, the causes and consequences of this remain open to 
speculation. Previous cases of N-cadherin upregulation have been reported; in particular 
in cancer biology the process is associated with subsequent alterations in cell growth 
behaviors resulting in invasive and motile cells (Tran, Nagle et al. 1999; Bussemakers, 
Van Bokhoven et al. 2000; Ho, Voura et al. 2001). However, reports of this nature in 
VSMC are less readily available. In the carotid artery an increase in N-cadherin and p- 
catenin is observed following injury and associated with healing and cell migration 
(Jones, Sabatini et al. 2002), however separate levels of intra-and extra-cellular N- 
cadherin have not been assessed.
7.5.1.1 Scope for Further Work
N-cadherin signaling has been reported to occur via three signaling pathways; the 
previously discussed P-catenin pathway, via receptor tyrosine kinases and lastly via Rho 
GTPases. Rho GTPases have been shown to regulate cellular signaling both from 
outside-in, and inside-out. These involve members of the small GTPase family cdc42, 
racl and Rho A, that have been observed to be upregulated in myoblasts following cell­
cell N-cadherin contact and ultimately resulting in myogenesis (Wheelock and Johnson 
2003). Further investigation may be o f interest to investigate this signaling pathway in 
VSMCs and any potential disruption to cell function/phenotype it may cause.
Additionally with regard to the small GTPases is an association with the juxtamembrane 
domain (JMD) in the cadherin molecule, a site that has been identified as a regulator o f 
cell migration and invasion (Noren, Liu et al. 2000). Interactions between the JMD and 
binding partners can influence the activity o f small GTPases and cytoskeletal dynamics 
(Piccoli, Rutishauser et al. 2004). Studies carried out by Piccoli et al 2004 demonstrated 
that in chick ciliary cells (of the ciliary body in the eye) the presence of the JMD resulted 
in a decrease in the calcium current thought to reflect the number of open voltage-gated 
N-type calcium channels (Piccoli, Rutishauser et al. 2004). This was subsequently
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attributed to small GTPase signalling although other unknown mediators could not be 
ruled out. The conclusion of this work was that voltage-gated calcium channel 
modulation by JMDs could be achieved via the action of ROCK and a change in the 
actin-myosin skeleton (Piccoli, Rutishauser et al. 2004) Although the N-type calcium 
channels are neuronal (Dolphin 1998) and it is the L-type channel that is predominantly 
found in VSMCs (Webb 2003) these channels are major regulators of calcium in their 
respective cells. Given that N-cadherin is found on VSMCs (Moiseeva 2001; Jones, 
Sabatini et al. 2002) it may be possible that changes to the cell-cell contacts via N- 
cadherin causes alterations to downstream signalling which may potentially cause 
contractile changes within the cell. However due to lack of information with regard to 
this process in VSMCs this is merely speculation and would require much further 
investigation.
7.5.2 CD9
While CD9 was observed in positive control testicular tissue, it was not detectable in 
aortic tissue of the mCIA model, possibly indicating that alterations to levels of this 
protein do not play a role in decreased vessel function. However due to animal number 
limitations only severe tissues were available. These experiments were performed prior 
to the N-cadherin work, and in hindsight it may have been of more value to measure 
levels in all disease severity cohorts. Since previous studies described higher levels of 
CD9 in dysfunctional compared to normal tissues (Scherberich, Moog et al. 1998; 
Nishida, Miyagawa et al. 2000) this course of action was deemed appropriate at the time.
Interestingly RANKL (Receptor Activator for Nuclear Factor k  B Ligand) has a positive 
post-translational effect on CD9 expression in macrophages (Ishii, Iwai et al. 2006). 
RANKL a member o f the TNFa superfamily and a key molecule key involved in 
osteoclast differentiation is upregulated during human RA, pushing osteoclast function 
towards degradation (Drexler, Kong et al. 2008) (see chapter one, section 1.2.2). It is 
known that levels o f RANKL are increased in early stages of experimental 
arthritis(Stolina, Adamu et al. 2005); as such changes in CD9 levels could be attributed to 
changes in systemic levels o f RANKL. Further work in this area is therefore essential to
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gain a better understanding of the role of tetraspanins in arthritis-associated vascular 
dysfunction.
7.5.3 A ssessing VSM C Hyperplasia
It became apparent that staining aortic segments was problematic due to problems 
associated with cutting the sections and subsequent staining. Often the action of the blade 
sweeping over the section caused damage and resulted in tearing or folding of the sample. 
Following this often during staining procedures sections became unstuck and float off in 
the media incubated in. As such it became difficult to obtain reproducible results 
regarding smooth muscle hyperplasia.
Although these final studies proved largely inconclusive, that changes in expression were 
seen indicate that further investigation into changes in the ECM in this tissue would be of 
interest to further elucidate the mechanism behind vascular dysfunction. Additionally in 
depth investigation of extracellular receptors and indeed cell-cell interactions may prove 
invaluable to further understanding disease pathology in this model.
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CHAPTER 8
GENERAL DISCUSSION
The original hypothesis stated that “Due to the highly inflammatory nature of RA, and 
similarities o f this exhibited in the murine model of RA, endothelial dysfunction will 
ensue following the onset o f arthritis” . Indeed it was proposed that such dysfunction 
would “be characterised by a decrease in bioavailable NO both in the vessel and 
circulation” and that “plasma levels o f inflammatory mediators will be increased and thus 
contribute to the detrimental effect on the vasculature”.
However to quote Thomas Huxley “the great tragedy of science - the slaying of a 
beautiful hypothesis by an ugly fact". To this end primary observations indicated that the 
presence of mCIA was not associated with endothelial dysfunction. Indeed following the 
onset of arthritis an unexpected contractile dysfunction was observed. Given the possible 
influence o f inflammatory mediators it was logically presumed that in mCIA irregular 
activity of NOS isoforms may have produced uncharacteristically large amounts of NO, 
thus impairing vasoconstriction. Subsequent experiments again rejected this hypothesis. 
Experiments using inhibitors o f both eNOS and iNOS failed to correct the contractile 
dysfunction, furthermore, total plasma NOx was not altered in mCIA over age-matched 
non-arthritic mice. COX inhibition using indomethacin also failed to restore contractile 
responses in arthritic mice which also rules out a role for vasodilators such as 
prostacyclin.
Contractile dysfunction in blood vessels has been characterised in a model of Marfan 
syndrome and subsequently an association was observed between the development of this 
pathology and MMP-9. We therefore investigated whether there was indeed a link 
between MMP-9 and attenuated contractile responses in mCIA. Levels o f MMP-9 were 
quantified using ELISA and immunohistochemistry and found to be elevated in the 
joints, plasma and aorta o f mCIA animals. MMP-9 concentrations in the joints and 
plasma did indeed increase as arthritis progressively increased in severity. Next we
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postulated that IL-ip, a potent pro-inflammatory cytokine which elicits catabolic 
responses within the joint via the induction o f MMPs, could be responsible for the raised 
MMP-9 expression we detected in mCIA. Whilst an in vivo role for IL-ip in the 
upregulation of MMP-9 could not be ruled out, the results of subsequent ex vivo 
experiments would argue against this possibility. Following this, ex vivo studies 
cemented belief that direct exposure of the aorta to MMP-9 is responsible for the 
contractile dysfunction seen in the mCIA model. The mechanism by which MMP-9 
expression is regulated within the vasculature requires further investigation. These data 
implicate MMP-9 in a distinct role during the development of vascular dysfunction 
associated with inflammatory arthritis; for example during RA.
Concrete conclusions regarding the mechanism by which MMP-9 may act on the vessel 
wall to affect contractile function cannot be drawn from this thesis. The cellular source of 
the enzyme within the vessel or indeed surrounding the vessel is unlikely to be restricted 
to a single cell type. Given that the pathological changes and pathways initiated during 
the development of mCIA are diverse and diffuse it is highly likely that multiple factors 
are involved. MMP-9 may prove to be an early defining marker for unwanted 
pathological changes in the vasculature. MMP-9 is perceived to play a minor role in the 
perpetuation of chronic joint pathology (when compared with other MMPs such as MMP- 
1 and MMP-3). However MMP-9s true role may as yet be unrecognised in the complex 
sequence of events which lead to both joint destruction and vascular dysfunction in RA. 
Further investigation is warranted.
Phenotypic switching of VSMCs from contractile to synthetic/proliferative functionality 
may also contribute to the defective contractile responses noted in the vasculature during 
inflammatory arthritis. N-cadherin has previously been linked to this VSMCs functional 
switch. Subsequent studies focussed upon establishing whether N-cadherin was indeed 
important in controlling vascular contractile responses in mCIA. In the first instance it 
was crucial to determine whether N-cadherin was indeed expressed in the vasculature of 
mice with CIA. Subsequent experimental findings eliminated extracellular N-cadherin 
shedding as a direct cause of VSMC phenotypic shedding. The exact activity of N- 
cadherin in this model remains to be seen.
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The research presented in this thesis goes in the face o f the vast majority of published 
data regarding vascular dysfunction in RA. As discussed in Chapter One, in many cases it 
has been suggested that inflammatory cytokines characteristic of RA become systemic 
and induce damage to the endothelium causing the initial insult that gradually progresses 
to endothelial dysfunction. That this pathology is not apparent in the mCIA model may 
be attributed to the duration o f the disease. Indeed in this model of arthritis the early 
upregulation of other factors such as the antioxidants superoxide dismutase and 
glutathione reductase may protect the endothelium and prevent the development o f overt 
endothelial damage, allowing VSMC dysfunction to present itself. In fact if mCIA was 
allowed to progress further endothelial dysfunction may well ensue if such initial 
mechanisms became overwhelmed by the inflammatory milieu presented in RA. That 
human RA is normally only diagnosed following the initial symptoms of disease, at 
which point approximately 30% of patients have visible bone erosion (van der Heijde 
1995), indicates that they may have been subjected to the systemic effects of RA for 
some time. Additionally it has been reported that many patients fail to realise the 
significance of their symptoms and will delay on average for three months before visiting 
their general practitioner (Kumar, Daley et al. 2007). As such, any contractile 
dysfunction may go unnoticed and subsequently only endothelial dysfunction is 
observed; the latter being the major vascular pathology detected during human disease 
duration. The consequences o f ignoring contractile dysfunction by simply looking for the 
development of endothelial dysfunction could be dire with regards to vascular pathology. 
Figure 8.1. summarises the detrimental effect that vessel stiffening, as a consequence 
contractile dysfunction, may have on the cardiovascular system, all o f which may be 
initially attributed to dysregulation o f VSMC function.
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Figure 8.1. Flow Diagram Showing the Potential Consequences of Aortic Stiffening
A factor that may play a part in the development of vascular pathology in human disease, 
in addition to the systemic inflammation, is the use of various treatment therapies. For 
instance the switch from commonly used NSAIDs to more recent selective COX-2 
inhibitors may be implicated. While such interventions were introduced to prevent the 
gastric toxicity side-effects o f the broad spectrum COX inhibitors, elimination of COX-2 
activity results in a pro-thrombotic environment for the vessel due to the removal of 
protective PGI2 without an associated change in thromboxane expression (Funk and 
FitzGerald 2007). This itself may produce an environment favouring the development of 
endothelial dysfunction and could explain the high incidence of this pathology reported 
within the RA population.
Another possible damaging intervention in RA is the commonly used antifolate agent 
methotrexate. As a result o f its mechanism of action it is known to increase plasma levels 
of homocysteine, the latter widely described as an independent risk factor for CVD and 
endothelial dysfunction (Desouza, Keebler et al. 2002). Consequently folic acid is often 
prescribed for use in combination with methotrexate (Visser, Katchamart et al. 2009) to 
lower homocysteine and reduce the risk of associated vascular toxicity. While the jury is 
still out as to the role of homocysteine in vascular disease risk per se a recent study 
suggests that high plasma homocysteine is indeed associated with increased
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atherothrombotic risk in RA patients (Berglund, Sodergren et al. 2009). Again a possible 
role for homocysteine in mCIA would be an interesting topic to follow up.
In an attempt to abolish toxicities associated with RA drugs alternative RA therapies have 
recently been developed which rely on the action of antibodies to neutralise the 
inflammation present (Nam, Winthrop et al. 2010). O f these, anti-TNFa therapy has been 
reported to have varying successes between groups o f patients in terms of improvement 
of RA symptoms (Olsen and Stein 2004), and interestingly has also shown concomitant 
improvements in endothelial function and reduction in arterial stiffness (Maki-Petaja, 
Hall et al. 2006; Bosello, Santoliquido et al. 2008). This evidence highlights the 
importance of evaluating the associated effects of each therapy, be they good or bad; 
those that are beneficial with respect to RA symptoms may be causing unseen damage 
elsewhere in the body. However, vascular damage may well be present before the RA 
intervention is initiated and the slightest risk from a therapy might contribute further to 
further CVD. In this case it may be beneficial to determine cardiovascular risk at the 
initial RA diagnosis, for example by utilising measurements of vascular stiffening such as 
augmentation index or flow-mediated dilation and so establish the overall disease risk for 
each patient. Unfortunately, the latter techniques are really research tools only at present. 
Improvements in technology may lead to such tailored individual diagnosis becoming a 
reality in the clinic and therefore provide significant health benefits.
It may well be of interest to investigate mechanisms involved in the potential 
“reversibility” o f the vascular pathology in RA following remission. Currently remission 
classification is vague; although the physician and patient agree they are in remission, 
there may still be residual RA activity present (Wolfe, Boers et al. 2009). As such this 
would complicate the identification o f vascular pathology for although the risk of this 
developing may be reduced, the initial inflammatory-disease associated insult could have 
initiated a cascade of damage that might be irreversible despite the amelioration of joint 
symptoms.
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8.1 Endothelial Progenitor Cells
Interestingly an additional reason why endothelial dysfunction is not observed in the 
mCIA model may be attributed to increased production of MMP-9 itself. Endothelial 
progenitor cells (EPCs) reside in the bone marrow before differentiating into cells bearing 
endothelial characteristics (van Zonneveld, de Boer et al. 2010). A role for these cells in 
re-endothelialisation has been described and evidence is accumulating in support of their 
function in endothelial repair (van Zonneveld, de Boer et al. 2010). Furthermore their 
role in the development of atherosclerosis has been demonstrated by studies showing the 
larger the risk of event, the smaller the number of circulating EPCs present (Hirata, 
Nagata et al. 2010). These cells normally reside in a quiescent state in the bone marrow, 
but stimulation by growth factors, namely VEGF (Asahara, Takahashi et al. 1999), or via 
injury (Kawabe, Ushikubi et al. 2010) causes migration into the peripheral blood where 
they are able to proliferate and differentiate contributing to re-endothelialization 
(Padfield, Newby et al. 2010). Importantly this process has been observed to be 
dependent on the secretion of MMP-9, which in the bone marrow stimulates release of 
the stem-cell active cytokine soluble kit-ligand, increasing motility of the bone marrow 
stem cells. The latter then translocate from their quiescent niche in the bone to the 
vasculature for repair (Heissig, Hattori et al. 2002). That increased levels of MMP-9 
have been demonstrated in the mCIA model both systemically and at the arthritic joint 
suggests that it may produce stimulated release of EPCs. Initiation of such repair 
processes could prevent endothelial dysfunction and subsequent damage to the vascular 
wail. As such, upregulation of MMP-9 may be both beneficial and detrimental to vessel 
function, repairing the endothelium whilst causing underlying damage to VSMC 
function. However, this theory is questionable given the duration of disease and extent of 
vascular damage in the mCIA model, and such is rather speculative.
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FINAL THOUGHTS
Underlying damage to the VSMCs in mCIA may precede damage to the endothelium 
implying that this pathology may play a greater role in the development of RA-associated 
cardiovascular co-morbidities than is currently recognised. Investigating these changes in 
patients with early RA and developing suitable therapies to target this could prove 
invaluable in preventing vascular disease and providing a better quality of life for the 
long-suffering RA cohort.
279
REFERENCES
Abeles, A. M. and M. H. Pillinger (2006). "The role of the synovial fibroblast in rheumatoid arthritis: 
cartilage destruction and the regulation of matrix metalloproteinases." Bull NYU Hosp Jt Pis 
64(1-2): 20-4.
Agrez, M. V. (1996). "Cell adhesion molecules and colon cancer." Aust N Z J Surg 66(12): 791-8.
Alvarez, Y., A. M. Briones, et al. (2008). "Role of NADPH oxidase and iNOS in vasoconstrictor responses 
of vessels from hypertensive and normotensive rats." Br J Pharmacol 153(5): 926-35.
Andreakos, E., U. Rauchhaus, et al. (2009). "Amphoteric liposomes enable systemic antigen-presenting 
cell-directed delivery of CD40 antisense and are therapeutically effective in experimental 
arthritis." Arthritis Rheum 60(4): 994-1005.
Aiming, P. B., B. Coles, et al. (2005). "Elevated endothelial nitric oxide bioactivity and resistance to 
angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice." Am J Pathol 166(3): 
653-62.
Asahara, T., T. Takahashi, et al. (1999). "VEGF contributes to postnatal neovascularization by mobilizing 
bone marrow-derived endothelial progenitor cells." Embo J 18(14): 3964-72.
Assoian, R. K., B. E. Fleurdelys, et al. (1987). "Expression and secretion of type beta transforming growth 
factor by activated human macrophages." Proc Natl Acad Sci U S A 84(17): 6020-4.
Bacon, P. A., R. J. Stevens, et al. (2002). "Accelerated atherogenesis in autoimmune rheumatic diseases." 
Autoimmun Rev 1(6): 338-47.
Basalyga, D. M., D. T. Simionescu, et al. (2004). "Elastin degradation and calcification in an abdominal 
aorta injury model: role of matrix metalloproteinases." Circulation 110(22): 3480-7.
Bayes-Genis, A., J. H. Campbell, et al. (2002). "Macrophages, myofibroblasts and neointimal hyperplasia 
after coronary artery injury and repair.” Atherosclerosis 163(1): 89-98.
Bazzichi, L., L. Ghiadoni, et al. (2009). "Osteopontin is associated with increased arterial stiffness in 
Rheumatoid Arthritis." Mol Med.
Bazzichi, L., L. Ghiadoni, et al. (2009). "Osteopontin is associated with increased arterial stiffness in 
rheumatoid arthritis." Mol Med 15(11-12): 402-6.
Beckman, J. S. (1996). "Oxidative damage and tyrosine nitration from peroxynitrite." Chem Res Toxicol 
9(5): 836-44.
Behrens, J., B. A. Jerchow, et al. (1998). "Functional interaction of an axin homolog, conductin, with beta- 
catenin, APC, and GSK3beta." Science 280(5363): 596-9.
Bell, D. M., T. E. Johns, et al. (1998). "Endothelial dysfunction: implications for therapy of cardiovascular 
diseases." Ann Pharmacother 32(4): 459-70.
Bendeck, M. P., M. Conte, et al. (2002). "Doxycycline modulates smooth muscle cell growth, migration, 
and matrix remodeling after arterial injury." Am J Pathol 160(3): 1089-95.
Berglund, S., A. Sodergren, et al. (2009). "Atherothrombotic events in rheumatoid arthritis are predicted by 
homocysteine - a six-year follow-up study." Clin Exp Rheumatol 27(5): 822-5.
Bijl, M. (2003). "Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic 
autoimmune diseases." Neth J Med 61(9): 273-7.
Birschmann, I. and U. Walter (2004). "Physiology and pathophysiology of vascular signaling controlled by 
guanosine 3',5'-cyclic monophosphate-dependent protein kinase." Acta Biochim Pol 51(2): 397- 
404.
Bocker, J. M., F. J. Miller, et al. (2001). "Calcium-activated potassium channels mask vascular dysfunction 
associated with oxidized LDL exposure in rabbit aorta." Jpn Heart J 42(3): 317-26.
Boer, R., W. R. Ulrich, et al. (2000). "The inhibitory potency and selectivity of arginine substrate site 
nitric-oxide synthase inhibitors is solely determined by their affinity toward the different 
isoenzymes." Mol Pharmacol 58(5): 1026-34.
Bohme, E., H. Graf, et al. (1978). "Effects of sodium nitroprusside and other smooth muscle relaxants on 
cyclic GMP formation in smooth muscle and platelets." Adv Cyclic Nucleotide Res 9: 131-43.
Bond, M., R. P. Fabunmi, et al. (1998). "Synergistic upregulation of metalloproteinase-9 by growth factors 
and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B." FEBS 
Lett 435(1): 29-34.
280
Bosello, S., A. Santoliquido, et al. (2008). "TNF-alpha blockade induces a reversible but transient effect on 
endothelial dysfunction in patients with long-standing severe rheumatoid arthritis." Clin 
Rheumatol 27(7): 833-9.
Brabletz, T., A. Jung, et al. (1999). "beta-catenin regulates the expression of the matrix metalloproteinase-7 
in human colorectal cancer." Am J Pathol 155(4): 1033-8.
Bradford, M. M. (1976). "A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding." Anal Biochem 72: 248-54.
Brantjes, H., N. Barker, et al. (2002). "TCF: Lady Justice casting the final verdict on the outcome of Wnt 
signalling." BioLChem 383(2): 255-61.
Bratt, J. and J. Palmblad (1997). "Cytokine-induced neutrophil-mediated injury of human endothelial 
cells." J Immunol 159(2): 912-8.
Braun, J. and R. Rau (2009). "An update on methotrexate." Curr Opin Rheumatol 21(3): 216-23.
Brew, K., D. Dinakarpandian, et al. (2000). "Tissue inhibitors of metalloproteinases: evolution, structure 
and function." Biochim Biophvs Acta 1477(1-2): 267-83.
Bruhl, H., J. Cihak, et al. (2009). "Important role of interleukin-3 in the early phase of collagen-induced 
arthritis." Arthritis Rheum 60(5): 1352-61.
Bryant, C. E., I. Appleton, et al. (1998). "Vascular endothelial growth factor upregulates constitutive 
cyclooxygenase 1 in primary bovine and human endothelial cells." Life Sci 62(24): 2195-201.
Bui, Q. T., M. Prempeh, et al. (2009). "Atherosclerotic plaque development." Int J Biochem Cell Biol 
41(11): 2109-13.
Bull, M. J., A. S. Williams, et al. (2008). "The Death Receptor 3-TNF-like protein 1A pathway drives 
adverse bone pathology in inflammatory arthritis." J Exp Med 205(11): 2457-64.
Bunag, R. D. (1973). "Validation in awake rats of a tail-cuff method for measuring systolic pressure." J 
AppI Phvsiol 34(21: 279-82.
Bussemakers, M. J., A. Van Bokhoven, et al. (2000). "Complex cadherin expression in human prostate 
cancer cells." Int J Cancer 85(3): 446-50.
Cai, S., J. Khoo, et al. (2005). "Endothelial nitric oxide synthase dysfunction in diabetic mice: importance 
of tetrahydrobiopterin in eNOS dimerisation." Diabetologia 48(9): 1933-40.
Can, C., M. G. Cinar, et al. (2002). "Vascular endothelial dysfunction associated with elevated serum 
homocysteine levels in rat adjuvant arthritis: effect of vitamin E administration." Life Sci 71(4): 
401-10.
Capone, M. L., S. Tacconelli, et al. (2003). "Clinical pharmacology of selective COX-2 inhibitors." Int J 
Immunopathol Pharmacol 16(2 Suppl): 49-58.
Carter, A. M. (2005). "Inflammation, thrombosis and acute coronary syndromes." Diab Vase Pis Res 2(3): 
113-21.
Catterall, W. A., E. Perez-Reyes, et al. (2005). "International Union of Pharmacology. XLVIII. 
Nomenclature and structure-function relationships of voltage-gated calcium channels." Pharmacol 
Rev 57(4): 411-25.
Chakraborti, S., M. Mandal, et al. (2003). "Regulation of matrix metalloproteinases: an overview." Mol 
Cell Biochem 253(1-2): 269-85.
Chang, Y. H., I. L. Lin, et al. (2008). "Elevated circulatory MMP-2 and MMP-9 levels and activities in 
patients with rheumatoid arthritis and systemic lupus erythematosus." Clin Biochem.
Chew, D. K., M. S. Conte, et al. (2004). "Matrix metalloproteinase-specific inhibition of Ca2+ entry 
mechanisms of vascular contraction." J Vase Sure 40(5): 1001-10.
Chia, W. T., Y. W. Chen, et al. (2008). "MMP-9 mRNA as a therapeutic marker in acute and chronic stages 
of arthritis induced by type II collagen antibody." J Formos Med Assoc 107(3): 245-52.
Cho, A. and M. A. Reidy (2002). "Matrix metalloproteinase-9 is necessary for the regulation of smooth
muscle cell replication and migration after arterial injury." Circ Res 91(9): 845-51.
Cho, Y. G., M. L. Cho, et al. (2007). "Type II collagen autoimmunity in a mouse model of human
rheumatoid arthritis." Autoimmun Rev 7(1): 65-70.
Choi, H. K., M. A. Heman, et al. (2002). "Methotrexate and mortality in patients with rheumatoid arthritis: 
a prospective study." Lancet 359(9313): 1173-7.
Choi, S. T., J. H. Kim, et al. (2009). "Therapeutic effect of anti-vascular endothelial growth factor receptor 
I antibody in the established collagen-induced arthritis mouse model." Clin Rheumatol 28(3): 333- 
7.
Chow, A. K., J. Cena, et al. (2007). "Acute actions and novel targets of matrix metalloproteinases in the 
heart and vasculature." Br J Pharmacol 152(2): 189-205.
281
Chung, A. W., K. Au Yeung, et al. (2007). "Loss of elastic fiber integrity and reduction of vascular smooth 
muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 
in the thoracic aortic aneurysm in Marfan syndrome." Circ Res 101(5): 512-22.
Chung, A. W., H. H. Yang, et al. (2009). "Upregulation of matrix metalloproteinase-2 in the arterial 
vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney 
disease." Circulation 120(9): 792-801.
Chung, A. W., H. H. Yang, et al. (2008). "Long-term doxycycline is more effective than atenolol to prevent 
thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2  
and -9." Circ Res 102(8): e73-85.
Chung, C. P., A. Oeser, et al. (2005). "Increased coronary-artery atherosclerosis in rheumatoid arthritis: 
relationship to disease duration and cardiovascular risk factors." Arthritis Rheum 52(10): 3045-53.
Clevers, H. (2006). "Wnt/beta-catenin signaling in development and disease." Cell 127(3): 469-80.
Cohen, R. A., R. M. Weisbrod, et al. (1999). "Mechanism of nitric oxide-induced vasodilatation: refilling 
of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated 
Ca2+ influx." Circ Res 84(2): 210-9.
Coles, B., R. Lewis, et al. (2007). "CD59 or C3 are not requred for angiotensin II-dependent hypertension 
or hypertrophy in mice." Immunology 121(4): 518-25.
Collin-Osdoby, P. (2004). "Regulation of vascular calcification by osteoclast regulatory factors RANKL 
and osteoprotegerin." Circ Res 95(11): 1046-57.
Courtenay, J. S., M. J. Dallman, et al. (1980). "Immunisation against heterologous type II collagen induces 
arthritis in mice." Nature 283(5748): 6 6 6 -8 .
Csiszar, A., N. Labinskyy, et al. (2007). "Vascular superoxide and hydrogen peroxide production and 
oxidative stress resistance in two closely related rodent species with disparate longevity." Aging 
Cell 6 (6 ): 783-97.
Cuchacovich, R. and L. R. Espinoza (2009). "Does TNF-alpha blockade play any role in cardiovascular 
risk among rheumatoid arthritis (RA) patients?" Clin Rheumatol 28(10): 1217-20.
Cuzzocrea, S. (2006). "Role of nitric oxide and reactive oxygen species in arthritis." Curr Pharm Des 
12(27): 3551-70.
Dale M. M, H. D. G. (2004). Pharmacology
Condensed, Churchill Livingstone. 1.
Dashwood, M. R. and J. C. Tsui (2002). "Endothelin-1 and atherosclerosis: potential complications 
associated with endothelin-receptor blockade." Atherosclerosis 160(2): 297-304.
Day, R. (2002). "Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis." Lancet 359(9306): 
540-1.
de Gasparo, M., K. J. Catt, et al. (2000). "International union of pharmacology. XXIII. The angiotensin II 
receptors." Pharmacol Rev 52(3): 415-72.
Dejam, A., C. J. Hunter, et al. (2005). "Erythrocytes are the major intravascular storage sites of nitrite in 
human blood." Blood 106(2): 734-9.
DeMaria, A. N. (2002). "Relative risk of cardiovascular events in patients with rheumatoid arthritis." Am J 
Cardiol 89(6A): 33D-38D.
Desouza, C., M. Keebler, et al. (2002). "Drugs affecting homocysteine metabolism: impact on 
cardiovascular risk." Drugs 62(4): 605-16.
Dinarello, C. A. (2002). "The IL-1 family and inflammatory diseases." Clin Exp Rheumatol 20(5 Suppl 
27): S1-13.
Do, K. H., M. S. Kim, et al. (2009). "Angiotensin II-induced aortic ring constriction is mediated by 
phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway." Exp Mol Med 41(8): 
569-76.
Dolphin, A. C. (1998). "Mechanisms of modulation of voltage-dependent calcium channels by G proteins." 
J Phvsiol 506 ( Pt 1): 3-11.
Dorrance, A. M. (2007). "Interleukin 1-beta (IL-1 beta) enhances contractile responses in endothelium- 
denuded aorta from hypertensive, but not normotensive, rats." Vascul Pharmacol 47(2-3): 160-5.
Dougall, W. C., M. Glaccum, et al. (1999). "RANK is essential for osteoclast and lymph node 
development." Genes Dev 13(18): 2412-24.
Dreier, R., S. Grassel, et al. (2004). "Pro-MMP-9 is a specific macrophage product and is activated by 
osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade." E xp Cell Res 297(2): 
303-12.
Drexler, S. K., P. L. Kong, et al. (2008). "Cell signalling in macrophages, the principal innate immune 
effector cells of rheumatoid arthritis." Arthritis Res Ther 10(5): 216.
282
Dwivedi, A., S. C. Slater, et al. (2009). "MMP-9 and -12 cause N-cadherin shedding and thereby beta- 
catenin signalling and vascular smooth muscle cell proliferation." Cardiovasc Res 81(1): 178-86.
Eklund, K. K. (2007). "Mast cells in the pathogenesis of rheumatic diseases and as potential targets for 
anti-rheumatic therapy." Immunol Rev 217: 38-52.
El-Hamamsy, I. and M. H. Yacoub (2009). "Cellular and molecular mechanisms of thoracic aortic 
aneurysms." Nat Rev Cardiol 6(12): 771-86.
Ersoy, S., I. Orhan, et al. (2008). "Endothelium-dependent induction of vasorelaxation by Melissa 
officinalis L. ssp. officinalis in rat isolated thoracic aorta." Phvtomedicine 15(12): 1087-92.
Fabunmi, R. P., A. H. Baker, et al. (1996). "Divergent regulation by growth factors and cytokines of 95 
kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit 
aortic smooth muscle cells." Biochem J 315 ( Pt 1): 335-42.
Feng, M., M. E. Deerhake, et al. (2009). "Genetic analysis of blood pressure in 8 mouse intercross 
populations." Hypertension 54(4): 802-9.
Feng, M., S. Whitesall, et al. (2008). "Validation of volume-pressure recording tail-cuff blood pressure 
measurements." Am J Hypertens 21(121: 1288-91.
Filippin, L. I., R. Vercelino, et al. (2008). "Redox signalling and the inflammatory response in rheumatoid 
arthritis." Clin Exp Immunol 152(3): 415-22.
Flamant, M., S. Placier, et al. (2007). "Role of matrix metalloproteinases in early hypertensive vascular 
remodeling." Hypertension 50(1): 212-8.
Flammer, A. J., I. Sudano, et al. (2008). "Angiotensin-converting enzyme inhibition improves vascular 
function in rheumatoid arthritis." Circulation 117(17): 2262-9.
Fleming, S. D. and G. C. Tsokos (2006). "Complement, natural antibodies, autoantibodies and tissue 
injury." Autoimmun Rev 5(2): 89-92.
Fontaine, J., A. Herchuelz, et al. (1984). "A pharmacological analysis of the responses of isolated aorta 
from rats with adjuvant arthritis." Agents Actions 14(5-6): 684-7.
Forstermann, U. (2006). "Endothelial NO synthase as a source of NO and superoxide." Eur J Clin 
Pharmacol 62 Suppl 13: 5-12.
Forstermann, U. (2008). "Oxidative stress in vascular disease: causes, defense mechanisms and potential 
therapies." Nat Clin Pract Cardiovasc Med 5(6): 338-49.
Forstermann, U. and T. Munzel (2006). "Endothelial nitric oxide synthase in vascular disease: from marvel 
to menace." Circulation 113(13): 1708-14.
Foster, R. W. (1986). Basic Pharmacology, Butterworths.
Foudi, N., L. Louedec, et al. (2009). "Selective cyclooxygenase-2 inhibition directly increases human 
vascular reactivity to norepinephrine during acute inflammation." Cardiovasc Res 81(2): 269-77.
Fujisaki, K., N. Tanabe, et al. (2007). "Receptor activator of NF-kappaB ligand induces the expression of 
carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor 
RAW264.7 cells." Life Sci 80(141: 1311-8.
Funk, C. D. and G. A. FitzGerald (2007). "COX-2 inhibitors and cardiovascular risk." J Cardiovasc 
Pharmacol 50(5): 470-9.
Furchgott, R. F. and J. V. Zawadzki (1980). "The obligatory role of endothelial cells in the relaxation of 
arterial smooth muscle by acetylcholine." Nature 288(5789): 373-6.
Gabriel, S. E. (2001). "The epidemiology of rheumatoid arthritis." Rheum Pis Clin North Am 27(2): 269- 
81.
Gadeau, A. P., M. Campan, et al. (1993). "Osteopontin overexpression is associated with arterial smooth 
muscle cell proliferation in vitro." Arterioscler Thromb 13(1): 120-5.
Galarraga, B., F. Khan, et al. (2009). "Etanercept improves inflammation-associated arterial stiffness in 
rheumatoid arthritis." Rheumatology (Oxford) 48(11): 1418-23.
Galis, Z. S., C. Johnson, et al. (2002). "Targeted disruption of the matrix metalloproteinase-9 gene impairs 
smooth muscle cell migration and geometrical arterial remodeling." Circ Res 91(9): 852-9.
Gamble, J. B. M. (2008). Theory and Practice of Histological Techniques.
Ganea, E., M. Trifan, et al. (2007). "Matrix metalloproteinases: useful and deleterious." Biochem Soc Trans 
35(Pt 4): 689-91.
Gao, Y., A. D. Portugal, et al. (2007). "Role of Rho kinases in PKG-mediated relaxation of pulmonary 
arteries of fetal lambs exposed to chronic high altitude hypoxia." Am J Phvsiol Lung Cell Mol 
Phvsiol 292(3): L678-84.
Garvey, E. P., J. A. Oplinger, et al. (1997). "1400W is a slow, tight binding, and highly selective inhibitor 
of inducible nitric-oxide synthase in vitro and in vivo." J Biol Chem 272(8): 4959-63.
283
Garvin, P., L. Nilsson, et al. (2008). "Circulating matrix metalloproteinase-9 is associated with 
cardiovascular risk factors in a middle-aged normal population." PLoS ONE 3(3): el774.
George, S. J. and C. A. Beeching (2006). "Cadherinxatenin complex: a novel regulator of vascular smooth 
muscle cell behaviour." Atherosclerosis 188(1): 1-11.
George, S. J. and A. Dwivedi (2004). "MMPs, cadherins, and cell proliferation." Trends Cardiovasc Med 
14(3): 100-5.
Gibson, C. L., D. Constantin, et al. (2005). "Progesterone suppresses the inflammatory response and nitric 
oxide synthase-2 expression following cerebral ischemia." Exp Neurol 193(2): 522-30.
Gielen, S., M. Sandri, et al. (2009). "Risk factor management: antiatherogenic therapies." Eur J Cardiovasc 
Prev Rehabil 16 Suppl 1: S29-36.
Gluszko, P. and A. Bielinska (2009). "Non-steroidal anti-inflammatory drugs and the risk of cardiovascular 
diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?" Pol Arch Med 
Wewn 119(4): 231-5.
Godecke, A., U. K. Decking, et al. (1998). "Coronary hemodynamics in endothelial NO synthase knockout 
mice." CircRes82(2): 186-94.
Goodson, N. (2002). "Coronary artery disease and rheumatoid arthritis." Curr Opin Rheumatol 14(2): 115- 
20 .
Gorman, C. L. and A. P. Cope (2008). "Immune-mediated pathways in chronic inflammatory arthritis." 
Best Pract Res Clin Rheumatol 22(2): 221-38.
Goronzy, J. J. and C. M. Weyand (2005). "Rheumatoid arthritis." Immunol Rev 204: 55-73.
Gorska, A., O. Kowal-Bielecka, et al. (2008). "Impairment of microcirculation in juvenile idiopathic 
arthritis - studies by nailfold videocapillaroscopy and correlation with serum levels of sICAM and 
VEGF." Folia Histochem Cvtobiol 46(4): 443-7.
Gosens, R., H. Meurs, et al. (2008). "The GSK-3/beta-catenin-signalling axis in smooth muscle and its 
relationship with remodelling." Naunvn Schmiedeberes Arch Pharmacol 378(21: 185-91.
Gradl, D., M. Kuhl, et al. (1999). "The Wnt/Wg signal transducer beta-catenin controls fibronectin 
expression." Mol Cell Biol 19(8): 5576-87.
Gravallese, E. M. (2003). "Osteopontin: a bridge between bone and the immune system." J Clin Invest 
112(2): 147-9.
Green, G. A. (2001). "Understanding NSAIDs: from aspirin to COX-2." Clin Cornerstone 3(5): 50-60.
Gregersen, P. K., J. Silver, et al. (1987). "The shared epitope hypothesis. An approach to understanding the 
molecular genetics of susceptibility to rheumatoid arthritis." Arthritis Rheum 30(11): 1205-13.
Gross, S. S. and R. Levi (1992). "Tetrahydrobiopterin synthesis. An absolute requirement for cytokine- 
induced nitric oxide generation by vascular smooth muscle." J Biol Chem 267(36): 25722-9.
Grosser, T., S. Fries, et al. (2006). "Biological basis for the cardiovascular consequences of COX-2 
inhibition: therapeutic challenges and opportunities." J Clin Invest 116(1): 4-15.
Gruber, B. L., D. Sorbi, et al. (1996). "Markedly elevated serum MMP-9 (gelatinase B) levels in 
rheumatoid arthritis: a potentially useful laboratory marker." Clin Immunol Immunopathol 78(2): 
161-71.
Gurjar, M. V., J. DeLeon, et al. (2001). "Mechanism of inhibition of matrix metalloproteinase-9 induction 
by NO in vascular smooth muscle cells." J Appl Physiol 91(3): 1380-6.
Guijar, M. V., J. Deleon, et al. (2001). "Role of reactive oxygen species in IL-1 beta-stimulated sustained 
ERK activation and MMP-9 induction." Am J Phvsiol Heart Circ Phvsiol 281(6): H2568-74.
Hall, F. C. and N. Dalbeth (2005). "Disease modification and cardiovascular risk reduction: two sides of 
the same coin?" Rheumatology (Oxford') 44(12V. 1473-82.
Halpem, W., M. J. Mulvany, et al. (1978). "Mechanical properties of smooth muscle cells in the walls of 
arterial resistance vessels." J Phvsiol 275: 85-101.
Hanke, H., S. Hassenstein, et al. (1994). "Accumulation of macrophages in the arterial vessel wall 
following experimental balloon angioplasty." Ew Heart J 15(5): 691-8.
Hart, F. D. and P. L. Boardman (1963). "Indomethacin: a New Non-Steroid Anti-Inflammatory Agent." Br 
Med J 2(5363): 965-70.
Hartog, A., J. Hulsman, et al. (2009). "Locomotion and muscle mass measwes in a murine model of 
collagen-induced arthritis." BMC Musculoskelet Disord 10: 59.
Haruna, Y., Y. Morita, et al. (2006). "Endothelial dysfunction in rat adjuvant-induced arthritis: vascular 
superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase." 
Arthritis Rheum 54(61: 1847-55.
Haruna, Y., Y. Morita, et al. (2007). "Fluvastatin reverses endothelial dysfunction and increased vascular 
oxidative stress in rat adjuvant-induced arthritis." Arthritis Rheum 56(6): 1827-35.
284
Hatta, K., A. Nose, et al. (1988). "Cloning and expression of cDNA encoding a neural calcium-dependent 
cell adhesion molecule: its identity in the cadherin gene family." J Cell Biol 106(3): 873-81.
Hatton, D. C., Y. Qi, et al. (2000). "Heritability of the blood pressure response to acute ethanol exposure in 
five inbred strains of mice." Alcohol Clin Exp Res 24(10): 1483-7.
Haynes, D. R. (2007). "Inflammatory cells and bone loss in rheumatoid arthritis." Arthritis Res Ther 9(3):
104.
Hayward, K. and C. A. Wallace (2009). "Recent developments in anti-rheumatic drugs in pediatrics: 
treatment of juvenile idiopathic arthritis." Arthritis Res Ther 11(1): 216.
Hegen, M., J. C. Keith, Jr., et al. (2008). "Utility of animal models for identification of potential 
therapeutics for rheumatoid arthritis." Ann Rheum Pis 67(11): 1505-15.
Heissig, B., K. Hattori, et al. (2002). "Recruitment of stem and progenitor cells from the bone marrow 
niche requires MMP-9 mediated release of kit-ligand." Cell 109(5): 625-37.
Hemler, M. E. (2001). "Specific tetraspanin functions." J Cell Biol 155(7): 1103-7.
Henderson B, E. J., Pettipher ER (1995). Mechanisms and Models in Rheumatoid Arthritis, Academic 
Press.
Hetzel, J., B. Balletshofer, et al. (2005). "Rapid effects of rosiglitazone treatment on endothelial function 
and inflammatory biomarkers." Arterioscler Thromb Vase Biol 25(9): 1804-9.
Higashiyama, S., R. Iwamoto, et al. (1995). "The membrane protein CD9/DRAP 27 potentiates the 
juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth 
factor." J Cell Biol 128(5): 929-38.
Hink, U., H. Li, et al. (2001). "Mechanisms underlying endothelial dysfunction in diabetes mellitus." Circ 
Res 88(2): E l4-22.
Hirano, K. (2007). "Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the 
contractile apparatus in vascular smooth muscle." J Pharmacol Sci 104(2): 109-15.
Hirata, Y., D. Nagata, et al. (2010). "Diagnosis and treatment of endothelial dysfunction in cardiovascular 
disease." Int Heart J 51(1): 1-6.
Hishinuma, T., H. Nakamura, et al. (2001). "Analysis of urinary prostacyclin and thromboxane/prostacyclin 
ratio in patients with rheumatoid arthritis using gas chromatography/selected ion monitoring." 
Prostaglandins Leukot Essent Fatty Acids 65(2): 85-90.
Ho, A. T., E. B. Voura, et al. (2001). "MMP inhibitors augment fibroblast adhesion through stabilization of 
focal adhesion contacts and up-regulation of cadherin function." J Biol Chem 276(43): 40215-24.
Hoge, M. and S. Amar (2006). "Role of interleukin-1 in bacterial atherogenesis." Drugs Today (Bare) 
42(10): 683-8.
Holmdahl, R., L. Jansson, et al. (1986). "Female sex hormones suppress development of collagen-induced 
arthritis in mice." Arthritis Rheum 29(12): 1501-9.
Holmdahl, R., M. Karlsson, et al. (1989). "Localization of a critical restriction site on the I-A beta chain 
that determines susceptibility to collagen-induced arthritis in mice." Proc Natl Acad Sci U S A 
86(23): 9475-9.
Honda, T., E. Segi-Nishida, et al. (2006). "Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 
signaling both mediate joint inflammation in mouse collagen-induced arthritis." J Exp Med 
203(2): 325-35.
Horowitz, M. C., Y. Xi, et al. (2001). "Control of osteoclastogenesis and bone resorption by members of 
the TNF family of receptors and ligands." Cvtokine Growth Factor Rev 12(1): 9-18.
Horvath, B., P. Orsy, et al. (2005). "Endothelial NOS-mediated relaxations of isolated thoracic aorta of the 
C57BL/6J mouse: a methodological study." J Cardiovasc Pharmacol 45(3): 225-31.
Howe, L. R., K. Subbaramaiah, et al. (1999). "Transcriptional activation of cyclooxygenase-2 in Wnt-1- 
transformed mouse mammary epithelial cells." Cancer Res 59(7): 1572-7.
Huang, A., D. Sun, et al. (1998). "Gender difference in flow-induced dilation and regulation of shear stress: 
role of estrogen and nitric oxide." Am J Phvsiol 275(5 Pt 2): R1571-7.
Hyafil, F., C. Babinet, et al. (1981). "Cell-cell interactions in early embryogenesis: a molecular approach to 
the role of calcium." Cell 26(3 Pt 1): 447-54.
Hynes, R. O. (2002). "Integrins: bidirectional, allosteric signaling machines." Cell 110(6): 673-87.
Ignarro, L. J. and C. Napoli (2004). "Novel features of nitric oxide, endothelial nitric oxide synthase, and 
atherosclerosis." Curr Atheroscler Rep 6(4): 281-7.
Ikonomidis, J. S., J. R. Barbour, et al. (2005). "Effects of deletion of the matrix metalloproteinase 9 gene on 
development of murine thoracic aortic aneurysms." Circulation 112(9 Suppl): 1242-8.
285
Inglis, J. J., C. A. Notley, et al. (2007). "Collagen-induced arthritis as a model of hyperalgesia: functional 
and cellular analysis of the analgesic actions of tumor necrosis factor blockade." Arthritis Rheum 
56(12): 4015-23.
Ishii, M., K. Iwai, et al. (2006). "RANKL-induced expression of tetraspanin CD9 in lipid raft membrane 
microdomain is essential for cell fusion during osteoclastogenesis." J Bone Miner Res 21(6): 965- 
76.
Itoh, T., H. Matsuda, et al. (2002). "The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 
in antibody-induced arthritis." J Immunol 169(5): 2643-7.
Jackson, C. J., J. Arkell, et al. (1998). "Rheumatoid synovial endothelial cells secrete decreased levels of 
tissue inhibitor of MMP (TIMP1)." Ann Rheum Pis 57(3): 158-61.
Jantzen, F., S. Konemann, et al. (2007). "Isoprenoid depletion by statins antagonizes cytokine-induced 
down-regulation of endothelial nitric oxide expression and increases NO synthase activity in 
human umbilical vein endothelial cells." J Phvsiol Pharmacol 58(3): 503-14.
Jimenez-Altayo, F., A. M. Briones, et al. (2006). "Increased superoxide anion production by interleukin- 
lbeta impairs nitric oxide-mediated relaxation in resistance arteries." J Pharmacol Exp Ther 
316(1): 42-52.
Jones, M., P. J. Sabatini, et al. (2002). "N-cadherin upregulation and function in response of smooth muscle 
cells to arterial injury." Arterioscler Thromb Vase Biol 22(12): 1972-7.
Juarranz, Y., C. Abad, et al. (2005). "Protective effect of vasoactive intestinal peptide on bone destruction 
in the collagen-induced arthritis model of rheumatoid arthritis." Arthritis Res Ther 7(5): R1034- 
45.
Judkins, C. P., C. G. Sobey, et al. (2006). "NADPH-induced contractions of mouse aorta do not involve 
NADPH oxidase: a role for P2X receptors." J Pharmacol Exp Ther 317(2): 644-50.
Kanatsu-Shinohara, M., S. Toyokuni, et al. (2004). "CD9 is a surface marker on mouse and rat male 
germline stem cells." Biol Reprod 70(1): 70-5.
Kaplan-Albuquerque, N., C. Garat, et al. (2003). "Platelet-derived growth factor-BB-mediated activation of 
Akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated 
protein kinase and redistribution of serum response factor." J Biol Chem 278(41): 39830-8.
Kaplan, M. J. (2006). "Cardiovascular disease in rheumatoid arthritis." Curr Op in Rheumatol 18(3): 289- 
97.
Karanian, J. W. and P. W. Ramwell (1996). "Effect of gender and sex steroids on the contractile response 
of canine coronary and renal blood vessels." J Cardiovasc Pharmacol 27(3): 312-9.
Kasapis, C. and P. D. Thompson (2005). "The effects of physical activity on serum C-reactive protein and 
inflammatory markers: a systematic review." J Am Coll Cardiol 45(10): 1563-9.
Kauser, K. and G. M. Rubanyi (1994). "Gender difference in bioassayable endothelium-derived nitric oxide 
from isolated rat aortae." Am J Phvsiol 267(6 Pt 2): H2311-7.
Kawabe, J., F. Ushikubi, et al. (2010). "Prostacyclin in vascular diseases. - Recent insights and future 
perspectives." Circ J 74(5): 836-43.
Kawano, Y. and R. Kypta (2003). "Secreted antagonists of the Wnt signalling pathway." J Cell Sci 116(Pt 
13): 2627-34.
Kawashima, S. and M. Yokoyama (2004). "Dysfunction of endothelial nitric oxide synthase and 
atherosclerosis." Arterioscler Thromb Vase Biol 24(6): 998-1005.
Kelm, M., S. Schafer, et al. (1997). "Nitric oxide induced contractile dysfunction is related to a reduction in 
myocardial energy generation." Cardiovasc Res 36(2): 185-94.
Kim, H., W. J. Kim, et al. (2005). "Cyclophilin A may contribute to the inflammatory processes in 
rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines 
from macrophages." Clin Immunol 116(3): 217-24.
Kim, J. K. and J. A. Diehl (2009). "Nuclear cyclin Dl: an oncogenic driver in human cancer." J Cell 
Phvsiol 220(21: 292-6.
Kirkpatrick, C. J., M. Wagner, et al. (1997). "Physiology and cell biology of the endothelium: a dynamic 
interface for cell communication." Int J Microcirc Clin Exp 17(5): 231-40.
Kiviranta, I., J. Jurvelin, et al. (1985). "Microspectrophotometric quantitation of glycosaminoglycans in 
articular cartilage sections stained with Safranin O." Histochemistry 82(3): 249-55.
Rnedla, A., E. Neumann, et al. (2007). "Developments in the synovial biology field 2006." Arthritis Res 
Ther 9(2): 209.
Kobayashi, Y. and H. Okunishi (2002). "Mast cells as a target of rheumatoid arthritis treatment." Jpn J 
Pharmacol 90(1): 7-11.
286
Koch, A. W., D. Bozic, et al. (1999). "Homophilic adhesion by cadherins." Curr Op  in Struct Biol 9(2): 275- 
81.
Kotha, J., C. Zhang, et al. (2009). "Functional relevance of tetraspanin CD9 in vascular smooth muscle cell 
injury phenotypes: a novel target for the prevention of neointimal hyperplasia." Atherosclerosis 
203(2): 377-86.
Kothapalli, C. R. and A. Ramamurthi "Induced elastin regeneration by chronically activated smooth muscle 
cells for targeted aneurysm repair." Acta Biomater 6(1): 170-8.
Krege, J. H., J. B. Hodgin, et al. (1995). "A noninvasive computerized tail-cuff system for measuring blood 
pressure in mice." Hypertension 25(5): 1111-5.
Kroll, J. and J. Waltenberger (1998). "VEGF-A induces expression of eNOS and iNOS in endothelial cells 
via VEGF receptor-2 (KDR)." Biochem Bionhvs Res Commun 252(3): 743-6.
Ku, I. A., J. B. Imboden, et al. (2009). "Rheumatoid arthritis: model of systemic inflammation driving 
atherosclerosis." Circ J 73(6): 977-85.
Kumar, K., E. Daley, et al. (2007). "Delay in presentation to primary care physicians is the main reason 
why patients with rheumatoid arthritis are seen late by rheumatologists." Rheumatology (Oxford) 
46(9): 1438-40.
Kwon, H. J., T. R. Cote, et al. (2003). "Case reports of heart failure after therapy with a tumor necrosis 
factor antagonist." Ann Intern Med 138(10): 807-11.
Labinskyy, N., P. Mukhopadhyay, et al. (2009). "Longevity is associated with increased vascular resistance 
to high glucose-induced oxidative stress and inflammatory gene expression in Peromyscus 
leucopus." Am J Phvsiol Heart Circ Phvsiol 296(4): H946-56.
Lalu, M. M., J. Cena, et al. (2006). "Matrix metalloproteinases contribute to endotoxin and interleukin- 
lbeta induced vascular dysfunction." Br J Pharmacol 149(1): 31-42.
Lamping, K. G. and F. M. Faraci (2001). "Role of sex differences and effects of endothelial NO synthase 
deficiency in responses of carotid arteries to serotonin." Arterioscler Thromb Vase Biol 21(4): 
523-8.
Lau, A. C., T. T. Duong, et al. (2009). "Inhibition of matrix metalloproteinase-9 activity improves coronary 
outcome in an animal model of Kawasaki disease." Clin Exp Immunol 157(2): 300-9.
Lau, A. C., T. T. Duong, et al. (2008). "Matrix metalloproteinase 9 activity leads to elastin breakdown in an 
animal model of Kawasaki disease." Arthritis Rheum 58(3): 854-63.
Lauer, T., M. Preik, et al. (2001). "Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide 
synthase activity but lacks intrinsic vasodilator action." Proc Natl Acad Sci U S A 98(22): 12814- 
9.
Lebre, M. C. and P. P. Tak (2008). "Dendritic cell subsets: their roles in rheumatoid arthritis." Acta 
Reumatol Port 33(1): 35-45.
Lebre, M. C. and P. P. Tak (2009). "Dendritic cells in rheumatoid arthritis: Which subset should be used as 
a tool to induce tolerance?" Hum Immunol 70(5): 321-4.
Lee, B. and S. K. Moon (2005). "Resveratrol inhibits TNF-alpha-induced proliferation and matrix 
metalloproteinase expression in human vascular smooth muscle cells." JNutr 135(12): 2767-73.
Lee, M. Y., H. F. Tse, et al. (2007). "Genomic changes in regenerated porcine coronary arterial endothelial 
cells." Arterioscler Thromb Vase Biol 27(11): 2443-9.
Lee, S. J., W. J. Kim, et al. (2009). "TNF-alpha regulates vascular smooth muscle cell responses in genetic 
hypertension." Int Immunopharmacol 9(7-8): 837-43.
Leibbrandt, A. and J. M. Penninger (2008). "RANK/RANKL: regulators of immune responses and bone 
physiology." Ann N Y Acad Sci 1143: 123-50.
Lerman, A. and A. M. Zeiher (2005). "Endothelial function: cardiac events." Circulation 111(3): 363-8.
Libby, P. (2008). "Role of inflammation in atherosclerosis associated with rheumatoid arthritis." Am J Med 
121(10 Suppl 1): S21-31.
Libby, P., S. J. Warner, et al. (1988). "Interleukin 1: a mitogen for human vascular smooth muscle cells that 
induces the release of growth-inhibitory prostanoids." J Clin Invest 81(2): 487-98.
Lincoln, T. M., N. Dey, et al. (2001). "Invited review: cGMP-dependent protein kinase signaling 
mechanisms in smooth muscle: from the regulation of tone to gene expression." J Appl Phvsiol 
91(3): 1421-30.
Lindblad, S. S., P. Mydel, et al. (2009). "Smoking and nicotine exposure delay development of collagen- 
induced arthritis in mice." Arthritis Res Ther 11(3): R88.
Liu, X., M. J. Miller, et al. (1998). "Diffusion-limited reaction of free nitric oxide with erythrocytes." J Biol 
Chem 273(30): 18709-13.
287
Lonn, E., S. Yusuf, et al. (2006). "Homocysteine lowering with folic acid and B vitamins in vascular 
disease." NEngU M ed354(15): 1567-77.
Lu, J., T. Kasama, et al. (2000). "Vascular endothelial growth factor expression and regulation of murine 
collagen-induced arthritis." J Immunol 164(11): 5922-7.
Luross, J. A. and N. A. Williams (2001). "The genetic and immunopathological processes underlying 
collagen-induced arthritis." Immunology 103(4): 407-16.
MacArthur, P. H., S. Shiva, et al. (2007). "Measurement of circulating nitrite and S-nitrosothiols by 
reductive chemiluminescence." J Chromatogr B Analvt Technol Biomed Life Sci 851(1-2): 93-
105.
MacNaul, K. L. and N. I. Hutchinson (1993). "Differential expression of iNOS and cNOS mRNA in human 
vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions." 
Biochem Biophvs Res Commun 196(3): 1330-4.
Maharaj, D. (1986). "Autoimmune haemolytic anaemia associated with rheumatoid arthritis and 
paroxysmal nocturnal haemoglobinuria." Acta Haematol 75(4): 241.
Makelainen, P., K. Vehvilainen-Julkunen, et al. (2008). "Rheumatoid arthritis patients' knowledge of the 
disease and its treatments: A descriptive study." Musculoskeletal Care.
Maki-Petaja, K. M., F. C. Hall, et al. (2006). "Rheumatoid arthritis is associated with increased aortic 
pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy." Circulation 
114(11): 1185-92.
Manoury, B., S. L. Etheridge, et al. (2009). "Organ culture mimics the effects of hypoxia on membrane 
potential, K(+) channels and vessel tone in pulmonary artery." Br J Pharmacol 158(3): 848-61.
Marinova-Mutafchieva, L., R. O. Williams, et al. (1997). "Dynamics of proinflammatory cytokine 
expression in the joints of mice with collagen-induced arthritis (CIA)." Clin Exp Immunol 107(3): 
507-12.
Mamett, L. J. and A. S. Kalgutkar (1999). "Cyclooxygenase 2 inhibitors: discovery, selectivity and the 
future." Trends Pharmacol Sci 20(11): 465-9.
Metsios, G. S., A. Stavropoulos-Kalinoglou, et al. (2008). "Rheumatoid arthritis, cardiovascular disease 
and physical exercise: a systematic review." Rheumatology (Oxford! 47(3): 239-48.
Mikuls, T. R. (2003). "Co-morbidity in rheumatoid arthritis." Best Pract Res Clin Rheumatol 17(5): 729- 
52.
Miller, V. M. and S. P. Duckies (2008). "Vascular actions of estrogens: functional implications." 
Pharmacol Rev 60(2): 210-41.
Miossec, P. (2008). "Dynamic interactions between T cells and dendritic cells and their derived 
cytokines/chemokines in the rheumatoid synovium." Arthritis Res Ther 10 Suppl 1: S2.
Mitchell, J. A. and T. D. Warner (1999). "Cyclo-oxygenase-2: pharmacology, physiology, biochemistry 
and relevance to NSAID therapy." Br J Pharmacol 128(6): 1121-32.
Moiseeva, E. P. (2001). "Adhesion receptors of vascular smooth muscle cells and their functions." 
Cardiovasc Res 52(3): 372-86.
Montecucco, F. and F. Mach (2009). "Common inflammatory mediators orchestrate pathophysiological 
processes in rheumatoid arthritis and atherosclerosis." Rheumatology (Oxford) 48(1): 11-22.
Moodley, I. (2008). "Review of the cardiovascular safety of COXIBs compared to NSAIDS." Cardiovasc J 
Afr 19(2): 102-7.
Mor, A., S. B. Abramson, et al. (2005). "The fibroblast-like synovial cell in rheumatoid arthritis: a key 
player in inflammation and joint destruction." Clin Immunol 115(2): 118-28.
Moscana A, M. A. (2003). Cell Surface Proteases: Vol 54 (Current Topics in Developmental Biology). San 
Diego, Academic Press.
Munzel, T., A. Daiber, et al. (2005). "Vascular consequences of endothelial nitric oxide synthase 
uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP- 
dependent protein kinase." Arterioscler Thromb Vase Biol 25(8): 1551-7.
Myers, L. K., E. F. Rosloniec, et al. (1997). "Collagen-induced arthritis, an animal model of 
autoimmunity." Life Sci 61(19): 1861-78.
Myllykangas-Luosujarvi, R., K. Aho, et al. (1995). "Shortening of life span and causes of excess mortality 
in a population-based series of subjects with rheumatoid arthritis." Clin Exp Rheumatol 13(2): 
149-53.
Nakamura, Y., K. Handa, et al. (2001). "Immunohistochemical distribution of CD9, heparin binding 
epidermal growth factor-like growth factor, and integrin alpha3betal in normal human tissues." J 
Histochem Cvtochem 49(4): 439-44.
288
Nam, J. L., K. L. Winthrop, et al. (2010). "Current evidence for the management of rheumatoid arthritis 
with biological disease-modifying antirheumatic drugs: a systematic literature review informing 
the EULAR recommendations for the management of RA." Ann Rheum Pis.
Newby, A. C. and A. B. Zaltsman (2000). "Molecular mechanisms in intimal hyperplasia." J Pathol 190(3): 
300-9.
Nishida, M., J. Miyagawa, et al. (2000). "Localization of CD9, an enhancer protein for proheparin-binding 
epidermal growth factor-like growth factor, in human atherosclerotic plaques: possible 
involvement of juxtacrine growth mechanism on smooth muscle cell proliferation." Arterioscler 
Thromb Vase Biol 20(51: 1236-43.
Noren, N. K., B. P. Liu, et al. (2000). "pi20 catenin regulates the actin cytoskeleton via Rho family 
GTPases." J Cell Biol 150(3): 567-80.
Nowell, M. A., A. S. Williams, et al. (2009). "Therapeutic targeting of IL-6 trans signaling counteracts 
STAT3 control of experimental inflammatory arthritis." J Immunol 182(1): 613-22.
Nozaki, K., H. Goto, et al. (2007). "Effects of keishibukuryogan on vascular function in adjuvant-induced 
arthritis rats." Biol Pharm Bull 30(6): 1042-7.
O'Brien, E. R., M. R. Garvin, et al. (1994). "Osteopontin is synthesized by macrophage, smooth muscle, 
and endothelial cells in primary and restenotic human coronary atherosclerotic plaques." 
Arterioscler Thromb 14(10): 1648-56.
O'Shaughnessy, M. C., E. K. Vetsika, et al. (2006). "The effect of substance P on nitric oxide release in a 
rheumatoid arthritis model." Inflamm Res 55(6): 236-40.
Ohmori, R., Y. Momiyama, et al. (2003). "Plasma osteopontin levels are associated with the presence and 
extent of coronary artery disease." Atherosclerosis 170(2): 333-7.
Olsen, N. J. and C. M. Stein (2004). "New drugs for rheumatoid arthritis." N Engl J Med 350(21): 2167-79.
Otero, M. and M. B. Goldring (2007). "Cells of the synovium in rheumatoid arthritis. Chondrocytes." 
Arthritis Res Ther 9(5): 220.
Owens, G. K. (1995). "Regulation of differentiation of vascular smooth muscle cells." Phvsiol Rev 75(3): 
487-517.
Owens, G. K., M. S. Kumar, et al. (2004). "Molecular regulation of vascular smooth muscle cell 
differentiation in development and disease." Phvsiol Rev 84(3): 767-801.
Padfield, G. J., D. E. Newby, et al. (2010). "Understanding the role of endothelial progenitor cells in 
percutaneous coronary intervention." J Am Coll Cardiol 55(15): 1553-65.
Palframan, R., M. Airey, et al. (2009). "Use of biofluorescence imaging to compare the distribution of 
certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen- 
induced arthritis." J Immunol Methods.
Panoulas, V. F., K. M. Douglas, et al. (2007). "Prevalence and associations of hypertension and its control 
in patients with rheumatoid arthritis." Rheumatology (Oxford) 46(9): 1477-82.
Panoulas, V. F., G. S. Metsios, et al. (2008). "Hypertension in rheumatoid arthritis." Rheumatology 
(Oxford) 47(9): 1286-98.
Park, Y. B., H. K. Choi, et al. (2002). "Effects of antirheumatic therapy on serum lipid levels in patients 
with rheumatoid arthritis: a prospective study." Am J Med 113(3): 188-93.
Pasceri, V. and E. T. Yeh (1999). "A tale of two diseases: atherosclerosis and rheumatoid arthritis." 
Circulation 100(21): 2124-6.
Peri, G., F. Chiaffarino, et al. (1990). "Cytotoxicity of activated monocytes on endothelial cells." J 
Immunol 144(4): 1444-8.
Piccoli, G., U. Rutishauser, et al. (2004). "N-cadherin juxtamembrane domain modulates voltage-gated 
Ca2+ current via Rho A GTPase and Rho-associated kinase." J Neurosci 24(48): 10918-23.
Pinder, A. G., S. C. Rogers, et al. (2009). "The measurement of nitric oxide and its metabolites in 
biological samples by ozone-based chemiluminescence." Methods Mol Biol 476: 10-27.
Pinson, K. I., J. Brennan, et al. (2000). "An LDL-receptor-related protein mediates Wnt signalling in mice." 
Nature 407(6803): 535-8.
Plehm, R., M. E. Barbosa, et al. (2006). "Animal models for hypertension/blood pressure recording." 
Methods Mol Med 129: 115-26.
Pollock, D. M., T. L. Keith, et al. (1995). "Endothelin receptors and calcium signaling." Faseb J 9(12): 
1196-204.
Prusakiewicz, J. J., A. S. Felts, et al. (2004). "Molecular basis of the time-dependent inhibition of 
cyclooxygenases by indomethacin." Biochemistry 43(49): 15439-45.
Pulichino, A. M., S. Rowland, et al. (2006). "Prostacyclin antagonism reduces pain and inflammation in 
rodent models of hyperalgesia and chronic arthritis." J Pharmacol Exp Ther 319(3): 1043-50.
289
Quinn, S., C. O'Brien, et al. (2003). "Role of cyclooxygenase and haemoxygenase products in nitric oxide- 
independent vasodilatation in the porcine ciliary artery." Eve 17(5): 628-36.
Quinones, M. P., C. A. Estrada, et al. (2005). "The complex role of the chemokine receptor CCR2 in 
collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis." 
J Mol Med 83(9): 672-81.
Rabelink, T. J. and T. F. Luscher (2006). "Endothelial nitric oxide synthase: host defense enzyme of the 
endothelium?" Arterioscler Thromb Vase Biol 26(2): 267-71.
Raffetto, J. D. and R. A. Khalil (2008). "Matrix metalloproteinases and their inhibitors in vascular 
remodeling and vascular disease." Biochem Pharmacol 75(2): 346-59.
Raffetto, J. D., X. Qiao, et al. (2008). "Prolonged increases in vein wall tension increase matrix 
metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose 
veins." J Vase Sure 48(2): 447-56.
Raffetto, J. D., R. L. Ross, et al. (2007). "Matrix metalloproteinase 2-induced venous dilation via 
hyperpolarization and activation of K+ channels: relevance to varicose vein formation." J Vase 
Sure 45(2): 373-80.
Ram, M., Y. Sherer, et al. (2006). "Matrix metalloproteinase-9 and autoimmune diseases." J Clin Immunol 
26(4): 299-307.
Rang H.P, D. M. M., Ritter J. M, Moore P.K (2003). Pharmacology. Churchill Livingstone.
Rannou, F., M. Francois, et al. (2006). "Cartilage breakdown in rheumatoid arthritis." Joint Bone Spine 
73(1): 29-36.
Rao, J. V., A. N. Swamy, et al. (1991). "In vitro brain acetylcholinesterase response among three inbred 
strains of mice to monocrotophos." J Environ Sci Health B 26(4): 449-58.
Ratcliffe, A. (2000). "Tissue engineering of vascular grafts." Matrix Biol 19(4): 353-7.
Ray, K. K. and C. P. Cannon (2004). "Intensive statin therapy in acute coronary syndromes: clinical 
benefits and vascular biology." Curr Op  in Lioidol 15(6): 637-43.
Rectenwald, J. E., L. L. Moldawer, et al. (2000). "Direct evidence for cytokine involvement in neointimal 
hyperplasia." Circulation 102(14): 1697-702.
Reddy, A. K., G. E. Taffet, et al. (2003). "Noninvasive blood pressure measurement in mice using pulsed 
Doppler ultrasound." Ultrasound Med Biol 29(3): 379-85.
Reilly, P. A., J. A. Cosh, et al. (1990). "Mortality and survival in rheumatoid arthritis: a 25 year prospective 
study of 100 patients." Ann Rheum Pis 49(6): 363-9.
Renart, J., J. Reiser, et al. (1979). "Transfer of proteins from gels to diazobenzyloxymethyl-paper and 
detection with antisera: a method for studying antibody specificity and antigen structure." Proc 
Natl Acad Sci U S A 76(7): 3116-20.
Rodriguez, J. A., J. Orbe, et al. (2007). "[Metalloproteases, vascular remodeling and atherothrombotic 
syndromes]." Rev Esp Cardiol 60(9): 959-67.
Rogers, S. C., A. Khalatbari, et al. (2005). "Detection of human red blood cell-bound nitric oxide." J Biol 
Chem 280(29): 26720-8.
Roh, C. R., W. J. Oh, et al. (2000). "Up-regulation of matrix metalloproteinase-9 in human myometrium 
during labour: a cytokine-mediated process in uterine smooth muscle cells." Mol Hum Reprod 
6(1): 96-102.
Ronday, H. K., W. H. van der Laan, et al. (2001). "Human granzyme B mediates cartilage proteoglycan 
degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis." 
Rheumatology (Oxford) 40(1): 55-61.
Rosenberg, L. (1971). "Chemical basis for the histological use of safranin O in the study of articular 
cartilage." J Bone Joint Surg Am 53(1): 69-82.
Ross, R. (1999). "Atherosclerosis—an inflammatory disease." N Engl J Med 340(2): 115-26.
Rubanyi, G. M., A. D. Freay, et al. (1997). "Vascular estrogen receptors and endothelium-derived nitric 
oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene 
disruption." J Clin Invest 99(10): 2429-37.
Sakurada, S., N. Takuwa, et al. (2003). "Ca2+-dependent activation of Rho and Rho kinase in membrane 
depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction." 
Circ Res 93(6): 548-56.
Sakuta, T., Y. Morita, et al. "Involvement of the renin-angiotensin system in the development of vascular 
damage in a rat arthritis model: Efect of angiotensin receptor blockers." Arthritis Rheum.
Salliot, C. and D. van der Heijde (2009). "Long-term safety of methotrexate monotherapy in patients with 
rheumatoid arthritis: a systematic literature research." Ann Rheum Pis 68(7): 1100-4.
290
Salo, T., J. G. Lyons, et al. (1991). "Transforming growth factor-beta 1 up-regulates type IV collagenase 
expression in cultured human keratinocytes." J Biol Chem 266(18): 11436-41.
Sattar, N., D. W. McCarey, et al. (2003). "Explaining how "high-grade" systemic inflammation accelerates 
vascular risk in rheumatoid arthritis." Circulation 108(24): 2957-63.
Sattar, N. and I. B. Mclnnes (2005). "Vascular comorbidity in rheumatoid arthritis: potential mechanisms 
and solutions." Curr Opin Rheumatol 17(3): 286-92.
Sauzeau, V., H. Le Jeune, et al. (2000). "Cyclic GMP-dependent protein kinase signaling pathway inhibits 
RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle." J Biol Chem 
275(28): 21722-9.
Scherberich, A., S. Moog, et al. (1998). "Tetraspanin CD9 is associated with very late-acting integrins in 
human vascular smooth muscle cells and modulates collagen matrix reorganization." Arterioscler 
Thromb Vase Biol 18(11): 1691-7.
Schwab, C., G. Bruckner, et al. (1990). "Different levels of acetylcholinesterase and choline 
acetyltransferase activities in C57B1/6 and DBA/2 mice are not accompanied with different 
density of cortical acetylcholinesterase reactive fibers." Neurochem Res 15(11): 1127-33.
Seasholtz, T. M., H. Gurdal, et al. (1997). "Desensitization of norepinephrine receptor function is 
associated with G protein uncoupling in the rat aorta." Am J Phvsiol 273(1 Pt 2): H279-85.
Senior, R. M., G. L. Griffin, et al. (1991). "Human 92- and 72-kilodalton type IV collagenases are 
elastases." J Biol Chem 266(12): 7870-5.
Shin, C. S., S. J. Her, et al. (2005). "Dominant negative N-cadherin inhibits osteoclast differentiation by 
interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion." J Bone 
Miner Res 20(121: 2200-12.
Shiva, S., X. Wang, et al. (2006). "Ceruloplasmin is a NO oxidase and nitrite synthase that determines 
endocrine NO homeostasis." Nat Chem Biol 2(9): 486-93.
Shore, A., S. Jaglal, et al. (1986). "Enhanced interleukin 1 generation by monocytes in vitro is temporally 
linked to an early event in the onset or exacerbation of rheumatoid arthritis." Clin Exp Immunol 
65(2): 293-302.
Shtutman, M., J. Zhurinsky, et al. (1999). "The cyclin D1 gene is a target of the beta-catenin/LEF-1 
pathway." Proc Natl Acad Sci U S A 96(10): 5522-7.
Shyu, K. G. (2009). "Cellular and molecular effects of mechanical stretch on vascular cells and cardiac 
myocytes." Clin Sci (Londl 116(5): 377-89.
Siddhanta, U., A. Presta, et al. (1998). "Domain swapping in inducible nitric-oxide synthase. Electron 
transfer occurs between flavin and heme groups located on adjacent subunits in the dimer." J Biol 
Chem 273(30): 18950-8.
Silman, A. J. and J. E. Pearson (2002). "Epidemiology and genetics of rheumatoid arthritis." Arthritis Res 4 
Suppl 3: S265-72.
Simionescu, M. (2007). "Implications of early structural-functional changes in the endothelium for vascular 
disease." Arterioscler Thromb Vase Biol 27(2): 266-74.
Singer, C. A., S. Salinthone, et al. (2004). "Synthesis of immune modulators by smooth muscles." 
Bioessavs 26(6): 646-55.
Slater, S. C., E. Koutsouki, et al. (2004). "R-cadherin:beta-catenin complex and its association with 
vascular smooth muscle cell proliferation." Arterioscler Thromb Vase Biol 24(7): 1204-10.
Soler, M., M. Camacho, et al. (2003). "Imidazolineoxyl N-oxide prevents the impairment of vascular 
contraction caused by interleukin-1 beta through several mechanisms." J Infect Pis 188(6): 927-37.
Somlyo, A. P. and A. V. Somlyo (1994). "Signal transduction and regulation in smooth muscle." Nature 
372(6503): 231-6.
Staines, N. A. and P. H. Wooley (1994). "Collagen arthritis—what can it teach us?" Br J Rheumatol 33(9): 
798-807.
Stolina, M., S. Adamu, et al. (2005). "RANKL is a marker and mediator of local and systemic bone loss in 
two rat models of inflammatory arthritis." J Bone Miner Res 20(10): 1756-65.
Stolina, M., B. Bolon, et al. (2008). "The evolving systemic and local biomarker milieu at different stages 
of disease progression in rat collagen-induced arthritis." Biomarkers 13(7): 692-712.
Storer, J. B. (1966). "Longevity and gross pathology at death in 22 inbred mouse strains." J Gerontol 21(3): 
404-9.
Streichert, L. C. and P. B. Sargent (1992). "The role of acetylcholinesterase in denervation supersensitivity 
in the frog cardiac ganglion." J Phvsiol 445: 249-60.
Stuart-Smith, K. (2002). "Demystified. Nitric oxide." Mol Pathol 55(6): 360-6.
291
Suleyman, H., B. Demircan, et al. (2007). "Anti-inflammatory and side effects of cyclooxygenase 
inhibitors." Pharmacol Rep 59(3): 247-58.
Sullivan, J. C. and J. S. Pollock (2006). "Coupled and uncoupled NOS: separate but equal? Uncoupled 
NOS in endothelial cells is a critical pathway for intracellular signaling." Circ Res 98(6): 717-9.
Sussman, J. L., M. Harel, et al. (1991). "Atomic structure of acetylcholinesterase from Torpedo califomica: 
a prototypic acetylcholine-binding protein." Science 253(5022): 872-9.
Suzuki, M., I. Tachibana, et al. (2009). "Tetraspanin CD9 negatively regulates lipopolysaccharide-induced 
macrophage activation and lung inflammation." J Immunol 182(10): 6485-93.
Svelander, L., H. Erlandsson-Harris, et al. (2009). "Inhibition of cathepsin K reduces bone erosion, 
cartilage degradation and inflammation evoked by collagen-induced arthritis in mice." Eur J 
Pharmacol 613(1-31: 155-62.
Tak, P. P. and B. Bresnihan (2000). "The pathogenesis and prevention of joint damage in rheumatoid 
arthritis: advances from synovial biopsy and tissue analysis." Arthritis Rheum 43(12): 2619-33.
Takeichi, M. (1990). "Cadherins: a molecular family important in selective cell-cell adhesion." Annu Rev 
Biochem 59: 237-52.
Tallant, C., A. Marrero, et al. (2009). "Matrix metalloproteinases: Fold and function of their catalytic 
domains." Biochim Bioohvs Acta.
Tamai, K., M. Semenov, et al. (2000). "LDL-receptor-related proteins in Wnt signal transduction." Nature 
407(6803): 530-5.
Tanasescu, C., C. Jurcut, et al. (2009). "Vascular disease in rheumatoid arthritis: from subclinical lesions to 
cardiovascular risk." Eur J Intern Med 20(4): 348-54.
Tchetverikov, I., H. K. Ronday, et al. (2004). "MMP profile in paired serum and synovial fluid samples of 
patients with rheumatoid arthritis." Ann Rheum Pis 63(7): 881-3.
Tetlow, L. C., M. Lees, et al. (1993). "Differential expression of gelatinase B (MMP-9) and stromelysin-1 
(MMP-3) by rheumatoid synovial cells in vitro and in vivo." Rheumatol Int 13(2): 53-9.
Tetsu, O. and F. McCormick (1999). "Beta-catenin regulates expression of cyclin D1 in colon carcinoma 
cells." Nature 398(6726): 422-6.
Thyberg, J., K. Blomgren, et al. (1997). "Phenotypic modulation of smooth muscle cells after arterial injury 
is associated with changes in the distribution of laminin and fibronectin." J Histochem Cvtochem 
45(6): 837-46.
Tilley, S. L., L. P. Audoly, et al. (1999). "Reproductive failure and reduced blood pressure in mice lacking 
the EP2 prostaglandin E2 receptor." J Clin Invest 103(11): 1539-45.
Todd, J. A., H. Acha-Orbea, et al. (1988). "A molecular basis for MHC class II—associated autoimmunity." 
Science 240(4855): 1003-9.
Tran, N. L., R. B. Nagle, et al. (1999). "N-Cadherin expression in human prostate carcinoma cell lines. An 
epithelial-mesenchymal transformation mediating adhesion withStromal cells." Am J Pathol 
155(3): 787-98.
Trentham, D. E., A. S. Townes, et al. (1977). "Autoimmunity to type II collagen an experimental model of 
arthritis." J Exp Med 146(3): 857-68.
Tsioufis, C., K. Dimitriadis, et al. (2007). "Low-grade inflammation and hypoadiponectinaemia have an 
additive detrimental effect on aortic stiffness in essential hypertensive patients." Eur Heart J 28(9): 
1162-9.
Turesson, C., L. T. Jacobsson, et al. (2008). "Cardiovascular co-morbidity in rheumatic diseases." Vase 
HealthRislLManag4(3): 605-14.
Turesson, C. and E. L. Matteson (2007). "Cardiovascular risk factors, fitness and physical activity in 
rheumatic diseases." Curr Op in Rheumatol 19(2): 190-6.
Uglow, E. B., S. Slater, et al. (2003). "Dismantling of cadherin-mediated cell-cell contacts modulates 
smooth muscle cell proliferation." Circ Res 92(12): 1314-21.
Urbina, E. M., R. V. Williams, et al. (2009). "Noninvasive assessment of subclinical atherosclerosis in 
children and adolescents: recommendations for standard assessment for clinical research: a 
scientific statement from the American Heart Association." Hypertension 54(5): 919-50.
Uz, O., E. Kardesoglu, et al. (2009). "The relationship between coronary calcification and the metabolic 
markers of osteopontin, fetuin-A, and visfatin." Turk Kardivol Pern Ars 37(6): 397-402.
van den Berg, W. B. (2001). "Anti-cytokine therapy in chronic destructive arthritis." Arthritis Res 3(1): 18- 
26.
van den Berg, W. B., P. L. van Lent, et al. (2007). "Amplifying elements of arthritis and joint destruction." 
Ann Rheum Pis 66 Suppl 3: iii45-8.
292
Van den Steen, P. E., B. Dubois, et al. (2002). "Biochemistry and molecular biology of gelatinase B or 
matrix metalloproteinase-9 (MMP-9)." Crit Rev Biochem Mol Biol 37(6'): 375-536.
Van den Steen, P. E., P. Proost, et al. (2002). "Cleavage of denatured natural collagen type II by neutrophil 
gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the 
formation of remnant epitopes in rheumatoid arthritis." Faseb J 16(3): 379-89.
van der Heijde, D. M. (1995). "Joint erosions and patients with early rheumatoid arthritis." Br J Rheumatol 
34 Suppl 2: 74-8.
Van Wart, H. E. and H. Birkedal-Hansen (1990). "The cysteine switch: a principle of regulation of 
metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene 
family." Proc Natl Acad Sci U S A 87(141: 5578-82.
van Zonneveld, A. J., H. C. de Boer, et al. (2010). "Inflammation, vascular injury and repair in rheumatoid 
arthritis." Ann Rheum Pis 69 Suppl 1: i57-60.
Vane, J. R. and R. M. Botting (1995). "Pharmacodynamic profile of prostacyclin." Am J Cardiol 75(3): 3A- 
10 A.
Vanhoutte, P. M. (1998). "Vascular biology. Old-timer makes a comeback." Nature 396(6708): 213,215-6.
Vanhoutte, P. M. (2009). "COX-1 and vascular disease." Clin Pharmacol Ther 86(2): 212-5.
Vaziri, N. D., Z. Ni, et al. (1998). "Upregulation of renal and vascular nitric oxide synthase in young 
spontaneously hypertensive rats." Hypertension 31(6): 1248-54.
Veale, D., G. Yanni, et al. (1992). "Production of angiotensin converting enzyme by rheumatoid synovial 
membrane." Ann Rheum Pis 51(4): 476-80.
Villar, I. C., A. J. Hobbs, et al. (2008). "Sex differences in vascular function: implication of endothelium- 
derived hyperpolarizing factor." J Endocrinol 197(3): 447-62.
Visse, R. and H. Nagase (2003). "Matrix metalloproteinases and tissue inhibitors of metalloproteinases: 
structure, function, and biochemistry." Circ Res 92(8): 827-39.
Visser, K., W. Katchamart, et al. (2009). "Multinational evidence-based recommendations for the use of 
methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic 
literature research and expert opinion of a broad international panel of rheumatologists in the 3E 
Initiative." Ann Rheum Pis 68(7): 1086-93.
Voskuyl, A. E. (2006). "The heart and cardiovascular manifestations in rheumatoid arthritis." 
Rheumatology (Oxford! 45 Suppl 4: iv4-7.
Wahl, S. M., N. McCartney-Francis, et al. (2003). "Nitric oxide in experimental joint inflammation. Benefit 
or detriment?" Cells Tissues Organs 174(1-2): 26-33.
Waites, G. T. and A. Whyte (1987). "Effect of pregnancy on collagen-induced arthritis in mice." Clin Exp 
Immunol 67(3): 467-76.
Walch, L., C. Taisne, et al. (1997). "Cholinesterase activity in human pulmonary arteries and veins." Br J 
Pharmacol 121(5): 986-90.
Walsh, F. S., C. H. Barton, et al. (1990). "N-cadherin gene maps to human chromosome 18 and is not 
linked to the E-cadherin gene." J Neurochem 55(3): 805-12.
Wang, S., K. H. Yiu, et al. (2009). "Prevalence and extent of calcification over aorta, coronary and carotid 
arteries in patients with rheumatoid arthritis." J Intern Med 266(5): 445-52.
Wang, X., Y. Xiao, et al. (2002). "A role for the beta-catenin/T-cell factor signaling cascade in vascular 
remodeling." Circ Res 90(3): 340-7.
Wang, Y., X. R. Zheng, et al. (2009). "ROCK isoform regulation of myosin phosphatase and contractility 
in vascular smooth muscle cells." Circ Res 104(4): 531-40.
Webb, R. C. (2003). "Smooth muscle contraction and relaxation." Adv Phvsiol Educ 27(1-4): 201-6.
Welch, G. N. and J. Loscalzo (1998). "Homocysteine and atherothrombosis." N Engl J Med 338(15): 1042- 
50.
Welland, A., P. E. Gamaud, et al. (2008). "Importance of the domain-domain interface to the catalytic 
action of the NO synthase reductase domain." Biochemistry 47(37): 9771-80.
Wessels, J. A., T. W. Huizinga, et al. (2008). "Recent insights in the pharmacological actions of 
methotrexate in the treatment of rheumatoid arthritis." Rheumatology (Oxford) 47(3): 249-55.
Wheelock, M. J. and K. R. Johnson (2003). "Cadherin-mediated cellular signaling." Curr Opin Cell Biol 
15(5): 509-14.
Wheelock, M. J. and K. R. Johnson (2003). "Cadherins as modulators of cellular phenotype." Annu Rev 
Cell Dev Biol 19: 207-35.
Williams, R. O., J. J. Inglis, et al. (2005). "Analysing the effect of novel therapies on cytokine expression in 
experimental arthritis." Int J Exp Pathol 86(5): 267-78.
293
Wills, A., M. M. Thompson, et al. (1996). "Pathogenesis of abdominal aortic aneurysms—cellular and 
biochemical mechanisms." Eur J Vase Endovasc Sure 12(4): 391-400.
Wimalasundera, R., S. Fexby, et al. (2003). "Effect of tumour necrosis factor-alpha and interleukin lbeta 
on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro." Br J Pharmacol 
138(7): 1285-94.
Wolfe, F., M. Boers, et al. (2009). "Remission in rheumatoid arthritis: physician and patient perspectives." 
J Rheumatol 36(5): 930-3.
Wooley, P. H., H. S. Luthra, et al. (1981). "Type II collagen-induced arthritis in mice. I. Major 
histocompatibility complex (I region) linkage and antibody correlates." J Exp Med 154(3): 688- 
700.
Xia, C., I. Misra, et al. (2009). "Regulation of interdomain interactions by calmodulin in inducible nitric 
oxide synthase." J Biol Chem.
Yasmin, C. M. McEniery, et al. (2005). "Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase 
activity are associated with systolic hypertension and arterial stiffness." Arterioscler Thromb Vase 
Bjol 25(2): 372.
Yki-Jarvinen, H., R. Bergholm, et al. (2003). "Increased inflammatory activity parallels increased basal 
nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis." Ann 
Rheum Pis 62(71: 630-4.
Yoshihara, Y., H. Nakamura, et al. (2000). "Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis." 
Ann Rheum Pis 59(6): 455-61.
Young, A. and .G. Koduri (2007). "Extra-articular manifestations and complications of rheumatoid 
arthritis." Best Pract Res Clin Rheumatol 21(5): 907-27.
Yumoto, K., M. Ishijima, et al. (2002). "Osteopontin deficiency protects joints against destruction in anti­
type II collagen antibody-induced arthritis in mice." Proc Natl Acad Sci U S A 99(7): 4556-61.
Zemse, S. M., R. H. Hilgers, et al. (2007). "Interleukin-10 counteracts impaired endothelium-dependent 
relaxation induced by ANG II in murine aortic rings." Am J Phvsiol Heart Circ Phvsiol 292(6): 
H3103-8.
Zieman, S. J., V. Melenovsky, et al. (2005). "Mechanisms, pathophysiology, and therapy of arterial 
stiffness." Arterioscler Thromb Vase Biol 25(5): 932-43.
Zou, M. H. and V. Ullrich (1996). "Peroxynitrite formed by simultaneous generation of nitric oxide and 
superoxide selectively inhibits bovine aortic prostacyclin synthase." FEBS Lett 382(1-2): 101-4.
294
